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heart failure (HF), the RyR2 apparently continues to leak Ca2+ into the cytosol leading 
to depletion of SR Ca2+, cytosolic Ca2+ overload and, ultimately, contractile dysfunction. 
We previously showed that long-term therapy with non-excitatory cardiac contractility 
modulation (CCM) electrical signals delivered to the LV myocardium during the absolute 
refractory period, improves LV function in dogs with HF. This study examined the effects of 
chronic CCM on the expression of PS2 and SOR in LV of dogs with HF.
Methods: RNA was extracted and tissue homogenate was prepared from LV of 7 CCM-
treated HF dogs, 7 untreated-HF dogs, and 6 normal (NL) dogs. mRNA expression was 
measured with RT-PCR and protein expression with Western blots. Bands were quantified 
in densitometric units (du).
Results: Compared to NL dogs, mRNA and protein expression of PS2 increased and that 
of SOR decreased in untreated HF dogs (Table). Therapy with CCM normalized mRNA 
and protein expression of both PS2 and SOR (Table).
Conclusions: In HF, disregulation of the excitation-contraction coupling proteins PS2 and 
SOR may be a cause of the SR Ca2+ leak . Long-term CCM therapy partially corrects 
this disregulation. Normalizing SR Ca2+ cycling can partly account for the observed 
improvement of LV function.
Expression of PSE and SOR
mRNA Expression (du) Protein Expression (du)
NL HF-Untreated HF + CCM NL
HF-
Untreated HF + CCM
PS2 0.29 ± 0.02 0.58 ± 0.02* 0.35 ± 0.02† 0.21 ± 0.02 0.55 ± 0.02* 0.25 ± 0.02†
SOR 0.52 ± 0.02 0.20 ± 0.02* 0.35 ± 0.02*† 0.71 ± 0.02 0.27 ± 0.01* 0.43 ± 0.01*†
*=p<0.05 vs. NL; †=p<0.05 vs. HF-Untreated
9:00 a.m.
1002-4 Expression of Phosducin Is Reduced in Left Ventricular 
Myocardium of Explanted Failed Human Hearts and 
Hearts of Dogs with Experimentally-Induced Heart 
Failure
Ramesh C. Gupta, Valerio Zaca, Menjung Wang, Alice Jiang, Hani N. Sabbah, Henry 
Ford Hospital, Detroit, MI
Background: Phosducin (PDU) is a 33 kDa cytosolic protein that inhibits βγ-mediated 
cellular signaling of triomeric guanine nucleotide binding protein (G). Adenovirally 
overexpressed PDU has been shown to increase contractility of isolated cardiomyocytes. 
In-vivo PDU gene transfer has also been shown to improve cardiac contractility in rabbits. 
This study examined the expression of PDU in left ventricular (LV) myocardium of failed 
human and dog hearts.
Methods: RNA was extracted from LV tissue of 6 explanted failed human hearts due 
to ischemic cardiomyopaty (ICM), 6 failed human hearts due to idiopathic dilated 
cardiomyopathy (IDC), and 6 donor (DNR) hearts deemed not suitable for transplantation. 
RNA was also extracted from LV tissue of 6 dogs with coronary microembolization-induced 
heart failure (HF) and 6 normal (NL) dogs. Using specific primers, mRNA expression of 
PDU and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), an internal control, was 
measured using reverse-transcriptase polymerase chain reaction. Bands identified on 
ethidium-bromide agarose gel were quantified in densitometric units (du).
Results: mRNA expression of GAPDH was similar in LV myocardium of DNR, ICM and 
IDC human hearts as well as between NL and failing dog hearts. mRNA expression of 
phosducin was significantly reduced in ICM and IDC hearts compared to DNR hearts 
(ICM: 0.72 ± 0.07, IDC: 1.06 ± 0.08 vs. DNR: 3.72 ± 0.11 du, p<0.05 vs. DNR). Similarly, 
mRNA expression of PDU was significantly reduced in LV myocardium of failed dogs 
compared to NL dogs (0.45 ± 0.06 vs. 1.55 ± 0.08 du, p<0.05).
Conclusions: mRNA expression of PDU is reduced in failed human LV myocardium 
regardless of etiology as well as in failing LV myocardium of dogs with experimentally-
induced HF. Down-regulation of PDU in HF may account, in part, for worsening of contractile 
dysfunction of the failing LV. These observations also suggest the possibility that therapies 
that restore expression of PDU may be useful in the treatment of chronic HF.
9:00 a.m.
1002-5 The Receptor for Advanced Glycation End Products 
Mediates Development of Cardiac Dysfunction in Type-
2 Diabetes
Jan M. Nielsen, Steen B. Kristiansen, Allan Flyvbjerg, Larry Denner, Torsten T. Nielsen, 
Hans E. Bøtker, Dept. of cardiology, Skejby hospital, Aarhus, Denmark
Background: The receptor for Advanced Glycation End Products (RAGE) has received 
considerable attention as a modulator of diabetes related complications. The receptor is 
activated by Advanced Glycation End Products formed at an accelerated rate in diabetes 
due to hyperglycemia and increased oxidant stress. In this study we evaluate the specific 
role of RAGE on development of cardiac dysfunction in a mice model of type 2 diabetes 
by blocking the effect of the receptor with a RAGE-antibody.
Methods: The development of cardiac dysfunction in db/db mice (diabetic, n=27) 
compared to db/+ mice (non-diabetic controls, n=27) was evaluated at 8,12 and 16 
weeks of age. Subsequently, RAGE-antibody or isotype-matched IgG (placebo) was 
administered to db/db mice (n=17) and db/+ mice (n=16) from the onset of diabetes 
at 7 weeks. After 5 weeks of treatment, left ventricular (LV) volumes were evaluated in 
vivo by magnetic resonance imaging (MRI) and the LV function was evaluated in vivo by 
miniaturized pressure-volume catheter (Millar instruments). Tissue samples from the LV 
were taken for gene expression analysis with qPCR.
Results: LV dysfunction was present from 8 weeks and progressed further at 12 and 
16 weeks in the diabetic mice. At 16 weeks, the Preload Recruitable Stroke Work 
(PRSW) was decreased (76.1 vs 100.1 mmHg, p< 0.01), the Tau index was increased 
(7.6 vs 5.9 µS, p<0.05) and the LV was dilated (systolic volume; 14.9 vs 6.5 µL, p<0.01 
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1002-1 Mesenchymal Stem Cells Enhance Proliferation, 
Migration and Differentiation of Cardiac Stem Cells
Chiaki Nakanishi, Masakazu Yamagishi, Kenichi Yamahara, Ikuo Hagino, Hidezo Mori, 
Yoshiki Sawa, Toshikatsu Yagihara, Soichiro Kitamura, Noritoshi Nagaya, National 
cardiovascular center, Suita, Japan, Kanazawa university, Kanazawa, Japan
Background: Mesenchymal stem cells (MSC) transplantation has been proved as 
a promising strategy to treat failing heart. The effect of MSC is supposed to mediate 
mainly by the supply of cell protective, angiogenic and mitogenic factors in a paracrine 
manner. Recent reports have suggested that multipotent cardiac stem cells (CSC) reside 
in adult heart. However, there is little information about the effect of MSC transplantation 
on endogenous CSC. In the present study, we investigated whether MSC had paracrine 
effects on proliferation, migration, and differentiation of CSC in vitro.
Methods and Results: CSC were isolated from neonatal rat hearts using explant method. 
Conditioned medium obtained from adult rat bone marrow-derived MSC significantly 
promoted CSC proliferation compared with standard medium. MSC-derived conditioned 
medium inhibited CSC apoptosis induced by hypoxia and serum starvation and significantly 
decreased the caspase-3 activity. Chemotaxis chamber assay demonstrated that MSC-
derived conditioned medium enhanced migration of CSC. In ELISA assay, MSC secreted 
a large amount of cytokines/chemokines, including hepatocyte growth factor (HGF) and 
stromal derived factor-1α (SDF-1α). In reverse transcription-PCR analysis, CSC expressed 
c-Met and CXCR4, which were the receptors of HGF and SDF-1α, respectively. Furthermore, 
MSC-derived conditioned medium upregulated expression of cardiomyocyte-related genes 
in CSC such as β-myosin heavy chain (β-MHC) and atrial natriuretic peptide (ANP).
Conclusion: MSC-derived conditioned medium enhanced proliferation and migration of 
CSC. Furthermore, it enhanced differentiation of CSC into cardiomyocytes. Thus, MSC 
may have paracrine effects on the heart through activation of CSC.
9:00 a.m.
1002-2 Relationship Between Physical Activity and CRP in 580 
High Risk Elderly Patients
Grace C. Verzosa, Marion E. Barnes, Stephen S. Cha, Kent R. Bailey, Bernard J. Gersh, 
Teresa SM Tsang, Mayo Clinic, Rochester, MN
Background: The association between fitness and C-reactive protein (CRP) in patients 
at high risk of cardiovascular (CV) events is not well known.
Methods: This prospective 5-year study aimed to investigate the pathophysiology of atrial 
fibrillation (AF) in subjects at high risk of first AF and other CV events. Participants were 
≥ 65 years, undergoing general medical exams at Mayo Clinic, and had at least 2 of 
the following: systemic hypertension, diabetes mellitus, proven coronary artery disease, 
or history of congestive heart failure. We analyzed the relationship between CRP at 
enrollment and physical activity categorized as follows: activities of daily living only (Level 
1); sustained activity ≥10 minutes once per week (Level 2), 1-3 times/ week (Level 3), >3 
times/ week (Level 4), and daily (Level 5). 
Results: Of the 580 patients (mean age 74 ± 5 yrs, 67% male); 462 (80%) were on aspirin, 
444 (77%) on statin therapy, 414 (71%) on angiotensin converting enzyme inhibitors /
angiotensin receptor blockers, and 385 (66%) on beta-blocker. The distribution of physical 
activity was Level 1, 202 (35%); Level 2, 23 (4%); Level 3, 83 (14%); Level 4, 141 (24%); 
Level 5, 131 (23%). The range of CRP was 0.19 to 51.3 mg/L. Physical activity level was 
strongly, inversely, and independently predictive of CRP level (all P<0.01) (Table).
Conclusion: In this well-treated elderly cohort at high risk of CV events, physical activity 
was inversely and independently related to CRP level. 
Variable Parameter Estimator SE P
Age, per year 0.005 0.008 0.5430
Female sex 0.331 0.094 0.0004
Physical activity, per level -0.070 0.026 0.0082
BMI, per kg/m2 0.049 0.008 <.0001
History of smoking 0.255 0.089 0.0042
Inflammatory conditions 0.238 0.115 0.0386
Use of statin therapy -0.277 0.097 0.0045
9:00 a.m.
1002-3 Cardiac Contractility Modulation Electrical Signals 
Normalize Expression of the Excitation-Contraction 
Coupling Proteins Presenillin-2 and Sorcin in Left 
Ventricular Myocardium of Dogs with Chronic Heart 
Failure
Ramesh C. Gupta, Sudhish Mishra, Sharad Rastogi, Menjung Wang, Alice Jiang, Valerio 
Zaca, Yuval Mika, Benny Rousso, Hani N. Sabbah, Henry Ford Hospital, Detroit, MI
Background: During membrane depolarization, presenillin-2 (PS2) activates the 
sarcoplasmic reticulum (SR) ryanodine channel (RyR2) to release Ca2+ from the SR. At 
the end of systole, sorcin (SOR) interacts with RyR2 to stop the SR Ca2+ release. In 
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- diastolic volume; 41.9 vs. 28.7 µL, p<0.05). RAGE-antibody treatment in diabetic mice 
(n=9) normalized systolic function (PRSW = 109.8 vs. 94.5 mmHg, p<0.05) and reduced 
ventricular stiffness (0.18 vs. 0.27 mmHg/µL, p<0.05) compared to placebo-treated 
diabetic mice. Anti-RAGE treatment prevented increased gene expression at mRNA level 
of RAGE and pro-collagen which was demonstrated in the diabetic mice.
Conclusion: Administration of a RAGE-blocking antibody at an early stage of diabetes 
prevents development of cardiac dysfunction in a mice model of type 2 diabetes suggesting 
RAGE to be of pathogenetic importance in the development of diabetic cardiomyopathy.
9:00 a.m.
1002-6 Integrin Stimulation Induced Hypertrophy in Neonatal 
Rat Cardiomyocytes is Nitric Oxide-dependent
Soban Umar, Elizabeth J. van der Valk, Martin J. Schalij, Ernst E. Van der Wall, Douwe 
E. Atsma, Arnoud van der Laarse, Department of Cardiology, Leiden University Medical 
Center, Leiden, The Netherlands
Background: Myocardial stretch does not only improve force generation, it also promotes 
growth. Integrins are receptors of stretch. We hypothesize that integrin stimulation induces 
cardiomyocyte hypertrophy that is nitric oxide (NO)-dependent.
Methods: Integrins of neonatal rat cardiomyocytes (NRCMs) were stimulated with 
a peptide containing the Arg-Gly-Asp (RGD) sequence (300 µg/mL) for 24 h. As a 
comparison, α1-adrenergic stimulation by phenylephrine (PE, 100 µmol/L for 24 h) was 
applied. Saline-treated NRCMs were used as control. The hypertrophic response was 
quantified by cell surface area (CSA). The state of phosphorylation of NO-synthase-1 
(NOS1) was assessed by immunocytochemistry. The effects of RGD and PE were studied 
without and with a general NOS-inhibitor (L-NAME, 100 µmol/L), specific NOS1-inhibitor 
(SMTC, 0.1 µmol/L), NO-donor (sodium nitroprusside, 10 µmol/L), ryanodine (100 
µmol/L), and pretreatment with BAPTA-AM (50 µmol/L), an intracellular Ca2+ chelator.
Results: CSA was increased by 42% with RGD and by 91% with PE vs. control (both 
p<0.01). NOS-1 phosphorylation was increased by 61±29% with RGD and by 21±11% 
with PE vs. control (both p<0.01). Hypertrophic effect of RGD was completely abolished 
by L-NAME and SMTC, whereas the hypertrophic effect of PE was inhibited only partly by 
L-NAME and SMTC (by 15% and 55%, resp.). Administration of NO-donor to NRCMs co-
incubated with RGD + L-NAME restored the hypertrophic effect of RGD (29% compared 
to 51% by RGD alone), but was without effect on NRCMs incubated with PE + L-NAME. 
Ryanodine as well as pretreatment with BAPTA-AM inhibited the hypertrophic effect of 
RGD completely, but not that of PE.
Conclusions: Integrin stimulation by RGD leads to NRCM hypertrophy, likely by activation 
of NOS-1. Absence of a hypertrophic response after NOS-inhibition but salvage of the 
hypertrophic effect by extracellular NO-donor suggests that integrin stimulation-induced 
hypertrophy of NRCMs is NO-dependent. As integrin stimulation induced hypertrophy 
is blocked by ryanodine and BAPTA, NO may establish Ca2+ release from sarcoplasmic 
reticulum.
9:00 a.m.
1002-7 Fibulin-2 Regulates Transforming Growth Factor 
(TGF)-β Activation in the Development of Angiotensin-
II-Induced Myocardial Hypertrophy
Hangxiang Zhang, Hailong Dong, Jing Wu, Mon-Li Chu, Takeshi Tsuda, Alfred I. duPont 
Hospital for Children, Wilmington, DE
Background: Angiotensin-II (Ang-II) is a potent neurohormone responsible for the 
progression of cardiac remodeling in which TGF-β serves as a principal downstream 
mediator. To study a potential role of fibulin-2 in Ang-II-induced cardiac remodeling, we 
performed continuous infusion of Ang-II in the mouse model and investigated the role of 
fibulin-2 in the progression of cardiac remodeling and TGF-β activation.
Methods: Subpressor dosage of Ang-II (0.2µg/kg/min) was continuously infused over 
4 weeks by mini-osmotic-pump in age matched wild-type (WT) and fibulin-2-deficient 
(Fbln2-/-) male mice. Sham mice received normal saline.
Results: There was no significant change in blood pressure or body weight after Ang-II 
treatment. Fibulin-2 mRNA expression was significantly increased by Ang-II in WT. WT 
mice developed significant myocardial hypertrophy by Ang-II, whereas there was no 
noticeable hypertrophy in Ang-II-treated Fbln2-/-, indicated by increased left ventricle (LV)/
body weight ratio (4.83± 0.18 vs. 4.01± 0.12 mg/g, p< 0.05) and increased LV posterior wall 
thickness by echocardiogram (0.76± 0.03 vs. 0.71± 0.02 mm, p< 0.05). Atrial natriuretic 
peptide (ANP) expression was significantly increased in Ang-II-treated WT mice, but not 
in Ang-II-treated Flbn2-/-. Although Ang-II induced significant up-regulation in Col I, Col III, 
and MMP-2 mRNA level in WT but not in Fbln2-/-, histological evidence of fibrosis was not 
discernible in either group. Both TGF-β1 mRNA and protein expression were significantly 
up-regulated in Ang-II-treated WT, but unchanged in Ang-II-treated Fbln2-/-. Activation of 
TGF-β downstream signaling proteins, phosphorylated forms of Smad2, TGF-β-activated 
kinase 1 (TAK-1) and p38, were all significantly increased in Ang-II-treated WT, whereas 
there was no increase in Ang-II-treated Fbln2-/-.
Conclusions: Our data suggest that fibulin-2 mediates Ang-II-induced myocardial 
hypertrophy via activation of TGF-β and its downstream mitogen-activated protein kinase 
(MAPK) pathways. The role of extracellular matrix protein fibulin-2 in the development of 
Ang-II-induced myocardial hypertrophy will add new insight into cardiac remodeling.
9:00 a.m.
1002-8 Anakinra, Recombinant Human Interleukin-1 Receptor 
Antagonist, Inhibits Apoptosis in Acute Myocardial 
Infarction
Antonio Abbate, Fadi N. Salloum, Stefania Straino, Anindita Das, Jon-Erik Houser, 
Nicholas N. Hoke, Amit Varma, Ian Z. Qureshi, Aldo Dobrina, Elena Vecile, George 
W. Vetrovec, Alfonso Baldi, Rakesh C. Kukreja, Virginia Commonwealth University, 
Richmond, VA
Background: Recent data suggest that Interleukin-1 receptor antagonist (IL-1Ra) may 
be cardioprotective during ischemia. The aim of the current study was to test the impact 
of exogenous recombinant human IL-1Ra (anakinra) in experimental acute myocardial 
infarction (AMI).
Methods: Two animal studies were conducted: a) immediate anakinra administration 
during ischemia in the mouse and b) delayed anakinra administration 24 hours after 
ischemia in the rat. Thirty-two ICR mice and 16 Wistar rats underwent surgical coronary 
artery ligation. Anakinra 1 mg/Kg was given during surgery (mouse) or on day 2 (rat) 
and then daily for 6 doses in half of the animals. Animals underwent transthoracic 
echocardiography (TTE) before surgery and 7 days later just prior to sacrifice. A blood 
sample was taken to detect circulating IL-1beta in 8 rats. Histological analysis was 
performed to evaluate cardiomyocyte apoptosis in the peri-infarct regions. The anti-
apoptotic effect of anakinra was tested in primary rat cardiomyocyte culture and on 
caspase-1 activity in vitro.
Results: At 7 days, 9 of the 10 mice and 4 of the 4 rats treated with anakinra were 
alive (93%) vs 7 of the 14 mice and 5 of the 8 rats treated with saline (54%, P=0.027). 
No differences in infarct size at 24 hours were observed. Anakinra significantly reduced 
apoptosis in both the immediate and delayed treatment groups (3.1±0.2 vs 0.5±0.3%, 
P<0.001, and 4.2±0.4 vs 1.1±0.2%, P<0.001; respectively). When compared with saline-
treated animals, anakinra-treated animals showed signs of significantly better ventricular 
remodeling (P<0.05 for EDD, ESD, and FS). We found no difference in IL-1beta between 
the 2 groups. Anakinra (0.025 ng/ml) significantly inhibited ischemia-induced apoptosis 
by approximately 40% in a primary rat culture (P<0.001) and anakinra (100 nM) also 
significantly inhibited caspase-1 activity by approximately 50% (P<0.001)
Conclusions: Immediate or delayed administration of anakinra during AMI significantly 
ameliorates the remodeling process by inhibition of cardiomyocyte apoptosis in an 
experimental model of AMI. This may have strong clinical implications for the prevention 
of post-ischemic cardiac remodeling and heart failure
9:00 a.m.
1002-9 Right Ventricular Cytoskeletal Remodeling in 
Restrictive Ventricular Septal Defects
Alistair Phillips, Gretel Monreal, Mark Galantowicz, John Anthony Bauer, Mark Gerhardt, 
Nationwide Children’s Hospital, Columbus, OH, The Ohio State University, Columbus, OH
Background: Pressure overload induces cytoskeletal remodeling characterized by 
increased desmin protein and sarcomeric translocation of chaperone protein alpha-B 
crystallin (αBC). Cytoskeletal remodeling in congenital heart disease is unknown and 
may be relevant in lesions such as restrictive ventricular septal defect (VSD) where there 
is not pressure overload. We measure desmin and αBC protein content in RV and LV, in a 
restrictive VSD porcine model, to gain insights into ventricular remodeling.
Methods: Mid-muscular VSDs were created in 3 pigs. Hemodynamics were measured, at 
baseline and 1 week post-VSD compared to controls. Western blot with densitometry was 
performed on LV and RV myocardium using desmin and αBC antisera. *p<0.05.
Results: Pressures (mmHg) from RV (17±1 vs 15±0.7), LV (37±2 vs 36±5), Ao (58±4 vs 
54±5), or PA (19±0.9 vs 18±0.7) in baseline vs VSD animals, were similar. O2 saturations 
were unchanged (Ao 100% pre and post, PA 85.8±2.7% vs 85.0±6.7%). RV desmin and 
αBC protein content increased 350% (p=0.001) and 79%* compared to controls. LV 
desmin decreased 67%* and αBC increased 72%*.
Conclusions: Restrictive VSDs, with insignificant hemodynamic changes, are associated 
with significant increases in RV sarcomeric desmin and αBC protein content. These VSDs 
are believed not be clinically significant; however, the cytoskeletal alterations suggests 
that intracellular myocyte remodeling is taking place and may represent a key early 
marker of future cardiac dysfunction.
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1002-10 The Association Between Serum Markers of Myocardial 
Fibrosis and Renal Function Variables in the Healthy 
Elderly: The Cardiovascular Health Study
Eddy Barasch, John S. Gottdiener, Gerard Aurigemma, Dalane Kitzman, Jing Han, 
Richard Kronmal, St. Francis Hospital/SUNY at Stony Brook, Roslyn, NY, University of 
Maryland, Baltimore, MD
Background: Increased serum level markers of collagen synthesis (procollagen type III 
aminoterminal peptide -PIIINP-, carboxyl-terminal propeptide type I -PIP-) and degradation 
(carboxyl-terminal telopeptide of collagen type I -CTIP-) has been identified in patients 
with heart failure (HF). We previously determined a strong association between fibrosis 
biomarkers and renal function variables in the elderly with HF. It is unknown whether in 
healthy elderly a similar association is present. Methods: Serum levels of PIIINP, PIP and 
CTIP were measured in a nested case control study of 279 participants (ppt) (mean age= 
76+/-6 years, 52% males, 55% white) with cardiovascular disease (CVD) but HF, and 280 
healthy controls (mean age = 78+/- 6 years, 51% males, 95% white) without any CVD. 
Serum creatinine, microalbumin/creatinine and cystatin C were measured. Results: The 
serum level of biomarkers are shown below. There was no correlation between PIP and 
the renal function variables. In both groups, the unadjusted, and age, gender and race 
adjusted analyses determined the strongest association between cystatin C and CTIP (r 
= 0.37 and p<0.0001, respectively). 
Variable
Controls (No HF) 
N= 279
Healthy Controls 
N = 280 p-value
Median Lower Quartile
Upper 
Quartile Median
Lower 
Quartile
Upper 
Quartile
PIP (µg/l) 4.5 3.2 5.9 3.8 2.8 5.3 NS
CTIP (µg/l) 384 321.4 467.4 403.3 336.2 491.4 0.0006
PIIINP 
(ng/ml) 3.7 2.8 5.0 3.1 2.4 4.0 <0.0001
Conclusions: 1. CTIP and PIIINP serum level were higher in the ppt with CVD, but HF, 
than in healthy elderly. 2. A significant correlation was found between CTIP, PIIINP and 
renal function variables, especially Cystatin C even in healthy elderly. 3. Cystatin C may also 
represent a link between kidney and heart in the pathophysiology of myocardial fibrosis.
9:00 a.m.
1002-11 Caspase-cleaved Cytokeratin-18: an Early Marker of 
Apoptosis in Cardiomyocytes
Nicholas N. Hoke, Fadi N. Salloum, Jon-Erik Houser, Alfonso Baldi, Rakesh C. Kukreja, 
Antonio Abbate, Virginia Commonwealth University, Richmond, VA
Background: A main component of intermediate filaments, cytokeratin-18 is a substrate 
of caspases 3, 6, and 7 which is cleaved early during apoptosis and involved in the 
apoptotic process. Caspase-cleaved cytokeratin-18 (ccCK-18) has an apoptosis-specific 
neo-epitope recognized by the monoclonal antibody M30 (CytoDeath). As a marker of 
caspase-3 activation, ccCK-18 has been tested in numerous epithelial cell types but 
not in cardiomyocytes. In the current study we aim to evaluate ccCK-18 expression 
in the myocardium in several pathologic conditions and its use as an early marker for 
apoptosis.
Methods: Several models were studied. We used a mouse model of coronary ligation 
in which we studied the myocardium 24 hours after surgery and a rat model 7 days 
after surgery to evaluate for interspecies differences. Moreover, samples from patients 
with acute myocarditis were taken at autopsy. Each sample was co-stained for DNA 
fragmentation (TUNEL) and ccCK-18. As a positive control, we used a rat mammary 
gland and a sham operated mouse as a negative control. Staining without the primary 
antibody was used to test for non-specific peroxidation of substrate. Staining of a 
secondary antibody without the primary antibody was to determine if there was any non-
specific binding.
Results: Many double positive TUNEL and ccCK-18 cells were found in the positive 
control. The sham-operated control was negative for both. No aspecific peroxidation of the 
substrate or nonspecific antibody binding was detected. In both animal models, ccCK-18 
expression was primarily localized to the peri-infarct area with minimal or no expression 
in the remote areas. Staining was diffuse in myocarditis samples. In all samples we found 
that nearly all nuclear staining of TUNEL positive cells were also ccCK-18 positive in the 
surrounding cytoplasm, with more intense perinuclear staining. Being an early marker for 
apoptosis, more ccCK-18 than TUNEL positive cells were present in each sample.
Conclusions: This study confirms that ccCK-18 maybe used as an early marker 
of apoptosis also in cardiomyocytes. The low molecular weight of ccCK-18 and 
transmembrane release of ccCK-18 make it a potential candidate for a plasma-based 
apoptotic assay.
9:00 a.m.
1002-12 Fixed Dose Isosorbide Dinitrate/Hydralazine Lowers 
Blood Pressure But Does Not Improve Cardiac 
Remodeling In Diastolic Heart Failure
Richard M. Wilson, Deepa S. De Silva, Flora Sam, Whitaker Cardiovascular Institute, 
Boston University School of Medicine, Boston, MA
Background: Hypertension (HTN) is a major cause of diastolic heart failure (DHF) and 
accounts for ~40% of HF admissions. HTN is associated with left ventricular hypertrophy 
(LVH). Fixed dose isosorbide dinitrate/hydralazine (I/H) results in improved cardiac 
remodeling and survival in systolic HF. There are no animal studies to test the mechanism 
by which chronic I/H affects cardiac remodeling in heart failure. We tested the hypothesis 
that chronic I/H prevents the progression from HTN and LVH to DHF. Methods: Ten-week 
old male FVB mice underwent sham surgery (n=10) or uninephrectomy, aldosterone-
infusion and fed 1% salt water for 4-weeks (ALDO). ALDO mice were either untreated 
(n=10) or treated with I/H (isosorbide dinitrate: 26mg/kg/day; hydralazine: 50mg/kg/day) 
for 4 weeks following surgery (n=10). Tail-cuff blood pressure (SBP) and echocardiogram 
were performed 4-weeks after surgery. Results: Four-weeks after aldosterone-infusion, 
SBP was increased in untreated-ALDO vs. sham mice (161±3 vs. 129±2mmHg; 
p<0.001). SBP was decreased in ALDO-I/H vs. untreated-ALDO mice (137±5mmHg; 
p<0.001). As expected, I/H decreased sham SBP vs. untreated-sham (114±2mmHg; 
p<0.01). LVH was increased in untreated-ALDO vs. untreated-sham mice (HW/BW ratio: 
4.2±0.1 vs. 3.6±0.1mg/g; p<0.0001). However, LVH was no different between ALDO-I/
H and untreated-ALDO mice (HW/BW ratio: 4.3±0.1; p=NS). ALDO increased LV end 
diastolic dimension vs. untreated-sham (2.3±0.1 vs. 2.0±0.1mm) but was not attenuated 
by I/H. Neither, ALDO or I/H affected LV end systolic dimensions. Similarly LV ejection 
fraction was unchanged in ALDO-I/H and untreated-ALDO hearts (69±1% vs. 67±1%). 
Additionally there was pulmonary congestion, as determined by the wet/dry lung ratio 
in untreated-ALDO mice (5.4±0.4 vs. 4.3±0.1; p<0.05 vs. untreated-sham) but was not 
affected by I/H. Conclusions: These data demonstrate that in diastolic HF, despite the 
reduction in SBP with chronic fixed dose I/H, LVH is not abrogated. Our findings suggest 
that in hypertension-mediated diastolic dysfunction regression of LVH is beneficial and 
this warrants further study.
9:00 a.m.
1002-13 Regional Differences in Mitochondrial Dysfunction in 
the Failing Heart
YeQing Pi, Michael J. Goldenthal, Gordon W. Moe, Jose Marin-Garcia, St Michael’s 
Hospital, Toronto, ON, Canada, The Molecular Cardiology Institute, Highland Park, NJ
Background: Our laboratory has previously demonstrated selective respiratory enzyme 
defects in the canine failing heart. Since regional differences in mitochondrial dysfunction 
have not yet been ascertained, we assessed respiratory activities in both subsarcolemmal 
(SSM) and intermyofibrillar (IFM) mitochondria in the left ventricle (LV) and left atrium (LA) 
of the canine failing hearts induced by 4 weeks of ventricular pacing.
Methods: SSM and IFM subpopulations of mitochondria were isolated from the free walls 
of the LA and LV of control (n=5) and heart failure (HF) dogs (n=5). Mitochondrial enzyme 
activities were assessed by spectrophotometric assays.
Results: In the LV of the HF dogs, both IFM and SSM exhibited decline in complex I, 
III and V activities albeit the IFM showed a more definitive decline (p< 0.05) for all 3 
enzymes. Complex V activity was the most affected with greater than a 60% decline in 
IFM and a 42% decline in SSM relative to control levels. Western immunoblot analysis 
revealed also a significant reduction (50%) in the levels of specific complex V subunits 
in the LV mitochondria. In the LA, a significant decline (p<0.05) was found in Complex V 
activity in both IFM and SSM (32% reduction in IFM and 28% in SSM) in HF, albeit the 
extent of the complex V dysfunction was not as severe as in the LV. Unexpectedly, both 
subtypes of LA mitochondria displayed a significant increase in complex IV activity in HF. 
Atrial SSM mitochondria also showed a mild increase in citrate synthase and complex I 
activities which in combination with the elevated complex IV activity, suggests increased 
mitochondrial proliferation in the atrial compartment. Similar activities for complex II in 
SSM and IFM fractions were detected in the LA and LV of both the HF and controls.
Conclusions: Mitochondrial enzyme dysfunction is not uniform but is location-dependent 
in both the LA and LV of the failing dog heart. Moreover, specific enzyme deficiencies 
present in failing hearts are unlikely the result of generalized mitochondrial DNA damage 
but may rather arise from highly localized damage and/or modification of specific enzyme 
subunits or the modulation of their gene expression.
9:00 a.m.
1002-14 Determinants of myocardial release of stromal derived 
factor-1 and stem cell factor
Justin A. Mariani, Tanneale Marshall, Anka T. Smolic, David M. Kaye, Baker Heart 
Research Institute, Melbourne, Australia, The Alfred Hospital, Mlebourne, Australia
Background: Activation of cytokines and their signaling pathways play a key role in the 
pathogenesis of myocardial injury and the subsequent response. Recently it has been 
shown that cytokine-mediated mobilization of CD34+ progenitor cells is an important 
response to acute myocardial injury. We therefore aimed to characterize myocardial 
cytokine secretion in the failing human heart, to investigate its regulation and further 
explored the relation between circulating cytokine levels and the abundance of CD34+ 
progenitor cells. Methods: In heart failure (HF) patients (n=19, NYHA class III) and age 
matched healthy controls (n=8), we performed right heart catheterization, coronary sinus, 
and peripheral venous and arterial blood sampling to determine levels of the cytokines 
stromal derived factor-1 (SDF-1) and stem cell factor (SCF). We sought to determine the 
abundance of peripheral CD34+ cells with assessment of co-expression of the SDF-1 
receptor, CXCR4, and the stem cell factor (SCF) receptor, CD117, utilizing fluorescence 
activated cell sorting. SDF-1 and SCF secretion in vitro by isolated neonatal rat 
cardiomyocytes in response to norepinephrine, atrial natriuretic peptide and angiotensin 
II was also examined. Results: Peripheral plasma levels of SDF-1 were significantly 
greater in HF (2491+302 vs 1796+121, p<0.05) whilst SCF levels did not differ. Plasma 
SDF-1 correlated significantly with right atrial pressure (r=0.86, p<0.01) and pulmonary 
capillary wedge pressure (r=0.71, p<0.01). A very significant relationship between 
transcardiac gradients of both SDF and SCF-1 (r=0.99,p<0.001) existed. In peripheral 
blood, there was a correlation between CD34+ cell levels and SDF-1 (r=0.50, p<0.05) and 
SCF (r=0.468, p=0.058), however no link was found between CD34+ cell co-expression of 
CXCR4 or CD117 and the corresponding cytokines. Isolated neonatal rat cardiomyocytes 
constitutively secreted both SDF-1 and SCF, and angiotensin II (100nM) induced a 2.5 
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fold rise in SDF-1 secretion (p<0.05). Conclusions: Cardiomyocytes and the failing 
heart have some capacity for cytokine secretion, responsive to both hemodynamic and 
neurohormonal stressors and linked to CD34+ cell mobilization.
9:00 a.m.
1002-15 Type D Personality and Chronic Kidney Disease as 
Predictors of Pro- and Anti-Inflammatory Cytokine 
Levels in Heart Failure
Nina Kupper, Angélique A. Schiffer, Martijn Kwaijtaal, Herbert Hooijkaas, Eric H. 
Hendriks, Jos W. Widdershoven, Johan Denollet, Tilburg University, Tilburg, The 
Netherlands, TweeSteden hospital, Tilburg, The Netherlands
Background: Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and soluble TNF-α 
receptors 1 (sTNFR1) and 2 (sTNFR2) are powerful predictors of mortality in chronic 
heart failure (CHF). However, little is also known about (i) the origins of pro-inflammatory 
cytokine production and (ii) the determinants of substantial interpatient variability 
in immune activation. We prospectively examined Type D personality (tendency to 
experience emotional distress) and chronic kidney disease (CKD) as predictors of 
cytokine production in patients with CHF.
Methods: At baseline, 125 CHF patients were assessed for Type D personality. At one 
year follow-up, we measured serum levels of IL-6, TNF-α, sTNFR1, sTNFR2, and the anti-
inflammatory cytokines interleukin-10 (IL-10) and interleukin-1 receptor antagonist (IL-1ra).
Results: At one-year follow-up, Type D patients had significantly elevated levels of 
sTNFR1 (p=0.009) and sTNFR2 (p=0.001) and decreased levels of IL-10 (p=0.006) as 
compared to patients without Type D or CKD. Patients with CKD also had elevated levels 
of sTNFR1 and sTNFR2 (p<0.0001) but their level of IL-10 was not decreased. Type D 
personality and CKD predicted increased sTNFR1/IL-10 and sTNFR2/IL-10 ratios (all 
ps≤0.007); Type D also predicted an increased IL-6/IL-10 ratio (p=0.013). Spironolactone 
and older age were also associated with elevated pro-/anti-inflammatory cytokine ratios. 
Adjusting for these variables, the odds to have an elevated ratio (highest 20%) was still 
increased in Type D patients (OR= 3.92, 19.88 and 3.12, respectively).
Conclusions: Type D personality and CKD independently predict unfavorable cytokine 
profiles, and play a role in the interpatient variability in immune activation among patients 
with CHF.
9:00 a.m.
1002-16 Patient-Specific Characteristics of the Novel Heart 
Failure Biomarker ST2
Shafiq Rehman, Martinez-Rumayor Abelardo, James Januzzi, Massachusetts General 
hospital, Boston, MA
Background: Levels of ST2 (an interleukin receptor family member) are associated with 
striking prognostic value in heart failure (HF). Specific clinical characteristics in HF and 
their effects on ST2 concentration are not defined
Methods: 209 patients with acute HF had ST2 measured. Associations between ST2 and 
characteristics such as demographics and severity/type of HF as well as with biomarkers 
such as NT-proBNP/BNP were examined. Subjects were examined as a function of 
clinical variables, as a function of ST2 values, and also were dichotomized as a function 
of a previously identified prognostically meaningful ST2 concentration of 0.20 ng/mL.
Results: ST2 values were lower among those with NYHA Class II HF symptoms 
compared to those with more severe dyspnea (0.29 vs 0.56 ng/mL for Class III or IV; P 
<.001); similarly, ST2 values were lower among those with preserved LV systolic function 
versus those with impaired LV function (0.42 vs 0.67 ng/mL; P =.012). Correlations were 
found with NT-proBNP (r=0.40; P <.001), BNP (r=0.33; P <.001) and CRP (r=0.58; P 
<.001). No associations were found between ST2 and renal function. Patients with an ST2 
value <0.20 ng/mL were more likely to have a ‘grey zone’ NT-proBNP value compared 
to those with higher ST2 concentrations (23% vs 6.7%; P <.001), and were less likely 
to have prevalent symptoms/signs of HF, including paroxysmal nocturnal dyspnea (8% 
vs 20%), orthopnea (13% vs 27%), and lower extremity edema (13% vs 29%; all P <.05 
compared to ST2 >0.20 ng/mL). Patients with ST2 <.20 ng/mL were more likely to have 
lower NT-proBNP compared to those with ST2 >.20 ng/mL (both P <.001). Most of these 
associations were not seen with other inflammatory markers, including CRP, interleukins, 
and TNF alpha receptors.
Conclusions: Although an inflammatory marker, in those with HF ST2 has strong clinical 
and biochemical correlates to natriuretic peptides, supporting the role of ST2 in the 
myocardial-specific inflammatory response to stretch/injury.
9:00 a.m.
1002-17 Kidney-Heart Connection: Cardiac Fibrosis and 
Differential Ventricular Gene Profiles After One Kidney 
Nephrectomy in the Absence of Heart Failure
Fernando L. Martin, Brenda K. Huntley, Gerald E. Harders, Horng H. Chen, Alessandro 
Cataliotti, John C. Burnett, Jr., Mayo Clinic, Rochester, MN
Background: Decreased renal function is associated with increased cardiovascular 
morbidity and mortality by mechanisms that remain unclear. We hypothesized that 
even mild renal insufficiency produced by unilateral nephrectomy results in changes in 
ventricular structure and gene expression in the absence of hypertension or volume 
overload underscoring a kidney-heart connection in the control of myocardial structure. 
Methods: Cardiorenal function and structure were assessed in Wistar rats [sham (S;n=10) 
and unilateral nephrectomized (UNX; n=9)] 4 weeks after UNX. GFR was determined by 
inulin clearance and renal blood flow (RBF) by PAH. Blood was obtained for BNP, PRA, 
and aldosterone. Hearts and kidneys were harvested for histological analysis. Cardiac 
function was assessed by echo. Genome-wide microarray analysis was performed on 
left ventricular myocardium (Affymetrix GeneChip® Rat Genome 230 2.0). Results: 
Glomerular hypertrophy was observed in UNX (S:1±0.04, Nx:1.6±0.1 u3x106, p<0.001). 
GFR tended to decrease with a reduction in RBF (S:8±1, Nx:5±1 ml/min, p<0.005). 
Sodium and water excretions were not different between groups with no activation of 
PRA, aldosterone or BNP. LVEF and LV end-systolic and end-diastolic diameters were 
normal. Blood pressure (BP) was not different between groups. Importantly, microarray 
analysis of ventricular myocardium revealed that 278 genes significantly changed with 
UNX (1.5 fold, P<0.05) compared to S in genes related to cell growth, bone remodeling 
and muscle contraction (Z >2). Further, Picrosirius Red staining in the ventricular 
myocardium of UNX compared to S revealed greater fibrosis (S:2.4±0.1, Nx:4.2±0.4 
%, p<0.001). Conclusion: We conclude that even mild renal insufficiency produced by 
unilateral nephrectomy initiates myocardial gene responses and fibrosis independent of 
alterations in the circulating RAAS, BNP, BP, volume overload or systolic dysfunction. 
These studies support a kidney - heart connection in early renal dysfunction resulting in 
molecular ventricular remodeling and fibrosis. These studies in experimental mild renal 
dysfunction produced by removal of one kidney reveal a renal mediated mechanism for 
LV remodeling.
9:00 a.m.
1002-18 Regional Gene Expression Fingerprints of the Non-
Failing and Failing Human Heart
Jason C. Hatch, Peter M. Buttrick, Karin Nunley, Michael R. Bristow, Brian D. Lowes, 
University of Colorado School of Medicine, Denver, CO
Background: Right heart embryology, anatomy and function are distinctly different from 
the left heart. Regional differences in gene expression in normal and failing hearts are 
poorly understood. This study investigates regional differences in 62 targeted genes with 
known involvement in cardiac function in both failing and nonfailing human heart.
Methods: Human heart tissue was obtained from the left and right ventricular free wall at 
the time of cardiac transplantation in patients with heart failure due to idopathioc dilated 
cardiomyopathies (n=8). Non-failing tissue was obtained from unutilized hearts from human 
donors (n=8). Gene expression was measured with the Affymetrix 133 plus 2 Array and 
gene expression analysis done with Genesifter software (VizX Labs, Seattle, WA). Statistical 
significance was based on Wilcoxon rank sum analysis with a p-value of <0.05.
Results: Global gene expression analysis identifies 1100 genes that are differentially 
expressed between the failing left and right ventricle. Of the 62 targeted genes, pyruvate 
dehydrogenase(p<.01), pyruvate dehydrogenase kinase(p<.05) and angiotensin 
II receptor type 1(p= <0.05) were upregulated in the right ventricle relative to the left 
ventricle. Tropomodulin (p<.01), SERCA Ca(2+)- ATPase (p<.01), and protein tyrosine 
kinase 2 (p<.05) were downregulated. In the nonfailing heart, of the prespecified 62 
genes, 22 were differentially expressed. These genes involve cardiac contraction (9 
genes), receptor/cell signaling function (5 genes), inflammation/apoptosis (3 genes), 
blood pressure/volume control (2 genes), metabolism (2 genes), and cytoskeleton 
component (1 gene).
Conclusions: Gene expression profiles suggest that there are important and unique 
differences between the right and left ventricle at baseline and in response to injury.
9:00 a.m.
1002-19 Genetic Determinants of Cardiac Contractility: A 
Genome-Wide Association Study
Sanjiv J. Shah, Jeanne M. DeCara, Lianne M. Kurina, Heidi Pollard, Keith A. Collins, 
Georgeanne Lammertin, Sanjeev G. Shroff, Lin Pan, Ying Sun, Roberto M. Lang, Carole 
Ober, Northwestern University, Chicago, IL, University of Chicago, Chicago, IL
Background: Identifying genes that influence cardiac contractility could lead to better 
understanding of the pathogenesis of heart failure. We hypothesized that cardiac 
contractility, assessed by a relatively load-independent measure, is a heritable trait, and 
that novel genes influencing contractility could be identified by a genome-wide association 
study (GWAS).
Methods: We conducted arterial tonometry and comprehensive 2D echo in the Hutterite 
Family Health Study (N=237), and quantified contractility as the ratio of end-systolic 
pressure (ESP, from arterial tonometry) to end-systolic volume (ESV, using biplane 
method of discs from echo). The Hutterites are a Caucasian founder population who live 
on communal farms in South Dakota (homogenous environment, communal meals). All 
are related in a 13-generation pedigree. Our sample was population-based, including 
all individuals age >18 yrs. We used a variance component approach that accounts for 
the relatedness between individuals to estimate heritability. Each subject was genotyped 
using the Affymetrix GeneChip® Mapping 500k Array, and a GWAS was conducted using 
an association test that accounts for both inbreeding and relatedness among individuals.
Results: In this sample of Hutterites (mean age 41±15 yrs, 51% female),
contractility (ESP/ESV) was significantly heritable, with 72% of the trait variance 
attributable to genetic variation (H2=0.72, standard error=0.11), whereas neither ESP nor 
ESV was significantly heritable in these individuals. Several novel genes were associated 
with contractility at p<0.00005. Of these, 2 were intronic single nucleotide polymorphisms 
within the gene encoding synaptic vesicle protein 2 (SV2C). SV2C is present in both the 
adrenal medulla and midbrain, and therefore could play a role in sympathetic nervous 
system regulation.
Conclusions: Cardiac contractility is a heritable trait in an unselected sample from a 
population with reduced environmental heterogeneity. 72% of the variance in contractility 
between individuals is due to genetic differences. Furthermore, we found novel genes with 
biologic plausibility, such as SV2C, which may play a role in influencing LV contractility.
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9:00 a.m.
1002-20 Furin Processes Human in ProBNP 1-108 to BNP 1-32 
In Vitro and Is Increased in Ventricular Myocardium in 
Experimental Heart Failure
Brenda K. Huntley, Lisa C. Costello-Boerrigter, Alessandro Cataliotti, John C. Burnett, 
Jr., Mayo Clinic, Rochester, MN
Background: ProBNP is the precursor of mature BNP 1-32 which mediates its biological 
actions via the NPR-A receptor. Previous studies demonstrated proBNP cleavage to BNP 
1-32 by corin, which processes proANP to circulating ANP29, while other studies suggest 
proBNP may also be processed by furin, which cleaves proCNP to circulating CNP53. We 
sought to determine if furin processes ProBNP, if so, to what molecular form, and whether 
furin expression is altered in experimental heart failure.
Methods: Recombinant human ProBNP (1-108) was digested with furin for 6 hours at 
room temperature. Unprocessed and furin processed ProBNP were separated by SDS-
PAGE electrophoresis and the resulting bands were sequenced. Furin presence was 
determined in normal canine left ventricular myocardium by immunofluorescence. Furin 
protein expression levels were then determined by western blot (WB) in left ventricular 
myocardium from normal dogs and from dogs with experimental heart failure produced by 
rapid ventricular pacing at180 beats/min for 10 days.
Results: Furin digestion of ProBNP resulted in two protein bands with approximate 
molecular weights of 7000Da and 4000Da. Protein sequencing revealed that the lower 
band was mature BNP 1-32 while the higher band was NT-proBNP 1-76. To verify furin 
expression in the left ventricle where BNP is largely expressed, normal canine LV tissue 
was stained for furin, and protein staining was observed. WB analysis was performed with 
normal and heart failure ventricular tissue, and demonstrated an increase in ventricular 
furin expression by western blot analysis.
Conclusion: Our studies demonstrate that furin is expressed in ventricular myocardium 
where BNP production is increased in heart failure suggesting these two proteins may 
be co-localized to facilitate cleavage. We demonstrate that furin protein expression is 
significantly increased in the ventricular myocardium in canine heart failure which may 
lead to greater proBNP to mature BNP 1-32 processing. Finally, these studies establish 
for the first time that human ProBNP 1-108 is processed by furin in vitro to the mature 
BNP 1-32 peptide, suggesting proBNP processing may involve both corin and furin 
processing pathways.
9:00 a.m.
1002-21 Mitochondrial and Extra-Mitochondrial Mechanisms of 
Enhanced Reactive Oxygen Species Generation in the 
Aging Heart
Mohammed Yousufuddin, Andrew Oberlin, Claudia Cabrera Aguilera, Alireza Matloobi, 
Viqar Maria, Paul Takahashi, Arshad Jahangir, Mayo Clinic, Rochester, MN
Background:Enhanced ROS production potentially mediates the aging process. But, the 
mechanisms of ROS production in aging heart are unclear.
Methods: We measured H2O2 (myocytes) and O2· (mitochondria) production in association 
with genes for enzymatic pathways of ROS production and clearance in ventricles from 15 
adult (6-month) and 15 aged (24-month) Fischer 344 rats.
Results: Aged rats showed:i) enhanced H2O2 production at baseline and in response to 
Ouabain,ii) increase in mitochondrial O2· production,iii) significant (p<0.05) transcriptional 
changes (table and figure).
Conclusions: The multiplicity of mechanisms that lead to augmented ROS production by 
the aging heart probably account for a lack of effects of antioxidants for the treatment of 
age-related cardiac disease in clinical trials.
Microarray-based gene analysis
Transcripts Enzymes Gene Regulation ROS pathways
NOX2,XDH NADPH oxidase, Xanthine 
oxidoreductase
Up-
regulation
Extra-mitochondrial 
production
Mitrochondrial 
Electron Chain Multiple
Down-
regulation
Mitochondrial 
Production
GPX3 Glutathione peroxidase Up-
regulation ROS clearance
SOD1/2, TXN2 Superoxide dismutase, Thioredoxin
Down- 
regulation ROS clearance
9:00 a.m.
1002-22 Cardiac Differentiated Mesenchymal Stem Cells Protect 
Against Diastolic Dysfunction by Preventing Post-
Infarct Remodeling
Genevieve Tan, Ling Qian, Shi Qi Li, Yacui Gu, Yee Jim Loh, Yeow Leng Chua, Chong 
Hee Lim, Yoong Kong Sin, Terrance Chua, Tian Hai Koh, Eugene Sim, Philip Wong, 
Winston Shim, National Heart Center, Singapore, Singapore, National University of 
Singapore, Singapore, Singapore
Background: We investigate functional difference of differentiated and undifferentiated 
mesenchymal stem cells (MSCs) in a rat myocardial infarction model.
Methods: Cardiomyocyte-like cells (CLCs) were derived from sternum-isolated MSCs 
of 42 patients undergoing CABG. One million bromodeoxyuridine (BrdU)-labeled CLCs 
(n=12) or MSCs (n=9) or serum-free medium (n=10) were injected into the peri-infarcted 
regions of myocardium, 1 week after ligating the left anterior descending coronary artery 
of Wistar rats. Left ventricular (LV) function was compared at pre-and post-transplantation 
via echocardiography and Mikro-tip pressure-volume (PV) catheter at 6 weeks.
Results: Changes in wall thickness before and after cell transplant at interventricular 
septum (IVS)
end-systole and IVSend-diastole increased by 30.6 ± 13.6% and 8.2 ± 9.6% in 
CLC-treated and 25.5 ± 15.1% and 11.9 ± 9.7% respectively in MSC-treated animals, 
while medium-injected animals deteriorated by 9.0 ± 17.6% (p<0.005) and 5.1 ± 11.9% 
(p<0.05) respectively. LV dimension (LVD)
end-systole reduced by 4.5 ± 16.4% in CLC group as 
compared to an increase of 3.8 ± 15.6% and 25.1 ± 17.6% (p<0.05) in MSC transplanted 
and medium-injected groups respectively. PV analysis showed that CLC (56.7 ± 21.8%) 
and MSC (54.6 ± 18.8%) transplantation improved global LVEF when compared to 
medium-injection group (25.9 ± 4.0%, p<0.05). Consistent with enhanced systolic 
function, CLC (13685 ± 3871 mmHg/s) and MSC (12930 ± 5548 mmHg/s) transplantation 
improved dP/dt
max
, but not medium-injected animals (5363 ± 3305 mmHg/s, p<0.05). 
Engraftment of CLCs, but not MSCs, restricted expansion of end-diastolic volume (139.1 
± 45.2 uL vs. 164.1 ± 69.5 uL, p<0.05) and improved Tau tissue relaxation index (10.13 ± 
1.43 msec vs. 12.8 ± 4.6 msec, p<0.001) as compared to medium-injection.
Conclusions: Cell transplantation improves systolic function of infarcted myocardium. 
CLCs further protect against diastolic dysfunction by preventing negative LV remodeling. 
These differentiated cells may be more effective than undifferentiated stem cells in 
sustaining post-infarct recovery of myocardial function.
9:00 a.m.
1002-23 Physical Training Increases Circulating Progenitor Cells 
and Modifies Metalloproteinases Profile in Patients 
With Heart Failure
Lucia Gatta, Andrea Armani, Claudia Consoli, Caterina Mammi, Giuseppe Marazzi, 
Giuseppe Caminiti, Massimiliano Caprio, Stefania Gorini, Andrea la Sala, Maurizio 
Volterrani, Giuseppe Maria Rosano, IRCCS S.Raffaele, Rome, Italy
Background: Circulating adult stem cells are thought to exert beneficial effects on re-
endothelialization after endothelial injury. In the site of injury, metalloproteinases and their 
inhibitors play a role in extra-cellular matrix turnover and favor repair of vascular injury together 
with Tumor Necrosis Factor-α (TNF-α). This latter factor has been shown to play a critical role 
in maintaining the balance in extra-cellular matrix. Aim of the study was to assess the effect 
of a cardiac rehabilitation program on the magnitude of the mobilization of CD34/KDR, CD34/
CD117 and CD34/CXCR4 positive cells in the peripheral blood and the changes in serum 
Matrix Metallo Proteinase-9 (MMP-9) and Tissue Inhibitor of Metallo Proteinase-1 (TIMP-1) 
concentrations as well as levels of the pro-inflammatory cytokine TNF-α in New York Heart 
Association (NYHA) class II heart failure patients (HF). Methods: Blood and serum were 
collected from 15 patients (10 male and 5 female) with HF undergoing an in-patient cycle of 
cardiac rehabilitation. PBMC were analyzed by flow cytometry on admission and on discharge 
for CD34, KDR, CD117 and CXCR4 expression. The presence of MMP-9, TIMP-1 and TNF-α 
in serum samples was detected by ELISA before and after rehabilitation. Results: The 
number of CD34/CXCR4 (10.22±5.8 vs. 14.62±5.2; p<0.05) and CD34/CD117(0.54±0.4 vs. 
0.95±0.6; p<0.05) positive cells was significantly higher on discharge. After physical training, 
in 9 patients out of 15 we found an increase in the number of CD34/KDR positive cells (121%) 
and a reduction of serum TNF-α concentration (20%). Moreover on discharge, all patients 
showed a significantly decrease in TIMP-1 (381±44 vs. 164±13 p<0.001) concentration and 
consequent increase in MMP-9 serum levels (286±45 vs. 383±96 p<0.05). Conclusions: 
Physical training in patients with New York Heart Association class II HF induces mobilization 
of bone marrow stem cells and modifies serum concentrations of TIMP-1 and MMP-9 that 
may favor vascular repair and remodeling of extra-cellular matrix. These results underlie 
exercise-related beneficial effects in patients with heart failure.
9:00 a.m.
1002-24 Total Body Irradiation Accelerates the Onset of 
Coronary Sclerosis Resulting in the Degeneration Of 
Heart Structure and Function
John E. Baker, Brian L. Fish, Jidong Su, Steven T. Haworth, Jennifer L. Strande, Richard 
A. Komorowski, Raymond Q. Migrino, Anil Doppalapudi, John E. Moulder, Medical 
College of Wisconsin, Milwaukee, WI
Background: Radiologic threats exist but the impact on the cardiovascular system is 
still poorly understood. We determined the effect of total body irradiation (TBI) on lipid 
profile, coronary microvasculature, ventricular function and expression of NOS, thrombin 
and PAR-1 protein.
Methods: WAG/RijMCW male rats (4 weeks old) were subjected to 10 Gy TBI followed by 
bone marrow transplantation and recovery for 120 days. Non-irradiated rats served as controls 
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(n=6 per group). Lipid profile, microcomputed tomography derived density of coronary vessels, 
histology and myocardial NOS, thrombin and PAR-1 were compared. 2D strain echo was 
performed in the parasternal short axis to assess global radial and circumferential strain.
Results: TBI resulted in increased total and LDL cholesterol (190+18 vs. 53+4; 482+36 vs. 
48+7 mg/dl, p<0.001). There was 35% decrease in density of small coronary arterioles on 
CT. Histology revealed complete blockage of some of these vessels while cardiomyocytes 
remained normal. TBI resulted in cellular peri-arterial fibrosis whereas control hearts had 
symmetrical penetrating vessels with less collagen and fibroblasts. TBI resulted in a 32% 
and 28% decrease in eNOS and iNOS and a 53% and 35% increase in thrombin and 
PAR-1 protein after 120 days recovery. TBI treated rats also had reduced global radial 
strain (19+8 vs 46+7%, p<0.001) and circumferential strain (-8+3 vs. -15+3%, p=0.001) 
compared to controls.
Conclusions: TBI worsened lipid profile, resulted in coronary microvasculature injury, 
altered endothelial physiology and myocardial mechanics. TBI at a dose relevant to 
radiological terrorist threats cause degeneration of heart structure and function and 
accelerates coronary sclerosis.
9:00 a.m.
1002-25 Serum From Patients With Mild or Severe Heart Failure 
Induces Apoptosis of Adult Cardiomyocytes
Claudia Consoli, Lucia Gatta, Caterina Mammi, Giuseppe Marazzi, Stefania Gorini, 
Andrea la Sala, Andrea Armani, Maurizio Volterrani, Lionel NJL Marlier, Giuseppe M. 
Rosano, IRCCS S.Raffaele, Rome, Italy, National Research Council CNR, Rome, Italy
Background: It is known that apoptosis is associated with cardiovascular diseases and 
proinflammatory cytokines like Tumor Necrosis Factor-α (TNF-α) and Interleukin-1β 
contribute not only to cardiomyocyte loss by apoptosis, they also play a critical role in 
maintaining the balance in extracellular matrix remodeling, showing the importance of 
chronic inflammation in myocardial remodeling. We investigated if serum from New York 
Heart Association (NYHA) class I-II and III-IV heart failure (HF) patients could induce 
cell death in adult cardiomyocytes and factors involved in matrix remodeling. Methods: 
Murine cardiomyocytes HL-1 are incubated for 24 hours with 2% human serum from 
20 mild NYHA class: I to II , 20 severe NYHA III to IV and 20 healthy subjects. TNF-α, 
Matrix Metalloproteinase-9 (MMP-9) and Tissue Inhibitor of Metalloproteinase 1(TIMP-1) 
concentrations in serum was measured by ELISA. Apoptosis induced by human serum 
was detected by measuring DNA fragmentation and by flow cytometry using Propidium 
Iodide. Nonapoptotic cell death was detected by Cytotoxicity Detection Kit.Results: 
Our data showed that TNF-α concentration was significantly higher in serum sample 
from severe and mild patients compared to controls (P<0.001) and that TNF-α was 
significantly higher in serum samples from severe HF patients than mild HF (P<0.01). 
TIMP-1 concentration was higher in serum sample from mild patients compared to 
controls (P<0.05) and TIMP-1 was significantly higher in serum samples from mild HF 
patients than severe HF (P<0.01) and in consequence MMP-9 was significantly higher in 
serum samples from severe HF patients than mild HF(P<0.05). There was no difference in 
nonapoptotic cell death between all patients and control subjects. FACS analysis and cell 
death showed that significantly higher degree of apoptosis was elicited when serum from 
both severe and mild HF patients was used compared to serum from healthy subjects. 
Conclusions: Elevated levels of TNF-α in serum sample of HF patients are responsible 
for the increase of cell death in adult cardiomyocytes and the imbalance between TIMP-1 
and MMP-9 could be induce an alteration in extracellular matrix turnover.
9:00 a.m.
1002-26 Physical Training Reduces the Ability of Serum From 
Patients With Heart Failure to Induce Endothelial Cells 
Death
Caterina Mammi, Claudia Consoli, Lucia Gatta, Andrea la Sala, Massimiliano Caprio, 
Stefania Gorini, Andrea Armani, Giuseppe Caminiti, Giuseppe Marazzi, Maurizio 
Volterrani, Giuseppe M. Rosano, IRCCS San Raffaele, Roma, Italy
Background: Physical training improves endothelial function and exercise capacity in 
patients with heart failure (HF). Serum from patients with cardiovascular diseases shows 
increased ability to induce apoptosis of human endothelial cells potentially contributing 
to atherosclerotic lesion activation and endothelial dysfunction. Aim of this study was to 
evaluate the effect of cardiac rehabilitation on the pro-apoptotic properties of serum in 
patients with heart failure.
Methods: Human Umbilical Vein Endothelial Cells (HUVECs) were incubated with serum 
from 20 patients (15 male and 5 female) with HF before and after rehabilitation and 20 
healthy matched controls. For the quantification of apoptosis, fragmented DNA was 
determined by sandwich ELISA with antihistone-coated microtiter plates and peroxidase-
conjugated anti-DNA antibodies using Cell Death detection ELISA kit. Necrosis was 
evaluated measuring the lactate dehydrogenase released from the cytosol of damaged 
cells into the supernatant using a cytotoxicity detection kit.
Results: Serum from patients with heart failure showed a significantly greater ability to 
induce apoptosis (67 ± 4,6% vs 23 ± 5,2%, p<0,001) and necrosis (44 ± 3% vs 32 ± 2,1%, 
p<0,05) of HUVEC cells compared with that of controls. Compared to baseline, cardiac 
rehabilitation significantly reduced the ability of patient serum to induce apoptosis (67 ± 
4,6% vs 42 ± 4,4%, p<0,001) and necrosis (44 ± 3% vs 33 ± 2%, p<0,01) of HUVEC cells.
Conclusions: Serum of patients with heart failure has increased pro-apoptotic properties. 
Physical training reduces the ability of serum-contained factors to induce cell death of 
endothelial cells in patient with heart failure.
9:00 a.m.
1002-27 Uncoupling Protein 3 Decreases Oxidant Stress and 
Protects Against Anthracycline Cardiotoxicity
Raymond R. Russell, III, Monica Palmeri, Kerry S. Russell, Yale University School of 
Medicine, New Haven, CT
Background: Anthracycline cardiotoxicity is mediated, at least in part, by oxidant injury. 
Uncoupling proteins (UCPs), which regulate proton leak across the inner mitochondrial 
membrane, have been shown to decrease oxidant injury by exogenous oxidant stress 
(hydrogen peroxide) as well as oxidant stress caused by hypoxia/reoxygenation. We 
hypothesized that UCPs play a role in protecting against anthracycline cardiotoxicity by 
decreasing oxidant injury caused by the agent.
Methods: To test this hypothesis, wild type (WT) mice and mice with UCP3 knocked out 
(UCP3-/-) were treated with a single dose of 10 mg/kg doxorubicin intraperitoneally. Left 
ventricular function was evaluated echocardiographically at baseline and 1 and 2 weeks 
following doxorubicin injection.
Results: In keeping with published findings, this dose of doxorubicin had no effect on left 
ventricular fractional shortening in WT animals for up to 2 weeks after doxorubicin injection. 
In contrast, there was a significant decrease in fractional shortening in UCP3-/- hearts 
(Figure). The content of reduced glutathione (GSH) following doxorubicin treatment was 
significantly lower in UCP3-/- hearts than in WT hearts (WT: 219±34 nmoles/mg, UCP3-/-: 
112±10 nmoles/mg; p<0.01), indicating greater oxidant stress in the UCP3-/- hearts.
Conclusions: We conclude that UCP3 plays a protective role against the development of 
anthracycline cardiotoxicity by reducing the level of oxidant stress caused by the agent. 
9:00 a.m.
1002-28 The impact of n terminal pro natriuretic peptide (NT 
pro BNP) on Number Needed to Screen (NNS) by 
echocardiography for systolic dysfunction
Mohammad Albarjas, P. Morris, Devi Nair, Joseph Davar, Royal Free Hospital, London, 
United Kingdom, University College London, London, United Kingdom
Background: NT pro BNP is a highly sensitive neurohormonal marker for heart failure. In 
this study we assess its value as a screening tool for left ventricular systolic impairment 
in patients referred from the community to One Stop Heart Failure Clinics based on the 
Number Needed to Screen (NNS) by echocardiography.
Method: Patients referred by their GP with new onset symptoms and signs of LV 
impairment were assessed in a One Stop Heart Failure Clinic within 2 weeks of referral. 
All patients underwent a full cardiological assessment including echocardiography, ECG 
and measurement of NT pro BNP. Ejection fraction (EF) of 50% was used as a cut off 
value for impaired left ventricular function on echocardiography. Receiver Operator 
Characteristic (ROC) curve was used to determine the most sensitive and specific NT pro 
BNP level for impaired left ventricular function (EF<50%). Positive Predictive Value (PPV) 
& Negative Predictive Value (NPV) were calculated. The number needed-to-screen (NNS) 
was also calculated based on the prevalence of LVF in our cohort of patients, sensitivity 
and specificity of NT pro BNP.
Results: 220 patients were included in the study. The mean age was 66 years (18-92). 
99 (45%) of patients were females. From 220 patients investigated there were 46 (21%) 
patients who had EF less than 50%.
Based on results of NT pro BNP and echocardiographic assessment of LV function in the 
study group of patients ROC curve was constructed. Area under the curve was of 0.92.
The cut off value of NT pro BNP with maximum sensitivity and specificity (96% & 77%) 
was found to be 125pg/ml. The prevalence of LVF in our cohort of patients referred from 
the community was 21%. NNS applied to 100 patient model without NT pro BNP testing 
is 1/prevalence = 4.76 patients and with NT pro BNP is1.92. NNS was reduced further to 
1.7 when NT pro BNP and ECG were applied together.
CONCLUSION:
As NT pro BNP has very good sensitivity and NPV for impaired LV function, its use in 
the community in liaison with the One Stop Heart Failure Clinics reduces the number of 
patients needed to be screened significantly and more importantly assists the primary 
care physicians with better determination of the clinical probability prior to referral.
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1002-29 Effects of Rosiglitazone on Myocardial Structure, 
Function and Insulin Signaling
Indu G. Poornima, Teresa Hentosz, Laurie Machen, Lee Zourelias, Craig Truman, Siva 
Bhashyam, Richard P. Shannon, Gerald McGinnis Cardiovascular Institute, Allegheny 
General Hospital, Pittsburgh, PA
Background: Thiazolidinediones improve skeletal muscle insulin sensitivity through 
transcriptional events following binding to PPAR-γ receptors and direct activation of AMPK. 
However effects on cardiac muscle are unclear. The effects of chronic rosiglitazone (RG) 
therapy on myocardial insulin signaling, AMPK activity and associated structural and metabolic 
alterations were studied in hearts of obese, insulin-resistant, Zucker Fatty (ZF) rats.
Methods: Echocardiographic measures of LV structure and function were assessed at 
baseline and after 9 weeks of treatment with RG 4mg po qd (ZF-RG; n=10) or placebo 
(ZF-C; n=10). Plasma substrates and hormones, components of the insulin signaling 
cascade in sarcolemmal membrane and myocardial AMPK activity were measured.
Results: ZF-RG hearts were dilated and hypertrophied compared to ZF-C and plasma 
adiponectin levels were higher (see table). Myocardial AMPK activity was 4-fold higher 
in ZF-RG compared to ZF-C (57.3 ± 12 vs 12.74 ± 2.4 pmol ATP/mg/min, p<0.05). 
Correspondingly, Glut-4 translocation was higher in ZF-RG compared to ZF-C as shown 
by higher sarcolemmal membrane to cytosolic ratios (1.47 ± 0.4 vs 1.14 ± 0.5, p=0.03). 
Reduced Akt phosphorylation present in ZF-C was unaltered by RG.
Conclusions: RG increases adiponectin which activates AMPK preserving GLUT4 
translocation, independent of Akt phosphorylation. However, these changes are 
associated with eccentric hypertrophy, yet preserved systolic function. 
Variables ZF-RG ZF-C
0 weeks 9 weeks 0 weeks 9 weeks
LVEDD (mm) 8.0±0.7 9.0±0.3* 7.8±0.4 7.6±0.1
LV mass index (g/m2) 20.5±3.7 23±1.7* 20±1.5 19±1.7
LVEF (%) 85±3 88±5 88±2 88±4
Weight (gms) 908±47 977±40 867±46 931±37
Adiponectin(µg/ml) 5.5±0.2# 2.7±0.5
* =p<0.05 ; # =p<0.3 for difference between ZF-RG and ZF-C at 9 wks
9:00 a.m.
1002-30 Apelin Improves Right Ventricle Contractility in 
Response To Acute Pressure Overload in Pulmonary 
Hypertension
Inês Falcão-Pires, Nadia Gonçalves, Daniel Moreira-Gonçalves, Tiago Henriques-
Coelho, Adelino F. Leite-Moreira, Faculty of medicine, Physiology Department, Porto, 
Portugal, Portugal
Background: Apelin is a vasoactive ligand of APJ receptor. It’s expressed in the heart 
and lungs. Its cardiovascular functions include endothelium-dependent vasodilatation, 
positive inotropic effect and improves cardiovascular function in different HF animal 
models. This study evaluates the chronic effects of apelin on biventricular function in a 
model of pulmonary hypertension(PH) induced by monocrotaline(MCT).
Methods: Male Wistar rats were injected with MCT(MCT group, 60mg/Kg,sc) or 
vehicle(CTRL group,day 0). One week later, CTRL and MCT were randomly treated with 
Pyr-apelin-13(200µg/Kg/day, ip) or vehicle, resulting 2 new groups: AP and MCT+AP. At 
day 24, rats were instrumented to record RV peak systolic(Pmax) pressures, dP/dtmax, 
dP/dtmin and Tau. Also, isovolumic cycles were performed and Pmax_ISO and dP/
dtmax_ISO recorded to analyse the RV response to acute pressure overload(%change 
from basal cycles). Finally, heart and lungs were weighted and collected for morphometric 
and histological measurements.
Results: Table 1
Conclusions: Apelin decreases PH, RV hypertrophy and improves right ventricle (RV) 
diastolic function. Here, we first demonstrate that apelin significantly increases RV 
contractility in response to acute pressure overload as dP/dtmax_ISO is increased in 
the MCT+AP group. Morphometric results show absence of interstitial fibrosis and no 
reduction in the vessel wall thickness demonstrating that apelin mainly induces heart but 
not pulmonary vascular changes. 
9:00 a.m.
1002-31 Relationship between Metabolic Syndrome, 
Paraoxonase-1 activity and Cardiovascular Disease
Stephen J. Nicholls, Stanley L. Hazen, Tammy Bhattacharyya, Cleveland Clinic, 
Cleveland, OH
Background: The HDL associated protein paraoxonase-1 (PON) is reported to contribute 
to anti-inflammatory and anti-atherosclerotic effects of HDL. The relationship between 
metabolic syndrome components and PON activity is unknown.
Methods: Serum PON activity was evaluated by an arylesterase assay in 1399 
sequential patients presenting for diagnostic coronary angiography. The relationship 
between metabolic syndrome components, angiographic disease indices and adverse 
clinical outcomes were investigated.
Results: 39% of patients met criteria for metabolic syndrome. Within the entire cohort, 
serum PON activity was less in patients with the metabolic syndrome (329 v 345 units, 
p<0.001). A striking dose dependent association was noted between decreasing serum 
PON activity and increasing number of components of metabolic syndrome (p<0.001), 
or increased CRP (p<0.01). Evidence of significant angiographic CAD (stenosis >50%) 
was associated with lower levels of PON activity both in patients with (326 v 363 units, 
p<0.001) and without (344 v 365 units, p<0.01) the metabolic syndrome. Furthermore, 
higher subsequent incidence of major adverse cardiovascular events (death, myocardial 
infarction or stroke) over the ensuing 3 years was associated with lower baseline levels 
of serum PON activity in patients with (303 v 338 units, p<0.01) and without (309 v 360 
units, p<0.001) the metabolic syndrome. On multivariate analysis, serum levels of PON 
activity remained an independent predictor of adverse clinical outcome both in subjects 
with (OR 2.7 [95% CI 1.2-5.7], p=0.01) and without (OR 3.4 [95% CI 1.8-6.6], p<0.001) 
metabolic syndrome.
Conclusion: Reduced serum PON activity is observed in subjects with metabolic 
syndrome, independent of obesity status. Amongst subjects undergoing elective 
diagnostic cardiac catheterization, serum PON activity predicts presence of angiographic 
disease and prospective adverse clinical events in patients with and without the metabolic 
syndrome.
9:00 a.m.
1002-32 Systemic levels of the Carbamylation Product Protein-
Bound Homocitrulline predict outcome in patients with 
Chest Pain
Stephen J. Nicholls, Zeneng Wang, John M. Galla, Kellan E. Ashley, Melanie Bodine, 
Danielle Brennan, Stanley L. Hazen, Cleveland Clinic, Cleveland, OH
Background: Plasma levels of thiocyanate are increased in smokers. The 
myeloperoxidase (MPO)-H2O2-thiocyanate system catalyzes protein carbamylation at 
sites of inflammation, resulting in generation of atherogenic and pro-apoptotic species 
within human atherosclerotic lesions. MPO colocalizes with superficial erosions and 
culprit lesions of subjects with intracoronary thrombosis and sudden cardiac death. 
Herein we determined whether systemic levels of the carbamylation product protein 
bound homocitrulline (PBHCit) predicted outcome in patients with chest pain.
Methods: 553 consecutive patients presenting for evaluation of chest pain of < 4h 
duration and suspected ischemic etiology were studied. Plasma PBHCit levels were 
measured by tandem mass spectrometry and the relationship with subsequent major 
adverse cardiovascular events (MACE: death, myocardial infarction, hospitalization for 
angina and revascularization) over the ensuing 30 days was determined.
Results: Initial plasma PBHCit levels predicted risk of acute coronary syndrome (45 
v 34%, p=0.008) and incident MACE (46 v 33%, p=0.002). Similarly, PBHCit levels 
predicted increased risk for incident 30 day MACE amongst those with negative (<0.03) 
serial troponin T levels (24 v 13%, p=0.02). Remarkably, elevated plasma PBHCit levels 
predicted increased likelihood of 30 day MACE in both non-smokers (53 v 35%, p=0.01) 
and smokers (53 v 38%, p=0.09) alike, and independent of MPO and CRP levels. 
PBHCit level predicted greater rates of MACE in patients with MPO≥1000 pM (55 v 33%, 
p<0.001) but not <1000 pM (35 v 31%, p=0.66). On multivariate analysis, levels of PBHCit 
independently predicted the likelihood of 30 day MACE with the highest (v lowest) quartile 
associated with a 3.5-fold (95% CI 1.8-6.8, p<0.001) increased risk.
Conclusion: Systemic levels of PBHCit predict near term adverse cardiovascular 
outcomes independent of troponin levels, particularly in the setting of systemic 
inflammation. These studies suggest MPO catalysed protein carbamylation both serves 
as a marker of risk and a target for therapeutic modification in cardiovascular prevention 
strategies.
9:00 a.m.
1002-33 Low-Dose Metformin Therapy Improves Cardiac 
Function in a Murine Model of Heart Failure
Susheel Gundewar, John W. Calvert, Saurabh Jha, Liran Blum, Sang Yong Ji, Arun 
Ramachandran, Sandeep Patel, David J. Lefer, Albert Einstein College of Medicine, 
Bronx, NY
Retrospective clinical studies have shown that metformin reduces the severity of 
cardiovascular disease in patients with diabetes independent of its anti-hyperglycemic 
effects. We hypothesized that administration of low dose metformin exerts beneficial 
effects on cardiac function in a non-diabetic murine model of heart failure (HF). Mice 
were randomized into three groups and subjected to 60 min left coronary artery occlusion 
followed by reperfusion (Rep) for 24hr and 4 wk. At 24 hr, hearts were excised and 
evaluated for infarct size (INF) and area-at-risk (AAR) using Evan’s blue and 2,3,5-
triphenyltetrazolium chloride (TTC) staining. Metformin (125 µg/kg) was administered as 
a single i.v. bolus at the time of Rep or once at Rep and then as daily intraperitoneal 
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(i.p) injections. Saline was administered as a vehicle at Rep i.v and then daily i.p. High-
resolution, two-dimensional echocardiography was performed at baseline and 4 wk to 
assess left ventricular (LV) function. Metformin, given at the time of Rep reduced infarct 
size relative to the AAR by 30% (p < 0.001). However, the reduction in infarct size alone 
was not beneficial, as a single administration of metformin at Rep alone did not improve 
LV function at 4 wk post infarction. In contrast, daily administration of metformin coupled 
with the reduction in infarct size significantly improved LV function by 30% (p < 0.01) 
at 4 wk. These results indicate that continuous metformin therapy may prove to be an 
important therapeutic strategy in the treatment of HF. 
9:00 a.m.
1002-34 EPO induced neovascularization in heart failure is 
mediated through Vascular Endothelial Growth Factor
B. Daan Westenbrink, Willem Peter Ruifrok, Rudolf de Boer, Adriaan A. Voors, Dirk J. 
van Veldhuisen, Regien G. Schoemaker, Wiek H. van Gilst, University MedicalCenter 
Groningen, Groningen, The Netherlands
Background: Erythropoietin (EPO) improves cardiac function and induces 
neovascularization in chronic heart failure (CHF), which is associated with increased 
myocardial expression of Vascular Endothelial Growth Factor (VEGF). It is unknown 
whether VEGF is crucial for EPO induced neovascularisation.
Methods: CHF was induced in rats by permanent coronary artery ligation to induce 
myocardial infarction (MI), or sham surgery. Three weeks after MI, rats were randomised 
to receive EPO (darbepoetin alfa 40µg/kg/3weeks) or vehicle with or without intermittently 
antagonising VEGF with two distinct neutralizing antibodies (3 x per week in the first week 
after EPO) or irrelevant control IgG. After 9 weeks cardiac function, myocardial infarct 
size, cardiac capillary density and myocardial incorporation of endothelial progenitor cells 
was determined.
Results: EPO significantly improved cardiac function and increased cardiac capillary 
density (all p<0.01 vs untreated MI). These beneficial effects were however abrogated 
by intermittent inhibition of VEGF, while VEGF inhibition alone had no effects. (p= NS vs 
untreated MI). Transgenic labeling of bone marrow cells demonstrated that in addition to 
reducing in situ endothelial cell proliferation, VEGF inhibition attenuated homing of EPCs 
into the myocardial vasculature (p<0.01).
Conclusions: EPO induced neovascularization in heart failure is dependent on VEGF, 
which mediates in situ angiogenesis and homing of EPC into endothelium.
9:00 a.m.
1002-35 Decreased Antibody Responses to Influenza Vaccine in 
Heart Failure Patients
Orly Vardeny, Mary S. Hayney, Michelle A. Detry, Maryl R. Johnson, Walter G. Kao, Elaine 
M. Winkel, John JM Moran, Nancy K. Sweitzer, University of Wisconsin, Madison, WI
Background: Heart failure (HF) patients (pts) are at risk for influenza despite widespread 
vaccination. Both antibody and T-cell responses are important for protection. Responses 
to individual vaccine antigens (H1N1, B, H3N2), may offer additional information about 
efficacy. We explored antibody and T-cell mediated responses to the influenza vaccine 
and its individual component antigens in HF pts.
Methods: We studied 29 HF pts (9 ischemic, 20 non-ischemic) maximized on HF 
therapies and 17 healthy controls. Participants had phlebotomy before and after influenza 
vaccination. Antibody production was measured in serum by hemagglutination inhibition 
assay (HIA), and T-cell responses (via IFNγ and IL-10 production) were measured in 
isolated peripheral blood mononuclear cells (PBMCs) using ELISA.
Results: All participants demonstrated antibody seroprotection (Table), however HF pts 
had lower seroconversion rates (p<0.05). Antibody-mediated response to the newest 
vaccine antigen, H3N2, was reduced in HF (p=0.017). T-cell responses demonstrated 
higher IL-10 production in HF pts after vaccination (p =0.001), but similar IFNγ responses 
to healthy controls.
Conclusions: HF pts had reduced antibody responses to influenza vaccine, due to 
diminished response to new vaccine antigens. Seroconversion and antigen-specific 
responses may be better indicators of vaccine protection against influenza in HF pts. 
These data suggest immunological memory may be important in conferring protection 
in HF.
Healthy controls 
(N=17)
Heart failure 
(N=29)
Age (yrs) 49 ± 9 58 ± 13#
Sex (M / F) 10 / 7 22 / 7
Seroprotection (antibody titer ≥ 1:40) 17 / 17 (100%) 29 / 29 (100%)
Seroconversion (4-fold Δ in antibody 
levels) 14 / 17 (82.3%) 19 / 29 (65.5%)##
Antibody responses, by antigen 4-fold Δ)
H1N1 6 / 17 (35.2%) 9 / 28 (32.1%)
B 10 / 17 (58.8%) 13 / 28 (46.4%)
H3N2 11 / 17 (64.7%) 23 / 28 (82.1%)*
# Results are mean ± SD
## p< 0.05, Fisher’s exact
* p= 0.001 between heart failure and control groups, Wilcoxon rank sum test
9:00 a.m.
1002-36 Humoral Activation in Human Heart Failure: A Potential 
Contributor for the Progression of Heart Failure
Guillermo Torre-Amione, Keith A. Youker, Christian Assad-Kottner, David Chen, Nashwa 
Khalil, Carlos M. Orrego, Guillermo Torre-Amione, The Methodist DeBakey Heart 
Center, Houston, TX
Little attention has been paid on the role of humoral immunity and its contribution to heart 
failure (HF) progression. While studies have looked for the presence of specific antibodies 
(Abs) in the blood of HF patients, the mere presence of Fc receptors within cardiac tissues 
regardless of specificity may mediate detrimental effects through humoral mechanisms. 
To address this in HF patients we conducted two complementary experiments: first, we 
determined the presence of IgG deposition in failing myocardium regardless of specificity 
using conventional immunohistochemistry and second, we determined whether patients 
with chronic vs acute decompensated heart failure (ADHF) demonstrated differences in B 
cell activation using flow cytometry. In normal controls (n=5) there was no IgG deposition 
while in failing myocardium of patients requiring transplantation (n=40) we found 70% of 
the samples with pronounced IgG staining (see Figure). In the second study, 15 patients 
admitted to the hospital for ADHF had blood analyzed for CD69/CD19 expression at 
baseline, 48 hrs, 72 hrs and 6 weeks. Compared to the chronic HF patient, there was 
a 3 fold increase in the B cell activation during hospitalization for ADHF that returned to 
baseline 6 weeks after discharge (p<0.001). Taken together these findings support the use 
of strategies aimed to decrease antibody formation or deposition in human heart failure and 
that a humoral response may contribute to complications in the heart failure patient. 
9:00 a.m.
1002-37 Chronic Type V Phosphodiesterase Inhibition In a 
Canine Model of Severe Experimental Heart Failure 
Modulates More Genes in the Kidney than in the Heart
Brenda K. Huntley, John C. Burnett, Jr., Alessandro Cataliotti, Fernando L. Martin, Horng 
H. Chen, Mayo Clinic, Rochester, MN
Background: Type V phosphodiesterase (PDE V) metabolizes cyclic GMP and is found in 
both the heart and kidney. Previous studies demonstrated that PDE V inhibition (PDE VI) 
prevents and reverses cardiac hypertrophy. Our previous work suggests a beneficial role 
for PDE V in maintaining kidney function, particularly in combination with BNP. In order to 
explore the possible mechanisms of such favorable actions, we used microarray analysis 
to identify genes affected by PDE V in the heart and kidney.
Methods: Two groups of dogs with pacing induced overt CHF (240 bpm for 10 days) 
were studied; Group 1 received Sildenafil 50 mg po tid throughout pacing and Group 2 
received no PDE VI. Microarray analysis was performed on the heart and kidney tissues 
(Affymetrix GeneChip® dog Genome 230 2.0).
Results: Using a lower threshold of 1.5 fold change and a p<0.05 cutoff, 313 genes in 
heart and 752 genes in kidney were modified in CHF with PDE VI compared to CHF 
alone. Heart analyses revealed the following results: left atria 12 genes up/27 down; right 
atria 52 up/83 down; left ventricle 33 up/18 down; right ventricle 37 up/51 down. Kidney 
analyses were divided into kidney cortex genes (60 up/196 down) and kidney medulla 
(KM) (105 up/391 down). Cluster analysis demonstrated that the increased differential 
gene expression seen in KM with PDE VI places these samples more closely linked to the 
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expression profile of the heart tissues than the other kidney tissue expression profiles.
Conclusions: Our studies indicate that many genes are affected by PDE V in the setting 
of CHF. We show more than twice as many genes are modified in the kidney as in the 
heart, with most of these genes localized to the KM. Interestingly, the gene expression 
profile of the sildenafil treated KM was more closely related to the heart expression profiles 
than to the kidney expression profiles, suggesting modifications in KM gene expression 
by sildenafil leads to a more “heart gene expression like” KM and may provide clues to the 
heart:kidney connection pathways. Genes which are more similar between sildenafil KM 
and heart than kidney include members of the peroxisome proliferator-activated receptor 
pathway (PPAR) and genes belonging to the renin-angiotensin system.
9:00 a.m.
1002-38 Mesenchymal Stem Cells Transplantation Improves 
Regulation of Intracellular Calcium and Reduces 
Mortality in a Murine Model of Heart Failure
Mariana Pazzine, Luisa Macedo Braga, Kaleizu Rosa, Christiane Malfitano, Alessandra 
Medeiros, Silvia Lacchini, Patrícia Brum, Kátia De Angelis, Maria Cláudia Irigoyen, 
Nance Beyer Nardi, Heart Institute (InCor) University of Sao Paulo, Sao Paulo, Brazil, 
Federal University of Rio Grande do Sul, Porto Alegre, Brazil
Purpose: To evaluate long-term effects of the transplantation of mesenchymal stem 
cells (MSCs) in the cardiac function of mice with heart failure induced by sympathetic 
overactivity.
Methods: MSCs were obtained from the bone marrow of GFP-transgenic mice and 
expanded in vitro. Male mice knockout for α2A and α2C-adrenergic receptors with 3 months 
of age were divided in 3 groups: mice injected with culture medium (KOM; n=6), injected 
with MSCs (KOC; n=6) and not injected (KO; n=10). Culture-expanded MSCs and culture 
medium were injected intramuscularly at the left ventricle. After one year, cardiac function 
was evaluated by noninvasive echocardiography. The protein expression (n=3 each 
group) of cardiac sarcoplasmic reticulum Ca2+ pump (SERCA2), phospholamban (PLB), 
phospho-Ser16-PLB, phospho-Thr17-PLB, sodium-calcium exchanger (NCX), ryanodine 
receptor (RYR), phospho-Ser2809-RYR2, and phosphatases 1 and 2A were analyzed 
using Western blotting. Immunohistochemistry was performed to verify the presence of 
GFP-positive cells.
Results: From 5th to 9th month, all animals injected with culture medium died, 4 animals 
KOC (33% of mortality) and 4 KO survived (60% of mortality). KOC presented better ejection 
fraction compared to KO (KOC: 45.5 ± 2.8 vs. KO: 24.2 ± 2.0 %). Isovolumetric relaxation 
time was reduced in KOC in relation to KO (KOC: 14.0 ± 1.0 vs. KO: 22.3 ± 0.7 ms). Groups 
presented similar left ventricle mass (KOC: 23.4 ± 0.8 vs. KO: 23.0 ± 1.4 mg). The improvement 
of echocardiographic parameters was associated with an increase of Phospho-Ser16-
PLB expression (KOC: 1.22 ± 0.07 vs. KO: 0.97± 0.07 AU) and reduction of phosphatase 
1 expression (KOC: 0.70 ± 0.06 vs. KO: 1.03 ± 0.10 AU) in KOC as compared to KO. No 
differences were observed in other protein expression. Mice injected with MSCs presented 
specific GFP labeling in endothelial cells of capillaries, small arteries and small veins.
Conclusion: Intramyocardial transplantation of MSCs attenuates cardiac dysfunction and 
reduces mortality in a murine model of heart failure. This finding is not only associated with 
improvement in cardiac vascularization but also with adaptation of molecular mechanisms 
involving calcium release and recapture.
9:00 a.m.
1002-39 The Apolipoprotein A-I Mimetic Peptide L-4F Improves 
Cardiac Performance in Septic Rodents
Zhenghao Zhang, Andrew P. Miller, Yun Zhang, Mayakonda Palgunachari, GM 
Anantharamaiah, CR White, University of Alabama at Birmingham, Birmingham, AL
Background: Cardiac failure is a common cause of death in septic patients, and reduced 
plasma HDL is associated with increased mortality. Previous studies showed that 
elevating plasma apoA-I and HDL reduces sepsis complications. Objective: We tested the 
hypothesis that the apoA-I mimetic peptide L-4F, which possesses HDL-like properties, 
improves cardiac function in rats undergoing cecal ligation and puncture (CLP), a 
polymicrobial model of sepsis.
Methods: Male Sprague-Dawley rats were randomized to undergo CLP or sham surgery. 
CLP rats were further subdivided to receive saline injection or L-4F (10mg/kg, ip) 6 
hours after sepsis induction. Sham-operated rats received saline. Cardiac function was 
assessed by echocardiography before and 24 hrs after CLP. Plasma lipoproteins were 
analyzed by column chromatography.
Results: Left ventricular end-diastolic diameter and end-diastolic volume were significantly 
reduced in CLP rats compared to shams. While heart rate was slightly elevated, there was 
a significant decrease in right atrial pressure, stroke volume (SV) and cardiac output (CO). 
These results suggest that impaired LV filling is a principal factor underlying reduced 
CO in CLP rats. L-4F administration blunted changes in right atrial pressure and cardiac 
dimensions in CLP rats, thus improving SV and CO. L-4F administration also increased 
ejection fraction and fractional shortening. While total cholesterol (TC: 96± 4 mg/dl), HDL 
(80± 3) and LDL (11± 1) were similar in all rats at baseline, lipoprotein profiles were 
altered by CLP surgery after 24 hrs. TC was 51± 4 in CLP rats and was characterized by 
a reduction in HDL (23± 3) and an increase in LDL (23± 3). In contrast, L4F administration 
to CLP rats attenuated this shift in lipoproteins (TC: 67± 5/HDL: 43± 3/ LDL: 20± 2).
Conclusions: L-4F treatment in CLP rats improved cardiac function and increased HDL 
relative to saline controls. A cardioprotective mechanism for L-4F in CLP rats may be due 
to enhanced binding/neutralization of inflammatory components, such as endotoxin, by 
HDL, thus reducing the pro-inflammatory milieu of sepsis.
9:00 a.m.
1002-40 The Impact of Aldosterone Receptor Antagonism on 
Ventricular Remodeling After Myocardial Infarction: 
Effect on Gene Expression Profile
Rosemeire M. Kanashiro-Takeuchi, Bettina Heidecker, Joshua M. Hare, University of 
Miami, Miami, FL
Background: Aldosterone antagonists reduce mortality and improve post-myocardial 
infarction (MI) remodeling. Female sex steroids modulate the renin-angiotensin-aldosterone 
system, and in this regard we previously demonstrated enhanced functional response to 
eplerenone in females post-MI. Here we test the hypothesis that distinct molecular profiles 
accompany the responsiveness to eplerenone post-MI in female and male rats.
Methods: MI induced by coronary artery ligation or sham surgery was performed in female 
and male 6-month-old Wistar rats. Animals were randomly assigned to receive either a 
4-week course of eplerenone (100 mg/kg per day, in food) or placebo starting 3 days post-
surgery and up to sacrifice 4 weeks later. Transcriptomic analysis of the left ventricle of the 
heart was performed with the Rat 230 2.0 microarray (Affymetrix) and Spotfire.
Results:  We found that more than 450 genes were differentially expressed between 
the MI and sham group. A total of 397 and 201 genes in females and males respectively 
expressed significantly higher after MI; the overlap between these was 22 genes. In 
addition, MI resulted in impressive downregulation of 74 and 252 genes in females and 
males respectively, of these 69 were overlapping genes. After MI, 19% of genes that 
were downregulated and 44% of genes that were activated in females were restored 
to normal levels by eplerenone treatment. However, eplerenone induced only minor 
changes in males, affecting none of the genes that were downregulated and only 4% of 
the overexpressed genes.
Conclusions: The present data confirm previous findings at cardiac function level 
and strongly support a selective responsiveness of aldosterone receptor antagonist 
in females compared to males following MI; detectable at the level of differential gene 
activation. Accordingly, these findings highlight the idea that gene expression profiling has 
remarkable potential to elucidate physiological differences between sexes, and provide 
better information regarding response to therapy, and prognosis in heart failure.
9:00 a.m.
1002-40A Cardiac Chimerism Following Intramyocardial 
Mesenchymal Stem Cell Transplantation
Konstantinos E. Hatzistergos, Henry Quevedo, Behzad N. Oskouei, Juan P. Zambrano, 
Qinghua Hu, Ramesh Mazhari, Alan W. Heldman, Ian McNiece, Joshua M. Hare, University of 
Miami, Leonard M. Miller School of Medicine, Interdisciplinary Stem Cell Institute, Miami, FL
Background: Mesenchymal stem cells (MSCs) are a promising source of cells for cellular 
cardiomyoplasty. Whether these cells are capable of differentiation into fully functional and 
integrated cardiac myocytes remains highly controversial. Here, we test the hypothesis that 
MSCs repair cardiac injury through mechanisms that include myocytes differentiation.
Methods: To address this issue we injected syngeneic male, GFP labeled MSC (n=3) 
or placebo (n=3) into female pigs 3 days following MI. Two weeks later, hearts were 
evaluated for the presence of GFP+ cells, α-sarcomeric actinin, β1- Integrin, laminin, 
connexin-43, and Y chromosome (Y+).
Results: Retention of exogenous MSCs residing in the myocardium was demonstrated 
both by the presence of GFP and Y+ cells. Transplanted cells were present in clusters 
in infarcted (IZ) and border (BZ) zones of the treated group. Several immature GFP+ 
cells co-stained with a-sarcomeric actinin, indicating the potential of exogenous 
MSCs for cardiomyocyte differentiation. In addition co-expression of Connexin-43 and 
β1-integrin, demonstrated the ability of those cells for homing and engraftment in the 
hosted myocardium. Cardiac chimerism, defined as the existence of newly- formed and 
functional, Y+ cardiomyocytes in the female heart was confirmed by co- localization of Y+ 
with α- sarcomeric actinin, connexin-43 and laminin. Y+ cardiomyocytes were present 
in all injected hearts and were found in the IZ and BZ but not in remote zones. These 
cardiomyocytes formed gap junctions with native cardiac myocytes.
Conclusions: These findings demonstrate that MSCs have the capacity to differentiate 
into fully functional and integrated cardiomyocytes, and as such offer the potential for an 
exogenous source of cells for cellular cardiomyoplasty.
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1:00 p.m.
1009-1 Reduced LV Distensibility and Stroke Volume Response 
During Tilt Table Induced Changes in Preload in Elderly 
Patients with Heart Failure and Normal Ejection Fraction
Jerry M. John, Kathryn P. Stewart, Brian Moore, Dalane W. Kitzman, Wake Forest 
University Health Sciences, Winston-Salem, NC
BACKGROUND: Patients with heart failure and normal ejection fraction (HFNEF) are 
thought to have decreased LV distensibility resulting in decreased stroke volume and 
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cardiac output responses to exercise. However, exercise induces large concomitant 
increases in heart rate (HR) and systolic blood pressure (SBP) which can confound 
assessment of intrinsic LV distensibility. In contrast, orthostatic gravitational stress on a tilt 
table induces potent changes in preload with minimal change in HR and BP. METHODS: 
Following quiet supine rest, 59 elderly (age 70 yrs) patients with HFNEF and 28 healthy 
age-matched controls were subjected to 15 minutes of head-up tilt at +45° angle followed 
by 15 minutes of head-down tilt at -45°. After reaching equilibrium at each stage, 2-D echo 
was performed and later analyzed in blinded fashion for: end diastolic volume (EDV, ml), 
end systolic volume (ESV), stroke volume (SV), and cardiac output (CO). The % posture-
induced changes were compared using analysis of covariance.
RESULTS: Data are shown in table. Compared to controls, HFNEF patients had 
significantly reduced posture-induced % change in EDV, SV, and CO at each tilt stage. 
ESV responses were similar.
CONCLUSION: Elderly HFNEF patients had reduced EDV response to passive variations 
in preload, and this was associated with reduced SV and CO response. These data are 
indicative of decreased LV distensibility and suggest decreased ability to use the Frank-
Starling mechanism to increase cardiac output during stress. 
Variable Stage DHF (% change) Controls (% change) p-value
EDV Head Up -7 ± 2 -17 ± 2 0.003
EDV Head Down 8 ± 2 15 ± 2 0.020
SV Head Up -7 ± 3 -27 ± 2 0.003
SV Head Down 11 ± 3 21 ± 3 0.002
CO Head Up -6 ± 4 -34 ± 4 0.001
CO Head Down 1 ± 4 12 ± 4 0.040
ESV Head Up -5 ± 2 -7 ± 2 0.191
ESV Head Down 3 ±1 6 ± 2 0.557
HR Head-Up -8 ± 1 -9 ± 2 0.458
HR Head-Down 2 ± 1 2 ± 1 0.873
SBP Head-Up -3 ± 1 1 ± 1 0.050
SBP Head-Down 0 ± 1 0 ±1 0.753
1:00 p.m.
1009-2 Conditional, Activated Heat Shock Factor 1 Expression 
Causes Pathologic Hypertrophy and Heart Failure in Mice
Jeetendra Patel, Andras Orosz, Ivor J. Benjamin, University of Utah, Salt Lake City, UT
Background: Increased levels of several heat shock proteins exert cardioprotective 
effects against experimental ischemia/reperfusion injury but their pathophysiological 
relevance in human heart failure remains poorly defined. Heat shock factor 1 (HSF1), the 
major stress-inducible transactivator, binds to heat shock elements (HSE) embedded in 
the promoter of genes encoding heat shock proteins (HSPs) under stressful conditions 
and transactivates the synthesis of HSPs.
Methods: We generated a transgenic mouse model expressing cardiac specific, 
inducible, but constitutively active HSF1, mHSF1(+), whose transcriptional competency 
does not require stressors. Herein we have characterized a transgenic mouse line, 
termed mHSF1 (+) High Tg, with ~5-10 fold HSF1 level. HSF1 expression was induced 
by doxycycline (DOX) diet in double transgenic rtTA X mHSF1 (+) mice. Mice underwent 
echocardiography at baseline, 1 week and 3 weeks after DOX diet. In the DOX reversal 
group, mice that were fed DOX for 3 weeks were switched to normal chow for four weeks. 
Nontransgenic HSF1 littermates were used as controls
Results: At 1 week, DOX feeding of rtTA X mHSF1(+) High Tg mice increased (i) HSF1 
expression by ~5-10-fold, (ii) HSPs by ~1.2-5-fold, and (iii) cardiac hypertrophy by 28% 
(LVW/BW 7.0 + 1.1 vs 5.0 + 0.71 mg/g, p< 0.05). At three weeks, DOX fed mHSF1mice 
developed severe cardiac hypertrophy (LVW/BW 9.3 + 1.56 vs 5.2 + 0.76) and reduced 
left ventricular (LV) function compared with Non-DOX animals (EF 0.42 + 0.04 vs 0.69 + 
0.01, respectively). In contrast, cardiac hypertrophy ( LVW/BW 6.5 + 1.27 Vs 4.9 + 0.85) 
and LV dysfunction (EF 0.58 + 0.12 vs 0.71 + 0.05 DOX vs no DOX) were reversed when 
mice were switched to standard diet for four weeks.
Conclusions: Chronic HSF1 activation triggers robust HSP expression with ensuing 
pathologic cardiac hypertrophy and LV dysfunction, an entirely reversible phenotype in 
vivo. Our findings suggest that chronic stress activation involving HSF1 pathways may 
contribute to pathologic cardiac hypertrophy and heart failure. Ongoing studies involving 
explanted and post left ventricular assist device (LVAD) hearts are underway to test this 
hypothesis in human heart failure.
1:00 p.m.
1009-3 Dynamic Left Ventricular Remodeling In Vivo In 
Response To Pressure Overload Is Independent Of 
AMPK-alpha2 Activation
Biao Lei, David Chess, Karen O’Shea, William C. Stanley, University of Maryland 
Medical Center, Baltimore, MD
Background: AMP-activated protein kinase (AMPK) has been shown to be activated 
by acute metabolic stress and playing important regulatory roles in energy metabolism. 
However, it is still controversial whether AMPK is activated in chronic pathological 
conditions such as LVH and remodeling in vivo. To address this question, we studied the 
phosphorylation status of its alpha2 catalytic subunit at different stages of LVH.
Methods: Fifty-seven male adult C57BL6/J mice were randomly assigned to receive 
transverse aortic banding (TAC) or sham surgery. At the end of 2, 4, 6 and 8 postoperative 
wks, each batch (n=13-15) of mice were anesthetized and undergone echocardiography. 
Under ventilator support, pieces of the LV apex were cut off from the beating hearts and 
freeze-clamped immediately for enzyme analysis.
Results:TAC surgery resulted in significant increase of LV mass/tibia ratio (Figure, panel 
A) and end-systolic diameter (panel B). Interestingly, both indices trended for decrease 
from 6 to 8 wks, indicating utilization of compensatory mechanisms in vivo. Surprisingly, 
phosphorylation (activation) of AMPK-alpha2 (% of sham) was not increased by TAC, 
even trend to decrease at 2 wks (panel C). This was further supported by the unchanged 
phosphorylation status of acetyl-CoA carboxylase (ACC), a downstream target of AMPK.
Conclusions: Dynamic LVH and remodeling in vivo induced by pressure overload 
are dissociated with AMPK-alpha2 activation, indicating the involvement of other 
mechanism(s). 
1:00 p.m.
1009-4 Metformin Use is Associated with Markedly Lower 
Mortality and Hospitalizations in Patients with Heart 
Failure and Type 2 Diabetes
Matlooba A. ALZadjali, Simon A. Ogston, Josie MM Evans, Faisel Khan, A. D. Morris, 
Allan D. Struthers, Chim C. Lang, University of Dundee, Dundee, United Kingdom
Background: Recent problems related to the use of thiazolidinediones highlight the 
difficulties in managing diabetes in patients with congestive heart failure (CHF). An 
alternative and cheaper approach is to use the insulin sensitizer, metformin. This study 
aimed to evaluate the safety of metformin and to explore any evidence of benefit of its use 
in CHF in a large population prescription database study.
Methods: The Health Informatics Centre (HIC) dispensed prescribing database for the 
population of Tayside, Scotland (400,000 people) was employed. Subjects with incident 
CHF (n=774) between 1994 -2003 were identified through administrative medical 
records based on ICD-9 code 428, ICD-10 code-50. Subjects were grouped according 
to oral hypoglycemic agents into three study cohorts: metformin monotherapy (n= 90), 
sulfonylurea monotherapy (n= 381) and combination (n= 303). Cox regression model 
was used to assess differences in all-cause mortality, all-cause hospitalization and 
combination of all-cause hospitalization or mortality by estimation of relative risks.
Results: Average age of subjects was 74 yrs, 55% were male; subjects were followed for 
10 years. All cause mortality rates were lower among patients treated with metformin alone 
(60.0%) compared with those treated with sulfonylurea monotherapy (77.4%, p<0.0001). 
for one year mortality there were fewer deaths with metformin and combination group 
than with sulfonylurea monotherapy. After adjusting for confounding factors and propensity 
score, the adjusted risk ratio for metformin was 0.45 (95% CI 0.23-0.89, p<0.05) and 0.66 
(95% CI 0.46-0.96, p<0.05) for combination group. patients in metformin group had lower 
risk of hospitalization, with adjusted risk ratio of 0.74 (95% CI 0.57 to 0.96, p<0.05). 
Combined end points (all-cause hospitalization or mortality) was lower in metformin group 
compared to sulfonylurea monotherapy 0.74 (95% CI 0.56-0.99, p<0.05).
Conclusions: In this large observational of CHF patients treated with oral hypoglycemic 
agents, those treated with metformin alone or in combination were associated with a 
markedly lower risk of morbidity and mortality when compared to those receiving 
sulfonylurea alone.
1:00 p.m.
1009-5 Quantitative Analysis of Ventricular Remodeling as 
a Surrogate for Drug/Device Effects on Mortality in 
Patients With Heart Failure and Reduced Ejection 
Fraction: an Updated Analysis
Daniel G. Kramer, Thomas A. Trikalinos, David M. Kent, George V. Antonopoulos, Marvin 
A. Konstam, James E. Udelson, Tufts-New England Medical Center, Boston, MA
Background: We examined the correlation between effects of a drug/device on remodeling, 
and effects of the same therapy on mortality, in pts with LV dysfunction (LVD).
Methods: Intervention-specific odds ratios for death were calculated with meta-analytic 
techniques for all therapies that had ≥1 randomized placebo-controlled trial (RCT) of ≥ 
500 pts with mortality outcomes and ≥6 mos follow-up. We used meta-analytic methods 
to estimate the summary effect of these therapies on LV remodeling using all placebo-
controlled remodeling RCTs. We estimated correlations between remodeling effect and 
the summary odds ratios for death for each intervention.
Results: We included 30 large outcome RCTs of 24 distinct drug/device therapies 
(n=68,841; median follow-up 19 mos) and 89 remodeling trials (n=14,808; median follow-
up 6 mos). The odds ratios for death in the outcome RCTs were significantly correlated 
with drug/device effects on LV end diastolic volume (EDV; r=0.42, p=0.003), LV end 
systolic volume (r=0.31, p=0.05) and EF (r=0.50, p<0.001). (Figure: each data point 
represents placebo-corrected change in EDV from an individual remodeling trial plotted 
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against the mortality odds ratio for the specific therapy).
Conclusion: In pts with LVD, short-term trial-level therapeutic effects on LV remodeling 
correlate with longer-term trial-level effects on mortality. The data set will allow quantitative 
modeling to predict the likelihood of a new agent’s mortality outcome given a short-term 
remodeling effect.
1:00 p.m.
1009-6 Differential Impact of ACE Inhibitors (ACE-I) and 
Betablockers (BB) on Ejection Fraction and End 
Diastolic Dimension in patients with depressed left 
ventricular function
Sabha Bhatti, Abdul Hakeem, Adin A. Christian, Carrie B. Chapman, Maryl R. Johnson, 
Elaine M. Winkel, Walter G. Kao, Nancy K. Sweitzer, University Of Wisconsin Hospital 
and Clinics, Madison, WI
Background: Heart failure (HF) trials demonstrate mortality benefits of many therapies, 
but trials enroll patients (pts) unlike those in practice. We studied the effect of aggressive 
multi-modality HF therapy on outcomes in a referral HF clinic.
Methods: 245 consecutive pts with left ventricular (LV) ejection fraction (EF)<40% were 
studied. Data including clinical characteristics and outcomes at baseline, 12 +/-3 months 
after referral (FUP), and at last encounter were collected. Endpoints were change in EF 
,mortality, NYHA class, and LV size.
Results: Mean age was 55+/- 13 years; 75% were male. Mean and median time from 
HF diagnosis (41% ischemic;44% idiopathic) to referral was 3.4 +/- 5.3 and 0.7 years. 
Number of HF therapies at referral was 2.1+/- 0.7 and 3.0 +/-1.0 at FUP. At referral, 55% 
were NYHA Class III or IV. The 1-, 2- and 3-year survivals were 0.93+/-0.02, 0.87+/- 
0.04 and 0.75+/- 0.07 respectively. At FUP, 221 pts were alive (15 transplant, 3 VAD). Of 
surviving pts 16% were NYHA Class III or IV. Rise in EF was greatest in pts with recent 
HF diagnosis, but improved EF was seen even in pts distant from diagnosis ( EF 6.2%, 
p = 0.002, time since diagnosis > 4.9 years). In multivariate analysis, therapy with BB 
predicted EF improvement (p=0.01) while ACE-I predicted reduction in LV end diastolic 
size (EDD, p =0.0001).[Table]
Conclusion: Aggressive heart failure therapy improves symptoms and remodeling in an 
unscreened referral clinical population. Survival was excellent given severity of illness 
at referral.
Changes in Echocardiographic Parameters Between Referral and Follow Up
N Rferreal Followup Change P vale for Change
LVEF(%) 182 22+/-8 34+/-15 12+/-15 <0.0001
LV EDD (mm) 133 66+/-10 61+/-11 -5+/-10 <0.0001
LV Mass (gms) 87 276+/-83 256+/-100 -20+/-82 0.04
1:00 p.m.
1009-7 Clinical Value of Cystatin C for mild to moderate chronic 
heart failure in elderly patients
Yasuhiko MITSUKE, Hiroyasu Uzui, Akira Nakano, Takehiko Satoh, Katsuhiko 
Sarazawa, Reiko Nakaya, Takanori Ueda, Jong-Dae Lee, University of Fukui hospital, 
Yoshida-gun, Japan
Background: Renal function is an important prognostic factor in patients with chronic 
heart failure (CHF). Cystatin C, a novel marker of renal function, has been implicated as 
a prognostic marker in cardiovascular disease. We investigated the prognostic value of 
cystatin C in elderly patients with CHF (those age >75 years, all were serum creatinine 
<1.0mg/dl). Methods:We studied 72 consecutive elderly CHF patients (NYHA II-III, 38 
men, LVEF < 45%). Circulating levels of cystatin C, norepinephrine (NE), B-type natriuretic 
peptides (BNP), and cytokine (interleukin(IL)-1beta, IL-6, and tumor necrosis factor-alpha) 
levels were measured. Estimaed GFR were caliculated by the Cockcroft-Gault equation. 
Plannar 123I-meta-iodobenzylguanidine (MIBG) images were obtained from all patients, 
123I-MIBG was assessed as the heart-to-mediastinum ratio of the delayed image (H/M) 
and the washout rate (WoR) from the early to the delayed image. Patients were followed 
up for an average of 27.5months, and 19 of 72 patients had cardiac events (all death 
and rehospitalization due to worsening heart failure). Results: The mean (±SD) serum 
concentrations of cystatin C were 1.10 ± 0.31 mg/L. Patients with events had significantly 
lower H/M ratio compared with those without events, and had significantly higher cystatin 
C, WoR, NE, BNP, and IL-6. By multivariate Cox proportional hazard analysis, cystatin C 
and BNP were significant predictors for cardiac events in those patients. Conclusions:
These results suggest that Cystatin C are useful tools for the evaluation of those elderly 
patients with chronic CHF.
1:00 p.m.
1009-8 BAY 58-2667, a Soluble Guanylate Cyclase Activator, 
Improves Cardiopulmonary Hemodynamics in Acute 
Decompensated Heart Failure and has a Favorable 
Safety Profile
Harald Lapp, Veselin Mitrovic, Norbert Franz, Hubertus Heuer, Michael Buerke, Judith 
Wolfertz, Wolfgang Mueck, Sigrun Unger, Georg Wensing, Reiner Frey, HELIOS Clinic Erfurt, 
Erfurt, Germany, Bayer HealthCare AG, Pharma Research Centre, Wuppertal, Germany
Background: BAY 58-2667 is a soluble guanylate cyclase activator that acts independently 
of nitric oxide. Data from preclinical studies show that BAY 58-2667 preferentially dilates 
diseased vessels, without the development of tolerance.1 In healthy humans, this novel 
agent has a favorable safety profile and is well tolerated.2 
Methods: In this phase II study in patients with acute decompensated heart failure 
(ADHF; pulmonary capillary wedge pressure [PCWP] ≥ 18 mmHg) (n = 33), BAY 58-
2667 was evaluated using a starting dose of 100 µg/h, which could be titrated to doses 
between 50 µg/h and 400 µg/h, depending on the hemodynamic response. Hemodynamic 
parameters were measured by pulmonary artery catheter and impedance cardiography. 
Patients were categorized as responders if their PCWP decreased by ≥ 4 mmHg 
compared with baseline.
Results: Hemodynamic parameters at baseline were: PCWP, 25 mmHg; right atrial 
pressure (RAP), 13 mmHg; mean pulmonary artery pressure (PAP
mean
), 36 mmHg; 
systolic blood pressure, 119
mmHg; systemic vascular resistance (SVR), 1581 dyn·s·cm-5; heart rate, 76.7 beats/min; 
and cardiac index, 2.1 L/min/m2. Final doses of BAY 58-2667 after 6 h of infusion were: 
50 µg/h (n = 2); 200 µg/h (n = 12); and 400 µg/h (n = 16). Compared with baseline, a 6-h 
infusion of BAY 58-2667 reduced PCWP by 7.9 mmHg, RAP by 2.9 mmHg, PAP
mean
 by 
6.5 mmHg, systolic blood
pressure by 13.9 mmHg and SVR by 597 dyn·s·cm-5, while increasing heart rate by 4.4 
beats/min and cardiac index by 0.82 L/min/m2. The responder rate was 53% after 2 h, 
83% after 4 h and 90% after 6 h. BAY 58-2667 was well tolerated. Of the 33 patients, 
six individuals reported 11 adverse events of mild-to-moderate severity. There was one 
serious adverse event not related to the study drug.
Conclusions: These first clinical results with BAY 58-2667 in patients with ADHF 
demonstrate the potential of this new therapeutic principle. Continuous parenteral 
administration of BAY 58-2667 was well tolerated and induced potent arterial and venous 
vasodilation, which resulted in significant reductions in cardiac pre- and after-load and an 
increase in cardiac index.
1Stasch JP et al. J Clin Invest 2006;116:2552-61.
2Frey R et al. BMC Pharmacology 2007;7(Suppl.):P21.
1:00 p.m.
1009-9 The Effect of Immune Modulation Therapy on 
Endothelial Function in Patients with Severe Chronic 
Heart Failure: Data from the Advanced Chronic Heart 
Failure Clinical Assessment of Immune Modulation 
Therapy (ACCLAIM) Trial
Michael Shechter, Yaron Arbel, Micha S. Feinberg, Michael Eldar, Nira Koren Morag, Nava 
Eizenberg, Dov Freimark, Heart Institute, Sheba Medical Center, Tel Hashomer, Israel
Background: Chronic heart failure (CHF) is associated with abnormal endothelium-
dependent vasodilation. Immune modulation therapy (IMT) is a novel, non-pharmacologic 
approach to reduce inflammation and induce biological responses that may be beneficial 
in the treatment of CHF patients. The impact of IMT on endothelium-dependent flow-
mediated dilation (FMD) in severe systolic CHF patients has not been assessed.
Methods: In a prospective, double-blind, placebo controlled substudy of the Advanced 
Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM) 
Trial, 62 consecutive severe CHF patients [New York Heart Association (NYHA) class 
II-IV] with mean left ventricular ejection fraction (LVEF) 22±4% were randomized to 
receive IMT (n=31) or placebo (n=31) for ≥6 months. Following overnight fasting and 
discontinuation of all medications for ≥12 hours, percent improvement in endothelium-
dependent brachial artery FMD (%FMD) and endothelium-independent, nitroglycerin-
mediated vasodilation (%NTG) were assessed using high resolution (15 MHz) linear 
array ultrasound in all patients at baseline and at 26 weeks. Percent improvement was 
compared between groups, using repeated measures analysis.
Results: The two groups were comparable in regard to coronary artery disease risk 
factors, concomitant medications, LVEF, lipids, electrolytes, hemoglobin, NYHA class 
(II,III,IV: 3,24,4 vs 2,29,0 patients in the active and placebo groups, p=0.10; respectively), 
blood pressure and heart rate, fasting blood glucose and renal function tests. There were 
no significant differences in baseline %FMD and %NTG in the active group compared 
to placebo (9.5±6.7% vs 7.9±8.1%, p=0.39, and 13.6±8.1% vs 12.1±9.0%, p=0.49; 
respectively). While there was no change in %NTG, %FMD improved significantly after 
26 weeks in both active and placebo groups as compared to baseline (p=0.02); however, 
there was no significant difference in improvement between the two groups (p=0.45).
Conclusion: Although the sample size is small, IMT for 6 months did not significantly 
improve brachial artery endothelial function compared to placebo in patients with CHF 
due to severe left ventricular dysfunction.
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1:00 p.m.
1009-10 Long-term Survivals of Patients Admitted with 
Decompensate Heart Failure and Atrial Fibrillation. 
Chilean Heart Failure Registry (ICARO) Santiago Chile
Roberto Concepcion, Pablo Castro, Hugo Verdejo, Jose L. Vukasovic, Eduardo Garces, 
Luis Sepulveda, Silvana Llaveneras, Fernando Lanas, Chilean Society of Cardiology, 
Santiago, Chile
Background: Atrial Fibrillation (AF) is common cause of admissions and descompensation 
of patients with heart failure (HF). Role of AF in long-term survival in this population not 
been established in our country.
Objective: Identify role of AF in long-term survival of patient admitted with acute 
decompensate HF (ADHF).
Methods: Prospective registry from 17 Chilean centers. Patients with ADHF on admissions 
were incorporated between January 2002 and July 2007. Mortality at the end of follow-
up was obtained from certificate databases. Categorical variables were evaluated with 
chi cuadrado. Continues variables were evaluated with t student. We used Kaplan-Meier 
survival curves and Cox proportional hazards modeling to identify the significance of AF 
in long term prognosis of patients with ADHF.
Results: 1147 patients were included and followed for 634 (+-18 days). 17.7% have AF 
at admissions. In comparison with patients in Sinus Rhythm at admissions the patients 
were more older (67+-13.8 vs. 70+-13.4 years, p<0.02), the past history of valvulopathy 
were more frequent in AF group (21.1% vs. 33.0%, p<0.01). Diabetes Mellitus were more 
frequent in patients without AF (36.6% vs. 24.2% , p<0.01) Not difference was observed 
in sex distribution and prevalence of hypertension (43.6% vs. 49.2% and 72.3% vs. 72.4% 
, p=NS respectively). AF at admissions were independent predictors of mortality in patient 
with left ventricular ejection fraction (LVEF) < 50%. HR= 1.41 (OR 1.03-1.92).
Conclusion: AF at admissions was a independent predictor of long-term mortality in 
patient with ADHF an LVEF <50%.
1:00 p.m.
1009-11 Negative Impact Of Cardio-renal Anemia Syndrome On 
Beta-blocker Tolerance And Subsequent Major Adverse 
Cardiac Events In Chronic Heart Failure
Yoko Masukata, Kazuhiko Hashimura, Takahiro Ohara, Hideaki Kanzaki, Jiyoong Kim, 
Satoshi Nakatani, Masafumi Kitakaze, National Cardiovascular Center, Suita, Japan
Background: Recent evidence has shown that comorbid renal insufficiency and anemia 
in chronic heart failure were associated with poor prognosis. Although beta-blocker 
therapy has been widely accepted for the treatment of heart failure, effect of cardio-renal 
anemia syndrome (CRAS) on beta-blocker tolerance has not been well documented. 
Methods: From January 2001 to May 2007, consecutive 219 patients who admitted due 
to non-ischemic, non-valvular left ventricular dysfunction were retrospectively reviewed. 
16 patients revealed to have a CRAS, defined as creatinine clearance < 60 ml/min and 
hemoglobin content < 13 (men), 12 (women) g/dl. Patients were divided into two groups; 
Group A: with CRAS (16 patients), Group B: without CRAS (203 patients). Results: There 
were no differences in baseline characteristics including age, blood pressure, heart rate, 
and right/left ventricular ejection fraction (LVEF). Univariate analysis showed Group A 
was associated with higher BNP (540.3 ± 136.6 vs 228.1 ± 46.2 pg/ml, p<0.05), lower 
serum sodium (136.6 ± 0.8 vs 139.1 ± 0.3 mEq/L, p<0.005) and lower % Lymphocyte 
count (24.9 ± 2.4 vs 30.6 ± 0.8 %, p<0.05 ). Although there was an increase in LVEF after 
medical treatment in group B (from 26.1 ± 13.0 to 35.2 ± 15.9, p=0.01), no significant 
change in LVEF was noted in group A (from 25.9 ± 13.7 to 25.6 ± 11.2%, p=0.93). 
Kaplan-Meier analysis showed that Group A had a higher major adverse cardiac event 
(cardiac death, re-hospitalization, left ventricular assist device implantation, implantable 
cardioverter-defibrillator shock episode) rate (p=0.018). Moreover, Group A had a higher 
rate of intolerance to beta-blocker administration (intolerance ratio: 42 vs 12 %, p< 0.001, 
Carvedilol maintenance dose: 6.0 ± 1.9 vs 14.2 ± 0.7 mg/day, p<0.001). Conclusion: 
Patients with CRAS had a higher rate of intolerance to beta-blocker therapy and CRAS 
appears to have a negative impact on the subsequent poorer prognosis.
1:00 p.m.
1009-12 Identification of p17 Fragment of Caspase-3 as a Novel 
Circulating Marker for Acute Heart Failure in Humans
Michael Gavin, Jayne Schumacher, Mary Beth Barry, Michael Fucci, Kim Dodge, David 
Hager, Bruce T. Liang, University of Connecticut School of Medicine, Farmington, CT
Background: Heart failure (HF) is a medical condition of immense public health 
magnitude and is the leading Diagnosis Related Group for hospital discharge in the U.S. 
A reliable circulating biomarker that can detect acute HF and monitor the success of 
HF therapy would aid the clinical evaluation and treatment of HF. Caspase-3 is a final 
executioner of apoptosis and apoptosis is a major mechanism causing acute HF. We 
tested the hypothesis that the cleaved p17 fragment of caspase-3 (p17) can be detected 
in human circulation and is increased during acute HF.
Methods and Results: Using a solid phase enzyme-linked immunosorbent assay, p17 
was detected with an assay sensitivity that was 10 times the blank value. Further, the 
assay was linear with varying serum p17 levels, indicating the ability to quantify the 
fragment. The p17 level was significantly higher during acute HF (OD450: 0.153 +/- 0.02, 
SE) than under stable compensated condition (OD450: 0.10 +/- 0.01) (n=16 patients, 
Wilcoxon signed rank paired test, P<0.0001; paired t test P=0.0012). Acute HF was 
associated with significantly higher p17 level as compared to stable compensated state 
whether the etiology of HF was diastolic (EF: 59 +/-3%, SE, P<0.05, 5 patients) or systolic 
(EF: 20.4 +/- 3%, P<0.05, 11 patients). Conclusions: Caspase-3 p17 fragment can be 
detected in human circulation, is elevated during acute HF, and represents a potentially 
novel circulating biomarker for human HF. 
1:00 p.m.
1009-13 Statin Therapy and Heart Failure After an Acute 
Myocardial Infarction
Doron Aronson, Michael Kapeliovich, Rafael Beyar, Haim Hammerman, Walter 
Markiewicz, Rambam Medical Center, Haifa, Israel
Background: The development of heart failure (HF) after an acute myocardial infarction 
(AMI) portends poor outcome. Recent studies indicate that statins may be beneficial 
in HF. However, few data are available regarding the potential effect of statins on the 
development of post-infarction HF. In addition, previous studies did not consider important 
predictors of HF in AMI, such as left ventricular ejection fraction (LVEF), right ventricular 
(RV) function, and concomitant mitral regurgitation (MR).
Methods: We studied 1860 patients (pts) who were admitted with AMI and survived the 
index event. Echocardiography was performed within 7 ± 3 days from admission. The 
primary endpoint was first re-admission for HF, and pts were followed for a median of 
17 months (range 6 to 48). The relation statin therapy and the primary endpoint was 
evaluated using a Cox model, adjusting for age, sex, diabetes, hypertension, previous 
AMI, smoking, Killip class, ST-elevation MI, anterior MI, and coronary revascularization. 
We also adjusted for LVEF, RV function, and severity of MR. Patients was censored if 
recurrent MI occurred during follow up.
Results: Statins were prescribed at discharge in 1236 pts (66.5%). Re-admission for 
the treatment of HF occurred in 7.3% and 14.4% of pts with and without statin therapy, 
respectively. In a multivariable Cox model, statin therapy was associated with a significant 
reduction of admissions for HF (Table).
Conclusions:Statin therapy reduces the risk of hospitalization for HF after AMI.
Cox Model for Admission for HF in Patients Receiving Statins
Model Hazard Ratio (95% Confidence Interval) P value
Unadjusted 0.50 (0.37-0.67) <0.0001
Adjusted for clinical variables 0.69 (0.50-0.93) 0.016
Adjusted for clinical variables and 
echocardiographic parameters 0.61 (0.44-0.86) 0.005
1:00 p.m.
1009-14 Effects of levosimendan on plasma signaling molecules 
of oxidative and nitrosative stress, and cyclic GMP in 
patients with advanced heart failure
John Parissis, Ioanna Andreadou, Sophia Markantonis, Vasiliki Bistola, Asimina Louka, 
Gerasimos Filippatos, Efstathios Iliodromitis, Dimitrios Kremastinos, Attikon University 
Hospital, Athens, Greece, Department of Pharmacology, Greece
Background:Oxidative stress is associated with maladaptive cardiac remodeling and 
vascular dysfunction and may be an important contributor to chronic heart failure (CHF) 
deterioration. We sought to investigate if the calcium sensitizer levosimendan beneficially 
modulates circulating markers of oxidative and nitrosative stress thus lessening their 
deleterious effects in patients with advanced CHF.
Methods:Thirty-nine patients with advanced CHF (mean NYHA 3.5±0.4; ischemic/
dilated: 23/16; mean left ventricular ejection fraction: 26±7%) who were hospitalized due 
to syndrome worsening, were randomized (2:1) to receive either a 24-h levosimendan 
infusion of 0.1µg/kg/min (n=26) or placebo (n=13). Plasma b-type natriuretic peptide 
(BNP), circulating markers of oxidative [protein carbonyls, malondialdehyde (MDA)] and 
nitrosative (nitrotyrosine) stress, and cyclic GMP (cGMP) were measured at baseline and 
48h after each treatment.
Results:Baseline characteristics and medications were well balanced in the two 
treatment groups. A significant improvement in left ventricular ejection fraction (30±7 from 
26±7%, p<0.01), NYHA class (p<0.01), and plasma BNP (716±494 from 1089±541 pg/ml, 
p<0.01) was observed post-treatment only in the levosimendan group. Markers such as 
MDA (2.8±0.1 from 2.7±0.1 µmol/l, p=NS), protein carbonyls (3.9±0.6 from 3.6±0.7 nmol/
mg protein, p=NS) and nitrotyrosine (p=NS) remained stable in the levosimendan-treated 
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group, but significantly increased (MDA: 3.1±0.2 from 2.4±0.2 µmol,p<0.05; protein 
carbonyls: 5.6±0.6 from 3.2±0.3 nmol/mg protein, p<0.05; nitrotyrosine: 33±10.9 from 
25±8.4 nmol/l, p<0.05) in the placebo-treated patients. Neither therapeutic intervention 
changed the levels of circulating cGMP.
Conclusions:Levosimendan does not increase markers of oxidative and nitrosative 
stress in contrast to the placebo treatment, thus, exerting cardioprotective effects in 
advanced CHF patients. Moreover, levosimendan may exert its biologic action through 
non-cGMP-dependent biochemical pathways.
1:00 p.m.
1009-15 Bioimpedance Analysis and Body Weight in Detecting 
Asymptomatic Diuretic-induced Volume Changes 
in Stable Patients with Left Ventricular Systolic 
Dysfunction
Marie Jennyfer Ng kam Chuen, Gregory Y. H. Lip, Robert J. MacFadyen, City Hospital, 
Birmingham, United Kingdom
Background: Detecting asymptomatic trends to volume overload or dehydration could 
avoid hospital admission prior to decompensation in left ventricular systolic dysfunction 
(LVSD). Current means of volume assessment in LVSD are insensitive and there is a 
need for better non-invasive methods.
Methods: 26 patients (23 male; age 70.4 ± 7.4, range 55-82; left ventricular ejection 
fraction 24.7 ± 7.3 %, range 10-36; New York Heart Association class I-III; body mass 
index 26.7 ± 5.6 Kg/m2, range 17.9-38.6; 17 on furosemide 40 mg daily, 9 on furosemide 
80 mg daily) with stable LVSD were studied over a 7-day protocol. Patients took normal 
oral diuretic Day 1; diuretic was omitted Days 2, 3 and 4, and followed by an intravenous 
injection of 50 mg of furosemide on Day 4. Normal oral furosemide was resumed on 
Days 5, 6 and 7. Whole body, trunk and right lung bioimpedance analysis (BIA) (Bodystat 
Quadscan 4000®) and body weight (Wt) were measured on Days 1, 2, 3, 4 and 7.
Results (Table 1): All patients remained asymptomatic throughout the protocol. Wt 
increased non-significantly from Day 1 to Day 4 and fell from Day 4 to Day 7 (p=0.225). 
In contrast whole body, trunk and right lung impedance (Z) reduced during the diuretic 
withdrawal phase and increased following resumption of diuretics.
Conclusion: BIA is more sensitive than Wt in defining fluid shift in response to diuretic 
cessation and diuretic induced volume loss in stable LVSD. Larger studies to assess its 
use in the practical management of chronic LVSD patients are justified. 
Parameter n
Day 1
Baseline
Mean (SD)
Day 4
Diuretic withdrawal
Mean (SD)
Day 7
Diuretic resumption
Mean (SD)
p value
Weight (Kg) 26 81.2 (19.0) 82.9 (19.0) 82.1 (19.0) 0.225
d Z5KHz (Ω) 25 537 (91) 518 (81) 533 (84) <0.0001
d Z100KHz (Ω) 25 452 (82) 423 (99) 444 (74) 0.025
d Z200KHz (Ω) 25 430 (77) 415 (71) 422 (70) <0.0001
p Z5KHz (Ω) 25 121 (16) 117 (12) 118 (13) 0.001
p Z50KHz (Ω) 25 106 (15) 103 (11) 104 (12) 0.004
p Z100KHz (Ω) 25 101 (14) 98 (11) 99 (11) 0.007
p Z200KHz (Ω) 25 96 (14) 93 (10) 93 (11) 0.035
rl Z5KHz (Ω) 25 54 (8) 50 (9) 55 (11) 0.009
Table1. Body weight and significant bioimpedance analysis changes in response 
to diuretic-induced volume changes in stable patients with left ventricular systolic 
dysfunction.
d: whole body; p: trunk; rl: right lung; Z: impedance; 5-200 KHz: current frequency.
1:00 p.m.
1009-16 Relationship between Extracellular Matrix Turnover and 
Cardiac Structure and function in patients with Chronic 
Heart Failure
Anil Verma, Roberto Latini, John JV McMurray, Aldo P. Maggioni, Bertram Pitt, Margaret 
F. Prescott, Deborah L. Keefe, Scott D. Solomon, Brigham and Women’s Hospital/
harvard Medical School, Boston, MA
Background: Increased procollagen type III amino-terminal peptide (PIIINP), a marker of 
extracellular matrix (ECM) turnover and cardiac remodeling, portends adverse outcomes. 
However, relationship between PIIINP and cardiac structure and function in patients with 
chronic heart failure (CHF) has not been well defined.
Methods: 299 patients from the ALiskiren Observation of Heart Failure Treatment 
(ALOFT) study underwent echocardiographic assessment of cardiac structure, function 
and measurements of PIIINP, B-type natriuretic peptide (BNP) and NT-proBNP. We related 
plasma PIIINP to neurohormonal measures and echocardiography.
Results: In multivariable model including age, gender, BMI, diabetes, systolic BP and 
aldosterone blocker use, baseline PIIINP was related to mitral regurgitation (MR) jet/left 
atrial (LA) area [figure], NT-proBNP (both P<0.01) and BNP (p=0.034). There was no 
association between PIIINP and baseline left ventricular (LV) ejection fraction, LV volumes, 
LV wall thickness, LA volume or right ventricular fractional shortening (all p>0.10). 
Moreover, after 3 months of follow-up, aliskiren had no effect on PIIINP, but reduced 
PIIINP was associated with reductions in MR, E/E’ and NT-proBNP (all p<0.01), even after 
adjusting for baseline values and treatment group in addition to above variables. 
Conclusions: Improvement in PIIINP, a marker of cardiac ECM turnover, paralleled 
reduction in MR and improvement in Doppler measures of filling pressure in stable CHF 
patients.
1:00 p.m.
1009-17 Preoperative Beta Blocker Reduce Mortality in Systolic 
Heart Failure Patients Undergoing Coronary Artery 
Bypass Grafting But Not Those With Normal Ventricular 
Function
Jun R. Chiong, Susan J. Krider, Tricia Aguilar, Terence Lin, Nan Wang, Anees J. 
Razzouk, Nahidh W. Hasaniya, Loma Linda University, Loma Linda, CA
Background: Clinical trials have shown the efficacy of beta-blocker (BB) therapy for 
coronary artery disease and systolic heart failure (SHF). Although BB is recommended for 
patients undergoing coronary artery bypass grafting (CABG), a North American Cardiac 
Surgery Registry reported that BB use was associated with worse outcomes in SHF. The 
incorporation of BB in the latest heart failure guidelines warrants further investigation of 
BB therapy in SHF patients undergoing CABG.
Our objective was to study the effect of beta-blockers on hospital mortality and 30-day 
mortality in patients with systolic heart failure (EF <40%) and patients with normal ejection 
fraction (EF >60%) undergoing CABG.
Methods: Between July 1993 and June 2007, 4908 patients underwent isolated CABG surgery 
at Loma Linda University Medical Center, CA. Using our cardiothoracic surgery database, 
patients were stratified by EF (<40% and >60%) then by preoperative beta blocker use.
Results: 1366 patients had systolic heart failure with EF <40%: 636 patients were on BB 
and 730 were not. Both systolic heart failure groups were similar in EF, gender, history of 
myocardial infarction, diabetes mellitus, renal failure, smoking and chronic lung disease. 
Systolic heart failure patients on beta-blockers were older, more hypertensive, and more 
often on ACE inhibitors and aspirin.
Hospital mortality for those with systolic heart failure (EF<40%) with and without beta-
blockers was 2.0% vs. 5.20% (p=0.002). The 30-day mortality was 2.83% vs. 6.16% 
(p=0.011), respectively. In comparison, hospital mortality and 30-day mortality for those 
with normal systolic function (EF>60%) with and without beta blockade was 0.3% vs. 
0.7% (p=ns) and 0.64% vs. 1.43% (p=ns), respectively.
Conclusions: CABG was associated with higher mortality among patients with systolic 
heart failure. However, preoperative beta-blockade was associated with significantly 
reduced hospital mortality and 30-day mortality in systolic heart failure patients undergoing 
CABG but not in patients with normal left ventricular ejection fraction. Patients on beta 
blockers were also more likely to be hypertensive and on Aspirin and ACE inhibitors.
1:00 p.m.
1009-18 The Combination of beta-1 Arginine389 and 
alpha-2cDeletion322-325 Adrenergic Receptor 
Polymorphisms Demonstrate the Greatest Improvement 
in Left Ventricular Ejection Fraction on Beta-blockade 
Therapy in the African American Heart Failure 
Population
Ronald Zolty, Mona Cantu, Benjamin D. Horne, JoAnn Lindenfeld, Simon S. Shakar, 
Eugene E. Wolfel, Andreas Brieke, Brian D. Lowes, Michael R. Bristow, Montefiore, 
Bronx, NY, UCHSC, Denver, CO
Background: Despite clear benefits of β-blockade in heart failure (HF), clinical response 
to β-blockers displays a high degree of inter-individual variation. Underlying genetic 
variation in adrenergic mechanisms is one potential explanation for this variability in 
response. Certain β1 (specifically at amino acid position 49 and 389) and α2c (deletion 
322-325) AR polymorphisms have been shown to act as disease modifiers in HF. The 
combination β1 Arg389 and α2cDel322-325 in African American (AA) patients was shown to act 
synergistically and increase the risk of developing HF. We hypothesized that patients with 
this genotype combination would respond most markedly to β-blockade therapy.
Methods: In this retrospective study, 66 AA HF patients with LVEF ≤ 40% from any 
etiology were selected from the HF Clinic at the University of Colorado Hospital. The 
subjects had an echocardiogram before and after 12 months of metoprolol or carvedilol 
therapy. ANOVA was performed to determine the effect of genotypes and other variables 
on changes in LVEF in response to β-blockade therapy. 
Results: The association between the different β1 and α2c AR combinations and change 
of LVEF is shown in table. The difference between the Arg389 homozygous/α2cDel322-325 
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carrier group and other combination groups was highly significant (P-value = 0.002).
Conclusions: AA HF patients with the combination β1 AR Arg389 homozygous/α2cDel322-
325
 carrier show greater improvement in LVEF on β-blockers compared to all other 
combinations.
Table
β1 and α2c AR polymorphism combinations
LVEF Improvement on β-blocker (in 
%EFUnit)
Gly389 carrier/α2c wild type homozygous 
(n=19) 2±15%
Arg389 homozygous/α2c wild type homozygous 
(n=7) 4±15 %
Gly389 carrier /α2cDel322-325 carrier (n=26) 4±15 %
Arg389 homozygous/α2cDel322-325 carrier (n=14) 19±14%*
1:00 p.m.
1009-19 Impact of age and gender on left ventricular diastolic 
performance and filling pressure
Michio Imai, Hiroshi Ito, Katsuomi Iwakura, Atsunori Okamura, Toshiya Kurotobi, Yasushi 
Koyama, Motoo Date, Yoshiharu Higuchi, Koichi Inoue, Hiroyuki Nagai, Yuko Toyoshima, 
Yoh Arita, Makito Ozawa, Norihisa Ito, Yukinori Okazaki, Masahiko Shibuya, Kenshi Fujii, 
Sakurabashi Watanabe Hospital, Osaka, Japan
Background:It is reported diastolic heart failure (HF) is more frequently observed in 
female than male in the elderly patients. The aim of this study was to investigate the 
impact of age and gender difference on left ventricular (LV) morphology and diastolic 
performance.
Methods:The study population consisted of consecutive 882 patients with >50 years old 
and LVEF>50%. They were divided into 4 groups based on age (50-59, 60-69, 70-79, 80- 
years old). We measured relative wall thickness (RWT), peak-E velocity, deceleration time 
of E wave (DT), peak early diastolic mitral annulus velocity (e’). E/e’ ratio was measured 
as an estimate of LV filling pressure.
Results:The e’ velocity decreased, and E/e’ ratio increased with aging. Although e’ 
velocity was comparable between men and female, the E/e’ ratio tended to be higher in 
female than male in each age group, but it did not reach statistical difference.
Conclusions:1) LV relaxation ability reduces and LV filling pressure increases with 
aging. 2) There was no significant difference in LV morphology and diastolic parameters 
between male and female in each age group. Factors other than cardiac morphology 
or function, such as nueurohumoral factors, may explain the gender difference in the 
occurrence of diastolic HF.
* p<0.05 Female vs. Male
Age, years, (n) 50-59(n=158) 50-59(n=158) 60-69(n=255) 60-69(n=255) 70-79(n=313) 70-79(n=313) 80-(n=156) 80-(n=156)
Gender,n
Female 
n=31
Male 
n=127
Female 
n=69
Male 
n=186
Female 
n=109
Male 
n=204
Female 
n=68
Male n=78
RWT 0.43±0.07 0.44±0.11 0.46±0.08 0.45±0.09 0.46±0.09 0.45±0.07 0.47±0.08 0.46±0.08
MR>2, % 13 9 19* 8 17 13 40* 18
E, m/s 0.68±0.29 0.61±0.18 0.62±0.21 0.57±0.19 0.62±0.26 0.58±0.23 0.62±0.26 0.61±0.27
DT, msec 202±63 206±57 234±68 222±59 228±80 224±61 229±74 233±78
e’, cm/s 7.0±2.2 6.6±1.7 6.0±1.8 5.7±1.5 5.4±1.6 5.4±1.4 5.1±1.7 4.9±1.7
E/e’ ratio 11.5±8.4 9.6±2.6 11.0±4.0 10.9±5.0 12.6±7.1 11.4±5.2 13.1±6.7 13.0±6.2
1:00 p.m.
1009-20 Effects of the Selective Adenosine A1 Receptor 
Antagonist KW-3902 in the Treatment of Patients With 
Acute Heart Failure and Renal Impairment: Results of 
the PROTECT Pilot
Christopher M. O’Connor, Barry Massie, Beth A. Davison, Marco Metra, Gad Cotter, 
Howard C. Dittrich, Duke University Medical Center, Durham, NC, San Francisco VA, 
San Francisco, CA
KW-3902 (rolofylline), an adenosine A1 receptor antagonist was shown in Phase II studies 
to facilitate diuresis in patients (Pts) with acute heart failure (AHF) and renal dysfunction
Methods: PROTECT is a prospective randomized study in AHF Pts, estimated creatinine 
(Cr) clearance of 20-80 ml/min and BNP ≥250 or NT Pro BNP ≥1000 pg/ml. 301 Pts 
were randomized in the pilot phase to placebo, 10, 20, or 30 mg of IV rolofylline given 
during 4 hours, for 3 days. The primary endpoint was the categorization of Pt response 
as Unchanged, Success (moderate or marked improvement in dyspnea and MD 
determination that IV diuretics could be stopped) or Failure (death, worsening HF or 
worsening renal function [Cr increase of ≥ 0.3 mg% at discharge or day 7])
Results: We observed a non significant trends towards less Failure and more Success 
in the rolofylline arms. Median weight loss at 72 hrs was 1 Kg in placebo and 2 Kg in the 
active arms. Dyspnea improvement at 24 hours occurred in 51%, 62%, 63% and 66% of 
Pts on placebo, 10, 20, and 30 mg. Cr changes at day 14 were +0.21±0.83, +0.13±0.54, 
+0.03±0.42 and -0.04±0.27 mg/dl respectively (p<0.05 for change in 30 mg vs placebo). 
Figure depicts re-admission for HF and death at 60 days (first secondary endpoint; p= 
0.12 for trend, 0.16 for placebo vs 30 mg). Conclusions: These findings support the 
epidemiological evidence that preservation of renal function in AHF may provide longer 
term benefit and that rolofylline may prove beneficial in AHF. The definitive PROTECT trial 
is underway with the 30 mg dose.
1:00 p.m.
1009-21 Changes in GFR, BUN and BUN/Creatinine During 
Treatment of Heart Failure and Volume Overload With 
Ultrafiltration or Intravenous Diuretics
Bradley A. Bart, James C. Fang, Maya Guglin, Karl Hibler, Michael P. Schollmeyer, Maria 
Rosa Costanzo, Hennepin County Medical Center, Minneapolis, MN, Midwest Heart 
Foundation, Lombard, IL
Background: Increased creatinine (Cr) during hospitalization for heart failure (HF) 
is associated with poor outcomes. Estimates of GFR may represent a more accurate 
description of renal function. We sought to describe changes in GFR, BUN and BUN/Cr in 
pts enrolled in UNLOAD receiving ultrafiltration (UF) or standard care (SC).
Methods: GFR (estimated using the modification of diet in renal disease (MDRD) 
formula), BUN and BUN/Cr were assessed at baseline, 24 hours, 48 hours and at 
discharge. Differences between treatment groups and changes over time in GFR, BUN 
and BUN/Cr within groups were tested. Correlations between changes in GFR, BUN and 
BUN/Cr and fluid loss were calculated.
Results: There were no differences between groups at any time in GFR, BUN or BUN/Cr. 
20% of pts in both groups developed GFR<60mL/min. Changes in BUN and BUN/Cr 
were greater in the UF group at 48 hours, but this difference was no longer present at 
discharge (see table). There was no correlation between changes in GFR, BUN or BUN/
Cr and net fluid removal. Changes in GFR, BUN and BUN/Cr per liter of net fluid removed 
were similar in the UF and SC groups at 24hr, 48hr and discharge. Conclusions: UF 
produces greater volume reduction than IV diuretics in HF pts without greater decreases 
in GFR or in the percent of pts with a fall in GFR below 60mL/min. The lack of correlation 
between amount of fluid removed and GFR, BUN or BUN/Cr suggests mechanisms other 
than volume depletion cause worsening renal function in HF pts during volume overload 
treatment.
*p<0.05 UF vs SC
Ultrafiltration Standard Care
Baseline d24hour d48hour dDischarge Baseline d24hour d48hour dDischarge
GFR(mL/min) 58.6(25) 0.7(11) -1.0(16) -3.4(13) 59.3(27) -0.9(11) -2.5(14) -2.8(17)
BUN (mg/dL) 32.1(16.2) 2.1(6.3) 6.0(10.1)* 6.2(13.1) 33.3(20.3) .97(4.9) 2.3(9.1) 6.9(15.6)
BUN/Cr 21.7(9.5) .76(3.8) 2.0(6.2)* 2.8(7.1) 22.2(9.4) .59(4.3) .69(5.4) 3.6(7.4)
1:00 p.m.
1009-22 Prognostic Advantage of Combined Analysis of 
Cystatin C and NTproBNP in Patients with Heart Failure
Piotr J. Rozentryt, Jolanta U. Nowak, Regina Deja, Aleksandra Chmura, Anna John, 
Jacek Sikora, Wiesława Bartnik, Lech Poloński, Stefan D. Anker, Silesian Centre for 
Heart Diseases, Zabrze, Poland, Applied Cachexia Research, Berlin, Germany
Background: The kidney and the heart are functionally tightly interrelated. Kidney 
dysfunction worsens heart function what leads to reduced kidney perfusion and 
diminishes GFR. Cystatin C and NTproBNP are respective biochemical markers 
of performance of these organs and both compounds were shown to be powerful 
independent prognosticators in HF. For prognostic purposes combined analysis of kidney 
and heart function might be superior to their separate assessments. We wanted to check 
prognostic performance of combined as compared to separate analysis of cystatin C and 
NTproBNP in patients with HF.
Methods: In 555 patients with HF (age: 54±10 years, 13% female, EF: 25±7%, 
NYHA: 2.5±0,8, ischaemic ethiology in 80%) we assessed NTproBNP and cystatin C 
(nephelometry). Patients were optimaly treated acording to current guidelines. Patients 
were followed for median 602 days ( 21 to 1660 days) and all-cause mortality was 
recorded. During follow-up 113 patients (20%) have died. We have calculated proportional 
hazard ratios (Cox model) for upper and lower tertiles of each marker and markers 
combination and compared Kaplan-Maier survival curves (log-rank test) for tertiles of 
cystatin C, NTproBNP and both markers respectively. Prognostic performance of separate 
and combined markers ware further analysed using receiver operating characteristics.
Results: Patients falling into upper tertiles of cystatin C, NTproBNP and combination 
of these two were more likely to die with hazard ratio of 3.3, 95%CI 2.0-5.5, p<0.0001, 
4.1, 95%CI 2.4-7.0, p<0.0001, and 10.6, 95%CI 4.2-26.9, p<0.0001, respectively. Areas 
under the ROC functions were: cystatin C: AUC=0.627, 95%CI - 0.585-0.668, p=0.0001, 
NTproBNP: AUC=0,649, 95%CI - 0.607-0.689, p=0.0001, cystatin C and NTproBNP; 
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AUC=0.733, 95%CI - 0.662-0.796, p=0.0001. AUC for combined analysis was significantly 
higher then AUC for cystatin C (p=0.027) and higher with borderline significance then 
NTproBNP (p=0.067).
Conclusions: Prognostic value of combined analysis of cystatin C and NTproBNP may 
be superior to separate assessment of these markers.
1:00 p.m.
1009-23 Patients With Dilated Cardiomyopathy Who Have 
Recovered Normal Ventricular Function Remain at 
Increased Risk for Sudden Death
Philip F. Binkley, Haseeb Jafri, The Ohio State Univeristy Heart and Lung Institute, 
Columbus, OH, The Ohio State University Division of Cardiovascular Medicine, 
Columbus, OH
Background: Patients with dilated cardiomyopathy (DCM) are at increased risk for sudden 
cardiac death (SCD). It is not known whether recovery of normal left ventricular systolic 
function (LVF) eliminates this risk. Microvolt T Wave Alternans (MTWA) is associated 
with an increased risk of SCD, and its absence has a 90% negative predictive value for 
SCD. Hypothesis: Patients who have a history of DCM and have recovered normal LVF 
(EF >40%) in response to medical therapy remain at risk for SCD.Methods: 21 patients 
were identified as having a history of DCM as well as a MTWA test result. Of these, 
13 had recovered normal LVF. The rate of non-negative MTWA tests in these patients 
was compared with the expected frequency of non-negative tests in normals ( 11%) 
and with patients with DCM who did not recover normal LVF. Results: Of the patients 
who recovered normal LVF, 4 were found to have a non-negative test result (p < 0.05 
compared to expected). The proportion of non-negative tests in patient with recovered 
LVF did not differ from that in patients with DCM who did not regain normal LVF(Chi-
Square p = 0.78). The odds of a non-negative test did not differ between the two groups 
when adjusting for age, gender, race or etiology of DCM.
Conclusion: These findings suggest the risk of SCD persists in patients with DCM 
despite restoration of normal ventricular function in response to medical therapy. This 
patient population should be carefully evaluated for the risk of SCD through non-invasive 
and potentially invasive means.
Microvolt T Alternans vs LV Function
Non-Negative Negative Total
Not Recovered 3 5 8
Recovered 4 9 13
Total 7 14 21
1:00 p.m.
1009-24 The β2 Adrenergic Receptor (ADRB2) Gln27Glu 
Polymorphism Affects Fasting Insulin, Insulin 
Resistance, and Beta Blocker-Mediated Differences in 
Glucose Dynamics in Patients With Heart Failure
Orly Vardeny, John JM Moran, Maryl R. Johnson, Nancy K. Sweitzer, University of 
Wisconsin, Madison, WI
BACKGROUND: Insulin resistance (IR) and heart failure (HF) commonly co-exist and 
choice of beta blocker may influence IR. Relative β2 adrenergic receptor (ADRB2) 
density is increased in HF due to β1 downregulation Previously we showed ADRB2 
polymorphism effects on glucose production in HF. We hypothesized that the ADRB2 
Gln27Glu polymorphism would influence IR and that choice of beta blocker would modify 
this effect.
METHODS: We studied 30 non-diabetic HF patients (21 male, 9 female) titrated to 
maximal beta blocker doses. We measured fasting glucose, insulin, and IR using the 
HOMA-IR equation. Genotyping used PCR and pyrosequencing at codon 27. Regression 
analyses were used to test for genotype/beta blocker interactions.
RESULTS: Mean age was 57.8±15. Etiology was ischemic (N=11) or non-ischemic 
(N=19); ejection fraction was 34.6±10%, mean HOMA-IR was 3.4±2.9. Subjects with 
Glu27Glu genotype had higher fasting insulin (15.3 ± 7.0 vs 11.6 ± 12.3 µIU/mL) and 
HOMA-IR (4.0 ± 2.1 vs 3.0 ± 3.4) compared to those with a Gln allele (p=0.025 and 
0.028). Gln carriers had less IR when treated with carvedilol compared to metoprolol 
(figure). When adjusted for BMI, there was a significant interaction between genotype and 
the outcomes of fasting insulin and IR stratified by beta blocker (p=0.002).
CONCLUSIONS: The Glu27Glu genotype of the ADRB2 Gln27Glu polymorphism is 
associated with higher fasting insulin and IR in HF patients. Insulin resistance in codon 27 
Gln carriers may be affected by choice of beta blocker. 
1:00 p.m.
1009-25 Is Continuous Furosemide Dosing Superior in Acute 
Heart Failure? Results of a Randomized Pilot Study
Larry A. Allen, Aslan T. Turer, Tracy DeWald, Wendy Gattis Stough, Gad Cotter, 
Christopher M. O’Connor, Duke Clinical Research Institute, Duke University Medical 
Center, Durham, NC
Background: Diuretics are the cornerstone of management of acute heart failure 
(AHF). Physiologic data suggest that intermittent high-dose furosemide promotes 
vasoconstriction and neurohormonal activation, which a slow continuous infusion might 
remediate. However, what limited clinical data do exist (Cochrane review, Salvador 2005) 
are confounded by unequal diuretic dosing and coadministration of sodium infusion.
Methods: We performed a randomized, open-label study of twice-daily bolus injection 
(BID) versus continuous-infusion (CONT) furosemide in AHF patients with volume 
overload. The primary outcome was change in creatinine from admission to day 2.
Results: Forty-one patients were randomized. Follow-up was 100% at discharge and 88% 
at 90 days. Baseline characteristics were balanced between arms except for gender, with 
mean age 60 years, ejection fraction 35%, glomerular filtration rate 54 ml/min/1.73m2. 
Mean dose of furosemide was identical between arms over the first 48 hours (161 mg/24 
hr). None of the outcomes differed between treatment arms, although every parameter 
trended in favor of bolus dosing (table). All patients survived to discharge; one death 
occurred in the CONT arm within 90 days.
Conclusions: Although not statistically significant, AHF patients treated with bolus 
dosing had smaller changes in creatine, increased weight loss, and decreased length 
of stay. These results reinforce the importance of a larger study addressing optimal 
administration of loop diuretics in AHF.
Primary and secondary outcomes for twice daily versus continuous dosing of furosemide 
in AHF
Variable (mean, SD) BID (N=21) CONT (N=20) P Value
Creatinine change at 48 hr (mg/dL) -0.02 (0.33) 0.06 (0.31) 0.14
Weight change at 48 hr (kg) -2.8 (2.7) -1.6 (2.7) 0.31
Urine output at 48 hr (L) 5.2 (2.3) 4.8 (2.2) 0.64
Length of hospital stay (days) 8.8 (3.8) 9.9 (11.7) 0.69
1:00 p.m.
1009-26 Combined Treatment With Beta Blockers and Selective 
Serotonin Reuptake Inhibitors Improves Survival 
of Patients With End-Stage Heart Failure and Major 
Depression
Dimitris Tousoulis, Apostolos Drolias, Charalambos Antoniades, Costas Tsioufis, Costas 
Tentolouris, Elli Stefanadi, Gerasimos Siasos, Kostas Toutouzas, Athanasios Trikas, 
George Latsios, Christodoulos Stefanadis, University of Athens, Athens, Greece
Background: Major depression (MD) is common in end-stage heart failure (HF). We 
examined the interaction between β-blockers and anti-depressive medication (which 
interferes with adrenergic signaling), on long-term survival of patients with severe heart 
failure and depression.
Methods: The population consisted of 250 pts with end-stage HF (NYHA IV, 61% suffering 
MD under selective serotonine reuptake inhibitors (SSRIs), serotonine norepinephrine 
reuptake inhibitors (SNRIs) and/or tricyclic antidepressants (TCA)). The depression severity 
score (DSS) was estimated, and the pts were followed up prospectively for 18 months.
Results: During the follow-up, 167 deaths were reported, and depression was a major 
predictor of cardiovascular death (HR[95%CI] 0.71[0.52-0.97], p=0.03 (Fig. A). B-blockers 
had a borderline effect on mortality in the overall population (p=0.47), (fig. B)), but they 
had a striking effect among patients with major depression receiving SSRIs (2.20[1.26-
3.86], p=0.006 for those not receiving vs those receiving β-blockers, fig. C), while they had 
a negative effect on mortality in pts receiving SNRIs/TCAs (0.19[0.04-0.81], p=0.025, fig 
D) and neutral effect in pts not receiving antidepressants (p=NS).
Conclusions: Depression is a major predictor of cardiovascular death in patients with 
end-stage HF. Beta-blockers improve survival in patients with end-stage HF and MD, only 
when they are combined with SSRIs, while their combination with SNRIs/TCAs may have 
the opposite effect. 
1:00 p.m.
1009-27 Effect of Atenolol, Metoprolol Tartrate and Carvedilol on 
Mortality in Heart Failure
John R. Kapoor, Paul A. Heidenreich, Stanford University, Stanford, CA
Background: Atenolol is commonly used for heart failure with low ejection fraction (EF) 
even though it has not been evaluated in outcome trials for this indication. We sought to 
compare survival among heart failure patients treated with atenolol (ATEN) with those 
treated with carvedilol (CARV) and metoprolol tartrate (METT).
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Methods: We enrolled 1,162 consecutive patients with EF<=40% treated with ATEN, 
CARV or METT during 150 days following echocardiography. After the 150 day 
observation period, we determined mortality at six months adjusted for the propensity 
to receive ATEN.
Results: The age of patients treated with ATEN (mean 69 yrs) and METT (70) were 
older than those treated with CARV (53, p<0.0001). Patients treated with ATEN had more 
malignancy and hypertension, but less coronary disease and prior heart failure than 
METT or CARV patients (all p< 0.01). Unadjusted all-cause mortality at 6-months was 
lower in the ATEN (3.2%) and CARV (5.6%) groups when compared to the group treated 
with METT (10.6%, p<0.0001). In logistic models of 6-month mortality that sequentially 
added patient characteristics (Figure) mortality with ATEN remained lower than METT 
and comparable to CARV treatment.
Conclusions: These data suggest a beneficial role for atenolol in heart failure 
management and the need for comparative randomized trials. 
1:00 p.m.
1009-28 Effect of Rosuvastatin on Plasma Levels of 
Myeloperoxidase in Patients With Heart Failure
Ioannis Andreou, Dimitris Tousoulis, Carmen Vasiliadou, Costas Tentolouris, Panagiota 
Gounari, Charalambos Antoniadis, Gerasimos Siasos, Christodoulos Stefanadis, Athens 
University, A Cardiology Department, Athens, Greece
Background: Myeloperoxidase (MPO), a leukocyte-derived enzyme, has been associated 
with disease progression and severity in heart failure (HF), while animal studies suggest 
that MPO may provide a mechanistic link between inflammation and adverse cardiac 
remodeling. Recent studies have shown that HMG-CoA reductase inhibitors and xanthine 
oxidase inhibitors may exert favorable effects in patients with HF. However, their effects on 
MPO in such patients have not been investigated.
Methods: Thirty-nine clinically stable patients with systolic HF (NYHA II-III, mean 
age 64±11 years, mean LVEF 28±8%, 74% ischemic) who were already on optimal 
conventional cardiovascular treatment were randomized to receive rosuvastatin 10 mg/
day (n=14), allopurinol 300 mg/day (n=14) or placebo (n=11) and followed up for 4 weeks. 
Plasma levels of MPO and serum levels of soluble CD40 ligand (sCD40L), interleukin-6 
(IL-6) and IL-1β were determined using ELISA. Fibrinogen and high sensitivity C-reactive 
protein (hsCRP) were also assessed. All measurements were made before and after 
4-week treatment.
Results: Rosuvastatin significantly reduced plasma levels of MPO [from 21.1 (12.9-36.9) 
to 10.7 (7.6-18.1) ng/mL, p=0.003], which remained unchanged in the other groups [from 
23.7 (12.6-38.3) and 22.3 (14.8-33.1) to 24.3 (13.8-37.1) ng/mL and 23.7 (14.1-29.9) ng/
mL respectively, p=NS for both]. Furthermore, there was a significant difference in the 
change of MPO levels in rosuvastatin group compared to the other groups (p<0.05). The 
other inflammatory markers remained unchanged in all groups. Baseline MPO levels were 
significantly associated with hsCRP (r=0.455, p=0.01), fibrinogen (r=0.479, p=0.007), 
sCD40L (r=0.427, p=0.017), IL-6 (r=0.529, p=0.002), while for IL-1β the correlation did 
not reach statistical significance (r=0.375, p=0.126).
Conclusions: Short-term rosuvastatin administration regulates inflammatory process in 
patients with HF by reducing plasma levels of MPO. This finding provides further insights 
into the role of statins in patients with HF.
1:00 p.m.
1009-29 Statins Increase Myocardial Glucose Uptake in Chronic 
Heart Failure Patients With Nonischemic Forms of 
Cardiomyopathy
Bobby V. Khan, Anbu Pandian, Walter T. Collinson, Emory University School of Medicine, 
Atlanta, GA, New York Medical College, Valhalla, NY
Background: Initiation of statin therapy is significant in clinical management of ischemic 
forms of cardiomyopathy. The potential mechanistic and clinical effects of statins in 
nonischemic forms of cardiomyopathy are less clear.
Methods: We enrolled 24 chronic heart failure patients with nonischemic forms of 
cardiomyopathy. All patients were on ACE inhibitor and beta-blocker therapy with a 
LDL cholesterol < 130 mg/dl. The patients were randomized in a double-blind fashion 
to placebo (n=12, average ejection fraction 33±5%) or simvastatin 20 mg/day (n=12, 
average ejection 32±5%) for a 24 week period. Myocardial glucose uptake was measured 
under euglycemic hyperinsulinemic clamp conditions using [18F]FDG and positron 
emission tomography (PET).
Results: There was a reduction in LDL cholesterol in patients treated with simvastatin 
(pre: 127±21, post: 98±15 mg/dl, p<0.005) and no change in placebo. Using two-
dimensional echocardiography, there was a significant improvement in ejection fraction in 
the simvastatin group (pre: 32±5%, post:38±5%, p=0.026) and no change in placebo (pre: 
33±5%, post:31±5%, NS). Baseline myocardial glucose uptake rates were increased in the 
simvastatin group (pre: 36.5±9.3, post: 53.0±8.5 umol/100g/min, p=0.008) but unchanged 
in placebo (pre: 40.3±6.2, post: 41.5±7.1 umol/100g/min, NS). The myocardial uptake 
calculated for the left ventricle was increased in the simvastatin group (pre: 158.9±44.5, 
post: 200.0±41.1 umol/min, p=0.022) and unchanged in placebo (pre: 155.5±45.9, post: 
159.7±49.3 umol/min, NS). There was no change in serum insulin, plasma glucose, or 
serum free fatty acid in either group during the 24 week study period.
Conclusions: These findings in this study suggest that statin therapy improves myocardial 
glucose uptake in patients with nonischemic forms of cardiomyopathy and may result in 
an overall improvement in the performance of the myocardium.
1:00 p.m.
1009-30 Metabolic Syndrome Does Not Imply Worse Prognosis 
in Systolic Heart Failure
Jorge Thierer, Nora Vainstein, Adriana Acosta, Javier Marino, Mónica Sultan, Alejandra 
Francesia, Alfredo Hirchson Prado, Daniel Ametrano, Laura Boero, Fernando Brites, 
Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina
Background: Metabolic syndrome (MS) is recognized as an adverse prognostic factor in 
general population. Its influence in patients (P) with systolic heart failure (SHF) is less 
established. The aim of this study was to define MS prevalence in SHF, its differential 
characteristics and prognostic value.
Methods: In 151 P with chronic heart failure and left ventricular ejection fraction (EF) 
<= 40%, the presence of MS was defined according to AHA 2005 criteria. Biochemical 
measures, Doppler and tissue echocardiogram, 6 minute walking test and body 
composition by bioelectrical impedance scan were compared between P with and without 
MS. Numerical variables are expressed as median and interquartile range. Prognostic 
value of MS was explored in Cox proportional hazards model.
Results : 64 P (42.4%) had MS. P with MS had higher body mass index (BMI), lower 
values of NT-proBNP and ventricular mass, and better diastolic function. 
Variable MS (n=64) not MS (n=87) p
BMI (kg/ m2) 31.1 (28.5-34.3) 26 (23.9-28.6) 0.001
Muscle mass ( kg) 30.4 (26.2-33.1) 26.9 (22.9-29.8) 0.002
Fat mass % 32.9 (29.6-39.3) 26.9 (23.4-31.7) 0.001
Total body water % 53.4 (49.5- 56) 55.9 (53.6-57.5) 0.005
Resting metabolic rate (kcal) 1505 (1367-1654) 1404 (1265-1557) 0.04
NT-proBNP (pg/ml) 852 (233-1717) 1267 (674-2543) 0.02
e/a relation 0.85 (0.58-1.5) 1.61 (0.75-3.61) 0.007
e/e’ relation 8.6 (7-12.7) 12.7 (7.2-21.2) 0.03
Ventricular mass (grams/ m2) 147 (131-185) 169 (142-205) 0.02
There were no significant differences in EF or 6 minute walking test among P with and 
without MS. During a mean follow up of 15 months there was a trend to lower mortality in P 
with MS: 9.3% vs. 18.4% (HR: 0.46 CI95 0.18-1.20, p = 0.11), and significant lower incidence 
of composite end point death-hospitalization: 21.8% vs. 39% (HR: 0.51 CI95 0.27-0.96, p = 
0.038). MS did not remain as an independent predictor in multivariate analysis.
Conclusion: MS is not related to adverse prognosis in SHF. This fact could be due to 
differential characteristics associated with MS.
1:00 p.m.
1009-31 Clinical Significance of Leptin in Heart Failure With 
Systolic Dysfunction
Jorge Thierer, Adriana Acosta, Nora Vainstein, Victor Mezzalira, Eduardo Gimenez de 
Paz, Monica Sultan, Javier Marino, Marcelo Trivi, Laura Boero, Fernando Brites, Instituto 
Cardiovascular de Buenos Aires, Buenos Aires, Argentina, Hospital de Clínicas, Buenos 
Aires, Argentina
Background: Leptin (L) is a hormon mainly released by adipose tissue. It is strongly 
correlated with fat mass and body mass index (BMI)), reduces food intake and has central 
sympathoexcitatory effect. Different studies suggest that high circulating levels are related to 
worse cardiovascular outcome. Its role in chronic heart failure with systolic dysfunction (SHF) 
still remains unclear. The objective of this study was to explore L role and the association with 
clinical variables, ventricular function, exercise capacity and prognosis in SHF
Methods: In 145 patients with chronic heart failure and left ventricular ejection fraction 
(LVEF) <= 40%, serum L levels were determined and then corrected for the respective 
individuals’ BMI. 4 quartiles of L/BMI were established: Q1 (0.029-0.170 ng.m2/ml.kg), 
Q2 (0.171-0.297 ng.m2/ml.kg), Q3 (0.298-0.465 ng.m2/ml.kg) and Q4 (0.466-0.896 
ng.m2/ml.kg). Patients underwent biochemical measurements, Doppler echocardiogram, 
bioelectrical impedance scan to determine body composition, and 6 minute walking test. 
Differences between quartiles were analyzed. Numerical variables are expressed as 
median and interquartile range. Prognostic value of incremental L values was explored in 
Cox proportional hazards model.
Results: see table. . 
JACC March 11, 2008   ABSTRACTS - Cardiac Function and Heart Failure  A51 
C
ardiac Function and H
eart Failure
Variable Q1 Q2 Q3 Q4 p
Male gender (%) 100 97.1 78.4 61.1 0.001
Leukocytes
(1000/mm3) 6.6 (5.9-7.6) 6.8(6.3-8) 7.3 (6.5-8.6) 7.7 (6.5-8.6) 0.001
Insulin resistance
(HOMA IR) 1.5 (0.8-2.4) 2.4 (1.6-3.9) 3.1 (2.2-4.4) 3.4 (2.2-5) 0.001
C Reactive
Protein (mg/l) 1.6 (0.9-5.2) 2.4 (1.1-4.6) 2.9 (1.5-5.3) 3.2 (1.8-6.5) 0.04
BMI (kg/m2) 25 (23-28) 27 (25-31) 29 (27-33) 30 (27-33) 0.001
Fat mass (kg) 18 (14.2-22) 22 (18.7-28) 26.7 (20-33.5) 30.6 (24-35) 0.001
Metabolic
syndrome (%) 16.2 40 51.3 66.6 0.001
Ventricular mass
index
(g/ m2)
183 (157-239) 157 (127-196) 162 (137-186) 142 (125-175) 0.001
LVEF (%) 28 (20-35) 29 (23-35) 30 (24-35) 29 (22-30) NS
6 minute walking
distance (meters) 315 (220-400) 230 (140-330) 290 (210-390) 280 (170-360) NS
1.2 year mortality *
(HR, CI95) 1 1.1 (0.3-3.7) 0.7 (0.2-2.4) 0.8(0.3-2.5) NS
*Q1 mortality rate at 1.2 years was 16.2%.
Conclusion: Increased L levels are associated with higher inflammation markers levels 
and insulin resistance in SHF, but do not imply worse functional status or prognosis
1:00 p.m.
1009-32 Are Complex Arrhythmias Predictive of Cardiovascular 
Death in Mitral Valve Prolapse? Results of a 17-Year 
Prospective Follow-up
Rita Nistri, Irene Betti, Alessandro Barchielli, Alfredo Zuppiroli, U.O. Cardiologia 
Ospedale S.M. Annunziata, Florence, Italy, Dipartimento del Cuore e dei vasi A.O.U. 
Careggi, Florence, Italy
Background:Complex rhythm disorders have been reported in patients (pts) with mitral 
valve prolapse (MVP) with widely varying incidence and their prognostic value still 
needs to be clarified. Conversely, the predictive role of age, gender and degree of mitral 
regurgitation (MR) is well established. Aim of the study was to assess the prognostic 
role of complex atrial (CAAs) and ventricular (CVAs) arrhythmias when assessed at 
enrollment in a hospital-referred population of pts with MVP.
Methods:Two-channel continuous 24-hour ambulatory electrocardiogram was recorded in 
101 consecutive pts with primary MVP diagnosed by M-Mode and 2D echocardiographic 
Devereux’s criteria. Age: 39±18 years (range 6-79), 56 females (55%), 60 (59%) were 
recruited for symptoms. CAAs were recorded in 10 pts, CVAs in 25 pts.
Results:During the follow-up (204±58 months, range 14-299) a total of 55 MVP-related 
events occurred in 34 pts (3.3 events/100 patient-years): mitral surgery: 25 (15 repair; 
10 replacement); cerebral embolism: 5; hospitalization for heart failure: 9; cardiovascular 
death: 16 (sudden: 3; heart failure: 9; stroke: 4). As expected, at univariate analysis (Cox 
linear regression) age (p=0.005), symptoms (p=0.04), left chamber enlargement (p=0.01) 
and degree of MR (p<0.001) were related to overall events; moderate-to-severe MR 
was the only predictive variable at multivariate analysis (HR 5.65;CI 2.6-12.2;p<0.001). 
MVP-related cardiovascular death was independently predicted by degree of MR (HR 
14.1;CI 3.4-59.6; p<0.001), and also CAAs (HR 4.7 ;CI 1.4-15; p=0.01) and CVAs (HR 
7.1; CI 1.5-16; p=0.05). Of note, the degree of MR was not statistically associated with 
sudden death, which was predicted by CVAs only (p=0.01). Conclusions:A prospective 
long-term follow-up of pts affected by MVP confirms the role of MR in predicting MVP-
related events and demonstrates an independent prognostic role of CAAs and CVAs for 
cardiovascular death and of CVAs for sudden death. Therefore, in MVP pts not only MR, 
but also arrhythmias should be carefully assessed.
1:00 p.m.
1009-33 Extent of Inotropic Contractile Reserve predicts 
Degree of Reverse Remodeling following Cardiac 
Resynchronization Therapy
Ajay S. Shah, Eftekhari Hossein, Rawa Sarji, Sripal Bangalore, Rajeev Joshi, Sameer 
Ather, Bilal Ayub, Danny Pudpud, Sandhya Balaram, Jonathan S. Steinberg, Farooq A. 
Chaudhry, St. Luke’s-Roosevelt Hospital Center, New York, NY
Background and Objective: Approximately one third of patients do not respond to cardiac 
resynchronization therapy (CRT). We have previously shown that presence of inotropic 
contractile reserve (ICR) is a strong predictor of response. However the correlation with 
extent of viability and reverse remodeling is not known.
Methods: 40 pts (67±11yrs;58%male) with end-stage heart failure (NYHA III/IV), LV 
ejection fraction (EF) ≤35%, QRS >120ms and LBBB were included. ICR was assessed 
with low dose (5-20 µg/kg/min) dobutamine stress echocardiography (LDDSE). ICR in 
≥ 5 segments was considered as positive. Number of segments of LV demonstrating 
adequate contractile reserve was assessed. LVEF were assessed at baseline (18±6%) 
and at follow-up (6±2mths). Responders were defined by post CRT improvement in LVEF 
of ≥15 % from baseline.
Results: 10 pts (25%) did not demonstrate ICR. In contrast to patients with ICR these 
pts showed a low response rate (20% vs. 80%, p=0.01). The ROC curve at a cut off ICR 
>5 segments showed a sensitivity of 92% and specificity of 87% to predict response to 
CRT. The presence of both ICR and dyssynchrony predicted response to CRT with a 
positive predictive value of 88% and a negative predictive value of 100%. There is strong 
correlation between ICR and reverse remodeling.
Conclusion. ICR is a strong predictor of response to CRT. There is a strong correlation 
between number of LV segments with ICR and degree of reverse remodeling.
1:00 p.m.
1009-34 The Prevalence of Asymptomatic Left Ventricular 
Dysfunction in Subjects at Risk of Heart Failure. 
Results of the PROBE-HF Study
Irene Betti, Gabriele Castelli, Alessandro Barchielli, Vittorio Boscherini, Gianni Messeri, 
Rita Nistri, Mihai Gheorghiade, Leonardo De Luca, Alan Maisel, Alfredo Zuppiroli, 
Cardiologia Ospedale S.M.Annunziata, Florence, Italy, Dipartimento del Cuore e dei 
Vasi A.O.U. Careggi, Florence, Italy
Background: As asymptomatic left ventricular (LV) dysfunction has a high incidence of 
heart failure and death, its early screening in subjects at risk of heart failure (A Stage, 
ACC/AHA Guidelines) can either affect clinical management and outcome if positive or 
avoid cost-uneffective strategies if negative. The PROBE-HF is a population-based study 
aimed to assess the prevalence of asymptomatic left ventricular dysfunction in subjects 
at risk of heart failure.
Methods: Out of 1162 subjects affected by systemic hypertension and/or type 2 diabetes 
randomly selected from the database of a large association of 110 general practitioners 
involved in 130,000 citizens primary care, 1012 (87%) showed a good quality echo 
(486 males, 48%, 526 females, 52%, age 66±8 yrs). LV dysfunction was diagnosed by 
Echocardiography according to current ACC/AHA/ASE Guidelines.
Results: 633/1012 (62.5%) pts resulted free from LV dysfunction, 368/1012 (36.4%) pts 
showed an isolated diastolic dysfunction, a systolic dysfunction was found in 11/1012 
(1.1%). Diastolic dysfunction: mild (grade I) 327/1012 (32.3%); moderate (grade II) 
28/1012 (2.8%); severe (grade III-IV) 13/1012 (1.3%). At multivariate analysis male gender 
(OR=16.5; IC 95% 1.5-183.8; p=.02) and age (OR=1.2/year; IC 95% 1.03-1.5; p=.02) 
independently predicted systolic dysfunction; diastolic dysfunction was independently 
predicted by age (OR 1.05/year; IC 95 1.03-1.07; p=.000), heart rate (OR=1.03/beat; IC 
95% 1.02-1.04; p=.000), metabolic syndrome (OR 1.75; IC95% 1.1-2.7; p=.01), valvular 
regurgitation (OR=3.04; IC95% 1.7-5.4; p=.000). 
Conclusions: A 5.1% prevalence of pooled systolic and moderate-to-severe diastolic 
asymptomatic LV dysfunction was detected by echocardiography in subjects at risk of 
heart failure. Such a high figure deserves cost-effective strategies aimed to reduce the 
burden of clinically overt heart failure. Primary care physicians should therefore be alerted 
to watchfully investigate hypertensive and/or diabetic patients.
1:00 p.m.
1009-35 The Role of NT-proBNP and Echocardiography for 
Screening Asymptomatic Left Ventricular Dysfunction 
in Subjects at Risk of Heart Failure. Results of the 
PROBE-HF Study
Irene Betti, Gabriele Castelli, Alessandro Barchielli, Vittorio Boscherini, Gianni Messeri, 
Rita Nistri, Mihai Gheorghiade, Leonardo De Luca, Alan Maisel, Alfredo Zuppiroli, U.O. 
Cardiologia Ospedale S.M.Annunziata, Florence, Italy
Background: NT-proBNP and Echocardiography have proved to be effective in the 
screening of left ventricular (LV) dysfunction, yet their role is still uncertain in asymptomatic 
patients .The PROBE-HF is a population-based study aimed to assess the prevalence 
of asymptomatic LV dysfunction in subjects at risk of heart failure and to evaluate the 
diagnostic role of NT-proBNP and Echocardiography.
Methods: Out of 1162 subjects affected by hypertension and/or type 2 diabetes randomly 
selected from the database of a large association of general practitioners, 1012 (87%) 
showed a good quality echo (486 males, 48%, 526 females, 52%, age 66±8 yrs).
Results: 633 subjects (62.5%, group A) resulted free from LV dysfunction, a total of 
379/1012 (37.5%) subjects showed LV dysfunction. Among them, 368 (36.4%, group B) 
showed an isolated diastolic dysfunction, 11 (1.1%, group C) a systolic one. NT-proBNP 
mean and median values resulted significantly different as follows: group A, 92 ± 169 and 
65 ng/L; group B, 170 ± 206 and 115 ng/L; group C, 859 ± 661 and 551 ng/L (p for mean 
and median values =.000). A NT-proBNP value >200 ng/L was independently predicted by 
age (65-74 years: OR = 2.6, p = .000; ≥ 75 years: OR = 6.6, p = .000), mitral regurgitation 
(OR = 1.8, p = .02), diastolic dysfunction (mild: OR = 2.3, p =.000; moderate-to-severe: 
OR = 15.5, p =.000), and systolic dysfunction (OR = 96.4, p = .000). Best cut-off values: 
125 ng/L for females <75 yrs (sens 100%, spec 73.6%, NPV 100%, AUC .75); 400 ng/L 
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for females ≥75 yrs (sens 100%, spec 88.8%, NPV 100%, AUC .89); 125 ng/L both for 
males < and ≥75 yrs (respectively, sens 93.7% and 100%, spec 83.9% and 53%, NPV 
99.7% and 100%, AUC .88 and .56)
Conclusions: NT-proBNP shows an excellent negative predictive value in the diagnosis 
of asymptomatic LV dysfunction in diabetic or hypertensive patients. Moreover, it highly 
correlates both with systolic and different grades of diastolic dysfunction, as assessed 
by echocardiography, and its specificity appears to be higher than previously reported. 
Different NT-proBNP cut-off values according to age and gender could help general 
practitioners in the management of subjects at risk of heart failure.
1:00 p.m.
1009-36 Anemia as a Risk Factor in Heart Failure With Normal 
Renal Function
Silvia M A Ferreira, Guilherme V. Guimaraes, Fatima D. Cruz, Fernando Bacal, Vitor S. 
Issa, Paulo Chizzola, Sandrigo Mangini, Germano E C Souza, Edimar A. Bocchi, Heart 
Institute (INCOR), University of Sao Paulo Medical School, Sao Paulo, Brazil
Background: Anemia in patients (pts) with heart failure (HF) is associated with poor 
prognosis. Nevertheless, anemia can be associated with renal insufficiency which is 
also common in HF and is associated with poor outcomes. Thus the value of anemia as 
predictor of risk in HF may be overlap by the value of impaired renal function.
Methods: 268 pts with HF were followed > 24 months. Pts were divided in two groups: A, 
glomerular filtration rate (GFR) ≥ 60 ml/min/1.73m2, and B, GFR < 60 ml/min/1.73m2. In 
each group pts were subdivided in anemic (Hb < 12 g/dl) and non-anemic (Hb ≥ 12 g/dl).
Results: Anemia was detected in 29 pts (10.8%) of overall HF population. In anemic 
patients 24-month survival was 58.6% compared to 76.6% in non-anemic pts (_=0.013). 
Group A included 177 pts (66.0%) and group B, 91 pts (34.0%). Anemia was detected 
in 15 pts (8.5%) of Group A and in 14 (15.4%) of group B (_=ns). In group A, anemic pts 
has a 24-month survival of 60.0% compared to 79.6% in non-anemic pts (_=0.035). In 
group B, anemic pts has a 24-month survival of 57.1% compared to 70.1% in non-anemic 
pts (_=ns).
Conclusion: Anemia is a significant predictor of poor outcome in heart failure pts with 
normal renal function. In pts with impaired renal function anemia do not provide additional 
information about prognosis.-
1:00 p.m.
1009-37 Atorvastatin Therapy in Compensated Heart Failure: 
Effects on Oxidative Stress, Remodelling, and 
Endothelial Function
Douglas Greig, Pablo Castro, Rodrigo Miranda, Luigi Gabrielli, Hugo Verdejo, Hernan 
Alcaino, Mario Chiong, Sergio Lavandero, P.U. Católica de Chile, Santiago, Chile
Introduction: Increased oxidative stress (OS) in chronic heart failure (HF) leads to 
enhanced metalloproteinase (MMP) activity and endothelial dysfunction (ED). Statins 
have known antioxidant properties, but its unknown if these beneficial effects are 
independent from changes in lipid profile. Methods: Sixty-one patients with compensate 
HF, left ventricular ejection fraction (LVEF) <40% and total serum cholesterol (TC) < 5.2 
mmol/L without previous treatment with statins. All patients received a 4 week course of 
placebo and then atorvastatin 20 mg daily for 8 weeks. Baseline, 4 and 12 weeks blood 
samples were obtained for LDL, malondialdehyde (MDA), endothelial-bound superoxide 
dismutase (ecSOD), MMP-9 and MMP-2. ED was assessed by ultrasonographic flow-
dependent endothelial mediated vasodilation (FDD). Groups were compared with ANOVA 
. Correlations were evaluated with Pearson’s method. Results: Mean age was 59±14, 51 
(84%) were men. HF etiology was ischemic in 14 cases (23%). Mean LVEF 28±8%. Main 
results are summarized in the table. 
Baseline Placebo Atorvastatin p1 p2
MDA (_M) 1.33±0.56 1.24±0.42 1.00±0.37 Ns <0.001
ecSOD(U*mL-1*min1) 126±36 130±28 188±58 0.01 <0.001
MMP2 0.21 ± 0.06 0.22±0.07 0.20 ± 0.08 0.05 0.02
MMP9 0.46 ± 0.25 0.44± 0.14 0.31 ± 0.12 Ns <0.001
LDL (mg/dl) 108±34 105±38 69±26 Ns 0.001
FDD (%) 4.0±1.5 4.57±2.1 6.9±2.7 Ns 0.01
p1= baseline vs placebo; p2: placebo vs atorvastatin.
Atorvastatin therapy was associated with a significative improvement in OS, ED and 
FDD markers. No significant correlations were observed between LDL, HDL or TC and 
changes in ecSOD, MDA or FDD.
Conclusion: In HF patients, treatment with atorvastatin reduces MMPs activity and 
improves ED and OS status. These effects are independent of changes in lipid profile.
1:00 p.m.
1009-38 Sodium Derangement and Associated Clinical and 
Financial Outcomes: Analysis of 115,969 Acute Heart 
Failure Admissions in 2004-2005
Andrew F. Shorr, Ying P. Tabak, Steven G. Kurtz, James Spalding, Vikas Gupta, 
Washington Hospital, Washington, DC, Cardinal Health, Marlborough, MA
Background: Sodium derangements are common in patients presenting with acute heart 
failure (AHF). Less is known on the clinical and economic implications. We sought to 
evaluate the prevalence of sodium derangements and the relation with morbidity, mortality, 
and cost burden for hospitalized AHF patients.
Methods: We retrospectively analyzed 115,969 AHF admissions across 185 US hospitals 
(teaching and non-teaching) in 2004-05. We categorized patients into one of four cohorts 
based on admission laboratory data: sodium < 130 mEq/L as severe hyponatremia; 131-135 
mEq/L as hyponatremia; and >145 mEq/L as hypernatremia. We used sodium 136-145 
mEq/L (normonatremia) as the reference group. We estimated excess risks for mortality, 
altered mental status, length of stay (LOS), and cost using multivariable analysis.
Results: The median age was 77. About 55% were women. Crude mortality was 3.6%. 
The prevalence of severe hyponatremia, hyponatremia, and hypernatremia was 5.3%, 
15.9%, and 3.2% respectively. The corresponding crude mortality was 7.6%, 4.9%, and 
6.7% compared to 2.9% for the normonatremia group. After controlling for admission 
severity and other risk factors, all three levels of sodium derangement were independent 
predictors for mortality, altered mental status, excess LOS, and cost (see table).
Conclusions: About a quarter of AHF patients presented to hospitals with deranged 
sodium levels, which were associated with adverse clinical and economic outcomes.
1:00 p.m.
1009-39 High Prevalence of Sexual Dysfunction in Women and 
Men With Chronic Heart Failure
Ernst R. Schwarz, Vishal Kapur, Sauragh Rastogi, Justin Fuess, Cedars Sinai Medical 
Center, Los Angeles, CA
Background: Only little information is available regarding the prevalence of sexual 
dysfunction in patients with compensated heart failure or its impact of quality of life. Moreover, 
physicians under-interogate sexual issues in cardiac patients for different reasons. Sexual 
dysfunction, on the other hand, is a common problem that is associated with multiple co-
morbid conditions and chronic diseases. Methods: A gender-specific questionnaire was 
modified from established sexual dysfunction questionnaires to correspond to a non-
randomized outpatient heart failure population in order to assess the prevalence and 
demographic distribution of sexual dysfunction and potential treatments expectations. One-
hundred twenty-five patients that were actively engaged in a sexual relationship and were 
in compensated cardiac conditons in NYHA classes I-III were recruited.
Results: In view of different degrees of male erectile dysfunction and different categories of 
female sexual dysfunction, cluster were formed that summarized personal dissatisfaction 
and reduced quality of life versus adequate quality of life as subjectively assessed. 
Alltogether, 87% of women were found to fullfill criteria for sexual dysfunction and 84% 
of men had criteria for erectile dysfunction, that impacted quality of life in both genders at 
all age groups (33 - 87years of age). 74% of men wanted drug therapy for improvement 
of their erectile capacity; 60% of women were willing to try a medication if it would help 
to improve their current symptoms leading to sexual dysfunction. 78% of females and 
64% of men complaint that most physicians did not inquire about sexual problems, and 
in those who did, most did not offer follow-up visits with regard to changes or response. 
55% of men and 52% of women considered sexual activity in their current condition as an 
essential aspect of quality of life.
Conclusions: Sexual dysfunction appears to be of high prevalence in patients with 
compensated heart failure. Sexual dysfunction direlcty impairs quality of life in both men 
and women. Most patients expect physicians to actively interogate sexual function issues 
and provide long-term treatment.
1:00 p.m.
1009-40 Relationship Between Renal Function and 
Cardiopulmonary Fitness in Patients With Systolic 
Heart Failure
Peter A. McCullough, Eric Leifer, Stephen Ellis, David S. Rendall, Tamara B. Horwich, 
James A. Hill, Gregg C. Fonarow, William Beaumont Hospital, Royal Oak, MI, UCLA 
Medical Center, Los Angeles, CA
Background: Both renal function and cardiopulmonary fitness are related to morbidity and 
mortality in heart failure (HF). The relationship between estimated glomerular filtration rate 
(eGFR) and measured peak oxygen consumption (peak VO2), has not been previously 
explored in HF patients.
Methods: The HF-ACTION trial was a prospective, randomized trial of exercise therapy in 
patients with class 2-4 systolic HF. The 4-variable modified MDRD equation was used to 
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calculate eGFR which was divided into groups (≥90, 89-60, 59-30, 29-15 ml/kg/1.73 m2). 
Peak VO2 was measured using gas-exchange analysis during maximal exercise testing.
Results: Of 2026 subjects with serum creatinine recorded, data are given in the Table. 
The correlation between eGFR and peak VO2 was R=0.23 (p<0.0001). Among those 
with a maximal effort (respiratory exchange ratio > 1.10), the relationship was similar, 
R=0.27, p<0.0001. In a multivariate model with peak VO2 as the dependent variable, 
and including eGFR group, BMI, age, gender, LVEF, and race as independent variables 
(all significant at the p < 0.0001 level), age explained 13% of the variation in peak VO2, 
eGFR group explained 2% of the variation, and the overall 7-variable model explained 
27% of the variation.
Conclusions: Although heavily confounded by age, renal function is independently 
associated with worsened cardiopulmonary fitness in patients with systolic HF. Further 
study is necessary to determine the mechanisms by which renal function influences peak 
VO2. 
Characteristic CKD Level (NKF KDOQI Stage in eGFR ml/min/1.73 m2)
All 1(> 90) 2 (89-60) 3 (59-30) 4 (29-15) P-Value 
for Trend
n 2026 332 992 711 61 -
Age 59±13 50±13 57±11 65±11 70±11 <0.0001
Male (%) 72 70 73 74 70 0.29
Diabetes 
Mellitus
33 33 26 41 47 <0.0001
Prior MI 42 27 41 50 56 <0.0001
ACEI 74 81 75 71 62 <0.0001
ARB 24 20 23 27 21 0.03
Beta Blockers 95 96 95 94 95 0.18
NYHA Class 2.38 2.30 2.32 2.45 2.57 <0.0001
LVEF 25±7 26±8 25±8 25±7 25±7 0.03
Peak VO2 (ml/
kg/min)
14.8±4.7 15.9±4.6 15.7±4.9 13.5±4.1 11.3±3.2 <0.0001
VO2 at 
Anaerobic 
Threshold
(ml/kg/min)
10.8±2.7 11.3±2.6 11.1±2.7 10.1±2.5 8.7±2.1 <0.0001
ACC.POSTER CONTRIBUTIONS
1016
Cardiomyopathies/Myocarditis/Pericardial 
Disease
Monday, March 31, 2008, 9:00 a.m.- 12:30 p.m.
McCormick Place, South Hall
1016-1 Early Administration of Nitroglycerin in Addition to 
Diuretic Improve Mortality in Patients With Chronic 
Kidney Disease Presenting With Acute Decompensated 
Heart Failure: A Two-Year Follow-Up
Emad F. Aziz, Marrick Kukin, Sripal Bangalore, Jules Aljammal, Bhatia Vivek, Jaime 
Upegui, Dan Musat, Steven Lee, Aaron Zigelbaum, Amanda Schneider, Anish Shah, Olivier 
Frankenberger, Eyal Herzog, St. Luke’s-Roosevelt Hospital center, New York City, NY
Background: Loop diuretics are considered the first-line of treatment for patients with 
acute decompensated heart failure (ADHF). Adding nitroglycerin to diuretics for alleviation 
of acute shortness of breath has been advocated in our institution. We evaluated the 
benefits of adding nitroglycerin to diuretics in the emergency department on initial 
presentation for ADHF in patients with chronic kidney disease (CKD).
Methods: 430 consecutive heart failure patients admitted with chief complaint of dyspnea 
were included in this retrospective study. Patients were divided into three groups. Group 
A was treated with neither diuretics nor Nitroglycerin (NTG), Group B was treated with 
diuretics only, and Group C was treated with both diuretics and Nitroglycerin. GFR was 
calculated according to the The Cockcroft-Gault formula. Follow up was 36 ± 9 months. 
The primary endpoint was readmission at 30 days and mortality at 24 month.
Results: 431 patients were included in this study. (42% men, mean age 69 ± 14 years), 
mean NYHA class 2.4 ± 0.7, and mean EF 28 ± 17. Group A included 258 (59%) patients; 
Group B had 127 (29%) patients and Group C had 46 (11%) patients. Group C were slightly 
older (mean age 72±13 years), with lower BMI 26±7, lower GFR 55.8±38 and higher BNP 
levels on admission 1120±876; p=NS. At 30 days there were 53 (12%) readmissions, 26 
for group A, 20 for group B and 7 for group C, p=NS. However; Survival probability at 24 
month was higher in Group C (87%) compared to groups A (79%) and B (82%), p=0.002. 
Using the Cox Proportional-hazards regression module; early administration of NTG + 
Lasix (95%CI 1.06-1.62; p=0.01) followed by CKD stage (95%CI 1.00-1.35; p=0.04), were 
the only predictors for survival.
Conclusions: Early administration of nitroglycerin in addition to diuretic in emergency 
department improved mortality at 24 month in Patients with chronic kidney disease When 
Treated for decompensated heart failure.
1016-2 High Central Pressure Is a Marker of Renal Failure in 
Patients With Normal Cardiac Output
Sofia C. Masri, Monica Colvin-Adams, Andrew Boyle, Carol Toninato, Lyle Joyce, Ken 
Liao, John T. Nguyen, Ranjit John, University of Minnesota, Minneapolis, MN
Background: Renal failure (RF) is a complication of heart failure (HF) and its presence 
carries a grim prognosis. Despite growing recognition of the “cardiorenal syndrome”, the 
pathophysiology is poorly understood. In advanced HF reduced cardiac output (CO) is 
often a contributor, but is not as important in mild-moderate HF. However, elevated right 
atrial pressure (RAP) is another cause and is often overlooked. Left ventricular assist 
devices (LVAD), used in end-stage HF, improve CO but not always improve RAP. Thus, 
this is a unique opportunity to explore the relation of elevated RAP and renal function.
Methods: Retrospective analysis of 56 consecutive patients with advanced HF who 
underwent LVAD placement. Patients were stratified based on RAP above or below 17 
mmHg after LVAD implantation. Comparisons in GFR were made between groups.
Results: At baseline no difference in GFR among patients with RAP< 17 and RAP 
>17 mmHg (76 + 20 vs 70 + 24 ml/min, respectively). After LVAD placement there was 
significant improvement in GFR compared to baseline in patients with lower RAP ( 94+ 
32 ml/min, p=0.004). Among patients with RAP> 17 mmHg, GFR did not improve ( 85+ 40 
ml/min, p=NS) despite similar improvements in CO.
Conclusion: These results suggest that elevated RAP, a marker of right ventricular failure, 
is an important cause of RF in HF patients. Also, improvement in RAP correlates with 
improvement in RF. Management of right HF may have important therapeutic implications 
in the management of “cardiorenal syndrome”.
Baseline
RAP < 
17 
(n=41)
RAP 
>17 
(n=15)
p 
value
After LVAD 
placement
RAP < 
17 
(n=41)
RAP 
>17 
(n=15)
p 
value
Age 56 + 13 50 + 13 NS RAP 
mmHg 13 + 3 21+ 3 0.0001
CI (liters/m2) 1.9 + 0.4
1.7 + 
0.5 NS CI (liters/m2) 3 + 3 3.1+ 1 NS
PCWP 
(mmHg) 25 + 7 24 + 8 NS
PCWP 
(mmHg) 16 + 5 22 + 5 <0.05
Mean pulmonary 
pressure 
(mmHg)
36 + 8 38+ 6 NS
Mean pulmonary 
pressure 
(mmHg)
23 + 6 28 + 7 <0.05
Mean Blood 
pressure 
(mmHG)
68 + 21 64 + 23 NS
Mean Blood 
pressure 
(mmHG)
76 + 21 78 + 15 NS
1016-3 Should We Check BNP Levels in Patients With 
Decompensated Heart Failure? Results of a Meta-
analysis of 49,273 Patients
Andrew Binder, Antonio Abbate, Michael Kontos, Giuseppe Biondi-Zoccai, Virginia 
Commonwealth University, Richmond, VA
Background: Brain natriuretic peptide (BNP) levels are a useful diagnostic and prognostic 
marker in patients (pts) with suspected congestive heart failure (CHF). Whether 
assessment of BNP levels is of added value in the prediction of death in pts admitted to 
the hospital with decompensated CHF is less clear. The aim of this study was to assess 
the predictive value of BNP for all-cause mortality in pts admitted to the hospital with 
heart failure.
Methods and Results: We performed a systematic search for studies assessing BNP 
and mortality in patients admitted with decompensated CHF using electronic search 
engines (Pubmed and Cochrane) and reference lists of included studies, including all 
studies that presented data on all-cause mortality according to admission BNP levels. 
Studies using dyspnea rather than CHF as diagnosis were excluded. Relative risk was 
calculated using fixed effect model. We retrieved 5 studies pooling results for 49,273 
patients. No heterogeneity was found for the outcome of interest. All studies showed a 
RR favoring survival for BNP levels ≤median value. At receiving operator curve (ROC) 
analysis, BNP>median had a sensitivity of 70% and a specificity as low as 50% to predict 
all-cause mortality.
Conclusions: Pooled data from a large number of patients confirms the prognostic value 
of BNP levels in selected patients admitted with decompensated CHF. The overall low 
discriminatory properties of BNP levels, however, question the clinical role of routine BNP 
determinations in such patients. 
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1016-4 A Novel Inotropic Agent That Activates Cardiac Myosin 
and Increases Cardiac Contractility Without Increasing 
MVO2 in Heart Failure With Left Ventricular Hypertrophy
You-Tang Shen, Yan Zhang, David J. Morgans, Stephen F. Vatner, Fady Malik, University 
of Medicine and Dentistry of New Jersey, Newark, NJ, Cytokinetics, Inc., South San 
Francisco, CA
Background: A major reason for failure of chronic inotropic therapy in heart failure (HF) is 
thought to be related to an increased MVO2 that causes a further imbalance between O2 
supply and demand, particularly in the subendomyocardium of the hypertrophic dilated 
left ventricle. CK-1827452 (CK-452) is a novel inotropic agent that acts by a downstream 
mechanism, directly activating the force generating protein cardiac myosin, as opposed to 
most Ca2+ dependent agents, which would provide a different and perhaps better profile 
as compared to other agents.
Methods: To confirm this hypothesis, we examined the effects of CK-452 in conscious, 
chronically instrumented dogs with HF either with or without pre-existing left ventricular 
(LV) hypertrophy (H). Surgically implanted instrumentation included an LV pressure 
gauge, ascending aortic and coronary flow probes, ultrasonic dimension crystals, pacers 
and catheters in the aorta and coronary sinus. HF was induced by a combination of 
coronary artery occlusion and ventricular pacing (240 bpm) and LVH was induced by 
aortic banding.
Results: HF was characterized by an increase (p<0.01) in LV end diastolic pressure 
(LVEDP) (from 7±1 to 26±2 mmHg), and decreases (p<0.01) in LV dP/dt (from 3065±138 
to 1730±109 mmHg/s), fractional shortening (FS) (from 14±2 to 7±1%), and stroke volume 
(from 30±4 to 13±2 ml). Infusion of CK-452 for 3 days in HF increased LVFS by 42±5% 
and stroke volume by 44±8%, while reducing LVEDP by 5±2 mmHg without a change 
in MVO2. In dogs with HF induced in the presence of pre-existing LVH, i.e., increase in 
LV/body weight of 40%, chronic infusion of CK-452 increased LVFS by 44±6%, systolic 
wall thickening by 40±6%, and decreased LVEDP by 8±3 mmHg, p<0.05. There was no 
change in either MVO2 or in LV endo/epi blood flow ratio as measured with microspheres 
(1.42±0.12 before and 1.38±0.13 after CK-452).
Conclusions: The novel cardiac myosin activator increased LV function and reduced filling 
pressures, but in contrast to conventional inotropic agents, does not increase MVO2 or 
reduce subendocardial blood flow in the setting of HF or in HF with severe LVH. These 
results suggest CK-452 should exert more stable and long-term beneficial effects in 
patients with HF.
1016-5 Chronic PDE V Inhibition in a Canine Model of Severe 
Experimental Heart Failure Decreased Atrial Natriuretic 
Peptide and Dipeptidyl Peptidase IV Gene Expression 
in the Kidneys
Brenda K. Huntley, John C. Burnett, Jr., Guido Boerrigter, Horng H. Chen, Mayo Clinic, 
Rochester, MN
Background: B-type natriuretic peptide (BNP) generates its second messenger cyclic 
GMP (cGMP) via the NPR-A receptor and is degraded by dipeptidyl-peptidase (DPP-
IV) to BNP3-32, which has reduced renal actions. Type V phosphodiesterase (PDE V) 
metabolizes cGMP and is abundant in the vasculature and kidney. We recently reported 
that chronic PDE V inhibition(PDEVI) with Sildenafil in experimental heart failure did not 
improve the renal function but did enhance the renal actions of exogenous BNP. The aim 
of this sub study is to profile the renal gene responses to chronic PDEVI so as to begin to 
explore the mechanism for the observed physiological response.
METHODS: Two groups of dogs with pacing induced overt CHF (240 bpm for 10 days) 
were studied ; Group 1 (n=6) received Sildenafil 50 mg po tid during the 10 days of 
pacing and Group 2 (n=5) received no PDEVI. Both groups received acute SQ BNP 
administration on day 11. Genome-wide microarray analysis was performed on the kidney 
(Affymetrix GeneChip® dog Genome 230 2.0) to profile renal gene response.
Results: As previously reported, renal function was similar between the two groups, 
however, both plasma ANP and urinary ANP excretion was significantly lower in the 
PDEVI gp. With SQ BNP, the PDEVI gp had a greater renal response. Using a lower 
threshold of 1.5 fold change and a p<0.05 cutoff, 752 genes in kidney were modified in the 
PDEVI gp as compared to untreated CHF. Focusing on the genes related to the natriuretic 
peptide system, the microarray analysis revealed that the ANP gene expression (2.9 
folds) and the DPP IV gene expression (4.9 folds) were significantly decreased in the 
PDEVI gp as compare to the untreated CHF.
Conclusion: In experimental overt CHF, chronic PDEVI decreased the gene expression of 
ANP in the kidneys consistent with the lower plasma and urinary ANP levels which may 
account for the lack of improvement of renal function. Chronic PDEVI also decreased 
DPP IV gene expression in the kidneys, suggesting that the enhanced renal response 
to exogenous BNP may go beyond just inhibition of PDE V but also via the prevention of 
degradation of BNP to BNP3-32 by decreasing DPP-IV. The findings support the strategy 
to combine PDEVI with BNP to enhance renal function in CHF.
1016-6 High Serum Uric Acid Is Associated With Increased 
Risk of New-onset Heart Failure in Community-dwelling 
Older Adults: A Propensity-Matched Study of the 
Cardiovascular Health Study
Ali Ahmed, O. James Ekundayo, University of Alabama at Birmingham, Birmingham, AL, 
VA Medical Center, Birmingham, AL
Background: High serum uric acid (sUA), considered a marker of inflammation, is 
associated with poor outcomes in heart failure (HF). However, whether high sUA is 
associated with increased risk of incident HF is unknown.
Methods: Of the 5588 participants in the NHLBI-funded prospective epidemiological 
Cardiovascular Health Study, 5461 had valid data on baseline sUA. Of these, 1505 had 
high sUA, defined as sUA levels ≥6 mg/dL for women and ≥7 mg/dL for men. Propensity 
scores for high sUA were calculated for each patient (based on 31 key baseline variables), 
and were used to match 893 high sUA participants with 2396 normal sUA participants. 
Matched Cox regression models were used to estimate effects of high baseline sUA on 
incident HF during 9.9 years of median follow-up.
Results: Participants had a mean (±SD) age of 73 (±6) years, 57% were women, 16% 
were non-whites, and 17% developed new-onset HF. Compared with 16% (rate, 20/1000 
person-years) of participants with normal sUA, 20% (rate, 24/1000 person-years) of of 
those with high sUA developed new-onset HF (hazard ratio, 1.22; 95% CI, 1.003-1.48; 
P=0.046; Figure 1). Among 5461 pre-match participants, high sUA was associated with 
increased risk of new-onset HF (HR, 1.63; 95% CI, 1.42-1.86; P<0.0001), which remained 
significant after multivariable (n=31) adjustment (adjusted HR, 1.26; 95% CI, 1.09-1.46; 
P<0.0001).
Conclusion: Among ambulatory community-dwelling older adults high baseline serum uric 
acid level was associated with increased risk of new-onset HF.
1016-7 Is Early Phase BNP a Reliable Marker for Left 
Ventricular Remodeling and Long-term Prognosis After 
Acute Myocardial Infarction?
min-soo Ahn, Byung-su Yoo, Junghan Yoon, Seung-Hwan Lee, Jang-Young Kim, Kyung-
Hoon Choe, Young-Jin Yoon, Seong-Yoon Kim, Kyung-Hoon Lee, Sung-Oh Hwang, 
Wonju College of Medicine, Yonsei University, Wonju, South Korea
Background: The progression of left ventricular (LV) remodeling after acute myocardial 
infarction (AMI) has been shown to adversely affect prognosis. We examine which time of 
BNP sampling is a reliable marker for left ventricular remodeling and long-term prognosis 
after acute myocardial infarction.
Methods: From April 2003 to June 2006, among 334 AMI patients, we prospectively 
analyzed 131 patients underwent echocardiography on 1 to 5th day (initial) and 6 to 9 
months (follow-up) and measurements of BNP(Triage®) on admission(≤24hr), early(24hr-
6day), and long-term phase(6 to 9 months) after AMI. LV remodeling was defined as an 
increase in end-diastolic volume (EDV) ≥15% between initial and follow-up period. We 
checked long-term adverse events (AEs; any cause of death and readmission due to 
heart failure). 
Results: Mean age was 59.7±11.6 and male was 71.8%. The median follow-up duration 
was 35.2 months. The incidence of LV remodeling was 32.3%. Symptom to reperfusion 
time (6.5±3.1 vs. 4.7±2.2 hours, p=0.000) and BNP at early phase (371.6±458.7 vs 
93.6 ±187.3 pg/dL, p=0.000) were higher in remodeling group. Multivariable regression 
analyses confirmed that level of BNP at early phase (p=0.003) and peak creatine kinase-
MB (p=0.002) were the powerful independent predictors of LV remodeling in patients 
with AMI. During median 9.5 month follow-up, eighteen (13.5%) AEs occurred: 12 (9.4%) 
readmission due to heart failure, 6 (4.7%) death. There was higher incidence of LV 
remodeling, diabetes, anterior myocardial infarction, previous history of coronary artery 
disease, older age, lower ejection fraction, longer symptom to treatment time, higher wall 
motion score index, E/E’ and BNP at early phase in AEs group (p<0.05). Cox regression 
analyses confirmed that level of BNP at early phase, LVEF and age was the significant 
predictors of AE (p<0.05).
Conclusions: The level of BNP at early phase is well correlate with LV remodeling. Also, 
BNP at early phase was the significant predictors of death and readmission due to heart 
failure after acute myocardial infarction.
1016-8 Early Diuretic Administration Combined With 
Admission B-Natriuretic Peptide Level Are the 
Strongest Predictors of Readmission at 30 Days in 
Patients Treated for Acute Decompensated Heart 
Failure Using a Novel Pathway
Emad F. Aziz, Eyal Herzog, David Djebali, Olga Kuteyeva, Dan Musat, Deborah Tormey, 
Steven Lee, Alexander Ritter, Evan Scheidmessar, Olivier Frankenberger, Marrick Kukin, 
St. Luke’s-Roosevelt Hospital Center, New York City, NY
Background: Loop diuretics have long been accepted as a first-line treatment for patients 
with acute decompensated heart failure (ADHF). Our newly developed unique ADHF 
pathways for emergency room physicians emphasize time to treatment. We hypothesis 
that adequate dosing of diuretics, time to treatment combined with admission BNP levels 
are a strong determinant of readmission at 30 days in this population.
Methods: 146 consecutive heart failure patients admitted to St. Luke’s-Roosevelt Hospital 
Center between the periods of September 2004 to January 2005 with chief complaint of 
dyspnea were included in this retrospective study. The time to dose was defined as the time 
of Emergency Room arrival to the documented time of first IV diuretic administration.
According to our pathway the dose given was either 40 mg IV Furosemide for those not 
taking diuretics or the equivalent mg dose of their daily Furosemide po dose. Time to IV 
diuretic dose was subdivided into three groups A <2 hrs, group B 2-4 hrs, and group C > 4 
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hrs after admission. Patients were also classified as per breathing not properly study into 
3 groups. Group A BNP <100, Group B 100-400, Group C > 400. Endpoint of readmission 
was then evaluated at 30 days.
Results: 146 patients were evaluated (56%) men, mean age 66 ± 14 years, mean NYHA 
class 2.4 ± 0.7, and mean EF 31.5 ± 23. Group A had 95 (65%) patients; Group B had 
26 (18%) patients and Group C 25 (17%). The average length of stay (LOS) was 4.3 ± 
1.4 days, 7.4 ± 6.2 days and 11.9 ± 7.5 days, respectively, p<0.0009. Using the multi 
regression analysis comparing age, creatinine on admission, EF, time to diuretic and 
BNP on presentation, the most significant predictor for the length of stay in the hospital 
was time to diuretic p=0.007. Admission BNP level added to time to Furosemide were the 
strongest predictors for readmission at 30 days (F=10, p=0.001).
Conclusions: Early outcome for patients admitted with acute decompensated heart failure 
depends on the early administration of first dose of IV diuretics. LOS is significantly 
affected by the time of first dose. Admission BNP level added to time to Furosemide were 
the strongest predictor for readmission at 30 days.
1016-9 Low-Dose Rather Than High-Dose Erythropoietin May 
Be Effective in a Rat Model of Dilated Cardiomyopathy 
That Is Not Anemic
Tatsuji Kono, Daisuke Nakagawa, Akiko Soyama, Yasushi kitaura, Yuka Kohda, Takao 
Tanaka, Osaka Medical College, Osaka, Japan
Background: Erythropoietin (EPO) has been shown to improve clinical symptoms in 
patients with dilated cardiomyopathy (DCM) in the presence of anemia. We proposed 
the hypothesis that low-dose rather than high-dose EPO may be useful for the treatment 
of DCM in the absence of anemia. Methods: DCM was induced by injection of 1 mg (0.1 
mL) porcine heart myosin mixed with an equal volume of Freund’s complete adjuvant 
into a footpad of rats on days 1 and 7. At five weeks after immunization, DCM rats were 
assigned to three groups; recombinant human EPO was intraperitonealy administered 
once a week at a dosage of 500 U/kg (EPO-L group, n=10), at a dosage of 5000U/
kg (EPO-H group, n=10) and saline alone was administered (sham-operated DCM 
group, n=10). The injections were continued for 3 weeks. Physiological and histological 
examinations were performed 1 month after randomization. Results: Hematocrit was 
unchanged among groups. Low-dose rather than high-dose erythropoietin improved left 
ventricular (LV) dysfunction and attenuated degenerative change in cardiomyocytes. EPO 
significantly increased the level of phospho-Akt (pAkt) dose dependently. Conclusions: 
These findings suggest that low-dose rather than high-dose erythropoietin may be 
an effective therapeutic strategy for the treatment of DCM in the absence of anemia, 
irrespective of the rise in hemoglobin levels, at least in part through optimal activation of 
the PI3K/Akt pathway. (*=p<0.05 vs. Normal, †=p<0.05 vs. DCM, ‡=p<0.05 vs. EPO-H). 
Normal 
(n=10)
DCM 
(n=10)
EPO-H 
(n=10)
EPO-L 
(n=10)
Hematocrit (%) 41±2 41±2 41±2 43±2
LV end-diastolic dimension (mm) 7.0±0.9 8.0±0.4* 8.2±0.5* 7.3±0.4†‡
LV fractional shortening (%) 44±7 27±5* 25±6* 35±4*†‡
LV peak dP/dt (mmHg/sec) 3880±451 3530±280* 3040±400*† 4140±450†‡
LV negative dP/dt (mmHg/sec) 3820±423 3050±200* 2520±400*† 3620±430†‡
Fibrosis (%) 2.60±0.84 17.50±2.14* 30.06±11.70*† 4.42±2.30†‡
β-myosin heavy chain 1.00±0.35 1.56±0.36* 1.77±0.30* 1.14±0.28†‡
Transforming growth factor-β 1.00±0.29 1.42±0.29* 1.44±0.35* 1.07±0.25†‡
pAkt 1.00±0.68 1.55±1.18 14.65±4.53*† 7.24±3.42*†‡
1016-10 Right Ventricular Dysfunction in Transient 
Stress Cardiomyopathy: Prevalence and Clinical 
Characteristics
Timothy P. Fitzgibbons, Christopher Madias, Adhar Seth, Joseph L. Bouchard, Natesa 
G. Pandian, Jeffrey T. Kuvin, Ayan R. Patel, Theo E. Meyer, Gerard P. Aurigemma, 
Dennis A. Tighe, University of Massachusetts Medical Center, Worcester, MA, Tufts-New 
England Medical Center, Boston, MA
BACKGROUND: Transient stress cardiomyopathy (TSC), or Takotsubo Syndrome, is 
an increasingly recognized cause of reversible LV dysfunction. While associated RV 
dysfunction (RVD) has been described, its prevalence and associated clinical findings 
are not well defined. METHODS: We identified 40 patients with TSC using the Mayo 
Clinic criteria. A single reviewer assessed 2D echocardiograms performed within 24 
hours of presentation . RV function was assessed by evaluating regional wall motion and 
calculating a wall motion score index (WMSI). RV dimensions were measured using the 
apical window (ASE scheme). RVD was defined as a RVWMSI >1.0. Characteristics of 
patients with and without RVD were compared. RESULTS: RVD was identified in 27% 
(11/40) of pts. RVWMSI was 1.2 ± 0.4 for the entire cohort and 1.7± 0.4 for the group with 
RVD. In each case of RVD, regional RV wall motion abnormalities involved the apex and 
spared the base. Mid-RV involvement occurred in only 3 pts. Patients with RVD had higher 
BNP levels and greater lengths of stay. RV dimensions, clinical characteristics, ECG 
findings, other biomarkers, and in-hospital complications were similar. CONCLUSIONS: 
In this cohort of patients with TSC, RV wall motion abnormalities, predominantly involving 
the apex and sparing the base, were present in approximately one-quarter of cases. 
Although associated with higher BNP levels and greater lengths of stay, RVD was not 
associated with increased cardiac morbidity or mortality. 
Entire Cohort 
(n=40) RVD- (n=29)
RVD+ 
(n=11)
P Value 
(RVD- vs +)
Age (yrs) 64.3 ± 14.1 62.9 ± 14.5 68.1 ± 13.1 NS
Female gender 37 (92%) 28 (96%) 9 (81%) NS
Emotional stressor 12 (30%) 10 (34%) 2 (18%) NS
Physiologic stressor 27 (67%) 18 (62%) 9 (81%) NS
LVEF presentation (%) 27.1 ± 9.4 27.5 ± 10.2 25.9 ± 7.3 NS
LVEF (%) follow-up 54.4 ± 10.8 53.1 ± 11.0 57.3 ± 10.4 NS
Mean QTc (msec) 504 ± 59 508 ± 60 491± 57 NS
ST elevation 17 (43%) 13 (46%) 4 (36%) NS
T-wave inversion 23 (57%) 16 (55%) 7 (63%) NS
Peak CK (ng/ml) 435 ± 511 482 ± 580 491 ± 219 NS
Peak CK-MB (ng/ml) 31 ± 40 36 ± 45 21± 25 NS
Peak Troponin I (ng/dl) 9.31± 17.13 11.23 ± 19.39 3.53 ± 3.56 NS
Peak BNP(pg/ml) 1284± 703 917± 460 1870± 645 <0.05
RVWMSI 1.20 ± 0.37 1.00 1.72 ± 0.35 <0.05
RV Dimension basal (cm) 2.88 ± 0.63 2.89 ± 0.67 2.87 ± 0.55 NS
RV Dimension mid (cm) 2.66 ± 0.64 2.63 ± 0.63 2.76 ± 0.70 NS
RV Dimension long-axis 
(cm) 7.48 ± 1.21 7.42 ± 1.28 7.62 ± 1.07 NS
Heart failure 24 (60%) 17 (58%) 7 (63%) NS
In-hospital Mortality 2 (5%) 2 (6.8%) 0 (0%) NS
Hypotension/shock 11 (27%) 8 (28%) 3 (27%) NS
Length of stay (days) 6.74 ± 6.08 5.17 ± 4.12 11.3 ± 8.49 <0.005
1016-11 Ventricular-Vascular Stiffening Is More Strongly 
Associated With Exercise Capacity Compared to Left 
Ventricular Outflow Tract Gradient in Hypertrophic 
Cardiomyopathy
Bethany A. Austin, Deborah H. Kwon, Carlos Dumont, Raymond Wong, Maran 
Thamilarasan, Scott D. Flamm, Harry M. Lever, Milind Y. Desai, Cleveland Clinic 
Foundation, Cleveland, OH
Background: Reduced exercise capacity in hypertrophic obstructive cardiomyopathy 
(HOCM) is due to dynamic left ventricular outflow tract (LVOT) obstruction & progressive LV 
stiffening. Ventricular-vascular stiffening (VVS), a ratio of effective LV & arterial elastance, 
is an aggregate measure of LV & aortic coupling. It is a good indicator of effective LV 
forward flow, independent of mitral regurgitation. Maximal oxygen consumption (MVO2) is 
an accurate marker of exercise capacity & can predict outcomes. We sought to determine 
the association between VVS, LVOT gradient & MV02 in HOCM patients with preserved 
ejection fraction.
Methods: 42 newly referred symptomatic HOCM patients (62% men, 52 +/- 14 years) 
underwent Doppler echocardiography, cardiopulmonary exercise testing & cine cardiac 
magnetic resonance (CMR, 1.5 T, Siemens, Germany) between 10/06-6/07. Immediate 
post exercise LVOT gradient (mm Hg), number of metabolic equivalents (METS), MV02 
(ml/kg/minute) & CMR LV indices [end-systolic, end-diastolic & stroke volume (all in ml) & 
ejection fraction] were measured. Resting VVS was calculated non-invasively as: Effective 
arterial elastance/ LV end-systolic elastance [(end-systolic pressure/stroke volume)/ (end-
systolic pressure/LV end-systolic volume index)].
Results: Mean resting ejection fraction, VVS, end-systolic volume, end-diastolic volume & 
stroke volume were 64 % ± 6, 0.6 ± 0.2, 63 ±21, 172 ± 44 & 110 ± 29 respectively. Mean 
post-exercise LVOT gradient, METS & MV02 were 98 ± 49, 6.8 ± 2 & 24 ± 7 respectively. 
VVS correlated with METS (p=0.001, r=0.47) & MV02 (p=0.004, r=0.44) but not with 
post-exercise LVOT gradient (r = 0.25, p = ns). On receiver operator characteristic curve 
analysis, VVS predicted MV02 < 24 & METS < 6 (areas under the curve 0.78 and 0.80 
respectively, p < 0.001). On multivariate analysis only VVS, age & gender were associated 
with MVO2 < 24 (p < 0.001 for the model).
Conclusion: In symptomatic HOCM patients with preserved ejection fraction resting VVS 
had a stronger association with MV02 as compared to LVOT gradient. Resting VVS may 
better predict exercise capacity in such patients and could represent both a potential 
therapeutic target and a prognostic indicator.
1016-12 Vincristine Attenuates Doxorubicin Cardiotoxicity
Chatterjee Kanu, Jianqing Zhang, Rong Tao, Norman Honbo, Joel Karliner, UCSF, San 
Francisco, CA, VA Medical Center, San Francisco, CA
Background: Doxorubicin, a widely used chemotherapeutic agent, produces considerable 
cardiotoxicity. A proposed mechanism of this cardiotoxicity is induction of oxidative stress. 
A previous study from our laboratory documented that the vinca alkaloid vincristine (VCR), 
which is often co-administered with doxorubicin, exerts cardioprotective effects in cultured 
adult mouse cardiac myocytes exposed to either chemical or hypoxic oxidative stress 
(JMCC 2007; 43:327-36). We hypothesized that VCR could also protect cardiac myocytes 
exposed to doxorubicin. Methods: Cultured adult cardiac myocytes prepared from male 
C57Bl/6 mice (19-25g) were incubated for 20-24 hours with 15 µg/ml doxorubicin with and 
without concurrent treatment with 10 µM VCR. Trypan blue exclusion assay (TBE) and 
the Live/Dead Viability/Cytoxicity Assay were used to measure myocyte survival. Western 
blots were employed to explore the mechanisms of doxorubicin myocyte toxicity and the 
effects of concurrent treatment with VCR. Results: TBE exclusion showed that only 43% 
+3% of myocytes treated with doxorubicin alone survived. Concurrent treatment with 
VCR increased survival to 89% +4% (n=5, p<0.01). The “Live/Dead” assay also showed 
that with doxorubicin treatment alone, the proportion of viable cells markedly decreased 
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and with concurrent VCR treatment cell survival was largely preserved. When myocytes 
were treated with doxorubicin + VCR , prosurvival signals were activated (increased 
phosphorylated Akt and phosphorylated GSK-3β) and mitochondrial cytochrome C 
release was reduced. Doxorubicin alone further decreased cell survival in the presence of 
the PI3K/Akt inhibitor Ly294002 and of the MEK/ERK inhibitor PD98059. With concurrent 
VCR treatment in the presence of these inhibitors the magnitude of salvage was reduced. 
Conclusion: Concurrent treatment with VCR activates survival signals that markedly 
attenuate doxorubicin induced cardiac myocyte death. These novel findings may have 
clinical implications for the prevention of doxorubicin cardiomyopthy.
1016-13 A Novel β Myosin Heavy Chain Gene Mutation 
p.Met531Arg Identified in Isolated Left Ventricular 
Noncompaction in Humans Resulted in Left Ventricular 
Hypertrophy That Progressed to Dilation in a Mouse 
Model
Tomoya Kaneda, Hidekazu Ino, Noboru Fujino, Katsuharu Uchiyama, Kenshi Hayashi, 
Kenji Sakata, Eiichi Masuta, Toshinari Tsubokawa, Akira Funada, Chie Naruse, Masahide 
Asano, Masakazu Yamagishi, Division of Cardiovascular Medicine, Kanazawa University 
Graduate School of Medicine, Kanazawa-shi, Japan, Division of Transgenic Animal 
Science, Advanced Science Research Center, Kanazawa University, Kanazawa, Japan
Background: Mutations in the β-Myosin heavy chain (βMHC), a sarcomeric protein are 
responsible for hypertrophic and dilated cardiomyopathy. However, the mechanisms whereby 
distinct mutations in βMHC gene cause two kinds of cardiomyopathy are still unclear.
Methods and Results: To find the responsible mutation, we searched for genomic mutations 
in 99 unrelated probands with dilated cardiomyopathy and 5 probands with isolated 
left ventricular noncompaction (LVNC), and identified a novel de novo p.Met531Arg 
mutation in βMHC in a 13-year-old girl with isolated LVNC. Next, we generated six lines 
of transgenic (Tg) mice carrying a p.Met532Arg mutant αMHC gene, which was identical 
to the p.Met531Arg mutation in the human βMHC. Among these, two lines with strong 
expression of the mutant αMHC gene were chosen for further studies. Although they did 
not exhibit the features characteristic of LVNC, approximately 50% and 70% of Tg mice 
in each line displayed left ventricular hypertrophy by 2-3 months of age. Furthermore, left 
ventricular dilatation developed in approximately 25% of Tg mice by 18 months of age, 
demonstrating biphasic changes in left ventricular wall thickness.
Conclusions: This study supports the idea that common mechanisms may be involved in 
the left ventricular hypertrophy and dilation. The novel mice model generated can provide 
important information for the understanding of the pathological processes and etiology of 
cardiac dilation in humans.
1016-14 Association of Left Ventricular Diastolic Dysfunction 
With Dyssynchrony in Acute Onset Cardiomyopathy
Hidekazu Tanaka, Masaki Tanabe, Randall C. Starling, Dennis M. McNamara, John 
Gorcsan, III, University of Pittsburgh, Pittsburgh, PA, Cleveland Clinic, Cleveland, OH
Background: Diastolic function plays an important role in heart failure, but the effect of 
left ventricular (LV) dysynchrony on diastolic function in acute onset cardiomyopathy is 
unclear.
Methods: We studied 50 patients with acute onset cardiomyopathy: 46±14 yrs, ejection 
fraction (EF) 24±9%, defined as recent onset nonischemic cardiomyopathy < 6 months. 
Echos were performed at presentation and 6 months follow-up. Diastolic function was 
assessed by mitral inflow E, mitral E’ annular velocity and E/E’ to estimate filling pressure. 
LV dyssynchrony was analyzed from apical views as the opposing wall delay by Velocity 
Vector Imaging (Siemens Corp.). Fifteen normal subjects were also studied.
Results: At presentation, patients had diastolic dysfunction (E/E’=14±6) and dyssynchrony 
(94±51ms), (p<0.001 vs. controls). Patients with dyssynchony >75 ms, had more diastolic 
dysfunction: E/E’ 15±6 vs. 12±4* (*p<0.05), even though EF was not significantly different: 
25+9% vs. 22+8 % in non-dyssynchony group. At 6 months, EF improved from 24±9% to 
40±12%* and dyssynchrony improved from 94±51ms to 49±25ms* (*p<0.001). Diastolic 
function also improved: E/E’ = 9±4*, and prevalence of restrictive filling was reduced from 
45% to 9%*, (*p<0.001 vs. baseline).
Conclusion: LV diastolic dysfunction is associated with dyssynchony in acute onset 
cardiomyopathy and improvements are associated with improvements in LV systolic 
function and synchrony. These observations may have clinical implications. 
1016-15 Evidence That Post-Contrast Delayed Enhancement 
Identified by Cardiovascular Magnetic Resonance 
Imaging Is an Arrhythmogenic Substrate in 
Hypertrophic Cardiomyopathy
A. Selcuk Adabag, Barry J. Maron, Evan Appelbaum, Caitlin J. Harrigan, Jacqueline 
L. Buros, Michael Gibson, John R. Lesser, Constance A. Hanna, James E. Udelson, 
Warren J. Manning, Martin S. Maron, Minneapolis Heart Institute Foundation, 
Minneapolis, MN, Tufts-New England Medical Center, Boston, MA
Background Delayed enhancement (DE) on contrast-enhanced cardiovascular magnetic 
resonance (CMR), representative of myocardial fibrosis is relatively common in the left 
ventricle (LV) of patients with hypertrophic cardiomyopathy (HCM). However, the clinical 
significance and arrhythmogenic potential of this finding remains unresolved. Therefore, 
the objective of the present study was to assess the prevalence and frequency of 
spontaneous tachyarrhythmias in HCM with regard to DE on contrast-enhanced CMR.
Methods A total of 177 HCM patients (age 41 ± 16 years; 95% asymptomatic or 
mildly symptomatic) were evaluated by 24-hour ambulatory Holter ECG and contrast-
enhanced CMR.
Results A total of 72 patients (41%) had DE (transmural in 39/72), occupying 8.5±7.8 
percent of the LV wall. Premature ventricular contractions (PVCs), couplets and 
nonsustained ventricular tachycardia (NSVT) occurred in a significantly higher proportion 
of patients with DE than those without DE (PVCs: 89% vs. 72%; couplets: 40% vs. 17%; 
NSVT: 28% vs. 4%, respectively; p < 0.0001-0.007). Patients with DE also had greater 
numbers of PVCs (202 ± 655 vs. 116 ± 435), couplets (1.9 ± 5 vs. 1.2 ± 10), and NSVT 
runs (0.4 ± 0.8 vs. 0.06 ± 0.4) than did non-DE patients (all p<0.0001); DE was an 
independent predictor of NSVT (relative risk 7.3, 95% CI 2.6 - 20.4; p<0.0001). Of note, 
however, extent (%) of DE was similar in patients with and without PVCs (8.2% vs. 9.1%; 
p=0.93), couplets (8.5% vs. 8.4%; p=0.99) and NSVT (8.3% vs. 8.5%; p=0.35).
Conclusions In this large HCM cohort with no or only mild symptoms, myocardial fibrosis 
detected by CMR was associated with greater likelihood and increased frequency of 
ventricular tachyarrhythmias (including NSVT) on ambulatory Holter ECG. Therefore, 
contrast-enhanced CMR identifies HCM patients with increased susceptibility to 
ventricular tachyarrhythmias. These findings have implications for sudden death risk 
stratification in HCM.
1016-16 Incremental Value of Combined Left Ventricular Volume 
and Matrix Metalloproteinase-2 for Risk Stratification of 
Patients With Non-Ischemic Dilated Cardiomyopathy
Dong Heon Yang, Jae Hee Kim, Hun Sik Park, Yongkeun Cho, Shung Chull Chae, Jae 
Eun Jun, Wee Hyun Park, Jang Hoon Lee, Kyungpook National University Hospital, 
Daegu, South Korea
Background: Extracellular matrix remodeling and apoptosis are known to play important 
roles in the progression of heart failure (HF). The aim of this study was to evaluate the 
prognostic value of serum levels of matrix metalloproteinase(MMP)-2, MMP-3, soluble Fas 
(sFas) and soluble Fas ligand (sFasL) in patients with non-ischemic dilated cardiomyopathy 
(DCM). Methods: Serum samples were obtained from 70 patients with DCM and analyzed 
for MMP-2, MMP-3, sFas and sFasL. Patients were followed up for the occurrence of either 
mortality or hospitalizations due to HF. Results: Cardiac events were occurred at 21(30%) 
patients (death: 10, hospitalization due to HF: 11). LV end-diastolic volume (LVEDV) and 
end-systolic volume (LVESV) were higher and mitral Ea was lower in cardiac event group. 
Serum level of MMP-2 was significantly higher in cardiac event group (287.2±99.3 vs 
221.0±68.9 ng/mL, p=0.01). However, serum levels of MMP-3, sFas and sFasL were not 
different between two groups. Kaplan-Meier event free survival curve stratified into 4 groups 
according to combinations of LVEDV and MMP-2 showed significantly different event rates 
(Fig 1). Cox proportional hazards analysis demonstrated that MMP-2 added significant 
incremental prognostic information (Fig 2). Conclusions: Serum level of MMP-2, but not 
MMP-3, sFas or sFasL is an independent prognostic factor and combined LVV and MMP-2 
have incremental value to predict cardiac events in patients with DCM. 
1016-17 High Frequency of Abnormalities of the Mitral Valve 
Apparatus and Papillary Muscles in Hypertrophic 
Cardiomyopathy Patients That Fail Alcohol Septal 
Ablation
Carmel M. Halley, Deborah H. Kwon, Samir R. Kapadia, Nicholas G. Smedira, Maran 
Thamilarasan, E Murat Tuzcu, Bruce W. Lytle, Harry M. Lever, Milind Y. Desai, Cleveland 
Clinic Foundation, Cleveland, OH
Background: Choice of treatment (surgery or alcohol septal ablation (ASA)) for drug-
refractory hypertrophic obstructive cardiomyopathy (HOCM) remains controversial 
as some patients undergoing ASA require repeat intervention. We sought to assess 
morphologic differences in HOCM patients with successful vs. unsuccessful ASA.
Methods: We compared 26 consecutive patients (group 1, mean age 55 ± 15 years , 
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46% male) with unsuccessful ASA (residual left ventricular outflow tract (LVOT) gradient 
> 30 mm Hg with symptoms) & referred for surgery with 20 consecutive patients (group 
2, mean age 68 ± 13 years, 25% male) and successful ASA (residual LVOT gradient ≤ 
30 mm Hg). Echocardiographic measurements [septal thickness (cm), maximal LVOT 
gradient (mmHg) & degree mitral regurgitation] were recorded at baseline & follow up (1-2 
months) in addition to papillary muscle (PM) & mitral valve (MV) morphology.
Results: Baseline echocardiographic measurements (septal thickness, maximal LVOT 
gradient, degree mitral regurgitation) were similar. However, group 1 had a significantly 
greater incidence of redundant anterior MV leaflets, anteroapical PM displacement and 
accessary chordal attachment at base of MV leaflet at baseline. (See table). During 
surgery, 8 (31 %) patients in group 1 had MV surgery along with myectomy.
Conclusion: In HOCM patients with unsuccessful ASA, there is a higher frequency of 
MV & PM abnormalities. Failure to identify these on pre-procedural imaging potentially 
increases the failure rate.
1016-18 Modulating Effect of Glycemic Control on the Left 
Ventricular Response to Afterload Stress in Diabetic 
Canines With Left Ventricular Dysfunction
Steven J. Lavine, Petar Prcevski, University of Florida, Jacksonville, FL, Wayne State 
University, Detroit, MI
Background: We have previously demonstrated that glycemic control with pre-existing LV 
dysfunction had a modulating effect on LV ejection fraction (EF), diastolic filling period 
(DFP), and on the index of myocardial performance (IMP). We hypothesized that afterload 
stress with LV dysfunction and poor control (PC) of diabetes would result in further 
reductions in EF, greater shortening of DFP, and greater increase in IMP as compared to 
diabetes with good control (GC).
Methods: Chronic LV dysfunction was induced in 11 mongrel dogs using coronary 
microsphere embolization resulting in EF between 35-40%. Diabetes was induced with 
sequential injections of alloxan tetrahydrate and randomized to either GC (fasting blood 
glucose:100-150 mg%) or PC (fasting blood glucose: 250-350 mg%) for 3 months using 
insulin. After 3 months, each dog was crossed over to the opposite glycemic control 
group. LV size and function were assessed at rest and following methoxamine afterload 
stress (increase arterial pressure > 40 mm Hg) with LV pressures, echo and Doppler prior 
to diabetes induction and with PC and GC.
Results: With PC (hemoglobin A1c: 8.9+3.1%), EF declined as compared to baseline LV 
dysfunction (38+6% vs 34+5%, p=0.04). LV end diastolic pressure increased 3 mm Hg 
(p<0.05). IMP increased (0.61+0.28 to 0.81+0.22, p<0.05) due to an increase in ICT (56+29 
to 108+36 msec, p<0.001) despite shortening of the isovolumic relaxation time (IRT) (65+26 
vs 39+20 msec, p=0.01). DFP shortened (516+146 vs 409+107 msec, P<0.001). The above 
parameters with GC (Hemoglobin A1c: 4.0+0.9) were similar to baseline LV dysfunction. 
With pressure loading (+58 mm Hg), as compared with GC, dogs with PC (p<0.05 for all 
parameters) demonstrated a 40% greater increase in both end diastolic and end systolic 
volumes, increased LV end diastolic pressure (by +3 mm Hg), increased IMP (by +0.201), 
ICT (by +20msec), and IRT (by +16 msec). DFP decreased by 46 msec (p<0.01) greater 
than GC due to later onset of mitral filling (by 36 msec, p<0.05).
Conclusions: Pressure loading in diabetic canines with poor glycemic control further 
exacerbated resting systolic and diastolic abnormalities as compared to GC.
1016-19 Impaired Myocardial Energetics Is Associated With 
Diastolic Dysfunction at Rest and During Exercise 
in Patients With Symptomatic Non-Obstructive 
Hypertrophic Cardiomyopathy (HCM)
Khalid Abozguia, Thanh T. Phan, Ganesh Nallur Shivu, Ibrar Ahmed, Abdul Maher, 
Mohammad Nassimizadeh, Kunal Chudasama, Stefan Neubauer, Perry Elliott, Hugh 
Watkins, Michael P. Frenneaux, University of Birmingham, Birmingham, United Kingdom
Background: We previously showed that patients with HCM typically exhibit a dynamic 
abnormality of diastolic function on exercise and this is thought to be important in the 
genesis of breathlessness. We hypothesized that impaired myocardial energy utilisation 
leads to diastolic dysfunction in HCM patients.
Methods: 23 symptomatic non-obstructive HCM patients (18 male and mean age of 
56 years) were enrolled. We measured maximal oxygen consumption (Vo2 max) and 
radionuclide indices of left ventricular diastolic filling (time to peak filling [TTPF]) during 
semi-erect cycle ergometry at rest and during 50% workloads of heart rate reserve. 
Myocardial energetic status (PCr/γ ATP ratio) was measured by 31P magnetic resonance 
spectroscopy (MRS) using a Philips 3Tesla scanner.
Results: All patients exhibited marked exercise limitation (mean Vo2 max 20.1 
ml.kg-1.min-1, which was 64 +/- 11% of age and gender predicted maximum) due to 
breathlessness or fatigue rather than angina; mean LVEF was 67% (range 55-80%). 31P 
MRS studies showed that these patients had significantly reduced PCr/γ ATP ratio at 1.24 
± 0.03 (mean ± SEM) as compared to age and gender matched controls 1.76 ± 0.04 
(mean ± SEM, p=0.003). This was associated with an abnormal increase in TTPF from 
rest to exercise as previously described (0.62 ± 0.03 sec to 0.98 ± 0.05 sec from rest to 
50% workloads of heart rate reserve respectively) (Mean ± SEM) p=0.003. The change 
in TTPF on exercise is known to be heart rate (HR) dependent. We indexed it to heart 
rate change (Δ TTPF/ Δ HR). This index was negatively correlated with cardiac PCr/ γ ATP 
ratio (r=-0.63, p=0.02).
Conclusions: We show here symptomatic patients with non-obstructive HCM have 
impaired resting myocardial energetics which correlates significantly with diastolic 
dysfunction at submaximal exercise. Augmenting myocardial metabolism may have a 
potential role in the management of these symptomatic patients.
1016-20 Ischemic Cardiac and Skeletal Myopathy by Fabry 
Disease
Cristina Chimenti, Luca Padua, Romina Verardo, Costanza Pazzaglia, Herribert Pavaci, 
Emanuela Morgante, Matteo A. Russo, Andrea Frustaci, La Sapienza University, Rome, 
Italy, Catholic University, Rome, Italy
Background: Skeletal muscle disturbances in Fabry disease (FD) are common, but their 
origin is unknown.
Methods: Six patients with FD (4M,2F, 51±6 ys), left ventricular hypertrophy (MWT=19±2.5 
mm) and normal ejection fraction (62±3.5 %), with angina and dyspnea on effort, had 
also pain and fatigability of limb-girdle muscles. All patients received a left ventricular 
endomyocardial biopsy, a clinical, ultrasonographic and electromyography evaluation 
of deltoid, biceps brachii, quadriceps femuri, tibilias anterior, a needle biopsy of the 
quadriceps femuri.
Results: Cardiac histology showed intracytoplasmic vacuoles consisting ultrastructurally 
of concentric lamellar figures denoting FD (Panel A). Intramural coronary arteries (Panel 
B) exhibited hypertrophy and proliferation of smooth muscle and endothelial cells, 
engulfed by glycosphingolipids, determining severe lumen obstruction, and perivascular 
areas of replacement fibrosis. Muscle ultrasound revealed a moderate to severe muscular 
disarray of deltoid and quadriceps femuri. Electromyography showed signs of myopathy 
in all. Muscle biopsy showed glycosphingolipid accumulation in the perinuclear area of 
myocytes (Panel C) and severe lumen narrowing of muscle arterioles (Panel D), with 
perivascular areas of fibrofatty replacement.
Conclusions: FD causes a direct damage of skeletal and heart muscle. This is similarly 
represented by cell infiltration and progressive obstruction of intramural vessels inducing 
focal ischemia. 
1016-21 Prevalence of Viral Genomes in the Endomyocardial 
Biopsies From Patients With Dilated Cardiomyopathy
Dong Heon Yang, Sung Chull Chae, Tae In Park, Hun Sik Park, Yongkeun Cho, Jae Eun 
Jun, Wee Hyun Park, Kyungpook National University Hospital, Daegu, South Korea
Background: Aside from enteroviruses, various viruses such as parvovirus B19 (PVB19) 
may be a new and important candidate for myocarditis and non-ischemic dilated 
cardiomyopathy (NDCM). There were few studies on the prevalence of viral genomes in 
Asian population. The purpose of this study was to investigate endomyocardial biopsies 
(EMBs) from patients with NDCM for the presence of viral genomes by polymerase chain 
reaction (PCR). Methods: EMBs were obtained from 42 patients with NDCM in Daegu, 
Korea. Active myocarditis by Dallas criteria was excluded. PCR and reverse transcription-
PCR were performed to detect the genomes of enterovirus (EV), adenovirus, PVB19, 
cytomegalovirus, Epstein-Barr virus, herpes simplex virus (HSV), human herpesvirus 6 
(HHV6). EMBs were also assessed by immunohistochemical staining (IHCS) for CD3, 
CD45, and CD68. Results: Mean age of patients were 48 (range: 17-69) and 24 (57%) 
were male. Patients with duration of symptoms less than 6 months were 30 (71%). 
Sixteen (38%) of the 42 EMB were positive to viral genomes: EV = 1 (2.4%), PVB19 = 
11 (26.2%), HHV6 = 4 (9.5%), HSV2 = 1 (2.4%), including 1 case with multiple infection 
(PVB19 + HHV6). Seventeen (59%) of 26 EMBs without viral genomes and 12 (75%) of 
16 EMBs with viral genomes were positive to IHCS for cellular or adhesion makers. There 
were no differences in initial echocardiographic parameters and clinical event rates during 
short-term follow-up between two groups. Conclusions: Thirty-eight percent of EMB were 
positive to viral genomes by PCR. PVB19 genome was most frequently detected in EMBs 
of patients with NDCM in this population.
1016-22 Viral Infection of Intramural Coronary Vessels in 
Patients With Cardiac Syndrome X
Cristina Chimenti, Patrizio Sale, Romina Verardo, Matteo A. Russo, Andrea Frustaci, La 
Sapienza University, Rome, Italy, IRCCS San Raffaele Pisana, Rome, Italy
Background: The role of intramural coronary vessels infection/inflammation in patients 
with cardiac Sindrome X (CSX) is still unknown. 
Methods: Twelve consecutive patients (3M, 9F, mean age 52 ± 12 ys) affected by CSX 
underwent left ventricular endomyocardial biopsy. Myocardial tissue was examined for 
histology, immunohistochemistry and for cardiotropic viruses by polymerase chain 
reaction. In presence of a viral infection on the whole tissue, laser microdissection was 
performed to selectively analyse the viral genome in intramural vessels (panel A-B) and 
cardiomyocytes (panel C-D). Controls were myocardial biopsies from 15 patients with 
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chronic stable angina and 20 patients with mitral stenosis and normal cardiac function.
Results: Histology showed focal lymphocytic myocarditis in 10 CSX, and in 2 hypertrophy/
degeneration of myocardiocytes. No vasculitis was observed. In 8 patients (66%), all with 
myocarditis, a viral infection was detected (Epstein Barr virus in 4, adenovirus in 2, human 
herpes virus 6 (HHV6) in 1, Epstein Barr-adenovirus coinfection in 1) and in none of 
controls. Blood samples from CSX patients were virus negative. Laser microdissection 
showed Epstein Barr and adenovirus localized in both cardiomyocytes and intramural 
vessels. HHV6 was confined to vessel wall (panel E).
Conclusions: Viral genomes can be detected in intramural vessels of up to 66% of CSX. 
Coronary small vessels infection can explain the poor response to antischemic drugs 
suggesting new therapeutic options. 
1016-23 Greater Degree of LV Septal Hypertrophy and 
Associated Coronary Arteriole Dysplasia Are 
Significantly Associated With Myocardial Fibrosis in 
Hypertrophic Cardiomyopathy
Deborah H. Kwon, E Rene Rodriguez, Raymond Wong, Carmela Tan, Maran 
Thamilarasan, Nicholas G. Smedira, Bruce W. Lytle, Harry M. Lever, Milind Y. Desai, 
Cleveland Clinic Foundation, Cleveland, OH
Background: The causality of myocardial fibrosis (scar), frequently identified in patients 
with hypertrophic cardiomyopathy (HCM), even without history of epicardial coronary 
artery disease (CAD) or myocardial infarction is unclear. There is a high prevalence of 
dysplastic intramural coronaries in such patients. Cardiac magnetic resonance (CMR) 
accurately measures myocardial thickness and detects scar. We sought to study the 
association between dysplastic intramural coronary arterioles, seen on histopathology 
(HP) in HCM patients, with septal thickness and scar, assessed by CMR. Methods: We 
studied 60 consecutive symptomatic HCM patients (37 men; mean age 51 ±14 years), 
with no evidence of epicardial CAD on angiography and preserved left ventricular 
ejection fraction (mean 64 ± 5 %), that underwent pre-operative CMR (cine and delayed 
post-contrast) using Siemens 1.5 T scanner (Erlangen, Germany), followed by septal 
myectomy. Maximal end-diatolic interventricular septal (IVS) thickness and upper septal 
scar were recorded on cine and delayed post-contrast CMR, respectively. Presence of 
dysplastic coronary arterioles was recorded on HP. Results: Dysplastic coronaries were 
seen in 45 (75 %) patients. Scar was seen in 38 (63%) patients on delayed post contrast 
CMR. Patients with dysplastic coronaries had higher IVS thickness vs. those without (2.3 
± 0.7 vs. 1.7 ± 0.3, p < 0.01), despite similar age and gender distribution (50 ± 14 vs. 51 ± 
15 years and 60 % vs. 67 % men, both p = ns). On multivariate analysis (age, gender and 
upper IVS thickness), only upper IVS thickness was associated with dysplastic coronaries 
(p < 0.01 for the model). On receiver operating characteristic curve analysis, upper IVS 
thickness was predictive of presence of dysplastic coronaries (area under curve 0.75, 
p < 0.001). Presence (vs. absence) of IVS scar was associated with greater upper IVS 
thickness (2.4 ± 0.7 vs. 1.7 ± 0.3, p < 0.01) and higher frequency of dysplastic coronary 
arteries (78 % vs. 8 %, p < 0.001). Conclusion: Greater degree of LV septal hypertrophy 
and associated coronary arteriole dysplasia have a significant association with myocardial 
scarring, commonly seen in HCM patients, even in absence of epicardial CAD.
1016-24 Correlation of Left Ventricular Contractility With 
Myocardial Heat Production and Systemic Inflammation 
in Idiopathic Dilated Cardiomyopathy
Konstantinos Toutouzas, Sophia Vaina, Maria Drakopoulou, Pavlos Stougiannos, Maria 
Riga, Christodoulos Stefanadis, 1st Department of Cardiology, University of Athens, 
Athens, Greece
Background: Patients (pts) with left ventricular heart failure have increased myocardial heat 
production, which may be assessed by coronary sinus (CS) thermography. Our study aimed 
to investigate the possible correlation between CS blood temperature, ejection fraction (EF) 
and systemic inflammatory activation in pts with idiopathic dilated cardiomyopathy (DCM).
Methods: Twenty-five pts with DCM and 22 healthy subjects were enroled. C-reactive 
protein (CRP) levels were measured before the procedure. Temperature measurements 
were performed by a new thermography catheter and ΔΤ was defined as the difference 
between CS and right atrium (RA) blood temperature.
Results: Pts with DCM had higher ΔΤ compared to controls (0.25±0.09 vs. 0.14±0.07°C, 
p<0.01). ΔΤ and EF were inversely correlated in pts with DCM (R=0.43). CRP was similar 
between the 2 groups (0.95±0.50 mg/dL vs. 1.33±1.32 mg/dL, p=0.83). Interestingly, 
when pts with DCM were categorised in two groups using a cut-off value of CRP ≤ 1 mg/
dL, ΔΤ was lower in pts with high CRP (0.21±0.06°C vs. 0.30±0.08°C, p=0.01) (figure).
Conclusions: The reduced mechanical efficiency of the failing myocardium in pts with 
DCM results in increased heat production, interestingly without correlation to the systemic 
inflammatory activation.
1016-25 Non-Dilated Cardiomyopathy: Clinical Characteristics, 
Left Ventricular Structure and Factors Influencing 
Improvement in Systolic Function
Alexander Doumas, Timothy S. Draper, Jr., Edgar C. Schick, William H. Gaasch, Lahey 
Clinic Medical Center, Burlington, MA
Background: Modern management of patients with chronic heart failure and those with 
asymptomatic left ventricular (LV) dysfunction has focused primarily on patients with a 
low ejection fraction (EF) and LV enlargement/dilatation. However, little attention has been 
paid to those with low EF and normal or near-normal LV chamber size. Accordingly, we 
sought to examine LV geometry, clinical characteristics and outcomes in patients with 
non-dilated cardiomyopathy (NDCM).
Methods: Of 3353 transthoracic echocardiograms performed over a 6-month period, 
696 had an EF≤45%. Those with LV end diastolic dimension (EDD) >56mm, regional 
wall motion abnormalities (asynergy) and valvular disease were excluded. Ninety eight 
patients met criteria for the study and their medical records were reviewed. Data are 
mean +/- SD.
Results: The average age was 71+/-14 years; 56% were male. Body mass index was 
27+/-5. Comorbidities: hypertension: 52%, atrial fibrillation (AF): 43%, bundle branch 
block: 36%, diabetes: 28%, renal insufficiency: 19%, hypothyroid: 14%. Only 22% had 
disabling cardiac symptoms (functional class ≥III). The average LV EDD was 49 +/- 5mm; 
EF was 34+/-8%. LV hypertrophy (LV mass >105 g/m2) was present in 11%. The average 
mass/volume (M/V) ratio was 1.4+/-0.3. M/V exceeded the upper limits of normal (1.3) 
in 35 of 69 patients (51%). Patients with an EF≤30% (n=41; avg. EF 25+/-5%) were 
more symptomatic (functional class ≥III: 37 vs. 12%) compared with those with EF>30% 
(n=57; avg. EF 39+/-4%); EDD in these two subgroups was similar (50+/-6 vs. 48+/-5mm; 
p=0.07). In 44 patients with a mean follow up of 294 days, the average EF increased 
(33+/-8 to 41+/-14%; p<0.05); chamber size was unchanged (50+/-4 vs 50+/-5mm). In 
patients with AF (n=20), EF increased (33+/-6 to 44+/-15%; p<0.01).
Conclusion: Fourteen percent of patients with EF≤45% had NDCM and more than half 
exhibited concentric remodeling/hypertrophy. Common clinical correlates were hypertension 
and AF and the latter was associated with a significant improvement in ejection fraction. 
Severe systolic dysfunction in the absence of LV enlargement suggests that NDCM and 
dilated cardiomyopathy are not points along a continuum of a progressive disorder.
1016-26 Enzymatic Correction in Heart of Fabry Mice by 
Neonatal Injection of a Recombinant Lentiviral Vector 
That Engineers Expression of Alpha-Galactosidase A
Koji Higuchi, Makoto Yoshimitsu, Toshihiro Takenaka, Jeffrey A. Medin, Chuwa Tei, 
Kagoshima University, Kagoshima, Japan, University of Toronto, Toronto, Canada
Background: Fabry disease is caused by a deficiency of α-galactocidase A (α-gal A), 
which leads to the systematic accumulation of glycosphingolipids. Cardiac variant of the 
disease is found in 3% of male patients with left ventricular hypertrophy. We demonstrated 
enzymatic correction of the heart in Fabry mice with neonatal intravenous injection, 
direct intraventricular injection or transplantation of gene modified hematopoietic stem 
cells (HSCs) using therapeutic and marking bicistronic lentiviral vectors (LVs). However 
intravenous injection of a therapeutic and marking bicistronic LV had marginal cardiac 
enzymatic correction, direct intraventricular injection had only short-term effect due to host 
immune response. Bone marrow transplantation of gene-modified HSCs needed invasive 
whole body irradiation as a pre-conditioning regimen. In addition, emerging evidence has 
raised a concern about using gene-modified HSCs for clinical gene therapy application 
due to leukemogenesis. Therefore we developed simple therapeutic LV and delivered it 
intravenously into neonatal Fabry mice for maximizing therapeutic outcome without any 
pre-conditioning. Methods: We employed monocistronic LV carrying human α-gal A cDNA 
(LV/α-gal A). LV carrying enGFP cDNA (LV/enGFP) was used as a control. We injected 
PBS (n=10) or recombinant LVs (LV/α-gal A (n=10) or LV/enGFP (n=6)) into temporal vein 
of neonatal Fabry mice (1-3-day old). C57Bl/6 mice were used as a wild-type control (WT, 
n=5). Plasma enzyme activity was measured every 4 weeks. We monitored treated mice 
for 24 weeks and evaluated organ enzyme activity at sacrifice. Results: Plasma α-gal A 
activity of LV/α-gal A treated Fabry mice was higher than that of PBS treated Fabry mice 
and WT over 24 weeks (LV/α-gal A vs PBS; 110.7±11.7 vs 13.9±0.2 nmol/hr/ml, p<0.001 
at 24 weeks after the treatment). Increased levels of α-gal A activities in the heart of LV/α-
gal A treated Fabry mice were observed 24 weeks after the treatment ( LV/α-gal A vs 
PBS; 31.3±1.6 vs 12.1±1.3 nmol/hr/mg protein, p<0.001 ). Similar results were obtained 
in other organs. Conclusion: Neonatal intravenous injection of therapeutic LVs could be a 
potential long-term therapy for Fabry disease.
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1016-27 Favorable Long-Term Outcome of Percutaneous Septal 
Ablation for Symptomatic Hypertrophic Obstructive 
Cardiomyopathy
Dirk Welge, Lothar Faber, Dieter Fassbender, Henning K. Schmidt, Ulrich Gleichmann, 
Dieter Horstkotte, Department of Cardiology, Heart and Diabetes Center North Rhine-
Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany
Background: To define the role of percutaneous septal ablation (PTSMA) as compared 
to surgical myectomy we analyzed the long-term outcome of all patients (pts.) treated 
with PTSMA for symptomatic hypertrophic obstructive cardiomyopathy (HOCM) between 
1/1996 and 12/2005.
Methods: 347 patients consecutively underwent PTSMA in our institution. Mortality, 
morbidity, clinical status, and echocardiographic measures of obstruction (LVOTO) were 
assessed during follow-up (FU), either at our institution or by the referring cardiologist.
Results: During FU (58±35 months, range: 12-150 ) overall mortality was 1.8%/year, 
cardiovascular mortality 1%/year. A repeat procedure directed towards outflow obstruction 
was needed in 8% (n=28) of pts.. Significant improvement of symptoms (NYHA class I 
or II at last FU) was reported by 89%. In 74% of pts. LVOTO was absent at rest, 60% 
were also free from provocable LVOTO. Atrial fibrillation was the most frequent adverse 
event during FU, observed in 12% of pts.. Alcohol dosage was identified as a procedural 
parameter related to adverse events. Figures 1 and 2 show survival curves for overall 
survival (1) and event-free survival in NYHA class I or II (2).
Conclusions: PTSMA significantly improves symptoms and obstruction in HOCM without 
evidence for an excess mortality. Alcohol dosage should be kept low to avoid late 
untoward effects. Residual morbidity suggests that even after elimination of LVOTO pts. 
need specialized care.
1016-28 Pilot Study of a Novel Percutaneous Treatment Strategy 
for Hypertrophic Obstructive Cardiomyopathy
Brian Hynes, Orla Constant, Gerard King, Angie Brown, David Keane, David Keane, 
Department of Cardiology, St. James’s Hospital, Dublin, Ireland, Department of Cardiac 
Arrhythmia, St. Vincent’s University Hospital, Dublin, Ireland
Background: Left ventricular outflow tract (LVOT) obstruction in the setting of hypertrophic 
cardiomyopathy (HCM) confers negative adverse outcomes. Current non-pharmacologic 
treatment options include surgical myectomy and percutaneous transcoronary abalation 
of septal hypertrophy (TASH). While TASH offers a less invasive procedure, concern 
remains with particular regard to the arrhythmogenic potential of the resultant myocardial 
scar. Percutaneous Endomyocardial Septal Cryoablation (PESC) may circumvent some 
of these potential limitations and offer a novel treatment strategy. The purpose of this 
study was to report our initial experience and short term outcome with percutaneous 
endomyocardial cryoablation of the interventricular septum in obstructive HCM.
Methods: Between March 2005 and May 2006, 3 patients (2 male, 1 female) with 
symptomatic obstructive HCM underwent PESC. Baseline peak Doppler LVOT gradients 
were 70, 144 and 130mmHg for Patient no. 1, 2 and 3 respectively. Using 7Fr (French) 
and 9Fr 8-mm-tip CryoCath Freezor catheters (CryoCath Technologies, Inc., Montreal, 
Canada), cryothermal energy was applied to the interventricular septum under 
fluoroscopic guidance.
Results: Twenty to 32 applications of cryothermal energy were delivered with the mean 
nadir temperature sustained during cryoablation being -88°C. Two of the three patients 
had an immediate reduction in the LVOT gradient of greater than 50mmHg. Corresponding 
peak Doppler gradients at 8 months were 44, 49 and 107mmHg respectively. No adverse 
events relating to the procedure were experienced.
Conclusions: Percutaneous transvalvular endomyocardial septal cryoablation is feasible. 
A significant sustained reduction in LVOT gradient was induced in one patient. The 
two remaining patients experienced a modest sustained LVOT gradient reduction. The 
technique warrants further study to improve the consistency and duration of reduction 
in outflow gradient.
1016-29 Acute Glycemic Manipulation Alters Diastolic Function 
in Control Dogs Compared to Type I Diabetic Dogs
Heidi Millner, Kathryn Hilpisch, Renee Gerhart, Theresa Sorenson, Rodolphe P. Katra, 
Ruth N. Klepfer, Medtronic, Inc., Minneapolis, MN
Background Diastolic dysfunction is an early manifestation of diabetic cardiomyopathy 
that may be linked to blood glucose levels. We hypothesized that in altered glycemic 
states, diabetic dogs would show differences in diastolic dysfunction compared to healthy 
dogs, not seen in euglycemia.
Methods Ten well-controlled diabetic (D) dogs (Type I) and 6 healthy control (C) dogs had 
their blood glucose manipulated to create acute states of hypoglycemia (Hypo, <80mg/
dl), euglycemia (Eug, 100± 20mg/dl) and hyperglycemia (Hyper, >300mg/dl). Two minutes 
of 3 lead ECG was collected and an echocardiographic (echo) exam was performed in 
each state. Blood glucose was measured before, during and after the echo.
Results There were no significant changes in heart rate, QRS width, QT interval and PR 
interval between C and D dogs in any of the glucose states, nor within C or D dogs, but 
across glucose states. Interestingly, however, there were differences in echo measures of 
diastolic function. We compared D and C dogs in Hypo, Eug and Hyper. In Eug, the only 
significant difference was in E/A ratio. In Hyper, E velocity was also significantly different. 
In Hypo, E’ velocity, peak E velocity and E/A were significantly different. The mean values 
of these measures suggest that the differences seen in E and E’ velocity were driven by 
changes in the C dogs, not the D dogs.
Conclusion These data suggest that while the control dogs were able to adjust their 
diastolic function to the stress of different glycemic states, the diabetic dogs were not. 
1016-30 Clinical Profile and Significance of Delayed 
Enhancement in Hypertrophic Cardiomyopathy
Martin S. Maron, Evan Appelbaum, Caitlin Harrigan, Jacki Buros, C. Michael Gibson, 
Connie Hanna, John R. Lesser, James E. Udelson, Warren J. Manning, Barry J. 
Maron, Tufts-New England Medical Center, Boston, MA, Minneapolis Heart Institute, 
Minneapolis, MN
Background: The presence of delayed enhancement (DE) detected by cardiovascular 
magnetic resonance (CMR) is an independent predictor of cardiovascular events 
in ischemic and non-ischemic dilated cardiomyopathy but its clinical significance in 
hypertrophic cardiomyopathy (HCM) remains unresolved.
Methods: Cine and CMR-DE were performed in 202 HCM patients (42±17 years; 71% 
male) with a mean follow-up period of 607±127 days. Adverse cardiovascular events are 
tabulated as a combined end-point of: sudden death, appropriate ICD discharge and 
progressive heart failure symptoms.
Results: DE was identified in 103 (51%) HCM patients, occupying 9±11% (range 0.2 
to 51%) of LV myocardial volume, including 12% with DE >25%. DE was present all 
10 patients with ejection fraction (EF) ≤ 50% (i.e., end-stage phase), 9/10 (90%) with 
EF 51-59% and 84/182 (45%) with EF ≥ 60% (p<0.001). %DE was inversely related to 
EF (r= -0.4; p<0.001), most extensive in patients with EF ≤50% (27% vs.9% for other 
patients, p<0.001) and an independent predictor of EF (r= -0.6; p<0.001). Of the 182 
patients with normal EF ≥60%, 49 (27%) were both asymptomatic and had DE (7±7% 
of LV; 51% transmural), including 7 patients ≥60 years. The cardiovascular event rate in 
HCM patients with DE was higher compared to patients without DE but did not achieve 
statistical significance (2.5% vs. 3.5%; p=0.3). In addition, %DE was greater in patients 
with adverse events (11.7% vs. 9.3%; p=0.6) with no association with heart failure 
symptoms (p=0.1) and age (r = 0.05; p = 0.6).
Conclusions: In a large HCM cohort, DE was common and often occupied substantial 
areas of LV myocardium. DE was an independent predictor of systolic dysfunction, but 
also occurred frequently in association with preserved LV function and absence of heart 
failure symptoms. Over a short-term follow-up, DE was associated with greater (but not 
statistically significant) likelihood of adverse cardiovascular events. These data suggest, 
at present, prudent restraint is appropriate before considering altering HCM management 
strategies based solely on presence of DE, but also support further longitudinal studies to 
clarify the independent prognostic importance of DE.
1016-31 Sarcomere Gene Mutations Are Frequent in Idiopathic 
Dilated Cardiomyopathy, Even in Nonfamiliar Forms
Daniel Vega Moller, Michael Christiansen, Mads Ersboll, Henning Bundgaard, Paal 
S. Andersen, Paula Hedley, Johanna Moolman-Smook, Lars Kober, Copenhagen 
University Hospital Rigshospitalet, Copenhagen, Denmark
Background: Dilated cardiomyopathy is one of the leading causes of heart failure with 
high morbidity and mortality. In the absence of significant coronary artery disease or 
other discernible causes, its origin is considered unknown and termed idiopathic dilated 
cardiomyopathy (IDC). About 20-35 % of the IDC cases are familial forms (FDC). Mutations 
in some sarcomer protein genes have been shown to cause hypertrophic cardiomyopathy 
(HCM) as well as IDC and this had led to the assumption that other disease-causing 
genes in HCM could be involved in IDC.
Aim: We aimed to investigate a heterogenic Danish cohort of IDC patients, consisting of 
22 FDC patients and 10 non-FDC patients assessing the hypothesis that mutations in 
sarcomer protein genes are associated with IDC.
Methods: Thirty-two unrelated patients with IDC were recruited from a tertiary referral 
centre in Copenhagen and screened by CE-Single Strand Conformation Polymorphism 
and DNA sequencing for mutations in the coding regions of the sarcomer genes MYH7, 
MYBPC3, TPM1, ACTC, MYL2, MYL3, TNNT2, CSPR3 and TNNI3.
Results: Ten probands (age 34-69, 8 heart-transplanted) carried suspected disease-
causing genetic variants (31%). Genetic variants were found in six FDC probands, (27%), 
and in four non-FDC probands (40%). In MYH7 a novel mutation (K637E) was found in 
two probands and a novel rod mutation (R1832C) in one proband. In MYBPC3, two novel 
variants (T494I and IVS14-61C>T) and two known mutations (R326Q and E619K) were 
found. One proband was compound heterozygous for the previously described mutations 
in MYL2 (K104E and IVS6-1 G>C). One proband was double heterozygote for the known 
mutation in MYBPC3 (R326Q) and a novel rod mutation in MYH7 (L1038P). Another 
proband was triple heterozygous for two novel variants in MYH7 (IVS39+7C>A) and 
MYBPC3 (IVS25+13T>A) and a previously described mutation in TNNT2 (K247R).
Conclusion: Sarcomer gene mutations are more frequent in IDC than previously 
anticipated. The genetics are as complex, as seen in HCM. Thus, a genetic work-up 
should include screening of all sarcomer genes. Furthermore, the study emphasises the 
importance of screening these genes in IDC even in the absence of familial occurrence.
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1016-32 Tumor Necrosis Factor Receptor 1 Level Is Associated 
With Left Ventricular Hypertrophy: The Northern 
Manhattan Study
Yasuyoshi Takei, Ralph L. Sacco, Shunichi Homma, Bernadette Boden-Albala, Tanja 
Rundek, Zhezhen Jin, Kazuo Eguchi, Rui Liu, Mitchell S.V Elkind, Marco R. Di Tullio, 
Columbia Universiy Medical Center, New York, NY
Background: Increased left ventricular (LV) mass is a risk factor for cardiovascular 
disease. Although serum levels of inflammatory markers may serve as measures of the 
risk of cardiovascular events, few data are available on their association with LV mass. 
The aim of this study was to evaluate whether inflammatory markers are independently 
associated with LV mass in a multiethnic population.
Methods: As part of the Northern Manhattan Study, 695 stroke-free subjects had both 
transthoracic echocardiography and inflammatory markers measured. Inflammatory 
markers included tumor necrosis factor (TNF)-alpha, TNF receptors 1 and 2, Interleukin-6, 
and high-sensitivity C reactive protein (hsCRP). LV mass was measured by transthoracic 
echocardiography. Multiple logistic regression analysis was used to calculate the odds 
ratio (OR) and 95% confidence interval (CI) for the association of inflammatory markers 
with LV mass >75th percentile, after adjusting for age, gender, race-ethnicity, education 
status, history of coronary artery disease, hypertension, diabetes mellitus, body mass 
index, and smoking.
Results: The mean age was 67.9±9.6 years, and 61% were men; 57% were Hispanic, 
21% were black, and 20% were white. In univariate analyses, hsCRP and TNF receptor 1 
were significantly associated with LV mass, but other markers were not. Multiple logistic 
regression analysis demonstrated that both hsCRP (OR=1.02, 95% CI=1.00-1.04) and 
TNF receptor 1 (OR=1.29, 95% CI=1.09-1.53) were independently associated with 
LV mass >75th percentile. When both markers were included in the same model, TNF 
receptor 1 remained associated with LV mass >75th percentile (OR=1.28, 95% CI 1.08-
1.53), but hsCRP did not. Compared with the lowest quartile of TNF receptor 1, those in 
the highest quartile had an elevated risk of LV mass >75th percentile (OR=1.99, 95% CI, 
1.15 to 3.44).
Conclusions: TNF receptor 1 was independently associated with increased LV mass 
in this multiethnic sample. TNF receptor 1-mediated pathways might be involved in the 
regulation of the growth of cardiac myocytes.
1016-33 Left Ventricular Diastolic Function and Dyssynchrony 
Assessed by ECG-Gated Single Photon Emission 
Computed Tomography and a Novel Program 
CardioGRAF in Patients With Cardiac Sarcoidosis
Yoshikazu Yazaki, Masanoro Kawaguchi, Hiroki Kasai, Atsushi Izawa, Uichi Ikeda, NHO 
Matsumoto Hospital, Matsumoto, Japan, Shinshu University, Matsumoto, Japan
Background:Advanced atrio-ventricular block and life-threatening ventricular arrhythmias 
are frequently observed in patients with cardiac sarcoidosis (CS). Although permanent 
pacemaker (PM) and implantable cardioverter defibrillator (ICD) are indicated in those 
patients, it remains unclear whether right ventricular apical pacing by those devices 
influences cardiac performance, especially diastolic function and dyssynchrony in CS 
patients. Methods:To assess left ventricular (LV) diastolic function and dyssynchrony, we 
underwent ECG-gated single photon emission computed tomography (SPECT) using 
99mTc-sestamibi for 21 CS patients. Right ventricular apical pacing was needed in 10 
patients (Group A). The other 11 patients (group B) included right bundle blanch block 
(RBBB) in 5 patients. Peak filling rate (PFR:end-diastolic volume [EDV]/sec) was applied 
as an index of diastolic function obtained from the ECG-gated SPECT. Using a novel 
program “cardioGRAF”, we divided LV into 17 segments and defined dyssynchrony 
index (DI) as a difference between mean time from R-wave to end-systole (TES, msec) 
in 5 septal and 5 lateral segments. Results:Log-BNP was correlated with PFR (r=0.70, 
p<0.01). Group A patients showed significantly higher plasma BNP levels (148±102pg/
ml vs. 48±36pg/ml, p<0.05) and lower PFR (73±22 EDV/sec versus 125±44 EDV/sec, 
p<0.01) as compared to those in the other group B patients, although LV end-diastolic 
volume index (LVEDVI), LV end-systolic volume index (LVESVI), and LVEF were similar 
between the two groups. There was no significant difference in DI between Device and 
No-device group. DI was correlated with LVEDVI (r=0.74, p<0.001) and LVESVI (r=0.78, 
p<0.001). A patient with left bundle branch brock (LBBB) showed a marked improvement 
in dyssynchrony after the disappearance of LBBB by steroid treatment (DI: 16.4 to 5.9). 
Conclusions:Enhanced BNP secretion may be related to impaired diastolic performance 
in CS patients with right apical pacing. Dyssynchrony is associated with ventricular 
remodeling, but right ventricular apical pacing does not always cause LV dyssynchrony in 
CS. This may be influenced by uneven distribution of sarcoid lesions in the myocardium.
1016-34 Cardiotoxicity Associated With Trastuzumab: A Meta-
Analysis of 6159 Patients
Gurusher S. Panjrath, Raffay Khan, Nagesh Jagdhav, Diwakar Jain, St. Lukes-Roosevelt 
Hospital Center, Columbia University College of Physicians and Surgeons, New York, 
NY, Drexel University College of Medicine, Philadelphia, PA
Background: Trastuzumab as an adjuvant chemotherapeutic has been useful in 
increasing survival and reducing recurrence in clinical studies. However, symptomatic 
as well asymptomatic decreases in left ventricular function have been identified as a side 
effect. Studies have reported a variable risk of cardiotoxicity related to trastuzumab use. 
We performed a meta-analysis of clinical studies to better define the risk of trastuzumab 
associated cardiotoxicity.
Methods: Studies were searched using key words “Trastuzumab” and “Cardiotoxicity’ in 
MEDLINE and PUBMED. References from individual studies were hand searched. Only 
studies reporting cardiotoxicity in both trastuzumab as well as non-trastuzumab (Control) 
arm were included in this analysis. Studies with mean follow up < 1 yr were excluded. 
Relative risk (RR) was estimated for author defined cardiotoxicity and 95% Confidence 
intervals (CI). To test for heterogeneity between trials the Q statistic was used. A random-
effects model was used due to significant heterogeneity.
Results: Initial search resulted in 125 studies. 22 studies were identified in which 
trastuzumab constituted one arm. Only 9 studies fulfilled our inclusion criteria. 6159 
patients were included in the analysis. Mean age was 54 years with mean duration of 
follow up of 2 years. Trastuzumab was associated with a much greater risk of developing 
cardiotoxicity (RR- 2.40, CI 1.20-4.83, p<0.02). Average annual event rate in the 
trastuzumab group was 9.59 %. Regression analysis reveals prior radiation therapy (r2= 
0.81 & 0.94; trastuzumab and control groups respectively)) and prior anthracycline use 
(r2 = 0.79 & 0.92; trastuzumab and control groups respectively) as an independent risk 
for developing cardiotoxicity. Concomitant chemotherapy did not correlate with increased 
cardiotoxicity.
Conclusions: Trastuzumab is associated with 140 % increase in risk of developing 
cardiotoxicity. Clinicians need to perform a thorough risk versus benefit assessment 
prior to initiating therapy. Future analysis should be directed at short term or reversible 
cardiac dysfunction. Additionally, future trials should employ a standard definition of 
cardiotoxicity.
1016-35 Endothelial Progenitor Cell-Mediated Lentiviral 
Erythropoietin Gene Therapy in a Rat Model of 
Doxorubicin-Induced Cardiotoxicity
Rho-Kwan Park, Kyung-Kuk Hwang, Yu-Kyung Kim, Il-Ha Jeong, A-Reum Han, Tae-Jin 
Shim, Jin-Sook Kwon, Jang-Whan Bae, Seung-Taik Kim, Dong-Woon Kim, Myeong-
Chan Cho, Department of Internal Medicine, College of Medicine, Chungbuk National 
University, Cheongju, South Korea
Background: Recent studies suggest protective effects of erythropoietin (EPO) protein 
against doxorubicin (DOX)-induced cardiotoxicity. However, these protective effects of 
EPO protein require large amount of protein and frequent administration. We assessed 
the hypotheses that human endothelial progenitor cell (hEPC) is more efficient than HeLa 
cell as a gene-delivered vehicle, and EPO gene therapy using hEPC infected lentivirus 
(hEPC/Lent-EPO) is safe and feasible in a rat model of DOX-induced cardiotoxicity.
Methods: Recombinant lentiviral vectors containing rat EPO gene were made by 
cotransfection of 293T cell with pRRL-cPPT-CMV-EPO-PRE-SIN, pMDL, pVSVG, and 
pREV plasmid. We identified Lenti-GFP expression and measured EPO levels at hEPC/
Lent-EPO, HeLa/Lenti-EPO. Sprague Dawley rats (8weeks, n=15) were given 5mg/kg of 
DOX intravenously 3 times over a 2-week period (15mg/kg). hEPC/Lenti-GFP and hEPC/
Lenti-EPO groups were evaluated for the effects of hEPC and Lenti-EPO (DOX, DOX+ 
hEPC/Lenti-GFP, DOX+ hEPC/Lenti-EPO). DAPI-labeled hEPC (1x106 cells) infected 
Lenti-GFP and Lenti-EPO were used. Echocardiographic and histological analyses 
including apoptosis by TUNEL were evaluated at 4weeks.
Results: The GFP expression of hEPC was similar with that of HeLa. In vitro, EPO level 
of hEPC was higher than HeLa (126 vs 90 mU/mL). In vivo, the EPO level at hEPC/
Lenti-EPO was consistently increased during 2 weeks compared to hEPC/Lenti-GFP. 
All animals of hEPC-treated including both Lenti-GFP and Lent-EPO, were survived 
without any complication. Although overt heart failure was not developed at 4 weeks, the 
apoptosis of cardiomyocytes was inhibited at hEPC/Lenti-EPO than hEPC/Lenti-GFP.
Conclusions: hEPC is efficient cell source as a gene-delivered vehicle compared to 
HeLa cell, and Lenti-EPO gene therapy using hEPC is safe and feasible. These findings 
suggest that hEPC-mediated Lenti-EPO gene therapy has a considering potential as an 
effective treatment.
1016-36 Prognostic Role of Persistence of Significant 
Functional Mitral Regurgitation in Idiopathic Dilated 
Cardiomyopathy
Bruno Pinamonti, Francesca Della Barca, Marco Merlo, Stylianos Pyxaras, Gabriele 
Secoli, Laura Massa, Serena Rakar, Irena Tavcar, Andrea Di Lenarda, Gianfranco 
Sinagra, Cardiovascular Department, Azienda Ospedaliero-Universitaria “Ospedali 
Riuniti”, Trieste, Italy
Background. Functional Mitral Regurgitation (FMR) is a known prognostic factor Idiopathic 
Dilated Cardiomyopathy (IDC), still remains unclear the role of FMR persistence in 
patients (pts) on tailored therapy. We sought to evaluate the prognostic role of FMR 
persistence in these pts.
Methods. 553 IDC pts were enrolled since January 1991 to June 2006 in the Heart Muscle 
Disease Registry of Trieste. 417 of them (males 73%, mean age 45±14 years, NYHA 
III-IV 25%, left ventricular (LV) ejection fraction 32±11%, 87% in beta-blockers, 92% in 
ACE-inhibitors) with FMR echocardiographic data at baseline and at 12 (3-36) month 
follow up, were considered. Our population was divided in four groups: 1st, moderate-
severe FMR (color-Doppler jet area >4 cm2) both at baseline and after 12 months (57 
pts); 2nd, absent-mild FMR at baseline and moderate-severe after 12 months (21 pts); 
3rd moderate-severe FMR at baseline and absent-mild after 12 months (65 pts); and 4th, 
absent-mild FMR both at baseline and after 12 months (274 pts).
Results. During a 99±54 month follow-up, 42, 43, 26 and 18% of pts experienced death or 
cardiac transplant (D/HTx) in the 1st, 2nd, 3rd and 4th group respectively. Cumulative free 
from D/HTx survival at 5, 10 and 15 years was 58, 51 and 35% vs 89, 62 and 47% vs 86, 
75 and 61% vs 92, 83 and 74% in the 1st, 2nd, 3rd and 4th respectively (p<0.0001). 1st vs 
2nd and 3rd vs 4th group had a cumulative survival free from D/HTx in the long term without 
significant difference. On the other hand, pts with moderate-severe FMR vs pts with absent-
mild FMR at 12 month follow-up after 5, 10 and 15 years experienced D/HTx in 33, 47 and 
61% vs 10, 18 and 28% respectively (p<0.0001). Independent predictors of moderate-severe 
FMR regression were heart failure duration (for a 12 month decrease, HR 0.65 C.I. 95% 
0.45-0.95, p=0.022), LV end diastolic diameter (for a 5 mm decrease, HR 0.51 C.I. 0.28-
0.90, p=0.022) and FMR jet area (for a 2 cm2 decrease, HR 0.55 C.I. 0.38-0.90, p=0.02) at 
enrolment. Conclusions. Persistence of significant FMR in IDC pts, despite tailored therapy, is 
associated to a worse outcome in the long term. Prognosis of IDC pts with FMR regression 
becomes equivalent with the one of pts with absent-mild FMR at enrolment.
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1016-37 Impact of Elevated Matrix Metalloproteinase-2 on 
Development of Myocardial Fibrosis and Prognosis in 
Hypertrophic Cardiomyopathy With Sarcomere Gene 
Mutations: Evidence From Myocardial Late Gadolinium 
Enhancement Study
Eiichi Masuta, Hidekazu Ino, Noboru Fujino, Katsuharu Uchiyama, Kenshi Hayashi, 
Kenji Sakata, Toshinari Tsubokawa, Yuichiro Sakamoto, Akira Funada, Masakazu 
Yamagishi, Kanazawa University, Kanazawa, Japan
Background:Previous studies suggest that production of matrix metalloproteinase-2 
(MMP-2) is responsible for left ventricular fibrosis and remodeling which determine 
prognosis of hypertrophic cardiomyopahty (HCM). However, few data exist regarding 
actual relationship between extent of myocardial fibrosis and production of MMP-2 in 
clinical settings. Therefore, we determined MMP-2 levels and correlated to myocardial 
fibrosis and prognosis in HCM with sarcomere gene mutations.
Methods:The extent of myocardial fibrosis was determined by late gadolinium 
enhancement (LGE) in cardiovascular magnetic resonance (CMR). CMR and 
echocardiography were performed in 27 HCM patients (9 men and 18 women, mean age 
58±14 years) with sarcomere protein gene mutation (TNNI3=21, MBPC=5 and BMHC=1). 
CMR images were acquired on a 1.5T scanner and contrast-enhanced images were 
performed. Analysis was performed by manually defining the areas of hyperenhancement 
on all short-axis slices from the base to apex. The extent of LGE was expressed as a 
percentage of total myocardium. Enzyme-linked immunoassays were used to measure 
the plasma concentrations of MMP-2 in all patients.
Results:On echocardiograms, septal wall thickness was 15±4 mm and percent fractional 
shortening (FS) was 34±10 %. LGE was found in 24 of the 27 patients and the mean 
extent of LGE was 10.8 + 12.4%. The extent of LGE was larger in the group of low FS 
(≤25%, n=6) than that in the group of high FS (30.1 + 7.0 % vs. 5.2 + 6.7%, p<0.001). 
There was negative correlation between the extent of LGE and FS (r=0.84 p<0.001). 
Under these conditions, MMP-2 concentration was greater in low FS than that in high 
FS (972 + 207ng/ml vs. 741 + 114ng/ml, p<0.01) and, MMP-2 levels positively correlated 
with extent of LGE (r=0.571, p<0.01). Interestingly, during 2 years follow-up period, 5 of 6 
patients low FS with high MMP-2 experienced congestive heart failure and 1 patient died, 
although all 21 patients with high FS with low MMP-2 did not have event.
Conclusions:These results demonstrate that myocardial fibrosis with remodeling in HCM 
could be derived from elevated plasma MMP-2. We suggest that plasma MMP-2 levels 
can be a predictor of prognosis of HCM with sarcomere mutations.
1016-38 Reduced Cardiac Energetics Associated With Impaired 
Active Relaxation During Exercise in Patients With 
Heart Failure With a Preserved Ejection Fraction 
(HfpEF)
Thanh T. Phan, Ganesh Nallur Shivu, Khalid Abozguia, Mahadevan Gnanadevan, Ibrar 
Ahmed, Abdul Maher, Rebekah Weaver, Ross Campbell, Kunal Chudasama, Simon 
Anderson, Mohammad Nassimizadeh, Michael Frenneaux, University of Birmingham, 
Birmingham, United Kingdom
Background:Previously we have shown a dynamic abnormality of active relaxation 
(measured as time to peak filling - TTPF) in patients with hypertrophic cardiomyopathy. 
These findings were associated with a reduced stroke volume response on exercise. We 
now hypothesize that the pathophysiology of patients with HfpEF involves a dynamic 
exercise-induced abnormality of LV active relaxation and furthermore, this dynamic 
abnormality of LV relaxation is related to a reduction in cardiac energetics.
Methods:We used 31P cardiac magnetic resonance spectroscopy to measure the 
myocardial energetic status and radionuclide multiple-gated acquisition (MUGA) scan to 
assess resting and exercise TTPF during semi-erect cycle ergometry, at workloads of 
20%, 35% and 50% of heart rate reserve, in 10 HfpEF patients (9 female) with no history 
of ischaemic heart disease and diabetes, and in 6 healthy volunteers (HV) (4 females).
Results: HfpEF patients were 68.4 ± 5.1 years old with a Left ventricular Ejection Fraction 
(LVEF) of 60.95 % ± 6.5 and a VO2 max of 19.0 ml/kg/min ± 4.0 (63% of predicted). 
HV were 68.7 ± 3.3 years old (p=0.88) with a LVEF of 65.1% ± 4.3 (p=0.19) and a VO2 
max of 32.1 ml/kg/min ± 5.7 (99% of predicted) (p=0.0001). Patients with HfpEF had 
significantly lower PCr/γ ATP ratio compared to healthy volunteers, 1.56 ±0.53 and 
2.16 ±0.47, respectively, P = 0.032. TTPF is influenced by heart rate (HR) which was 
significantly higher in healthy volunteers at workload 35% and 50% heart rate reserve. 
In order to correct for HR, ΔTTPF/ΔHR was calculated. At stage III of exercise ΔTTPF/
ΔHR in HfpEF patient and HV were +0.0111 ± 0.015 and -0.0046 ± 0.005, respectively 
(P = 0.027). (Mean ± SD)
Conclusions: We show here an attractive patho-physiological link between abnormal 
cardiac energetics leading to a reduction in active relaxation at sub-maximal exercise, 
which may lead to symptoms and a reduction in VO2 max in patients with HfpeEF.
1016-39 Association Statin-Indometacin in the Treatment of 
Acute Pericarditis: Preliminary Findings
Gaspare Parrinello, Pietro Di Pasquale, Salvatore Paterna, Internal and Specialist 
Medicine Department University of Palermo, Palermo, Italy
Background:The aim of the study was to evaluate the safety and efficacy of the 
combination of indomethacin and statin versus indomethacin plus placebo in patients 
with a first episode of pericarditis
Methods:. Fifty five consecutive patients with acute pericarditis were randomized in 
double blind fashion into two groups: group 1 was treated with indomethacin 150 mg plus 
rosuvastatin 10 mg and group 2 was treated with indomethacin 150 mg plus placebo. 
Both groups received treatment up to the normalization of inflammation markers and for 
the following week. Clinical and laboratory assessments (WCc, ESR, CRP, TNI, CK/MB, 
BNP plasma levels) and ECG and echocardiogram were performed at baseline and daily 
up to discharge. All the patients were followed as outpatients for 3 months to evaluate a 
recurrence of pericarditis.
Results:The two groups were similar in age, sex and laboratory parameters. Group 1 
(the statin group) included 28 patients, 18 M/10 F, age 29.5±5.7 years; group 2 (placebo 
group) comprised 27 patients 16 M/11 F, age 29.2±4.8 years. The statin group showed a 
significant faster reduction in CRP values (5.0±1 vs 6.0±2 days, p=0.022), in ST segment 
normalization (3.5±1 vs 4.5±1 days, p=0.001), pericardial effusion (4.5±1 vs 5.5±1 days, 
p=0.001) and ESR (5..0±1 vs 6.0±2, p=0.022). In addition a reduction of ospitalization 
(5.5±2 vs 6.5±2,p=0.069) was observed too.
Conclusions:Our data show that the combination of statin and indomethacin in patients 
with acute pericarditis is feasible, showing a significant reduction in inflammatory markers 
and a favourable trend in hospitalization time.These preliminary findings require further 
studies on a larger patient sample.
1016-40 Impact of Acute Response Of Obstructive Hypertrophic 
Cardiomyopathy to Oral Disopyramide and Correlates 
of Response
Dan Musat, Emad F. Aziz, Rimvida Obeleniene, Sripal Bangalore, Glenda Winson, Vilma 
Castaneda, Claudia Musat, Farooq A. Chaudhry, Mark V. Sherrid, St. Luke’s Roosevelt 
Hospital, New York, NY
Background: Disopyramide (diso) has been shown to be safe and effective treatment for 
symptomatic patients (pts) with obstructive hypertrophic cardiomyopathy (HCM). Based on 
clinical and echo characteristics we developed a score for prediction of response to diso.
Methods: Of 93 pts treated with diso in HCM clinic, we studied 48 pts (age 60 ± 18 years, 
gradient 85 ± 33 mmHg) admitted for initiation of diso with good quality echo pre- and 
24 ± 32 hrs on oral diso. A gradient reduction to less than 30 mmHg was considered a 
good response. 
Results: A good response was seen in 69% of pts with reduction in gradient to 14 ± 5 mm 
Hg; 15 (31%) were poor responders (59 ± 36 mm Hg). Predictors of response were older 
age, 63 ±17 vs. 51 ± 18 yrs (p<0.04), shorter anterior mitral valve (MV) leaflet length 28 ± 
4 vs. 36 ± 7 mm (p<0.001), and lower pretreatment gradient, 75 ± 23 vs.109 ± 41 mmHg 
(p=0.007). We assigned one point for the favorable characteristics: age ≥ 45, anterior MV 
length < 32 mm, and gradient < 80 mmHg. Point score varied from 0 to 3. A score of 2 or 
3 predicts 94% likelihood of good acute response compared with score of 0 or 1 which 
predicts only 13%. On long term follow up, poor responders were more likely to require 
myectomy 53% vs 15% (p=0.006). Overall in the 93 pts followed 4.4 ± 3.7 yrs annual 
cardiac death rate was 1.1%/yr and annual sudden death rate was 0.2%/yr.
Conclusions: Acute response to diso can be predicted by age, MV leaflet length and 
resting gradient. Poor response to diso treatment trial predicts the need for invasive 
intervention. 
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807-3 Novel Injectable Alginate Scaffold and Fetal 
Cardiomyocyte Transplantation as a Staged Procedure 
Improve Cardiac Remodeling and Function After 
Myocardial Infarction in Rat
Natalie Landa, Micha S. Feinberg, Radka Holbova, Liron Miller, Orna Tsur-Gang, 
Smadar Cohen, Shmuel Tubia, Jonathan Leor, Neufeld Cardiac Research Institute, Tel- 
Hashomer, Israel, Ben-Gurion University, Beer-Sheva, Israel
Background: Adverse cardiac remodeling after MI is associated with excessive damage to 
the extracellular matrix (ECM). We hypothesized that injection of in-situ forming alginate 
hydrogel into the infarct would provide a temporary scaffold, and attenuate adverse 
cardiac remodeling and dysfunction. The aim of our study was to determine and compare 
the effect of injectable alginate scaffold, with staged cardiomyocyte transplantation, 
injectable collagen scaffold, or saline on left ventricular (LV) remodeling and function after 
myocardial infarction (MI) in rat. 
Methods and Results: We developed a novel injectable, absorbable biomaterial composed 
of a calcium cross-linked alginate solution, which displays low viscosity and and 
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undergoes phase transition into hydrogel after injection into the infarct. Rats (n=48) were 
subjected to anterior MI and alginate biomaterial (n=24), collagen (n=12), or saline (n=12) 
were injected into the infarct. One week later, 12 of 24 alginate-treated rats received 
rat fetal cardiomyocytes transplantation (1x10 6 cells) into scar (staged procedure). 
Echocardiography was performed at 3 days (baseline), 1 and 2 months after MI and 
showed that both collagen and saline-treated animals developed significant LV dilatation 
accompanied by progressive deterioration in LV contractility (p<0.01 ). On the other hand, 
injectable alginate scaffold with and without staged transplantation of cardiomyocytes 
attenuated LV dysfunction. Hemodynamic studies, performed with pressure-volume (PV) 
system (Millar instruments) two months after MI, showed that LV end-diastolic and systolic 
volumes were significantly smaller in animals treated with injectable alginate, with and 
to lesser extent without staged cell transplantation, compared with animals treated with 
collagen scaffold and saline. (426 ±14 and 549±42 vs 661±40 and 623±53 uL, p=0.02; 
and 349±2 and 448±42 vs 607±49 and 552±60 uL, p=0.01). 
Conclusions: The present study shows, for the first time, that injectable alginate scaffold 
with staged transplantation of fetal cardiomyocytes improve the favorable effects of 
injectable alginate on cardiac remodeling and function after MI.
1:15 p.m.
807-4 Identification of a Novel Mutation in the Beta-Myosin 
Heavy Chain Gene Associated With Variable Phenotypic 
Presentation of Cardiomyopathy
Osama Bishara, Amy Sturm, Elizabeth A. Sparks, Subha V. Raman, Judith Westman, 
Christine Seidman, William T. Abraham, Ohio State University, Columbus, OH, Harvard 
Medical School, Boston, MA
Background: Hypertrophic cardiomyopathy (HCM) resulting from mutations in genes 
encoding sarcomeric proteins is the most common genetic cardiovascular disease. The 
aim of this study was to investigate the genetic etiology of a mixed phenotype of HCM, 
dilated cardiomypopathy (DCM) and sudden cardiac death segregating in an autosomal 
dominant fashion in a large kindred
Methods: Nineteen individuals from 2 generations were available for analysis. For this 
abstract, we focused on a subset of 6 individuals within these kindred: the proband, her 
husband, and their 4 offspring, one son and three daughters, ages 20, 25, 23 and 18 
years of age, respectively. The proband had a known history of DCM; offspring were 
evaluated with echocardiography and cardiac magnetic resonance (CMR) before and 
after the onset of cardiomypopathy so that the initial phenotypic expressions could be 
determined. Direct DNA sequencing of the coding regions and splice sites of the MYH7, 
MYBPC3, TNNT2, TNNI3, and TPM1 genes was performed on all 19 members of this 
nuclear family.
Results: The genotyping in this selected family revealed a heterozygous 2105T>A 
(I702N) missense mutation in exon 19 of the MYH7 gene in the proband, the son and one 
daughter. The 3 unaffected family members tested negative for this mutation. Genotype 
results for the remaining 13 family members are pending. The presenting phenotype in 
the proband and her 18 year old daughter was a DCM, while her son was found to exhibit 
HCM with asymmetrical septal hypertrophy; all diagnoses were confirmed with CMR and 
echocardiogram. The 3 other members of the family had a normal echocardiogram and 
CMR.
Conclusions: We report a novel mutation in exon 19 of the MYH7 gene that is 
associated with variable phenotypic expression including both dilated and hypertrophic 
cardiomyopathies within the same family. This report provides support to the previous 
finding that mutations in sarcomeric protein genes can cause both HCM and DCM and 
provides further insight into the full spectrum of the molecular mechanisms for both HCM 
and DCM. Such information will provide better understanding of these disease processes 
and potentially impact the management and outcome of these disorders.
1:30 p.m.
807-5 Increased Expression of Periostin in Left Ventricular 
Myocardium of Patients and Dogs With Heart Failure
Sharad Rastogi, Rasha Bazari, Hani N. Sabbah, Henry Ford Hospital, Detroit, MI
Background: Periostin (Pn) is a component of the extracellular matrix and is associated 
with epithelial-mesenchymal transition during cardiac development. Pn is re-expressed in 
adult life after myocardial injury. Administration of recombinant Pn was shown to induce 
proliferation of differentiated cardiomyocytes and promote cardiac repair. In this study, 
we tested the hypothesis that protein expression for Pn is increased in the failing left 
ventricular (LV) myocardium.
Methods: Protein expression for Pn was measured in LV myocardium of explanted 
failed human hearts due to ischemic cardiomyopathy (ICM, n=6), idiopathic dilated 
cardiomyopathy (IDC, n=6) and in of normal donor human hearts (NL-DNR, n=6) that 
were deemed not suitable for transplantation. Pn expression was also measured in LV 
myocardium of dogs with intracoronary microembolization-induced heart failure (HF-
Dogs, n=6) and in LV myocardium of normal dogs (NL-Dogs, n=6). Tissue homogenate 
was prepared from all samples and Pn protein expression was measured using Western 
blots and bands quantified in densitometric units (du).
Results: Pn expression was significantly increased in LV myocardium of patients with 
ICM compared to LV myocardium from NL-DNR hearts (5,238 ± 841 vs. 1,794 ± 281, 
p<0.05 ). Pn expression was also significantly increased in LV myocardium of patients 
with IDC compared to LV myocardium from NL-DNR hearts (8,782 ± 934 vs. 1,794 ± 281, 
p<0.05). Similarly, a significant increase was also seen in protein expression of Pn in LV 
myocardium of HF-Dogs compared to NL-Dogs (1,750 ± 57 vs. 1097 ± 74, p<0.05).
Conclusions: The results indicate that protein levels of Pn are markedly increased in LV 
myocardium of explanted failed human hearts as well in LV myocardium of dogs with 
experimentally-induced heart failure. Increased expression of Pn in the failing heart 
represents an endogenous trigger that drives re-entry of cardiomyocytes into the cell 
cycle. As such, Pn over-expression can be viewed as a positive adaptation if cell division 
occurs and leads to myocardial regeneration. However, if entry into the cell cycle is 
aborted, programmed cell death is evoked and PN over-expression can then be viewed 
as an adverse adaptation.
1:45 p.m.
807-6 Soluble Angiotensin Converting Enzyme 2 Activity 
Is Associated With Worsening Myocardial Function 
and Clinical Outcomes in Patients With Chronic Heart 
Failure
Slava Epelman, Richard W. Troughton, Kevin Shrestha, Gary S. Francis, Subha Sen, 
Allan L. Klein, W. H. Wilson Tang, Cleveland Clinic, Cleveland, OH
Background: Angiotensin converting enzyme 2 (ACE2) is an endogenous counter-
regulator of the renin-angiotensin system. Our group has demonstrated that soluble ACE2 
(sACE2) activity is increased in patients with heart failure (HF) and animal models have 
suggested that both membrane and sACE2 can be detected during disease progression. 
However, the relationship between sACE2 activity, myocardial function and clinical 
outcomes in patients with HF is unknown.
Methods: We developed a sensitive and specific fluorometric assay to measure sACE2 
activity in plasma, and then measured sACE2 activity in 113 patients with chronic systolic 
HF (left ventricular ejection fraction (LVEF)</= 35%, New York Heart Association (NYHA) 
class II-IV). Echocardiography, including color M-mode and tissue Doppler measurements, 
was performed at the time of blood sampling. We prospectively examined adverse clinical 
events (death, cardiac transplant, and HF hospitalizations) over 34 +/- 17 months.
Results: Patients who had higher sACE2 plasma activity were more likely to have a lower 
LVEF (Spearman’s r= -0.36, p <0.001), larger LV end diastolic diameter (r=0.23, p=0.02), 
greater RV systolic dysfunction (r=0.33, p<0.001), higher estimated pulmonary artery 
systolic pressure (r=0.35, p=0.002), and higher plasma NT-proBNP levels (r=0.35, p<0.001). 
sACE2 was less associated with diastolic dysfunction (E/septal E’, r=0.19, p=0.05) and 
was similar between patients with ischemic and non-ischemic cardiomyopathies. Patients 
were divided into tertiles of sACE2 activity and three year Kaplan-Meier estimates of 
adverse clinical events were 15.5%, 18.8% and 46.9% (p<0.002). After adjusting for age, 
gender, NT-proBNP, and LVEF, sACE2 activity remained an independent predictor of 
adverse clinical events (HR=1.7 [95% CI: 1.10 - 2.58], p=0.018).
Conclusions: Elevated plasma sACE2 activity was associated with more advanced 
myocardial dysfunction, and was a powerful independent predictor of adverse clinical 
outcomes. Consistent with animal data, sACE2 is associated with disease progression 
in human HF.
2:00 p.m.
807-7 Intramyocardial Transplantation of Allogeneic 
Mesenchymal Precursor Cells Alters Natural History 
of Heart Failure in an Ovine Model of Ischemic 
Cardiomyopathy
Yanping Cheng, Kai Xu, Naritatsu Saito, Timothy Martens, Michael Schuster, Genghua 
Yi, Silviu Itescu, Jie Wang, Cardiovascular Research Foundation, Orangeburg, NY
Background: Cell therapy with bone marrow mesenchymal stem cells (MPCs) may 
provide a new therapy for heart failure (HF). The goal of this study was to assess whether 
allogeneic MPCs can improve cardiac function and reverse left ventricular (LV) remodeling 
in HF due to myocardial infarction (MI) in sheep.
Methods: Acute MI was induced in 10 sheep by 90 min of left anterior descending artery 
(LAD) balloon occlusion followed by reperfusion; 4 wks after MI, animals were randomized 
into either the MPCs transplantation (MI-MPCs, n=5) group or the control (MI-Media, n=5) 
group. Allogeneic MPCs (225x106 cells) or control media were injected into the center 
and the border zone of infarct area via an open chest surgical approach. Hemodynamics 
and echocardiography were measured at baseline, 4 wks after MI and 8 wks after cell 
transplantation.
Results: 4 wks after MI, all animals developed signs of HF characterized by reduction in 
EF% and dilated LV chamber. 8 wks after MPCs injections and compared to MI-Media 
group, LVEDP was significantly lower (11±1 vs. 17±3 mmHg, P<0.05), EF was significantly 
higher, while LV end systolic diameter (ESD) and volume (ESV) were decreased, and 
there were no further increases in LV end diastolic diameter (EDD) and volume (EDV). 
Data are summarized in the table.
Conclusion: Intramyocardial allogeneic MPCs transplantation improved LV function and 
partially reversed LV remodeling in MI-induced HF, resulting in altered natural history of HF. 
EDD(cm) ESD(cm) LVEDV(ml) LVESV(ml) EF%
Baseline 4.00±0.25 2.51±0.19 47±4 17±1 61±1
4 wks After MI 4.49±0.31* 3.19±0.29 57±4 31±3* 45±4*
8 wks MI-Media 4.98±0.52* 3.59±0.46 67±5* 38±5* 40±4*
Baseline 3.35±0.14 2.35±0.16 47±2 18±2 63±1
4 wks After MI 4.04±0.23* 2.84±0.17* 52±3 28±1* 45±1*
8 wks MI-MPCs 4.03±0.14* 2.54±0.17† 53±1‡ 26±1*†‡ 51±1*†‡
Mean ± SE. *P<0.05 vs. Baseline; †P<0.05 vs. 4 wks after MI; ‡P<0.05 vs. MI-Media
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807-8 Lack of Association Between Beta Adrenergic Receptor 
Genotype and Survival in Heart Failure Patients Treated 
With Carvedilol or Metoprolol
Amy J. Sehnert, Susan E. Daniels, Michael Elashoff, James A. Wingrove, Christopher R. 
Burrow, Bridget Moore, Benjamin Horne, John F. Carlquist, Joseph B. Muhlestein, Mark 
Donahue, Stephen B. Liggett, Jeffrey L. Anderson, William E. Kraus, CardioDx, Inc., 
Palo Alto, CA, Duke University Medical Center, Durham, NC
Background: Discordant results of genetic associations between beta adrenergic receptor 
(BAR) genes and survival in beta-blocker treated heart failure (HF) patients have been 
reported, and different gene combinations and beta-blockers have been studied. We 
performed a clinical-genetic analysis to study the effect of genotypes and haplotypes 
in three BAR genes on transplant-free survival in a large cohort of HF patients from two 
institutions treated with carvedilol or metoprolol.
Methods: We identified 655 subjects (75% white, 73% male, mean age 61.7 yrs) with 
left ventricular dysfunction (LVEF < 40%) from the Duke CathGen (n=354) and the 
Intermountain Heart Collaborative Study Cardiovascular Registries (n=301). All subjects 
were diagnosed with HF (ischemic or non-ischemic) and were discharged on diuretic, ACE 
inhibitor and/or angiotensin receptor blocker, and beta blocker (metoprolol or carvedilol) 
between Jan 1, 1998 and Jun 30, 2006. Five polymorphisms in three genes: ADRB1 
(S49G, R389G), ADRB2 (G16R, Q27E), and ADRA2C (ins/del 322-325) were genotyped. 
Patients were followed for the primary endpoints of death or cardiac transplant. The study 
was powered at 80% to detect a 10% difference in outcomes.
Results: Complete genotypes were generated for 637 patients and there were 190 events 
(29.8%) over a median follow-up of 1070 days. Event-free survival was not significantly 
different between patients from the two institutions (p=0.34). Multivariate analysis of 
clinical factors revealed a significant effect of age (p=0.0063), male sex (p=0.0047), low 
EF (p=0.00019), and low hemoglobin (p=0.00010) on survival. No significant effect was 
found for SNP or haplotype analyses of ADRB1 or ADRB2. There was a weak trend by 
univariate analysis toward better survival seen as an additive function of number of alleles 
in the ADRA2c deletion polymorphism that was influenced by race (HR 0.48 [.20-1.16], 
p=.0988; for non-white only).
Conclusion: Genotypes and haplotypes in beta adrenergic receptor genes did not 
significantly affect survival in this multi-site cohort of HF patients treated with metoprolol 
or carvedilol. These results will be discussed in the context of other published studies.
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1023-1 Multiple Segmental Left Ventricular Asynergy in 
Patients With Cardiac Sarcoidosis With Septal Thinning: 
Quantitative Assessment by Speckle-Tracking 
Echocardiography
Jun Koyama, Hirohiko Motoki, Kazunori Aizawa, Hiroki Kasai, Atsushi Izawa, Takeshi 
Tomita, Setsuo Kumazaki, Hiroshi Tsutsui, Uichi Ikeda, Shinshu University School of 
Medicine, Matsumoto, Japan
Background: Previous studies have suggested that myocardial thinning at the base 
of the intra-ventricular septum characterize the presence of cardiac sarcoidosis. We 
hypothesized that basal septal thinning indicates multiple segmental wall motion 
abnormalities in patients with sarcoidosis.
Methods: Twenty-seven consecutive patients with sarcoidosis were examined. Fourteen 
of 27 patients had myocardial thinning at the base of the intra-ventricular septum by visual 
assessment (group A), and 13 had no septal thinning (group B). Ten normal volunteers 
served as control. Standard 2 dimensional/ Doppler echocardiography was performed. 
Left ventricular (LV) short-axis views at basal and mid-level were obtained for the 
measurements of speckle tracking strain. Results: There were no significant difference in 
standard/ Doppler echocardiographic parameters other than fractional shortening (group 
A: 30±12%, group B: 43±9%, control: 36±2%, P<0.05). In group A, circumferential strain 
values in all segments other than posterior wall at basal LV were lower than in group B. 
Radial strain values in group A were lower in all segments except for the segment of 
inferior wall at papillary muscle level compare to group B. There was no difference in 
circumferential and radial strain values between group B and control.
Conclusions: Multiple segmental LV systolic dysfunction exists in patients with basal 
septal LV thinning associated with cardiac sarcoidosis.
Radial strain (%)
Anteroseptum Anterior Lateral Posterior Inferior Inferoseptum
Basal LV 
Group A 13±10+ 12±10* 14±14* 17±15* 17±9* 13±9*
Basal LV 
Group B 34±15 42±18 49±18 50±18 46±19 39±18
Basal LV 
Control 24±6 31±8 41±13 46±13 41±8 32±5
Mid LV 
Group A 16±14+ 23±15* 28±19* 30±18* 30±20 22±19*
Mid LV 
Group B 34±18 41±20 47±21 50±22 47±22 41±21
Mid LV 
Control 32±14 42±14 51±13 54±13 49±13 40±11
*: P<0.05 vs 
group B, control
+ : P<0.05 vs 
group B
1023-2 Tissue Doppler-Derived Ventricular Stiffness Index 
Can Predict the Long-Term Survival in Patients With 
Restrictive Cardiomyopathy
Byung Ho Lee, Eui-Young Choio, Jong-Won Ha, Chi-Young Shim, Sung-Ai Kim, Yangsoo 
Jang, Namsik Chung, Yonsei cardiovascualr center, Seoul, South Korea
Background: Restrictive cardiomyopathy (RCM) has been shown to be characterized 
by restrictive ventricular filling associated with increased ventricular stiffness. However 
prognostic importance of severity of ventricular stiffness has not been studied yet. In this 
study, we sought to investigate whether tissue-Doppler derived indices of left ventricular 
(LV) filling and stiffness can be used as prognostic parameters in patients with RCM.
Methods: Eighty four RCM subjects with preserved LV systolic function (48 male, 36 
female; mean age 59.4±16.7 years) were followed during average 19 months after 
comprehensive clinical and echo-Doppler evaluations. Results: During follow-up, 37 deaths 
were occurred. In univariate analysis, age, blood hemoglobin concentration and creatinine 
level were significant predictors for mortality. Echo-Doppler derived-left ventricular (LV) 
end-diastolic elastance (defined as E/E’/stroke volume, Ed), time difference between 
early mitral inflow (E) and annular veolicity (E’) [T(E’-E)], LV end-systolic elastance (peak 
velocity/acceleration time at LV outflow tract, Es), LV ejection fraction and LV mass index 
could predict the mortality. On multivariate analysis, hemoglobin concentration, LVEd, 
and T(E’-E) emerged as independent predictors of mortality.Conclusion: In patients with 
RCM, echo-Doppler derived Ed and T(E’-E) can be independent predictors for long-term 
survival.
Multivariable analysis of ehocardiographic and clinical variables in RCMP 
p-value Hazard Ratio(HR) 95.0% CI for HR Lower Upper
LV ejection fraction .974 1.001 .938 1.068
T (E’-E) .021 4.266 1.241 14.658
LV mass index .752 1.003 .983 1.024
Age .218 1.025 .986 1.065
Hemoglobin .001 .628 .478 .826
Serum creatinine .246 1.111 .930 1.329
Log(LVEd) .028 .322 .117 .888
Log(LVEs) .463 .404 .036 4.530
1023-3 Risk Factors for Relapse and Death in Patients 
With Cardiac Sarcoidosis: An 18 Year Experience of 
Corticosteroid Treatment
Yoshikazu Yazaki, Shinichi Aso, Hiroki Kasai, Atsushi Izawa, Minoru Hongo, Uichi Ikeda, 
Morie Sekiguchi, NHO Matsumoto Hospital, Matsumoto, Japan, Shinshu University, 
Matsumoto, Japan
Background:Corticosteroid treatment is generally indicated in cardiac sarcoidosis (CS). 
Although an initial dose of 30mg/day and a maintenance dose of 5 to 10mg/day have been 
offered as a treatment regimen, the optimal dose and period of this medication remains 
to be established in CS. Risk factors for clinical relapse and prognostic indicators in CS 
patients treated with predonisolone also remain unknown. Methods:To assess the efficacy 
of corticosteroids on long-term survival, we analyzed clinical findings and outcome in 
consecutive 53 CS patients diagnosed between 1988 and 2007. Forty-five patients were 
treated with oral corticosteroids. Results:During the maintenance dose of prednisone (5 to 
10 mg/day), we clinically detected relapse of cardiac lesions in 12 CS patients presenting 
with recurrence of abnormal myocardial gallium-67 uptake, conduction disturbance or 
arrhythmias, or rapid worsening left ventricular ejection fraction (LVEF) after the long-
term stable clinical course. The 12 showed higher incidence of myocardial gallium-67 
uptake (82% vs. 25%, p<0.01) and thickening of ventricular wall (73% vs. 20%, p<0.05) 
before steroid therapy. During a mean follow-up of 80 months, cardiac death occurred in 
12 patients. Lower LVEF (hazard ratio [HR]:1.14/1% decrease, p<0.001), greater LV end-
diastolic dimension (HR: 1.10/1mm increase, p<0.001), positive granuloma obtained from 
endomyocardial biopsy (HR:9.21, p<0.001), sustained ventricular tachycardia (HR:5.3, 
p<0.05), thinning of the ventricular wall (HR:5.1, p<0.05) were associated with poor 
prognosis. Multivariate analysis identified lower LVEF (HR: 1.14/1% decrease, p<0.001) 
and positive granuloma obtained from endomyocardial biopsy (HR:5.40, p<0.05) as 
independent predictors of mortality. Conclusions:Relapse occurred in at least one-
forth of CS patients during the course of maintenance steroid therapy. More aggressive 
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steroid treatment may be required for CS patients showing abnormal gallium-67 uptake 
in the myocardium and/or thickening of the ventricular wall. Histological confirmation of 
sarcoidosis from the heart as well as severe systolic dysfunction is strongly related to 
poor clinical outcome in CS.
1023-4 Tissue Iron Loading and Cardiac Function in 
Transfusion-Dependent HbE-Beta Thalassemia
Thu-Thao Le, Marc HL Wong, Yin-Jun Toh, Liang Zhong, Ru-San Tan, National Heart 
Centre, Singapore, Singapore
Background: HbE-beta thalassemia (HbE/β), a common form of thalassemia in Southeast 
Asia, exhibits diverse clinical severity. Severe cases are transfused regularly. This exposes 
patients to tissue iron accumulation and premature death from heart iron overload. Heart 
and liver T2* values, a magnetic resonance (MR) relaxation parameter, decrease in 
heart and liver iron overload, respectively. We compared tissue iron loading and cardiac 
function in HbE/β versus beta thalassemia major (TM) patients, all of whom received 
regular transfusion and chelation therapy.
Methods: Age- and sex-matched HbE/β (group A, n=22) and TM (group B, n=22) patients 
underwent MR scan (1.5T Avanto, Siemens). Left ventricular (LV) end-diastolic and 
-systolic volumes and ejection fraction (EF), heart and liver iron loading were analyzed 
using CMRTools (CVIS, UK). Serum ferritin and pre-transfusion hemoglobin concentration 
(Hb) were determined in all patients.
Results: There were 11 males and 11 females, mean age 21 ± 8 years in each group. In 
group A, 1 patient had mild heart iron overload (T2* 10ms to <20ms); 3 had severe heart 
iron overload (T2* <10ms). In group B, 7 and 5 patients had mild and severe heart iron 
overload, respectively.
Conclusion: Compared to TM, HbE/β patients are more prone to liver iron overload. 
Further, their indexed LV volumes are significantly larger, and LVEF lower, despite lower 
prevalence and severity of T2*-assessed heart iron overload, and similar Hb levels, blood 
transfusion and chelation therapy.
Left ventricular function, treatment and tissue iron loading parameters (mean ± SD)
Group A (n=22) Group B (n=22) p value
Indexed LVEDV (ml/m2) 98.1 ± 20.0 86.6 ± 10.5 0.022
Indexed LVESV (ml/m2) 37.5 ± 8.5 29.8 ± 5.2 0.001
LVEF (%) 61.7 ± 4.1 65.5 ± 5.0 0.010
Transfusion duration (years) 17.0 ± 6.5 19.5 ± 7.7 0.251
Pre-transfusion Hb (g/l) 86 ± 12 87 ± 09 0.976
Chelation duration (years) 9.3 ± 5.9 13.1 ± 6.4 0.053
Serum ferritin (υg/l) 3792 ± 3145 3010 ± 1922 0.337
Heart T2* (ms) 36.0 ± 19.0 23.0 ± 14.9 0.015
Liver T2* (ms) 1.8 ± 1.0 3.6 ± 3.5 0.031
1023-5 Increased Myocardial Lipid Accumulation in 
Patients With Heart Failure Due to Nonischemic 
Cardiomyopathy
Frederick L. Ruberg, Itamar Ronen, Andreia Biolo, Samir Thadani, Brian Betensky, 
Elena Tokareva, Kevin Hallock, James A. Hamilton, Wilson S. Colucci, Boston University 
School of Medicine, Boston, MA
Background: Myocardial lipid is increased in patients with type-2 diabetes mellitus (DM). 
Experimentally, lipid accumulation has been shown to cause myocardial dysfunction due 
to lipotoxicity. In the absence of DM, adipokines are elevated in patients with chronic 
systolic heart failure, suggesting abnormal lipid metabolism. Therefore, we hypothesized 
that increased myocardial lipid accumulation might be involved in the pathophysiology of 
heart failure (HF) in patients both with and without DM.
Methods: Myocardial and hepatic triglyceride (TG) content was measured in vivo using 
ECG-gated, proton magnetic resonance spectroscopy at 3.0T. Measurements were made 
in 3 control subjects and 12 patients with clinical HF due to non-ischemic cardiomyopathy 
as evaluated by catheterization or stress perfusion imaging. Of the 12 HF patients, 7 had 
DM and 5 had no evidence of DM, as determined by random glucose levels. Cardiac 
function was quantified using cine MR imaging. Cardiac spectra were analyzed and TG 
content expressed as the percentage of water signal.
Results: Myocardial TG content in control subjects was 0.3±0.1%, similar to reported 
values. In patients with HF and no DM, myocardial TG content was elevated to 3.2±1.4% 
(p=0.025), and elevated further to 7.6±2.9% (p=0.017) in patients with HF and DM. 
Hepatic TG content was 1.6±0.1% in control subjects. In contrast to myocardial lipid, 
hepatic TG content was not increased in patients with HF and no DM (1.4±0.9%), but was 
increased in the patients with HF and DM (11.6±6.3%, p<0.01 vs. both control subjects 
and HF patients without DM). 
Conclusions: There is myocardial lipid accumulation in patients with HF due to non-ischemic 
cardiomyopathy, independent of DM. In contrast to patients with DM, myocardial but not 
hepatic lipid accumulation is present in patients without DM. This selective myocardial 
lipid accumulation raises the possibility that lipotoxicity contributes to the pathophysiology 
of myocardial dysfunction in patients with non-ischemic cardiomyopathy.
1023-6 Asymptomatic Left Ventricular Dysfunction Is More 
Prevalent in Pregnant Women Than in the General 
Population
Patricia P. Chang, Thomas S. Ivester, Caryline Salzmann, Melissa Caughey, Alan L. Hinderliter, 
Carla S. Dupree, Wayne D. Rosamond, University of North Carolina, Chapel Hill, NC
Background: Peripartum cardiomyopathy (PPCM) is usually diagnosed only after 
symptoms develop, but the prevalence of peripartum asymptomatic left ventricular 
dysfunction (ALVD) is unknown. Our aim was to estimate the prevalence of peripartum 
ALVD in pregnant women without history of cardiac dysfunction, heart failure, or 
congenital heart disease.
Methods: 203 pregnant women underwent echocardiography, serum B-type natriuretic 
peptide (BNP) testing, and survey examination during the last month of pregnancy. ALVD 
was defined by LV ejection fraction (EF) <50% by the biplane method of disks (modified 
Simpson’s rule).
Results: 18 (8.9%) pregnant women had mild ALVD (LVEF range 41-49%) (Table 1). 
Women with peripartum ALVD had lower BNP levels than those with no ALVD (p=0.005), 
and were younger (age >30 years: 27.8% vs 63.3%, p=0.003); their LV mass was also 
higher but this was not statistically significant. Both groups were similar in terms of: 
race; parity; comorbidities including hypertension, preeclampsia, diabetes; symptoms of 
dyspnea and pedal edema; and presence of diastolic dysfunction.
Conclusion: The prevalence of ALVD during pregnancy was 8.9%, which is higher than 
in the general population (3.0% in the Framingham Study). Peripartum ALVD was not 
associated with elevated BNP or PPCM risk factors such as black race, advanced 
maternal age, multiparity, and gestational hypertension. Further follow-up of this cohort 
will determine whether this ALVD persists post-partum.
Table 1
(+)ALVD (N=18) (-)ALVD (N=185) p value
Age (yr, mean, SD) 27.6±3.8 31.8±5.1 0.0008
Race (n, %) 
White 
Black 
Hispanic 
Asian
12 (66.7) 
3 (16.7) 
3 (16.7) 
0
128 (69.2) 
21 (11.4) 
28 (15.1) 
8 (4.3)
0.75
Parity (mean, SD) 2.5±1.8 2.2±1.3 0.39
LVEF (%, mean, SD) 46.3±2.8 58.4±4.8 <0.0001
Fractional shortening (%, mean, 
SD) 26.9±8.1 33.3±7.6 0.0009
Diastolic dysfunction (n, %) 5 (27.8) 36 (19.5) 0.40
LV mass (g, mean, SD) 158.7±40.4 146.8±31.2 0.13
LV end-diastolic dimension (cm, 
mean, SD) 4.6±0.4 4.5±0.4 0.42
BNP (pg/ml, mean, SD) 16.2±10.2 24.6±8.3 0.005
1023-7 Hypertrophic Cardiomyopathy in Exertional and 
Nonexertional Sudden Deaths
Allen Burke, Nathaniel B. Cresswell, Robert Kutys, Teri Franks, Ling Li, Renu Virmani, 
CVPath Institute, Inc, Gaithersburg, MD
Background: The pathologic features that characterize hypertrophic cardiomyopathy 
(HCM) in exertional vs. non-exertional sudden deaths have not been extensively studied.
Design: We prospectively performed gross measurements and histologic analysis on 107 
autopsy cases of HCM and correlated them with clinical findings.
Result: There were 107 cases, separated into four groups: exertional sudden death 
(SD) (n=38), non-exertional SD (n=36), non-sudden deaths in patients with known HCM 
(n=14), and incidental HCM in patients dying of non-cardiac cases (n=19). Pathologic 
features of the 74 SD were compared between exertional and non-exertional deaths. 
Age at death was significantly lower in exertional (26.6±13.6 years) vs. non-exertional 
SD (42.7±15.0 years, p <.0001). There was no significant difference in the incidence of 
syncope in the exertional SD (27%) compared to the non-exertional SD (26%, p=0.8), 
or in the rate of a prior diagnosis of HCM (13% vs. 17%, respectively). The proportion 
of women was significantly less in the exertional SD group (7.9%) vs. the non-exertional 
SD group (36%, p=.01). The mean heart weight in men was significantly less in the 
exertional SD (521±169 g) vs. the non-exertional SD (698±190 g, p<.001). There was no 
difference in the proportion of hearts with septal:free wall ratios >1.3 (43%) in exertional 
vs. non-exertional (43%) SD, in macroscopic septal scarring (15% vs. 15%), or intramural 
coronary dysplasia (37% vs. 42%). There was a non-significant increase in myocardial 
bridging >3 mm (21 vs. 13%, p=.06) and left ventricular outflow tract plaque (58 vs. 38%, 
p=.06), respectively. By multivariate analysis, including all categories of HCM, only age 
(p=.002) and heart weight (p=.02) were significantly associated with exertional SD, both 
in an inverse relationship.
Conclusion: There are no pathologic features which would identify patients with HCM 
at risk for exertional death. Because a high proportion of exertional sudden deaths with 
HCM are not associated with significant asymmetry or severe cardiomegaly, cardiologists 
should be careful in excluding the diagnosis of HCM in athletes with mild or moderate 
degrees of hypertrophy.
1023-8 Identification of T-Cell Proliferative Response to Cardiac 
Troponin I in Autoantibody-Positive Patients With 
Idiopathic Dilated Cardiomyopathy
Jason M. Lappe, Clara M. Pelfrey, Anne Cotelur, W. H. Wilson Tang, Cleveland Clinic, 
Cleveland, OH
Background: Autoantibodies (AAb) against cTnI are found in some patients with idiopathic 
dilated cardiomyopathy (IDCM). Animal models have demonstrated a pathogenic role of 
anti-cTnI AAb in the development and progression of cardiomyopathy, but such association 
has yet been identified in humans. We aim to examine the association between anti-
cTnI AAb production and the presence of a cellular mediated immune response to cTnI 
stimulation in patients with IDCM.
Methods: Peripheral blood monocytes and serum samples were obtained from stable 
ambulatory IDCM patients. AAb against cTnI were detected by ELISA, and a positive 
response defined as a titer >1:1000. Specificity of anti-cTnI AAb binding was confirmed 
by competitive inhibition studies. Cellular responses were identified by staining peripheral 
blood monocytes with carboxy fluoroscein succinimidyl ester (CFSE) dye and culturing 
for 7 days with 10 µg/mL of cTnI. Cells were phenotyped as CD3+ (T-lymphocytes) and 
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proliferation was measured using flow cytometric techniques.
Results: Among the 11 subjects with samples collected, 5 (45%) demonstrated the 
presence of anti-cTnI AAb. Presence of CD3+ proliferative response to cTnI incubation 
was directly associated with the presence of detectable anti-cTnI AAb (figure).
Conclusions: In this pilot study, we demonstrate the ability to measure and phenotype a 
lymphocyte proliferative response to cTnI in a subset of patients with IDCM.
1023-9 Right Ventricular Doppler Myocardial Imaging for the 
Early Diagnosis of Cardiac Involvement and Risk 
Stratification in Patients With Primary Systemic 
(AL) Amyloidosis: Comparison With Standard 
Echocardiographic Measurements
Diego Bellavia, Ghormallah Al-zahrani, Patricia A. Pellikka, Theodore P. Abraham, Jae K. 
Oh, Angela Dispenzieri, Francesco Pitrolo, Fletcher A. Miller, Mayo Clinic, Rochester, MN
Background: To date, no data exist about the Right Ventricular (RV) function in patients 
with AL amyloidosis. The aim of this study was to determine the role of assessment of RV 
function, using standard echo measurements and Doppler Myocardial Imaging (DMI) in 
early diagnosis of CA and in prediction of mortality.
Methods: 244 patients with primary systemic amyloidosis and 38 age and sex matched 
healthy controls were enrolled and divided into four groups based on LV thickness and E’ 
velocity (Table 1). Standard Echocardiographic parameters of RV function were assessed, 
and longitudinal systolic tissue velocity (sTVI), strain rate (sSR) and strain (sS) were 
determined for the basal and middle RV free wall segments. ROC curves were created to 
depict diagnostic accuracy. Patients were followed for the endpoint of all-cause mortality.
Results: sS of basal segment of RV free wall was the best to differentiate AL-normal-
echo patients from controls (AUC 0.73 cut-off value -31%; positive predictive value: 69%, 
negative predictive value: 58%). During median follow-up of 17 months, 77 patients died. 
Systolic RV PAP and sSR of the RV basal segment were independent predictors of death 
(HR 1.03, p-value 0.01; HR 1.3, p-value 0.005 for PAP and sSR, respectively).
Conclusions: DMI, and specifically sS of the basal segment of the RV free wall, identified 
early systolic RV dysfunction in patients with AL amyloid and normal standard echo. 
RV DMI and Systolic PAP were independent predictors of mortality in patients with AL 
amyloid. 
Table 1
Controls AL-Normal-Echo (n=53)
variable (mean ± SD) (n = 38) (Lvthick ≤ 12 mm E'' ≥ 0.07 cm/sec)
(p-value)
Age (years) 60 ± 13 59 ± 10 1.03 (0.006)
Males n (%) 18 (47) 27 (51) NS
LV Thickness (mm) 9 ± 1 10 ± 1 1.12(<0.0001)
E'' (cm/sec) 0.09 ± 0.02 0.08 ± 0.01 0.5 (<0.0001)
Free Wall Thickness 
(mm) 6 ± 1 5 ± 1 1.1 (0.01)
Fractional Area Change 
(%) 51.12 ± 12 45 ± 8 NS
Pulmonary Artery 
Press. (mmHg) 31 ± 6 32 ± 7 1.04 (<0.0001)
RV Ejection Time 
(msec) 307 ± 37 286 ± 43 NS
Right index of myoc. 
performance 0.26 ± 0.2 0.3 ± 0.2 NS
TAPSE (mm) 2.7 ± 0.5 2.3 ± 0.5 0.9 (0.002)
sTVI basal (cm/sec) 10.56 ± 2 9.1 ± 3 NS
sTVI middle (cm/sec) 7.59 ± 2 5.94 ± 3 NS
sSR Basal ( -2.39 ± 1 -2.06 ± 1 1.3 (0.001)
sSR Middle -2.21 ± 1 -1.8 ± 1 NS
sS Basal -34.77 ± 5 -28.26 ± 9 1.04 (0.002)
sS Middle -34.09 ± 7 -28.46 ± 8 NS
* HR= Hazard Ratio (Survival analysis considers AL-Normal-Wall-Thickness
and Advanced-CA patients together); NS: Not significant
1023-10 Immunosuppressive Therapy in Autoreactive 
Myocarditis--Sequential Analysis From ESETCID
Bernhard Maisch, Sabine Pankuweit, Susanne Koelsch, Reinhard Funck, Guenther 
Hufnagel, Wolfram Grimm, Alexander Sattler, Department of Cardiology, Marburg, 
Germany
Background: In the European Study on Epidemiology and Treatment of Cardiac 
Inflammatory Disease (ESETCID) pts with autoreactive (virus-negative) myocarditis (AM) 
and an ejection fraction <45% were randomised for 6 months of treatment with azathioprin 
(2mg/kg BW/day for 1 m and 0.85mg/kg BW/day for 5 m) + prednisolone (1.25mg/kg BW/ 
for 1 m and 0.3mg/kg BW/day for 5 m) or placebo on top of their heart failure treatment 
and followed-up for up to 8 years.
Methods: 3149 pts with dilated cardiomyopathy were screened, 103 pts (mean age 47± 
9 years, 81 male, 22 female) with AM and an EF <45% were randomised for ESETCID 
after informed consent and continuously followed-up. Endomyocardial biopsies (EMB) 
were examined for lymphocytes & macrophages by immunhistochemistry (> 14 infiltrating 
cells/mm²), persistence of viral or bacterial genomes for Parvo B19, coxsackie-, 
influenza-, adeno-, cytomegalo-, HHV 6, EBV, chlamydia and borrelia were excluded 
from the analysis. 56 pts (45 m) with AM were treated with verum, 47 pts ( 38m) with 
placebo. MACE are defined as cardiac death, heart transplantation, ICD implantation or 
hospitalisation for cardiac decompensation.
Results: Inflammation was eradicated in 63% in the treatment group, but it also vanished 
spontaneously in 40% in the placebo arm(p<0,05).
After 12 months the Kaplan Mayer MACE curves began to diverge. At 4 years freedom 
from MACE was 50% in the verum and 40% in the placebo group. Respective data at 8 
years were 40% and 20% freedom from MACE.
NYHA-association class and Minnesota Heart Failure Score improved in treatment and 
placebo arms. Ejection fraction by echo and radioventriculography improved in both arms 
with a trend for immunosuppression(IS).
Independent from IS pts with no inflammation in the follow-up biopsy (n=45) showed a 
better NYHA-class (p<0,05), ejection fraction and superior long term freedom from MACE 
than those with persistent inflammation.
Conclusions: Immunosuppression is superior to conventional heart failure treatment in 
the acute eradication of the inflammatory infiltrate iDCM patients and bears better long-
term prognosis.
1023-11 Gender and Race/Ethnicity Differences in Atrial 
Fibrillation Prevalence in Patients With Nonischemic 
Cardiomyopathy
Somjot Brar, Colin Watanabe, Albert Yuh-Jer Shen, Columbia University, New York, NY, 
Kaiser Permanente, Los Angeles, CA
Background: There is little published data regarding the influence of gender or race/ethnicity 
on the prevalence of atrial fibrillation in patients with non-ischemic cardiomyopathy.
Methods: We identified 805 consecutive persons with non-ischemic cardiomyopathy 
between 1996 and 2005. We excluded individuals with known coronary artery disease by 
screening for outpatient or inpatient diagnosis of angina, myocardial infarction, coronary 
artery bypass grafting, or percutaneous coronary intervention. Logistic regression was 
performed to determine both unadjusted and adjusted odds ratios (95% CI, p-values) for 
atrial fibrillation based on gender and race/ethnicity.
Results: The mean age of the cohort was 63 +/- 15 yrs and 40% were female. The overall 
prevalence of atrial fibrillation was 28%. The racial/ethnic composition of this cohort was: 
48% White, 27% Black, 13% Hispanic, 10% Unknown, and 3% Asian. The mean ejection 
fraction for the cohort was 0.26 +/- 0.07. 
Odds Ratio 95% CI p-value
Female vs. Male
Unadjusted 0.69 0.50 - 0.95 0.02
Adjusted* 0.46 0.32 - 0.68 <0.0001
Race/Ethnicity (White referent)
Black (unadjusted) 0.21 0.13 - 0.34 <0.0001
Black (adjusted*) 0.28 0.16 - 0.47 <0.0001
Hispanic (unadjusted) 0.44 0.26 - 0.75 0.002
Hispanic (adjusted*) 0.56 0.31 - 1.01 0.055
Asian (unadjusted) 0.51 0.20 - 1.29 0.15
Asian (adjusted*) 0.62 0.22 - 1.72 0.36
Unknown (unadjusted) 0.96 0.58 - 0.75 0.88
Unknown (adjusted*) 1.11 0.65 - 1.91 0.7
*Includes: age, ejection fraction, diabetes, hypertension, thyroid disorder, chronic 
obstructive pulmonary disease, rheumatic and non-rheumatic valve disease, beta blocker 
use, statin use, sleep apnea, income and education level.
Conclusion: We observed significant variation in the incidence of atrial fibrillation by 
gender and race/ethnicity. Women had a 54% lower odds of atrial fibrillation. Blacks had 
a 72% lower odds of atrial fibrillation compared to Whites.
1023-12 Changes in Diastolic Dysfunction in Diabetes Mellitus 
Over Time: A Population Study in Olmsted County, MN
Aaron Matthew From, Horng Chen, Mayo Clinic, Rochester, MN
Background: Identification of diabetic patients at highest risk of having cardiac dysfunction 
could help with early identification of a “Diabetic Cardiomyopathy”. The duration of diabetes 
may be associated with diastolic dysfunction. However, the degree of diastolic dysfunction 
in association with the duration of diabetes has not been well defined. The objective of our 
study is to confirm that the cardiac diastolic dysfunction worsens with duration of diabetes 
and to quantify the severity of dysfunction as a function of diabetes duration.
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Methods: From 1996 to 2007 all Olmsted County, MN residents with diabetes mellitus 
free of heart failure who had a subsequent measurement of diastolic function using tissue 
Doppler echocardiography were identified. Patients were excluded if the echocardiogram 
evaluation was missing ejection fraction or if severe mitral or aortic valve regurgitation 
was present.
Results: We identified a validated group of 488 patients with incident diabetes mellitus 
with a subsequent tissue Doppler echocardiographic assessment of diastolic function. 
In multivariable linear regression analysis the E/e’ increased 0.23 for every 1 year 
after the onset of diabetes (95% CI=0.17-0.29; p<0.001) after adjustment for age, 
gender, body mass index, coronary disease, hypertension, ejection fraction, left atrial 
volume and deceleration time. Multivariable logistics regression analysis showed that a 
duration of diabetes ≥ 7 years was independently associated with diastolic dysfunction 
in multivariable logistic regression modeling after adjustment for age, gender, body 
mass index, coronary disease, hypertension, ejection fraction, left atrial volume and 
deceleration time (OR=1.79, 95% CI=1.05-2.96; p=0.03).
Conclusions: Duration of diabetes is associated with increased E/e’ ratio independent of 
age , sex, coronary disease and hypertension suggesting that asymptomatic diastolic 
dysfunction among diabetes worsens with the duration of diabetes.
1023-13 Risk Profile of Women with Peripartum Cardiomyopathy 
and Heart Failure with Preserved Ejection
Somjot Brar, Gagandeep K. Sandhu, Sumit Khandhar, Steven Khan, Albert Yuh-Jer 
Shen, Michael B. Jorgensen, Jin-Wen Y. Hsu, Columbia University, New York, NY, Kaiser 
Permanente, Los Angeles, CA
Objective: We sought to determine risk factors for peripartum cardiomyopathy (PC) 
compared to a non-PC cohort in a large population based study. We also sought 
to characterize the risk profile and outcomes of women with heart failure and normal 
ejection fraction in the peripartum period (PHFnEF).
Methods: Between 1996 and 2005, 248,481 unique women delivered within the Southern 
California Kaiser Permanente healthcare system. By searching ICD-9 codes for heart 
failure (HF), we identified patients who were hospitalized with HF 6 months before to 
12 months after delivery. The cases thus identified underwent chart review. Patients 
were considered to have PC if they satisfied all the following criteria: (1) LV ejection 
fraction <0.50 (2) met the Framingham criteria for HF (3) new symptoms of HF or initial 
echocardiographic diagnosis of LV dysfunction occurred in the month before or in the 5 
months after delivery and (4) no alternative cause of HF could be identified. PHFnEF 
was diagnosed when all PC criteria were met except the EF was >0.50. The controls 
comprised women who did not meet criteria for either PC or PHFnEF.
Results: We identified 63 women with PC and 45 with PHFnEF. The mean age was 32 
± 8 years, and did not differ between groups (p=0.22). The table highlights between the 
groups: 
PC PHFnEF Controls p-value
Gestational diabetes 19.0% 15.6% 0.9% <0.01
Gestational hypertension 36.5% 24.4% 2.7% <0.01
Pre-eclampsia 22.2% 26.7% 2.7% <0.01
Eclampsia 1.6% 0 1.8% >0.90
Tocolytic exposure 12.7% 15.5% 0% <0.01
Twins or triplets 6.3% 11.1% 0.90% 0.02
Ejection fraction 0.31 ± 9.7 0.60 ± 10.4
Preterm birth 31.7% 22.2% 4.5% <0.01
HELLP syndrome 1.6% 2.2% 0% NS
Hyperemesis gravidarum 0% 2.2% 0% NS
Conclusion: The PC group was more likely to have gestational diabetes and hypertension, 
pre-eclampsia, multiple births, and pre-term birth compared to controls. Women with 
PHFnEF also had a similar comorbidity profile to PC women.
1023-14 Overexpression of Transforming Growth Factor-β1 in 
Left Ventricle and Coronary Artery Is Associated With 
the Development of Cardiac Allograft Vasculopathy in 
pateints After Heart Transplantation
Jianping Tang, Guanggen Cui, Hillel Laks, Shouguo Yang, Abbas Ardehali, Fardad 
Esmailian, Mark Plunkett, Ramin Beygui, Daniel Marelli, Luyi Sen, University of 
California Los Angeles School of Medicine, Los Angeles, CA
Background: Long-term pateint survival after heart transplantation has not substantially 
improved mainly owing to cardiac allograft vasculopathy (CAV), and the mechanism 
causing CAV remains elusive. Transforming Growth Factor (TGF)-β1 is considerd to play 
a crucial role in CAV pathogenesis based on reported studies on human endocardial 
biopsies.
Methods: Left ventricle and coronary artery samples were obtained from 32 CAV and 
39 ischemic cardiomyopathy (ICM) patients who underwent heart transplantation or re-
transplantation. Proteins extracted from tissues were taken to detect TGF-β1 expression 
by western blotting, and paraffin-embedded sections were used to observe TGF-β1 
distribution by immunoflurescent and histological stainings. The correlations between 
TGF-β1 expression and patient clinical features were analyzed.
Results: Quantitative western blotting showed that within left vntricle tissues TGF-
β1 expression and ratio of TGF-β1/ actin(3.53±1.48, 1.38±0.44) in CAV group were 
significantly higher than in ICM group (2.44±0.91, 1.02±0.32) (both P<0.01). In coronary 
artery samples TGF-β1 expression and ratio of TGF-β1/ actin (3.32±0.94, 1.62±0.39) 
in CAV group were also increased than in ICM group (2.41±1.00, 1.08±0.35) (P<0.05, 
P<0.01). Under immunoflurescent staining, in CAV pateints TGF-β1 distribution in 
intima of coronary artery and in left ventricle(mainly in myocytic cytoplasma) were 
strongly observed compared to ICM group. There was a great thickening intima in CAV 
coronary artery seen in HE and MT stainings. TGF-β1 expression was decreased with 
increasements of left ventricular end-diastolic dimension (LVEDD) and grown ages, but 
increased with growing left ventricular ejection fraction (LVEF), and more expressed in 
non-white people than in white persons.
Conclusions: TGF-β1 over-expressed in left ventricle and coronary artery tissues and 
localized mainly in neointima of coronary artery and inside the myocytes is associated 
with the development of human CAV. TGF-β1 expression is negatively correlated with 
increased LVEDD and human ages, but positively correlated with increased LVEF 
clinically.
1023-15 Effects of Infarct Size on Left Ventricular Contractility 
and Preload: A Model Study
Ying Sun, Salvatore Chiaramida, Rumei Dong, Michael Craig, Frederick Vetter, 
University of Rhode Island, Kingston, RI, Medical University of South Carolina, 
Charleston, SC
Background: An impaired left ventricle (LV) that is compensated by preload elevation 
cannot be characterized by use of a finite element model alone. In this study, a finite 
element LV model was combined with an analog electrical model to jointly assess the 
effects of infarct size on hemodynamics.
Methods: Using LV pressure as the initial condition a 3D finite element model determined 
the LV volume. The resulting LV elastance (pressure over volume ratio) was entered into 
a sophisticated hemodynamic model to determine the instantaneous response of the 
cardiovascular system. This interaction was carried out continuously at a time resolution 
of 5 ms. A time-varying Young’s modulus over the cardiac cycle was assigned to each 
finite element. The infarct zone was defined by a reduced Young’s modulus. In the 
simulation study, the size of the infarct zone was the only effecting variable. The increase 
in LV preload was a natural response of the hemodynamic model to compensate for the 
reduction in LV contractility.
Results: Figures below show the model-predicted LV ejection fraction and volume indices 
for increasing percentage of LV infarct size with linear regression lines (solid) compared to 
reference data (dashed lines, reported by Sciagra et al. EJNMMI 31:969-974, 2004).
Conclusions: The model predictions were consistent with clinical data. The model is 
unique for assessing the hemodynamic consequences of LV infarction with various size, 
location, and severity.
 
1023-16 Clinical Implications of Biological Aspirin Non-
Responsiveness Following Ventricular Assist Device 
Implantation
Farhan Majeed, Robert Poston, Willem Kop, Seeta Kallam, Mandeep Mehra, University 
of Maryland Medical Center, Baltimore, MD
Background: Antiplatelet strategies to prevent thromboembolic (TE) events have had sub-
optimal success in patients with ventricular assist devices (VAD). This study evaluated 
aspirin non-responsiveness (NR) as a mechanism for TE events in heart failure patients 
after VAD implantation.
Methods: Prospectively, 26 patients with end-stage systolic heart failure (age 52±17 years) 
were assessed after VAD implantation (median 315 days: 9-833 days) for cerebrovascular 
accidents (CVA), transient ischemic attacks (TIA), and other TE events. Serial analyses of 
in vitro platelet function and aspirin NR were performed using thrombelastography (TEG) 
and whole blood aggregometry (WBA) (≈25 samples/patient). Aspirin NR was defined as 
≥50% platelet response to 1mM arachidonic acid or ≥50% impedance change to 1 or 5 
mcg/mL collagen for TEG and WBA assays, respectively.
Results: Aspirin NR occurred in 52% and 92% of patients before and after VAD 
implantation. Marked variability for aspirin NR was noted in both assays (coefficient of 
variability (CV) for WBA = 0.63, CV for TEG = 8.78). 17 TE events occurred in 8 (31%) 
patients (9 CVA, 7 TIA, 1 mesenteric thrombosis; median time till event =26 days, range 
4-127 days). 9/17 TE events (53%) occurred in the presence of aspirin NR (Figure 1).
Conclusions: Aspirin NR is common in patients with end-stage heart failure and increases 
after VAD implantation. Occurrence of TE events correlated poorly with aspirin NR. Serial 
assays are too variable to guide clinical management. 
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1023-17 ECG and Echocardiographic Abnormalities in Traumatic 
Brain Injury
Mariya Shaad, Elizabeth Hill, Abbas Y. Rampurwala, Charlotte Ng, John C. Bailey, 
Krannert Institute of Cardiology, Indiana University, Indianapolis, IN
Background: ECG changes are seen with traumatic brain injury (TBI) but their prognostic 
significance is not known. We studied the prognostic impact of ECG and echocardiographic 
(echo) abnormalities on morbidity, mortality and heart transplantation in patients with TBI.
Methods: A cohort of 131 TBI survivors and 59 TBI patients who died and were seen by 
local organ procurement organization was studied (n=190). Inclusion criteria:
1) Age <50 yrs
2) Absence of chest trauma
3) No history of brain injury/ disease in the past
4) ECG and/or echo within first 4 days post-TBI available
Abnormal echo was defined as wall motion abnormalities and/or ejection fraction <50%. 
We defined abnormal ECG by ST segment depression and/or T wave flattening and/or 
T wave inversion. Prolonged QTc was defined as QTc >450msec. SAS version 9.1 was 
used for statistical analysis. Logistic regression models were used to adjust for serum 
potassium and calcium abnormalities while analyzing ECG data.
Results: Mean age was 30.0 + 12.5 years (79% males). Table 1 summarizes outcome 
results. The proportion of each outcome, odds ratios with 95% confidence intervals, and 
p-values are shown.
Table 1. Logistic Regression results 
Died Odds Ratio 95% CI p-value
Yes No
Abnormal ECG 10/47 29/113 0.69 0.30 - 1.60 NS
Abnormal ECG with 
prolonged QTc 25/47 47/113 1.34 0.66 - 2.72 NS
Prolonged QTc 20/47 28/113 2.05 0.98 - 4.30 0.0580
Abnormal Echo 15/50 3/31 4.00 1.05 - 15.21 0.0419
Needing Rehabilitation Odds Ratio 95% CI p-value
Yes No
Abnormal ECG 16/37 13/76 3.37 1.36 - 8.40 0.0090
Abnormal ECG with 
prolonged QTc 23/37 24/76 3.04 1.31 - 7.09 0.0100
Prolonged QTc 13/37 15/76 1.99 0.80 - 4.96 NS
Abnormal Echo 1/12 2/19 0.77 0.06 - 9.58 NS
Non-Transplantable Heart Odds Ratio 95% CI p-value
Yes No
Abnormal ECG 3/21 7/26 0.44 0.09 - 2.00 NS
Abnormal ECG with 
prolonged QTc 14/21 11/26 2.78 0.81 - 9.09 NS
Prolonged QTc 12/21 8/26 3.23 0.93 - 11.11 NS
Abnormal Echo 11/19 4/31 9.09 2.33 - 33.33 0.0017
Conclusions: In TBI patients, an abnormal echo is a significant risk factor for mortality and 
non-transplantable cardiac organ; prolonged QTc was a marginally significant risk factor. 
In survivors, abnormal ECG with and without prolonged QTc are significant risk factors for 
morbidity requiring inpatient rehabilitation.
1023-18 Serum Adiponectin Concentration Is Elevated in Heart 
Transplantation Patients
Ioannis D. Laoutaris, Athanasios Dritsas, Sophie Mavrogeni, Ioannis K. Vasiliadis, 
Athanassios Manginas, Manolis S. Kallistratos, Dimitrios Degiannis, Antigoni 
Chaidaroglou, Petros Sfirakis, Peter A. Alivizatos, Dennis V. Cokkinos, Onassis Cardiac 
Surgery Center, Athens, Greece
Background: In contrast to normals, high plasma adiponectin (Ad) has been associated 
with cachexia and increased mortality in patients with heart failure (HF). We sought to 
investigate whether plasma Ad and NT-Pro BNP levels are reduced in patients after heart 
transplantation (HTx) compared to normals and HF patients.
Methods: Twelve HTx patients (>1 yr post-HTx), age 44.8±11 yrs, BMI 29.6±14.9 kg/
m2, LVEF 59±5 % and 17 normal human subjects age 63±9 yrs, BMI 26.5±4 kg/m2 with 
LVEF>60% as well as 40 patients with HF, age 58±11 yrs, BMI 28.8±4.2 kg/m2, NYHA II/
III, and an LVEF of 28±8 %, were tested for plasma Ad and NT-Pro BNP levels. Exercise 
capacity was also assessed by ergospirometry and the 6-min walk test (6MWT) in both 
HTx and HF patients. HTx patients were significantly younger when compared to HF 
patients (p<0.001) and normals (p<0.001) but matched to both groups for BMI.
Results: In HTx patients mean peak oxygen consumption (peakVO2) was 20.7±2 ml/kg/
min and the 6 MWT distance 469±75 m. In HF patients peak VO2 was 16.2±3.6 ml/kg/
min and the 6 MWT distance 361±79 m. Plasma Ad levels were elevated in both HTx 
patients (29.6±14.9 µg/ml, p<0.0001) and HF (23.8±18.2 µg/ml, p=0.01) when compared 
to normals (13.5±5 µg/ml). NT-Pro BNP levels were also elevated in both HTx patients 
(585.2±329.2 pg/ml, p=0.001) and HF (747.04±51.3 pg/ml, p<0.001) compared to 
normals (353.7±93.4 pg/ml), but higher in HF. In HF patients, Ad positively correlated with 
NT-Pro BNP (r=0.479, p=0.002) and inversely with BMI (r=-0.384, p=0.01).
Conclusions: Although HTx patients presented with a better LVEF and exercise capacity 
compared to HF patients, similarly to HF, plasma Ad concentration was significantly 
elevated compared to normals. Potential reasons include a balancing effort to regulate 
persistent increasing energy metabolism, although the role of Ad in this population needs 
further investigation.
1023-19 Coagulation Indices and Prediction of Thromboembolic 
Events After Ventricular Assist Device Implantation
Farhan Majeed, Robert Poston, Willem Kop, Seeta Kallam, Mandeep Mehra, University 
of Maryland Medical Center, Baltimore, MD
Background: Thromboembolic (TE) events occur after ventricular assist device (VAD) 
implantation, despite anticoagulation therapy. This study examined whether coagulation 
and fibrinolytic measures are predictors of TE events in VAD patients.
Methods: Prospectively, 26 heart failure patients (age 52+17 years) were assessed 
after VAD insertion (median 315 days: 9-833 days) for cerebrovascular accidents (CVA), 
transient ischemic attacks (TIA), and other TE events. Plasminogen activator inhibitor-1 
(PAI-1), a marker of decreased fibrinolysis, and prothrombin activation fragment (F1.2), 
an index of in vivo thrombin generation, were measured daily using ELISA.
Results: 17 TE events occurred in 8 (31%) patients (9 CVA, 7 TIA, 1 mesenteric thrombosis; 
median time till event =26 days, range 4-127 days). PAI-1 was elevated immediately after 
VAD placement (p<0.001), and at 30 days (p<0.001) (Figure 1). 6/8 (75%) patients had 
TE events within 30 days post VAD (Figure 2). Increased F1.2 was observed immediately 
post VAD placement (p=0.001), and returned to baseline by day 3 (p=0.13). PAI-1 and 
F1.2 were not significantly elevated immediately prior to TE events. Substantial variability 
was noted in PAI-1 and F1.2 (coefficient of variability 0.26 and 1.68, respectively).
Conclusion: PAI-1 is elevated early after VAD insertion, indicating impaired fibrinolysis. 
75% of TE events occurred during this period. Variability in PAI-1 and F1.2 resulted in a 
low predictive value immediately prior to TE events. 
1023-20 Effect of Gender on Left Ventricular Assist Device 
Insertion as Bridge-to-Transplant
Forum Kamdar, Andrew Boyle, Monica Colvin-Adams, Sara Shumway, Kenneth Liao, 
Lyle Joyce, Ranjit John, University of Minnesota, Minneapolis, MN
Background: Despite the incidence of heart failure being similar between men and 
women, men are more frequently recipients of left ventricular assist devices (LVADs). 
The large body surface area required for LVAD implantation may contribute to the under-
representation of women. Previous studies involving cardiac surgery and LVAD recipients 
have typically shown male patients having superior survival. Our objective was to analyze 
and evaluate the effect of gender on patients undergoing LVAD insertion as a bridge to 
transplant (BTT).
Methods: A retrospective study was performed of all patients receiving LVAD as BTT at a 
single center between January 2003 and May 2007.
Results: A total of 75 patients received LVAD as BTT; of these, 80% (60) were male and 
20% (15) female. This included 45 pulsatile HeartMate XVE (39 male, 6 female) and 30 
continuous flow HeartMate II (21 male, 9 female). Women were significantly younger and 
more likely to have idiopathic cardiomyopathy than men. The mean support was similar 
between the two groups, with average duration of support being 221 days [8-590] for 
males and 233 days [8-680] for females (p=NS). Women had higher RVAD use and had 
lower transplant rates. Survival at 6 months calculated by Kaplan-Meier was 84.6% for 
males and 86.6% for females.
Conclusions: Women have been underrepresented in the LVAD population, however 
increasing use of smaller axial flow devices has allowed for wider application for women, 
as evidenced by 30% of HeartMate II LVAD recipients being women. Further, survival on 
LVAD support is comparable for both men and women, in contrast to previous studies. 
The increased applicability of newer generation LVAD to women may contribute to the 
increasing success of LVAD implantation in the female gender.
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1023-21 Abnormalities on Cardiac MRI Are Associated With the 
Presence of Cardiac Allograft Vasculopathy in Heart 
Transplant Recipients
Parag C. Patel, Mark H. Drazner, Ronald Peshock, Clyde W. Yancy, W. Steves Ring, 
Michael DiMaio, Pradeep PA Mammen, David W. Markham, Sharon C. Reimold, 
University of Texas Southwestern Medical Center, Dallas, TX
Background: Cardiac MRI is useful in detecting coronary artery disease in patients 
with cardiomyopathy. Cardiac MRI may also be useful in assessing cardiac allograft 
vasculopathy (CAV).
Methods: A review of the UTSW Transplant Database identified 100 patients who had 
a cardiac MRI with gadolinium (GAD) within three months of coronary angiography 
between 2003 and 2006. Delayed enhancement (DE) was defined as GAD enhancement 
of any cardiac segment greater than 0%. Wall motion abnormality (WMA) was defined as 
abnormal motion in two or more LV segments. CAV was classified as greater than 50% 
angiographic narrowing of coronary vessels or luminal irregularities.
Results: 33 patients had CAV. Patients with CAV had received organs from older donors 
(36 vs. 26 years, p = 0.0003), were further out from transplant (8 vs. 5 years, p = 0.003), 
and were more likely to have had cellular rejection (48% vs. 22%, p = 0.01). DE (p = 0.02), 
WMA (p = 0.002), and the presence of either (p = 0.01) were significantly associated with 
CAV based on univariable analysis (see table). Multivariable analysis revealed a strong 
trend for the association of an abnormal cardiac MRI (either DE or WMA) with CAV (OR 
2.93, 95% CI 0.95 - 9.04, p = 0.06) after adjusting for clinical risk factors (donor age, time 
since transplant, and prior cellular rejection).
Conclusion: Cardiac MRI abnormalities may identify transplant recipients with a 3-fold 
increased risk of CAV. Further large studies assessing the utility of cardiac MRI as a 
screening tool for CAV are needed. 
Percent of Transplant Recipients With and Without Vasculopathy Stratified by MRI 
Abnormalities
With Vasculopathy 
n=33
Without Vasculopathy 
n=67 P Value
Delayed Enhancement (DE) 0.02
Yes (n=15) 67% 33%
No (n=85) 27% 73%
Wall motion Abnormality (WMA) 0.002
Yes (n=23) 61% 39%
No (n=77) 25% 75%
Either DE or WMA 0.01
Yes (n=27) 56% 44%
No (n=73) 25% 75%
1023-22 No Relief for the Poor After Heart Transplantation
Michelle Kittleson, Dhruv Patel, Jignesh Patel, Matt Kawano, Krista Kiyosaki, Abbas 
Ardehali, Jon Kobashigawa, David Geffen School of Medicine at UCLA, Los Angeles, CA
Background: Medical insurance can reflect socioeconomic status (SES). Patients with 
private health insurance pay insurance premiums and thus may be of higher SES. 
Patients on Medicare are often older or chronically ill, and mainly of lower SES. After 
heart transplant, health care costs can cause financial stress and lowering of one’s SES. 
We followed transplant patients over time to determine the effect to changing insurance 
(and indirectly, changing SES) on outcomes.
Methods: Between 1994 and 2006 we reviewed 649 heart transplant patients, divided 
based on medical insurance at transplant: Medicaid (group 1, n=78), private insurance 
(group 2, n=474), and Medicare (group 3, n=70). HMO (Kaiser, n=20) patients were 
excluded because they were not followed at our institution.
Results: Over 10 years, group 1 had significantly lower survival vs. group 2 (61.5% vs. 
75.9%, p=0.04, see graph) and a trend to lower survival vs. group 3 (61.5% vs. 71.4%, 
p=0.26). During the 10-year follow up, no patient in group 1 changed insurance, while 22 
patients (4.6%) in group 2 and 17 patients (24.3%) in group 3 switched to Medicaid. Of 
those patients who switched from private insurance to Medicaid, survival was less than 
those patients who did not switch (68.2% vs. 76.3%, p = 0.32).
Conclusions: Patients starting on Medicaid at transplant (in a lower SES) have lower 
survival 10 years after heart transplant. Switching to Medicaid from private insurance or 
Medicare is also associated with poorer outcome. This warrants further assessment. 
1023-23 Destination Left Ventricular Assist Device Therapy for 
Advanced Age Patients With Heart Failure: Is There an 
Age Limit?
Stephanie A. Moore, Clark N. Madsen, Corey J. Bishop, Karl Nelson, James W. Long, 
LDS Hospital, Salt Lake City, UT, Massachusetts General Hospital, Boston, MA
Introduction: The Randomized Evaluation of Mechanical Assistance for the Treatment of 
Congestive Heart Failure (REMATCH) trial first demonstrated that Left Ventricular Assist 
Devices ( LVADs) as destination therapy( DT) can provide survival benefit to patients with 
end stage heart failure not eligible for transplant. As the population with heart failure ages, 
we continue to evaluate more advanced age patients for this therapy. The average age at 
implantation in the REMATCH study was 66 ±9.1 years. From REMATCH data the one-year 
survival rate is known to be 52%. Post REMATCH recently published data that includes 
222 patients (age 60.7 ±12) implanted with Heartmate XVE between November 2001 and 
December 2005 revealed a one-year survival of the group to be 56%. We describe single 
center outcomes experience with patients greater than 75 years of age at implantation.
Methods: A retrospective mechanical support database was reviewed at a single large 
volume center. Destination therapy patients over 7 years were reviewed (n= 69). Of these 
patients, 15 were age 75 or greater (avg.=76) at time of LVAD implant (22 pt-yrs). 4 were 
receiving a replacement LVAD. 4 patients (27%) underwent 2 LVAD implants while age 75+. 
Devices utilized included the Heartmate VE, Heartmate XVE, Heartmate II, and Novacor.
Results: The 30, 90 and 180-day survival rate after LVAD implant was 100.0%, 80.0% and 
60.0% respectively. The one-year survival was 50.0%. The discharge from hospital rate 
was 100% and average length of stay was 35 ±19 days.
Conclusion: When compared, patients greater than age 75 in this single center experience 
had one-year survival similar to results published using REMATCH and Post REMATCH 
era patients. Advanced age should not prevent patients from being considered for LVAD 
therapy. Pre implant optimization may have contributed to early perioperative survival and 
100% discharge from hospital. Continued diligence toward optimal patient selection will 
improve long term outcomes.
1023-24 Cardiac Improvement During Mechanical Unloading in 
Idiopathic Dilated Cardiomyopathy: Criteria for Weaning 
From Left Ventricular Assist Devices
Michael Dandel, Yuguo Weng, Henryk Siniawski, Evgenij Potapov, Hans Lehmkuhl, 
Miralem Pasic, Roland Hetzer, Deutsches Herzzentrum Berlin, Berlin, Germany
Background: During ventricular unloading, cardiac recovery which allows ventricular 
assist device explantation is possible not only in patients with acute myocardits, but also 
in patients with idiopathic dilated cardiomyopathy (IDCM). To improve weaning decisions 
we sought predictive parameters for post-weaning cardiac stability.
Methods: Among 80 patients weaned since 3/1995, a homogenous group of 35 
IDCM patients weaned from left ventricular assist devices (LVADs) were selected for 
evaluation.
We evaluated “off-pump” echocardiographic parameters obtained before LVAD 
explantation, histological changes and serum anti-ß1-adrenoreceptor-autoantibody 
disappearance during unloading, LVAD-support duration and heart failure (HF) history.
Results: The 8-year post-weaning survival reached 78.1 ±8.2%. Of the first 4 patients 
weaned in 1995, 3 patients are still alive. Post-weaning freedom from HF recurrence at 4 
years after LVAD explantation was 69.3 ±8.1%. Patients with post-weaning cardiac stability 
were younger, HF history and recovery time during unloading were shorter, LV short/
long axis-ratio lower and systolic wall motion velocity (measured by pulsed-wave tissue 
Doppler) higher (p< 0.05). For LVEF ≥ 45% at enddiastolic diameter (LVEDD) ≤ 55mm the 
positive predictive value for ≥ 4years cardiac stability reached 90.5%. There was no HF 
recurrence during the first 4 years after weaning if LVEF was ≥ 45%, LVEDD ≤ 55% and 
history of HF < 5years. The LVEF time-course during the first 6 post-weaning months also 
appeared predictive for long-term cardiac stability. History of HF > 5years showed a 90% 
predictive value for HF recurrence during the first 3 years. Neither reduction in myocardial 
hypertrophy and fibrosis nor anti-ß1-adrenoreceptor-autoantibody disappearance during 
ventricular unloading appeared predictive for post-weaning outcome.
Conclusions: Off-pump LVEF and LVEDD, time-course of LVEF during the first 6 post-
weaning months and HF duration are predictive for outcome after LVAD removal in 
IDCM patients. Patients’ age, sherical LV geometry, low wall motion peak velocity ( < 
8 cm/s) and prolonged LVAD support until improvement (> 6months) are risk factors for 
HF recurrence.
1023-25 Trans-Membrane Signaling Mucins Are Reduced in the 
Failing Human Heart and Are Up Regulated By LVAD 
Therapy
Laurie Shekels, Ruth Anway, Soma Sen, Inder Anand, Y. Chandrashekhar, VAMC/
University of Minnesota, Minneapolis, MN
Background: MUC1 and MUC3 are members of trans-membrane glycoproteins that 
mediate intra-cellular & intra-nuclear survival signaling, reduce oxidative injury, suppress 
apoptosis and facilitate restructuring of the damaged cellular architecture. Their role in the 
failing heart (HF) is unclear.
Hypothesis: Since apoptosis, oxidative injury and damaged architecture are common in 
HF, we postulated that MUC1/MUC3 might have a role in the failing heart and that MUC1/
MUC3 might be up-regulated by LVAD therapy.
Methods: We measured myocardial MUC1 and MUC3 (Real Time PCR) in the non-scar 
myocardium from patients with HF at LVAD implantation & transplant (n=6, ischemic in 
4, LVAD to transplant: 151-681 days) & 3 controls. Myocyte apoptosis (apologix stain) 
& ventricular remodeling (Echo) were measured. The effect of blocking the renin-
angiotensin system on MUC1 & MUC3 mRNA levels, was also evaluated in Post MI rats 
(LAD ligation, n=6 each) given placebo, ACE Inhibition (ACE-I) or Angiotensin Receptor 
Blockade (ARB) for 4 weeks post MI.
Results: MUC1 & MUC3 mRNA was found in the normal heart. Interestingly, MUC1 & 
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MUC3 mRNA was significantly decreased in both, ischemic and dilated cardiomyopathy. 
MUC1 was significantly up regulated by LVAD & this correlated with less myocyte 
apoptosis. MUC1 & MUC3 were also found in the rat heart and were reduced in rats with 
HF. ACE-I or ARB up-regulated MUC1& MUC3 message in these rats.
Conclusions: We show for the first time that MUC1 & MUC3 are expressed in the human 
and rat myocardium. MUC1 & MUC3 are reduced in human end-stage heart failure and 
this is significantly reversed with LVAD therapy. MUC1 & MUC3 are also up regulated 
after ACE-I or ARB in rats with ischemic HF. Since MUC1 & MUC3 suppress apoptosis 
& oxidative injury and also help in tissue repair, a lack of MUC1/MUC3 might play a role 
in the genesis of HF.
1023-26 Percutaneous Ventricular Assist Device (TandemHeart) 
Use: An Overall Single Center Experience
Reynolds M. Delgado, III, Ahmed Abugiazya, Yazan S. Khouri, Andrew Civitello, Pranav 
Loyalka, Biswajit Kar, Texas Heart Institute, Houston, TX, Baylor College Of Medicine, 
Houston, TX
Introduction: Left Ventricular Assist Devices (LVADs) have been used in end stage heart 
failure for over 25 years. The Percutaneous VAD (TandemHeart) is implanted fast in the 
cardiac catheterization laboratory and is less invasive than other LVADs, making it an 
excellent support during high risk revascularization procedures and in severe cardiogenic 
shock as a bridge to a long term device, transplant or recovery. The device circulates 
blood from the left atrium to the femoral artery unloading the left ventricle and providing 
non pulsatile circulatory support.
Methods:We reviewed our database of patients who underwent TandemHeart placement 
from 2003 to 2007 and analyzed indications of insertion, outcomes, survival, duration of 
support, hospital stay and complications.
Results:74 males and 22 females whose ages ranged from 17 to 84 years with 10 of 
them over 75 were supported for 428 days, and the overall hospital stay was 2878 days. 
We supported 4 patients for high risk CABG, 2 were discharged alive and two expired. 
For high risk PTCA, 11 devices were implanted, 3 patients expired and 8 discharged. We 
implanted 81 total patients for cardiogenic shock; 14 patients expired while on support, 
9 patients expired after weaning, and 4 patients failed implant and expired. 23 patients 
were bridged to recovery and were discharged, 5 patients were transplanted, and in 26 
patients it was a bridge to a long term LVAD of which 15 survived and 11 expired. The 
overall mortality in the cardiogenic shock subgroup was 47%.
Conclusions: This represents the largest single center experience with the TandemHeart 
device to date. The outcomes of such patients with cardiogenic shock who fail conventional 
therapies such as the intraaortic balloon pump is poorly defined in prior studies. The closest 
comparison is with short term surgically implanted LVADs or extra corporeal membrane 
oxygentation. In comparison with studies of these devices our experience shows a significantly 
better overall outcome. Thus we believe that the current data indicate that the TandemHeart 
device may offer hope for improved outcomes in patients with refractory cardiogenic shock 
and during high risk revascularization than previous treatment strategies.
1023-27 Agonizing Over High Circulating Antibody Levels in 
Preheart Transplant Patients
Jignesh Patel, Matt Kawano, Michelle Kittleson, Eric Sue, Krista Kiyosaki, Abbas Ardehali, 
Jon Kobashigawa, David Geffen School of Medicine at UCLA, Los Angeles, CA
Background: Significantly elevated circulating antibodies, known as panel reactive 
antibodies (PRAs), is a contraindication to heart transplant in many programs. High PRA 
levels are a risk for hyperacute rejection for patients undergoing heart transplant. Some 
patients develop 100% PRAs which are refractory to aggressive therapies. We report the 
outcome after therapy of pre-heart transplant patients with 100% PRAs.
Methods: Between 1994 and 2006, we evaluated 3381 patients for heart transplant and 
found 15 patients with 100% PRAs on evaluation for heart transplant. These patients 
were treated with combinations of therapy including plasmapheresis, IVIG, rituximab, 
and cyclophosphamide. 493 patients without elevated pre-heart transplant PRAs who 
underwent heart transplant during this period served as controls.
Results: 9 of 15 patients had successful reduction of PRAs by an average of 40 percentage 
points (range 4-96%). These 9 patients underwent successful heart transplant surgery 
(all with negative prospective donor specific crossmatches) without hyperacute rejection. 
In 1997, 1 patient maintained 100% PRAs, despite therapy, and underwent heart 
transplant (positive prospective donor specific crossmatch) with plasmapheresis and IVIG 
administered immediately prior to transplant and intraoperatively due to worsening heart 
failure. This patient had hyperacute rejection and died. The remaining 5 patients were not 
able to reduce PRAs despite aggressive therapy. 4 of the 5 patients who did not undergo 
heart transplant died from heart failure. The final patient is currently on mechanical assist 
for destination therapy. For the 10 transplanted patients, 1-year survival was numerically 
lower than controls (70% vs. 86%, p=0.122). Freedom from 1st year rejection was 
significantly lower in the 100% group vs. controls (60% vs. 89%, p<0.001).
Conclusions: Patients with 100% PRAs are not all responsive to antibody reduction 
therapy. Those that do respond appear to have increased rejection, but acceptable 
survival. For these 100% PRA patients, option of ventricular assist device for destination 
therapy should be weighed against the morbidity and mortality risk after heart transplant.
1023-28 Increasing Axial Flow Pump Speed Is Associated With 
a Significant Reduction in Left Ventricular Diastolic 
Dimension in Patients With Refractory Heart Failure 
Supported by a Continuous Flow Left Ventricular Assist 
Device
Jerry D. Estep, Tharak Yarrabolu, Htut K. Win, OH Frazier, Raymond Stainback, Baylor 
College of Medicine, Houston, TX, The Texas Heart Institute, Houston, TX
Background: Axial, continuous flow left ventricular assist devices (LVADs) are used to 
treat refractory decompensated congestive heart failure. Improving myocardial function as 
reflected by a reduction in left ventricular diastolic dimension (LVDd) after LVAD support 
has been reported. There is paucity of data to the degree of LVDd reduction that can 
be achieved with increasing axial flow LVAD support. We analyzed the use of axial flow 
speed pump change transthoracic echocardiograms (TTEs) to evaluate the instantaneous 
change in LVDd achieved at varying pump speeds as a simple, non-invasive indicator of 
left ventricle unloading during support with a continuous flow LVAD.
Methods: We retrospectively identified 58 patients with refractory heart failure who were 
supported by either the Heartmate II (HMII) LVAD [21 patients, baseline LVDd of 6.63 cm (±1.07)] 
or the Jarvik 2000 [37 patients, baseline LVDd of 6.74 cm (±1.25)] as bridge to transplantation, 
destination therapy, or recovery with LVAD explantation. Each patient had a TTE performed at 
different pump speeds within 6 months after their LVAD implant as part of a protocol to evaluate 
myocardial function with increasing LVAD support from 8,000 to 11,000 revolutions per minute 
(rpms). We compared the LVDd measured from the parasternal long axis view at 8,000 rpm 
versus 11,000 rpm within each group by using the paired Student t test.
Results: The mean LVDd difference at pump rate 8,000 vs 11,000 rpms for HM II and 
Jarvik were [6.01 cm (±1.26) vs. 4.84 cm (±1.06); p <0.001] and [6.4 cm (±1.21) vs. 
5.89cm (±1.23); p=0.038] respectively.
Conclusion: There is a significant reduction in LVDd with increasing LVAD pump speed 
in patients supported by the HM II and Jarvik LVAD. The LVDd reduction achieved with 
LVAD pump speed change echocardiograms is a non-invasive, easily obtained indicator 
of increased left ventricular unloading and should be further prospectively evaluated as a 
tool to guide optimal LVDd reduction for patients supported by a continuous flow LVAD.
1023-29 Increasing Diagnostic Accuracy of Acute Cellular 
Cardiac Allograft Rejection Applying Nonlinear 
Algorithms to Whole Genome Microarrays
Martin Cadeiras, Esteban Tabak, Cristina Turner, Stella M. Yala, Manju M. John, Anshu 
Sinha, Farhana Latiff, Manuel Bayern, Andrea Califano, Mario C. Deng, Columbia 
University, New York, NY, New York University, Courant Institute of Mathematical 
Sciences, New York, NY
Background: Non-invasive diagnostic tests for acute cellular cardiac allograft rejection 
(ACCAR) carry high negative (NPV) but low positive predictive value (PPV). We 
hypothesized that a genomic algorithm may improve non-invasive detection of ACCAR 
using PBMC.
Methods: We used whole genome microarrays from PBMC of 50 heart transplant 
recipients, 25 samples with ACCAR (> grade 0) and 25 without ACCAR (grade 0). Our 
algorithm extracts from the whole genome (41K features) 50 independent nonlinear 
combinations of the each feature that optimally explain their variance, through an iterative 
nonlinear extension of a principal component approach. Then, using each of the 50 
samples as a test and the other 49 as training, the phenotype of ACCAR is predicted 
using a least squares procedure, applied to a subset of the 50 optimal variables, chosen 
so as to maximize the correlation with the rejection data, while explaining a significant 
proportion of the total variance. A numerical score is obtained. Values > or < the mean 
(0.5) are classified as [+] or [-] respectively.
Results: We successfully classified the ACCAR samples with a high NPV (78.6%) but 
also, with a high PPV (86.3%). A score and its associated probability is calculated for 
each sample.
Figure 1: Predicted score for each testing sample and actual observed phenotype ([-] 
left, [+] right).
Conclusions: A genome-wide approach to predict ACCAR with high PPV, is possible by 
using novel non-linear techniques and whole genome PBMC microarray analysis. 
1023-30 Comparing Improvements in Functional Capacity 
in NHYA Class IV Patients Between a Continuous 
Flow Left Ventricular Assist Device and Cardiac 
Resynchronization Therapy
Andrew J. Boyle, Stuart D. Russell, Ranjit John, Leway Chen, Keith D. Aaronson, David 
J. Farrar, Joseph G. Rogers, University of Minnesota, Minneapolis, MN
Background: The clinical benefits of CRT/CRT-D as well as the low implant morbidity and 
mortality have led to its broad adoption for pts with advanced HF. However the functional 
improvement associated with CRT in pts with severe symptomatic HF may be insufficient to 
impact activities of daily living. New LVAD technologies employing small, light rotary blood 
pumps have been designed for similar pts. This analysis compares functional capacity 
improvements in NYHA Class IV pts treated with HeartMate II (HM) LVAD versus CRT.
Methods: A cohort of NYHA class IV pts and paired 6 minute walk tests (6MW) were 
analyzed from the HM bridge to transplant trial (n=64 on active transplant list; 90% treated 
with intravenous inotropes; 47% with an existing CRT/CRT-D) and the COMPANION trial 
(n=69; Circulation 2007;115:204). HM pts were further stratified based upon baseline 
6MW: Group A= pts unable to perform the baseline 6MW due to inotropic and/or IABP 
therapy (n=56) were assigned 0 m distance walked, and Group B= pts who could walk 
at baseline (n=8).
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Results: At 6 mos, Group A HM pts experienced a median improvement of >370 m on the 
6MW. Improvement in functional capacity from baseline to 6 mos in Group B HM pts was 
greater than four times that of NYHA Class IV CRT/CRT-D patients.
Conclusions: There is greater improvement in functional capacity with HM LVADs 
compared to CRT/CRT-D devices in NYHA class IV pts. Differential efficacy in exercise 
performance may ultimately be an important aspect of the selection of therapies in 
advanced HF. 
n
Baseline 6MW 
(m)
Median Improvement at 6 mo (m) 
(Q1, Q3)
HM II A 56 0 373 (165, 461)
HM II B 8 176±105 225 (45, 298)
CRT/CRT-D 69 170±106 46 (-15, 106)
1023-31 Rheumatoid Arthritis Is Independently Associated 
With Increased Left Ventricular Mass but Not Reduced 
Ejection Fraction
Rebecca L. Rudominer, Mary J. Roman, Richard B. Devereux, Stephen A. Paget, 
Joseph E. Schwartz, Michael D. Lockshin, Mary K. Crow, Lisa Sammaritano, Daniel 
M. Levine, Jane E. Salmon, Weill Medical College of Cornell University, New York, NY, 
Hospital for Special Surgery, New York, NY
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated 
with premature atherosclerosis, vascular stiffening, and congestive heart failure (CHF). 
Whether RA is associated with underlying structural and functional abnormalities of the 
left ventricle (LV) is poorly understood.
Methods: 89 patients with RA without clinical coronary artery disease or significant valvular 
disease were matched to 89 healthy controls. All subjects underwent echocardiography, 
carotid ultrasonography, and radial tonometry to measure arterial stiffness. Disease 
specific aspects and treatment were analyzed.
Results: RA patients and controls were similar in body size, hypertension and diabetes 
status, and cholesterol, but RA patients had more carotid atherosclerosis (39.3% vs. 
12.4%, p < 0.001). LV diastolic diameter (4.92 vs 4.64 cm, p <0.001), mass (136.9 vs 
121.7 g, p = 0.001 or 36.5 vs 32.9 g/m 2.7, p = 0.010), ejection fraction (EF) (71% vs 67%, 
p <0.001), and prevalence of LV hypertrophy (LVH) (18% vs 6.7%, p = 0.023) were all 
higher among RA patients. LV EF was normal in all RA patients (range 56-81%). Results 
were comparable when analyses were limited to normotensive patients and controls (75 
in each group). In multivariate analysis, presence of RA (p = 0.004) was an independent 
correlate of LV mass. Furthermore, RA was independently associated with the presence 
of LVH (OR 4.14, [95% CI 1.24-13.80; p 0.021]). Among RA patients, age at diagnosis 
(p = 0.032) and disease duration (p=0.026) were independently related to LV mass. RA 
patients with LVH were older (p < 0.001) and had higher systolic pressure (p < 0.001), 
damage index score (p = 0.050), CRP (p = 0.022), homocysteine (p <0.001), and stiffness 
index (p = 0.045) compared to those without LVH.
Conclusion: RA is associated with increased LV mass as well as a 3-fold increase in overt 
LVH. Disease duration is independently related to an increased LV mass, suggesting a 
pathophysiological link between chronic inflammation and LVH. In contrast, LV systolic 
function is preserved in RA patients without concurrent coronary or valvular disease, 
suggesting that systolic dysfunction is not an intrinsic feature of RA.
1023-32 Cardiac Contractility Modulation With Non-Excitatory 
Electrical Signals Normalizes Expression of 
Phospholemman in Left Ventricular Myocardium of 
Dogs With Chronic Heart Failure
Ramesh C. Gupta, Priya Goyal, Hani N. Sabbah, Henry Ford Hospital, Detroit, MI
Background: Phospholemman (PLM), a regulator of the activity of the Na+-K+-ATPase 
pump and Na+-Ca2+ exchanger (NCX), is up-regulated in LV myocardium of humans 
and dogs with heart failure (HF). PLM forced expression in rat cardiomyocytes results in 
contractile and Ca2+ transient abnormalities. In dogs with HF, delivery of non-excitatory 
cardiac contractility modulation (CCM) electric signals to the LV muscle during the 
absolute refractory period, improves LV function and normalizes expression of the NCX. 
This study examined the effects of long-term CCM therapy on PLM expression in LV 
myocardium of dogs with HF.
Methods: RNA was extracted and tissue homogenate was prepared from LV myocardium 
obtained from 6 CCM-treated HF dogs, 6 untreated HF dogs and 6 normal (NL) dogs. 
mRNA expression for PLM and GAPDH was measured using RT-PCR. Protein expression 
of PLM and calsequestrin (CSQ) was measured in homogenate with Western blotting. All 
bands were quantified in densitometric units (du).
Results: Expression of the housekeeping gene GAPDH and the protein CSQ was 
unchanged among groups. mRNA and protein expression of PLM was significantly 
increased in untreated HF dogs compared to NL (Table). CCM therapy normalized both 
mRNA and protein expression of PLM.
Conclusions: In dogs with HF, long-term CCM monotherapy restores physiologic expression 
of PLM. This finding is consistent with the observed normalization of expression of the 
NCX and the improved LV function seen in HF following long-term CCM therapy.
Expression of Phospholemman
NL HF-Untreated HF+CCM
PLM mRNA (du) 0.30 ± 0.02 1.37 ± 0.07* 0.66 ± 0.03*†
PLM Protein (du) 0.38 ± 0.02 1.01 ± 0.03* 0.67 ± 0.02*†
*=p<0.05 vs. NL; †=p<0.05 vs. HF-Untreated
1023-33 Pharmacological Stress Echocardiography Predicts 
Left Ventricular Reverse Remodeling After Cardiac 
Resynchronization Therapy
Quirino Ciampi, Lorenza Pratali, Rodolfo Citro, Michele Della Porta, Marcello Piacenti, 
Bruno Villari, Eugenio Picano, Fatebenefratelli Hospital, Benevento, Italy, CNR, Institute 
of Clinical Physiology, Pisa, Italy
Background: Pharmacological stress echocardiography (SE) is widely used for 
evaluation of myocardial contractile reserve in heart failure (HF) patients. We evaluated 
the relationship between response to cardiac resynchronization therapy (CRT) and 
myocardial contractile reserve.
Methods: We studied 49 HF patients (age 68±9 years, 53% with ischemic etiology) 
referred to CRT, with NYHA class >IIb, QRS duration ≥130 ms and ejection fraction 
≤35%. Before CRT, 48 patients underwent SE with dobutamine (up to 40 mcg/kg/min) 
and 1 with dipyridamole (up to 0.84 mg/kg). The variation between rest and stress in wall 
motion score index (WMSI, from 1=normal, to 4=dyskinetic, 17 segment model of LV) 
≥0.20 identify a significant contractility reserve. All repeated resting echocardiography at 
6 months; a reduction of LV end-diastolic volume ≥20% from baseline was considered a 
reverse remodeling.
Results: Contractile reserve was present in 12 of the 14 patients with, and 15 of the 
35 patients without LV reverse remodeling (86% vs 43%, p=0.006). The change in 
WMSI during follow-up was related to change of WMSI during SE (r=0.589, p<0.001, 
figure); and to a lesser extent with BNP levels before CRT (r=0.395, p=0.011) and peak 
oxygen consumption before CRT (r=-0.523, p=0.004). The change of WMSI during SE 
(beta=-0,630, p=0.002) was the best predictor of reverse remodeling in the follow-up.
Conclusions: Myocardial contractile reserve assessed by SE before CRT predicts LV 
reverse remodeling at mid-term evaluation after CRT. 
1023-34 Validation of a Multiparametric Strategy As 
a Comprehensive Approach to Optimize 
Echocardiographic Selection of Patients for CRT
Stephane Lafitte, Julie Chabaneix, Pierre Bordachar, Patrcia Reant, Antoine Deplagne, 
stephanie Brette, Jacques Clementy, Raymond Roudaut, Anthony DeMaria, University 
of Bordeaux 2, Pessac, France, UCSD, San Diego, CA
Background: Cardiac resynchronization therapy (CRT) significantly improves both the 
symptoms and prognosis of end-stage heart failure patients. However, the 30% non-
responder rate remains a limitation. Although dyssynchrony by echo has been used to 
increase the rate of responders, the complexity of LV contraction has resulted in only 
moderate improvement using any of several individual parameters.
We sought to develop and validate a comprehensive multiparametric algorithm by 
applying previously validated criteria to predict CRT response.
Methods: 75 end-stage heart failure patients (NYHA 3-4 & EF < 35%) with one 
echo parameter predictive of CRT response were studied. Echo parameters were 
atrioventricular dyssynchrony (LV filling time/RR), interventricular dyssynchrony (pre-
ejection delay difference), intraventricular dyssynchrony which integrated radial (PSAX 
M-mode) and longitudinal (TDI) evaluations for spatial (wall to wall) and temporal (wall 
end-systole to mitral valve opening) dyssynchrony diagnosis. After CRT implantation, 
patients were followed 6 months with functional and echo evaluations defining responders 
by a 15% reduction in end-systolic volume.
Results: Mean QRS and EF were 127±31ms and 28±8%. CRT response occurred in 
52%, independent of QRS width. Conventional single parameters resulted in a mean rate 
of non-responders of 24% [13-36%] and a range of sensitivities from 14% to 74% and 
specificities from 64% to 74% with a mean of 45% and 73%. Multiparametric approach 
dramatically decreased the mean rate of non-responders to 6% and 3% when 2 or 4 
associated parameters were used respectively. Importantly, 100% of patients in whom all 
parameters were absent were non responders.
Conclusions: Independent of QRS width, a multiparametric strategy based on the 
association of conventional criteria enables the prediction of CRT response better than 
existing single parametric approaches.
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1023-35 Influence of Sex on Clinical Outcomes With Cardiac 
Resynchronization Therapy: Insights From the 
COMPANION Study
Teresa De Marco, JoAnn Lindenfeld, Jalal Ghali, Aaron Hesselson, Matthew Flemming, 
Elizabeth Galle, Patrick Yong, Michael R. Bristow, University of San Francisco California 
Medical Center, San Francisco, CA, Boston Scientific Corporation, Saint Paul, MN
Background: Although major initiatives are underway to examine the relationship between 
sex and heart disease, the effect of sex on outcomes with cardiac resynchronization 
therapy (CRT) in a large randomized trial has not been published.
Methods: The COMPANION database was stratified by sex and analyzed retrospectively 
based on six month function outcomes [six minute walk (6MW), symptoms (NYHA Class), 
quality of life (QoL)] and time-to-event analyses [all-cause mortality (ACM) alone and 
in combination with all-cause, cardiovascular, and heart failure hospitalization (ACH, 
CVH, and HFH, respectively). Analyses were adjusted for treatment effect and baseline 
differences between sexes. Event driven outcomes are expressed as hazard ratios (HR).
Results: A total of 1520 pts were enrolled and characterized as male (68%), NYHA Class 
III (86%), mean age 67 years, mean ejection fraction 22%, mean QRS duration 157 ms, 
and ischemic etiology (56%). Women at baseline had significantly shorter 6MW (219m 
vs 268m, p<0.001), less ischemia (32% vs 66%, p<0.001), and were more likely to be 
taking beta blockers in combination with ACE/ARB (66% vs 58%, p<0.01). Outcomes 
are shown below:
Conclusions: Both sexes demonstrated functional and symptomatic improvement with 
CRT. In event-driven outcomes, men uniformly derived benefit from CRT while women 
only benefited from CRT when assessing ACM+HFH and possibly also ACM. ACM was 
more likely among males. Further study is required due to the retrospective nature of 
this analysis.
1023-36 Perioperative Outcomes, Risk Stratification and Longer 
Term Mortality for Heart Failure Patients Undergoing 
Noncardiac Surgery
Kirsten Healy, Columbia University, New York, NY
Background: As the population continues to age, more elderly patients with heart failure 
(HF) will be undergoing non-cardiac surgery. Most of the data concerning risk assessment 
and outcomes for cardiac patients undergoing non-cardiac surgery has been developed 
in patients with coronary artery disease. In order to delineate outcomes and identify risk 
factors for adverse events, we performed an analysis of HF patients at our institution 
undergoing intermediate to high risk non-cardiac surgery.
Methods: Approximately 410 patients with the diagnosis of HF undergoing non-cardiac 
surgery from 2001-2004 were identified from a central data repository. After review of the 
medical records, 174 subjects were included in the analysis. Demographic and clinical 
characteristics were recorded and adverse perioperative complications were identified 
including myocardial infarction, worsening heart failure and death in-hospital and longer 
term mortality using the Social Security death index. Risk factor were identified using 
univariate and multivariate logistic regression analysis. Potential predictor variables for 
long term mortality were assessed with multivariable cox proportional hazards methods 
to generate a prediction model.
Results: The 174 subjects (mean age 75 ± 12 years, 47% male) underwent the 
following surgical procedures: 69 (39.5%) orthopedic, 82 (47%) vascular, 17 (10%) 
abdominal, 4(2.3%) urologic and 2 (1%) thoracic. Fifty-three subjects (30%) had at 
least one perioperative event including 14 (8%) deaths, 26 (15 %) MI, and 44 (25%) HF 
exacerbations. Risk factors for adverse events include age, GFR < 50 ml/min, BUN > 45 
mg/dl, peripheral vascular disease, and vascular surgery. During a median follow-up of 
3.5 years follow-up, 89 (51%) of the patients died.
Conclusion: Elderly patients with HF undergoing non-cardiac surgery are at significant 
risk for adverse outcomes in the perioperative period and mortality is high during longer 
term follow-up. Several clinical variables are risk factors for adverse outcomes in such 
patients in whom the benefit of perioperative intervention warrants further consideration.
1023-37 Association of Depression Development Following 
Coronary Artery Disease Diagnosis to Heart Failure 
Incidence
Heidi T. May, Benjamin D. Horne, Tami L. Bair, John F. Carlqust, Joseph B. Muhlestein, 
Intermountain Medical Center, Murray, UT
Background: Depression has been shown to be a risk factor for poor outcomes among 
coronary artery disease (CAD) patients. However, little is known about its role in influencing 
heart failure (HF) development. HF is a public epidemic that affects 5 million people in the 
U.S. and has an incidence rate of 550,000 new cases per year. The purpose of this study 
was to evaluate the influence of post-CAD depression on the incidence of HF.
Methods: Patients free from HF and not on anti-depressant therapy at time of CAD 
diagnosis (>70% stenosis) were studied. Two groups within this cohort were evaluated: 
those who had a subsequent hospitalization (N=7466) and those with available 
outpatient pharmacy records (N=1622) (overlap between the cohorts occurred in 1002 
of the patients). Among the hospitalized group, patients were excluded if a myocardial 
infarction (MI) occurred prior to HF admission. Depression was defined as use of an 
anti-depressant medication (ADM). Results were determined by Cox Hazard Regression 
models with adjustment for traditional CAD risk factors, presentation at CAD diagnosis 
(stable angina, unstable angina, or MI), CAD treatment approach (medical, interventional, 
surgical), prior MI, and statin use.
Results: Among those hospitalized, a total of 746 (10.0%) initiated ADM therapy. The 
incidence of HF among those not using ADMs was 4.8 per 100 compared to 7.1 per 100 for 
ADM use. ADM use was associated with an increased risk for HF admission in univariable 
analysis (HR=1.68, p<0.0001), and this relationship remained but was attenuated in 
multivariable analysis (HR=1.35, p=0.04). Among those with pharmacy records, a total 
of 386 (23.8%) initiated ADM after CAD diagnosis, with 4.1% subsequently admitted for 
HF (vs. 1.7% for no ADM, p=0.005), with some attenuation of HF risk after multivariable 
adjustment (HR=1.74, p=0.10).
Conclusion: Depression, indicated by anti-depressive medication use, was associated 
with an increased risk of developing HF after CAD diagnosis. Though potentially limited by 
the clinical surrogate definition of depression (defined by ADM use), this study suggests 
the need to further study the association of depression with the risk of HF development 
following CAD diagnosis.
1023-38 Relation of Ventricular-Vascular Coupling to Exercise 
Capacity in Ischemic Cardiomyopathy: A Cardiac Multi-
Modality Imaging Study
Raymond Ching-Chiew Wong, Carlos A. Dumont, Bethany A. Austin, Deborah H. Kwon, 
Scott D. Flamm, James D. Thomas, Randall C. Starling, Milind Y. Desai, Cleveland Clinic 
Foundation, Cleveland, OH
Background: Left ventricular (LV) systolic dysfunction due to ischemic cardiomyopathy 
(I-CMP) leads to reduced exercise capacity. Ventricular-vascular coupling (VVC), a ratio 
of effective arterial to LV elastance, represents forward flow efficiency of LV independent 
of mitral regurgitation. In I-CMP patients, we sought to a) assess relationship between 
rest VVC and maximum oxygen consumption corrected for heart rate (MVO2/pHR), an 
accurate measure of exercise capacity with β-blocker use, and b) compare value of VVC 
versus other determinants of exercise capacity.
Methods: 43 patients with I-CMP (age 59 ± 9 years, 88% on β-blocker) underwent 
metabolic exercise testing, echocardiography and cardiac magnetic resonance (1.5 T 
CMR) for transplant evaluation. MVO2/pHR, diastolic filling variables and CMR LV indices 
[end-systolic (ESV), end-diastolic (EDV), stroke volume (SV), all in ml, and LVEF were 
measured. VVC was calculated as: [Effective arterial elastance (end systolic pressure 
÷ stroke volume index)/ LV end-systolic elastance (end systolic pressure÷LV systolic 
volume index)].
Results: Mean LVEF, ESV, EDV, and SV were 24 ± 8%, 228 ± 107ml, 297 ± 111ml, and 
66 ± 20ml respectively. Mean MVO2/pHR was 13 ± 3 ml/beat. Predictors of MVO2/pHR 
are shown in Table 1. On stepwise regression, VVC remained the only significant predictor 
of MVO2.
Conclusions: In I-CMP patients with LV systolic dysfunction, VVC is an important predictor 
of MVO2/pHR, potentially becoming a target for therapeutic interventions. 
1023-39 Relationship of Depression and Severity of Illness in 
Heart Failure: An Analysis From HF ACTION
Stephen S. Gottlieb, Stephen Ellis, Phillip Binkley, Jonathan Howlett, Christopher 
O’Connor, James Blumenthal, Gerald Fletcher, Ann M. Swank, University of Maryland, 
Baltimore, MD
Background: Depression is common in CHF patients (pts), prognostic & believed to be 
secondary to disease severity. HF ACTION is a large, randomized study of exercise 
in which psychological & physiologic factors were assessed. We hypothesized that 
depression would affect perception of disease severity more than actual limitations. We 
compared the relationship of objective & subjective parameters with depression.
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Methods: At baseline, 2178 pts entered into HF ACTION completed questionnaires to 
assess depression (BDI) & quality of life (KCCQ). They also had baseline cardiopulmonary 
exercise testing (CPX, with evaluation of peak VO2, duration & respiratory quotient 
(RER)), 6 minute walk, BNP, & demographics. The association of BDI with other factors 
was determined by univariate & multivariable analyses.
Results: Table shows associations with BDI. Objective assessments of disease severity 
were slightly (VO2) or not (BNP, LVEF) related to BDI. Race was slightly (r2=0.0038) & 
sex not related to BDI. By multivariable analysis (KCCQ not included), however, only 
age (slope=-0.14,p<0.0001) & the subjective NYHA (slope=3.0,p<0.0001) & motivation-
influenced 6 minute walk (slope=-0.0074,p=0.0001) & RER (slope=-3.9,p=0.018) 
independently predicted BDI.
Conclusions: In CHF, depression is minimally related to severity of disease, but affects 
patients’ self-perception (& perception of others) of disease severity. Subjective endpoints 
in trials, such as NYHA & KCCQ, are likely influenced by depression.
Univariate Predictors of BDI, * = p < 0.01
Variable Slope estimate SE t statistics R squared
Age -0.12 0.014 -8.5 0.0324 *
6 minute walk -0.0088 0.0018 -5.0 0.0117 *
CPX duration -0.17 0.046 -3.7 0.0064 *
Peak VO2 -0.10 0.039 -2.6 0.0032 *
BNP 0.00005 0.0005 0.09 0.0000
LVEF -0.0030 0.025 -0.12 0.0000
Peak RER -5.9 1.7 -3.6 0.0060 *
NYHA (II v. III/IV) 3.20 0.37 8.6 0.0327 *
KCCQ -0.26 0.0069 -38 0.4051 *
1023-40 Sleep, Sleep-Disordered Breathing, and Markers of 
Severity in Heart Failure (HF)
Paul J. Mills, Joel E. Dimsdale, Michael G. Ziegler, Alan Maisel, Barry H. Greenberg, 
University of California, San Diego, San Diego, CA
Background: Sleep-disordered breathing is a significant non-cardiac comorbidity in HF. 
This study characterized sleep in HF and determined whether markers of HF severity are 
related to sleep parameters.
Methods: 25 stable NYHA class II-IV HF patients (LVEF < 40%; mean 56.2 years) were 
recruited from the UCSD Heart Failure Program and the VA Medical Center Coronary 
Care Program. 32 healthy age-matched volunteers (mean 54.1 years) served as controls. 
Sleep was recorded using standard polysomnography at the UCSD General Clinic 
Research Center Gillin Laboratory of Sleep and Chronobiology. Records were scored 
using Rechtshaffen and Kales criteria. Number of apneas and hypopneas/hour of sleep 
were used to determine the apnea hypopnia index (AHI). BNP levels were determined 
in plasma.
Results: A MANOVA testing all sleep variables and controlling for age, BMI and gender 
was significant for HF vs. non-HF classification (p=.016). HF patients had more central 
apneas/hour [29.5 (SD=51) vs. 8.22, (SD=25) (p=0.03)] but no difference in the number 
of obstructive apneas/hour [20.2 (SD=29) vs. 18.1 (SD=27)]. More of the HF patients 
were apneic (i.e, AHI’s > 10) [64% vs. 25%) (ń2=8.7, p=.003)]. HF patients spent more 
time in stage 1 sleep [54 min. (SD=39) vs. 35 min. (SD=22) (p=.03)], had more respiratory 
awakenings following apneic or hypopneic events [27.2 (SD=38) vs. 4.2 (SD=6) (p=.001)], 
and spent marginally less time in slow wave sleep [37 min. (SD=33) vs. 51 min. (SD=36), 
p<.10]. HF patients had lower mean O2 saturations [92.7% (SD=3.4) vs. 94.7% (SD=2.7) 
(p=0.02)]. Among HF patients, LVEF was negatively correlated with number of central 
apneas (r=-.414; p=.044) and AHI (r=-.547, p=.007). Higher BNP levels were associated 
with a greater number of central apneas (r=.442; p=.011), more time in stage 1 sleep 
(r=.396; p=.023) and a greater number of respiratory awakenings (r=.662; p=.001).
Conclusions: HF patients wake up more frequently during the night and spend more 
of their sleeping hours in light sleep. The severity of sleep-disordered breathing in HF 
reflects the severity of disease and is reflected by elevated BNP levels.
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1030-1 Left Ventricular Diastolic Function and Mass Improve 
After Bariatric Surgery
Joshua G. Leichman, David Aguilar, Erik B. Wilson, Terry Scarborough, Sherman Yu, 
Heinrich Taegtmeyer, University of Texas, Houston Medical School, Houston, TX, Baylor 
College of Medicine, Houston, TX
Background: Clinically severe obesity is associated with cardiovascular comorbidities 
including heart failure. In this context diastolic dysfunction may be a precursor to the 
development of overt heart failure. Our hypothesis was that weight loss induced by 
bariatric surgery may improve cardiovascular function.
Methods: In a prospective longitudinal cohort study, we enrolled 43 obese participants 
[BMI 50.6 kg/m2(1.76) all data mean (+/-SEM)] who subsequently underwent bariatric 
surgery. The mean age was 42 (2.7) years and 86% were women. Each patient had a 
resting transthoracic echocardiogram with tissue Doppler imaging before, as well as three 
and nine months after surgery. Changes in the outcome measures where analyzed using 
repeated measures ANOVA.
Results: At baseline 42% of the cohort met criteria for age-adjusted diastolic dysfunction 
(DD) by tissue Doppler imaging (TDI). Of those with DD the mean left ventricular ejection 
(LVEF) fraction was normal 62% (2.5) while TDI age-adjusted systolic velocities (Sms) 
were abnormal [8.8 cm/sec (0.33)]. At baseline the mean indexed left ventricular mass 
(LVM/ht2.7) was 50 g/m2.7 (4.0) and mean systolic blood pressure was 133 mmHg 
(2.9). Body mass index and waist circumference decreased 25% and 19%, respectively 
(p<0.0001 for both) nine months after surgery. TDI diastolic velocities (Ems) increased 
from 8.3 cm/sec to 10.2 cm/sec (p=0.01) at three months and did not change significantly 
at nine months after surgery. Other measures of diastolic function such as deceleration 
time and early mitral inflow velocity followed the same trend as Ems. There were no 
significant changes in systolic measures during weight loss, either LVEF or Sms. 
Furthermore systolic blood pressure did not change significantly at either time point. 
While LVM/ht2.7 did not significant decrease at three months there was decreased of 
14% at nine months of weight loss (p=0.02).
Conclusions: TDI diastolic function improves early in the weight loss process. This 
improvement occurs independent of the changes in heart mass suggesting a direct effect 
of weight loss on diastolic function.
1030-2 Real Time Intrathoracic Impedance Is Correlated With 
Arterial Pressure
Todd M. Zielinski, Mattias Rouw, Kevin Vincent, Kevin Knox, Douglas A. Hettrick, 
Medtronic, Inc, Moundsview, MN, Medtronic, Inc, Arnhem, The Netherlands
BACKGROUND: Heart failure monitoring using intra thoracic impedance measured via 
an implantable device has been shown to be clinically useful. However, the source of the 
change in intra thoracic impedance (Z) during the cardiac cycle in an implantable device 
is not well understood. We compared Z waveform morphology to left ventricular (LV), 
Aortic (AO), Right Ventricular (RV) and Pulmonary Artery (PA) pressure. METHODS: Ten 
anesthetized pigs (37 ± 4.9 kg) were instrumented with micromanometers positioned 
in the LV, AO, RV and a fluid-filled transducer catheter positioned in the PA. A pacing/
defibrillation lead was positioned in the RV apex and a can emulator placed in the 
anterior thorax. Z and pressure waveforms were recorded during one cardiac cycle at 
end expiration. Pearson’s correlation coefficient was calculated comparing Z to LV, AO, 
RV, and PA pressure waveforms. RESULTS: Impedance waveform morphology was 
significantly correlated with aortic pressure (r = 0.79 ± 0.11; p < 0.001) compared to LV (r 
= 0.67 ± 0.22), RV (r = 0.55 ± 0.28) and PA (r = 0.65 ± 0.17), during one cardiac cycle at 
end expiration. Figure depicts example from one animal. The timing of specific physiologic 
events such as aortic valve opening and closing was also evident. CONCLUSIONS: The 
impedance component may yield higher sensitivity to specific physiologic parameters 
such as arterial pressure. Such measurements may be useful for monitoring changes in 
afterload, including systemic vascular resistance and total arterial compliance. 
1030-3 Reverse Left Ventricular Remodeling Predicts Mortality 
but Not Symptomatic Improvement Following Cardiac 
Resynchronization Therapy
Paul William Foley, Kayvan Khadjooi, Nick Irwin, Shajil Chalil, Russell EA Smith, 
Francisco Leyva, Good Hope Hospital, University of Birmingham, Sutton Coldfield, 
United Kingdom
Background: We determined whether the reverse left ventricular (LV) remodelling that 
accompanies cardiac resynchronization therapy (CRT) relates to mortality as well as to 
symptomatic improvement.
Methods: 196 patients [age 68 ± 11 yrs, LVEF <35%, class III (n=133) or IV (n=63), 
QRS = 155.1 ± 30.5 ms, (mean ± SD)] with ischemic (n=143) or non-ischemic (n=53) 
cardiomyopathy underwent assessment of 6-min walking distance, quality of life and 
echocardiography, before and 453 days after CRT. Changes in left LV end-systolic volume 
were used to define echocardiographic responders (ER, ≥15% reduction) and non-
responders (non-ER, <15% reduction or increase).
Results: In Kaplan-Meier analyses, non-ER were more likely than ER to reach the 
composite endpoints of death from any cause or unplanned hospitalization for major 
cardiovascular events (log-rank p=0.0152), death from any cause or heart failure 
hospitalization (p=0.0003, see Fig.) as well as death from any cause (p=0.0004) and 
cardiovascular death (p=0.0072, see Fig.) over a follow-up of up to 6.5 years. No difference 
in the change from baseline in 6-min walking distance (ER: 92.8 ± 103.1, non-ER: 81.8 ± 
101.8) or symptom scores (ER: -23.7, non-ER:-20.1) emerged between ER and non-ER.
Conclusions: Although reverse LV remodelling predicts mortality and morbidity following CRT, 
it does not predict symptomatic benefit. These findings suggest that mechanisms other than 
reverse LV remodelling contribute to the symptomatic improvement gained from CRT.
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1030-4 Value of QRS Duration for Prediction of Response to 
Cardiac Resynchronization Therapy in Patients With 
End-Stage Heart Failure
Sjoerd A. Mollema, Gabe B. Bleeker, Ernst E. Van der Wall, Martin J. Schalij, Jeroen J. 
Bax, Leiden University Medical Center, Leiden, The Netherlands
Background: Despite current selection criteria, approximately 20%-30% of patients treated 
with cardiac resynchronization therapy (CRT) do not benefit. It has been suggested that 
QRS duration may not be the optimal criterion for selecting patients for CRT. However, 
a systematic evaluation in a large patient population undergoing CRT has never been 
performed. The objective of this study is to evaluate the value of QRS duration to predict 
response to CRT.
Methods: A total of 242 consecutive heart failure patients scheduled for implantation of 
a CRT device were studied. The selection criteria for CRT included: moderate to severe 
heart failure (NYHA class III/IV), LV ejection fraction (LVEF) ≤35% and QRS >120 ms. 
Before CRT implantation, clinical status was assessed and 2D-echocardiography was 
performed to determine LV volumes and LVEF. The clinical status and changes in LVEF 
and LV volumes were reassessed at 6 months follow-up. The QRS duration was measured 
from the surface ECG before implantation of the CRT device.
Results: At 6 months follow-up, mean NYHA class decreased from 3.1 ± 0.2 to 2.2 ± 0.6 (p 
<0.0001), quality-of-life score improved from 40 ± 17 to 25 ± 19 (p <0.0001) and 6-minute 
walking distance increased (288 ± 120 m versus 378 ± 134 m, p <0.0001). Mean LVEF 
increased from 23 ± 7% at baseline to 31 ± 10% at 6 months follow-up (p <0.0001) and 
LV reverse remodeling was observed with a mean decrease in LVESV from 182 ± 70 ml to 
143 ± 68 ml (p <0.0001) and a mean decrease in LVEDV from 236 ± 80 ml to 203 ± 76 ml 
(p <0.0001). After 6 months of CRT, 68% of patients were classified as clinical responders 
and 60% as echocardiographic responders. At baseline, no significant differences were 
observed in QRS duration between clinical responders and non-responders (165 ± 21 
ms vs. 164 ± 25 ms respectively, p = NS), and between echocardiographic responders 
and non-responders (167 ± 22 ms vs. 162 ± 22 ms respectively, p = NS). Furthermore, 
no significant correlation was demonstrated between baseline QRS duration and 
improvement in both clinical and echocardiographic variables at 6 months follow-up.
Conclusions: QRS duration before implantation is not predictive for clinical and 
echocardiographic response to CRT at 6 months follow-up.
1030-5 Impact of Red Cell Distribution Width on Left Ventricular 
Remodeling and Outcomes in Congestive Heart Failure 
With Anemia
Naoki Fujimoto, Katsuya Onishi, Kaoru Dohi, Masaki Tanabe, Tairo Kurita, Takeshi 
Takamura, Masaaki Ito, Mie University Graduate School of Medicine, Tsu, Japan
Backgrounds: The link between congestive heart failure (HF), chronic renal dysfunction 
and anemia is well known. Red cell distribution width (RDW) is a strong independent 
predictor of morbidity and mortality in HF patients; however, characterization and 
prognosis of high RDW values in HF patients with anemia have not been fully described. 
Purpose: The purpose of this study is to examine the relation of RDW values to the cardiac 
function, hemodynamics and readmission rates in HF patients with anemia. Methods: 
Left ventricular (LV) function and hemodynamics obtained by conductance catheters with 
microtip-manometers, and RDW levels were examined in consecutive 57 HF patients with 
anemia (hemoglobin less than13 mg/dl in men and 12 mg/dl in women, age; 66±12 y.o., 
male; 65 %). After the follow-up periods (mean 31±9 months), the readmission rate was 
compared. Results: LV ejection fraction and BNP levels were 0.41±0.15 and 330±326 
pg/ml, respectively. The median value of RDW was 13.9%. Accordingly, patients were 
divided into two groups; high RDW (16.2±2.0 %; n=28) and low RDW (13.2±0.4%; n=29). 
Total bilirubin and BNP levels and New York Heart Association functional class (2.3±0.7 
vs. 1.9±0.5) were higher in high RDW, while there were no differences in hemoglobin 
levels and glomerular filtration rate. End-diastolic (185±89 vs. 144±47 ml) and end-
systolic volume (123±82 vs. 85±41 ml) were significantly larger, and end-systolic pressure 
was smaller (104±20 vs. 124±30 mmHg) in high RDW than low RDW. There were no 
differences in heart rates, LV ejection fraction, LV end-diastolic pressure, LV relaxation 
and LV end-systolic elastance. Kaplan Meier analysis showed that patients in high 
RDW had a higher risk for readmission due to exacerbated HF than those in low RDW 
(P=0.047) and a multivariate analysis showed that LV end-diastolic volume was positively 
associated with RDW levels. Conclusions: RDW levels reflect LV remodeling and predict 
the readmission due to exacerbated HF.
1030-6 Is There a Difference in 3-Dimensional Derived Ejection 
Fraction Between the Sexes: A CV MRI Study in 2,500 
Patients
Robert W. W. Biederman, Diane A. Vido, Geetha Rayarao, June Yamrozik, Ronald 
Williams, Saundra Grant, Mark Doyle, Allegheny General Hospital, The Gerald McGinnis 
Cardiovascular Institute, Pittsburgh, PA
Introduction Classically, it has been assumed that the standard mechanical parameter 
ejection fraction (EF) is identical across the sexes. Until recently, however, the fidelity and 
reproducibility of imaging techniques guaranteed virtual superimposition of EF, nullifying 
any differences even if they were they to be present in nature.
Hypothesis Using high resolution 3D CV MRI, we hypothesized that there would be 
decreased EF in females as compared to males when examined on a population basis.
Methods A database composed of consecutive patients who underwent CVMRI scanning 
(GE EXCITE HD 1.5T, Milwaukee, WI) enrolled between Aug 2002 and May 2007 was 
interrogated to yield all normal pts classified by strict criteria: EF>55%, no valvular 
disease >1+, no evidence of CAD, HTN, or cardiomyopathy. EF was determined primarily 
by standard FIESTA 3D methodology or 2D when available. Patients were stratified only 
by sex and age.
Results 2500 consecutive patients were evaluated, from which 844 were classified as 
normal, comprising of 403 males and 441 females (mean age 50±9yrs). All pts passed 
the Kolmogorov-Smirnov test for Normality. The mean EF for men was 63±5%; range: 59-
68%, while for women it was 65±5%; range: 60-69%, p<0.005. Under the assumption that 
EF>55% may not be appropriate for normal thresholding, EF>60 and >65% were also 
stratified but did not yield significant differences between sexes. Similarly, stratification by 
decade did not reveal a significant difference. A subset of 150 patients with clinical CV 
disease, representing the entire range of EF (5%-81%), underwent intra and interobserver 
reproducibility for LVEF and was 0.13 and 0.85%, respectively.
Conclusion Contrary to conventional doctrine, LV ejection performance (EF) as measured 
clinically, using highly reproducible and accurate 3D CV MRI, is significantly lower for 
males than females as determined in the largest CV MRI database to our knowledge 
(2500 patients) to date examining this subject. Thus, beyond establishing normal ranges 
for LVEF, these observations have far reaching clinical implications in defining thresholds 
of normality, as well as belying potential, albeit subtle, intrinsic differences in contractile 
mechanisms.
1030-7 Analysis of Transthoracic Impedance Data in Heart 
Failure Patients
Nicholas Hodgman, Nathaniel Madsen, Brenda Dole, Daniel Lustgarten, Peter 
VanBuren, University of Vermont/Fletcher Allen Health Care, Burlington, VT
Background: The impedance of electricity traveling through the chest cavity inversely 
correlates with total lung water and thus is a potential measure of compensation in heart 
failure. A feature of some biventricular pacers and ICDs is the ability to serially measure 
transthoracic impedance. If lung impedance was accurate in detecting impending heart 
failure events, this information would be vital in the management of heart failure patients.
Methods: An Insync Sentry Biventricular pacing ICD with trans-thoracic impedance 
measuring capabilities was implanted in 58 heart failure patients over a 19 month period 
(from May 2005 to Jan 2007). Impedance data were obtained during device interrogation. 
Impedance levels falling below a manufacturer-defined threshold were recorded as 
“impedance events”. Clinical heart failure (HF) events following device implant were 
recorded by chart review. HF events were defined as symptoms of dyspnea, orthopnea, 
paroxysmal nocturnal dyspnea, lower extremity edema, weight gain, medication changes, 
and hospitalizations for HF.
Results: There were a total of 21 HF events in 15 patients (25.9% of total patients) 
recorded from the medical record. Impedance events occurred in 15 out of the 21 heart 
failure events (71.4%). Thus, the device detected lung water properly in 12 patients out of 
the 15 patients that had HF events (80.0%). There were a total of 70 impedance events 
detected by the device in 30 patients (51.7% of patients) without a corresponding heart 
failure event. There were a total of 6 heart failure events out of 21 (28.6%) total heart 
failure events that did not have a corresponding pacemaker impedance event.
Conclusions: Non-invasive measurement of transthoracic impedance was reasonably 
sensitive in detecting heart failure symptoms in heart failure patients but had poor 
specificity. More data are needed to verify the utility of transthoracic impedance monitoring 
in heart failure patients.
1030-8 Acute Haemodynamic Effects of Cardiac 
Resynchronisation Therapy in Heart Failure With a 
Narrow Qrs Duration and No Measurable Dysynchrony
Lynne K. Williams, Susan M. Ellery, Kiran C. Patel, Francisco Leyva, Rob A. Bleasdale, 
Paul Steendijk, Vince Paul, Michael P. Frenneaux, University Of Birmingham, 
Birmingham, United Kingdom
Background: Cardiac resynchronisation therapy (CRT) is currently restricted to those 
patients with a QRS duration>120ms. We hypothesized that CRT would result in an 
acute haemodynamic benefit in patients with heart failure, a narrow QRS duration and no 
dyssynchrony (Yu dyssynchrony index≤32).
Methods: Twenty eight patients with a left ventricular ejection fraction (LVEF) ≤ 35%, in 
sinus rhythm, and with NYHA Class III/IV heart failure underwent invasive haemodynamic 
studies at the time of pacemaker implantation. The conductance catheter method was 
used to measure pressure and volume simultaneously. External constraint (EC), LV stroke 
work, maximum +dp/dt, and the slope of the preload recruitable stroke work relation 
(PRSWR - a load-independent measure of LV contractility), were measured from the 
end-diastolic pressure-volume relation recorded during inferior vena cava occlusion, at 
baseline, during biventricular pacing (BIVP), and during left ventricular pacing (LVP).
Results: EC was present in 15 of the 28 patients, and was reduced from 5.3 to 0.3mmHg 
(p<0.01) during BIVP, and from 5.3 to 0.9mmHg (p<0.01) in response to LVP. The slope of 
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the PRSWR increased in response to both BIVP (11.3 to 15.2; p < 0.01) and LVP (11.3 to 
15.3; p<0.01). LV stroke work increased in response to both BIVP (2450 to 3123; p<0.01) 
and LVP (2450 to 3403; p<0.01). Maximum dp/dt increased from 977 to 997 (p=0.20) with 
BIVP, and from 977 to 1014 (p<0.01) with LVP.
Conclusions: Both BIVP and LVP result in an improvement in acute haemodynamic 
variables in heart failure patients with a narrow QRS duration and no measurable 
dysynchrony. 
1030-9 The Heart Failure Clinical Composite Score at Six 
Months Predicts Subsequent Morbidity and Mortality
William T. Abraham, Angel R. Leon, Luigi Tavazzi, Jing Ping Sun, Petros 
Nihoyannopoulos, John Merlino, Eugene S. Chung, Stefano Ghio, Christophe Leclercq, 
The Ohio State University Heart Center, Columbus, OH
Background: The PROSPECT trial was designed to evaluate if echocardiographic 
parameters predict response to CRT. The primary endpoint was the Clinical Composite 
Score (CCS) (assessed at 6 months), which classifies patients as Worsened (death, HF 
hospitalization, worsened NYHA class or worsened Patient Global Assessment (PGA)), 
Improved (improved NYHA class or PGA) or Unchanged.
Methods: We assess whether CCS at 6 months is predictive of subsequent death or HF 
hospitalization, using time to event analysis beginning at 6 months.
Results: Of 276 PROSPECT subjects with long-term outcomes data, CCS at 6 months was 
Improved in 199 (72%), Unchanged in 36 (13%), and Worsened in 41 (15%). Survival at 18 
months was 92.9% for those Improved versus 72.8% for those Unchanged or Worsened 
(Figure, 6 months = 100%, log rank p < 0.001). Freedom from HF hospitalization at 18 
months was 88.1% for those Improved versus 75.3% for those Unchanged or Worsened 
(log rank p < 0.01).
Conclusion: The Clinical Composite Score at 6 months is a predictor of subsequent 
mortality and morbidity in CRT patients. This observation further supports the use of this 
composite assessment in heart failure clinical trials.
1030-10 Body Mass Index Is a Major Determinant of Left 
Ventricular Mass Among Obese Women: A Volumetric 
Cardiovascular Magnetic Resonance Study
Rahul R. Jhaveri, Thomas H. Hauser, Kraig V. Kissinger, Lois Goepfert, Benjamin 
Schneider, Daniel Jones, Warren Manning, Kyle K. Pond, Beth Israel Deaconess 
Medical Center, Harvard Medical School, Boston, MA
Background: Obesity is associated with left ventricular (LV) hypertrophy. Whether this 
hypertrophy represents a proportional increase in LV mass (LVM) for body weight or 
excess LVM is uncertain. To examine the etiology of LV hypertrophy we prospectively 
studied a group of morbidly obese women before and after bariatric surgery with 
cardiovascular magnetic resonance (CMR).
Methods: Sixteen morbidly obese women (age 44±11 years; body mass index (BMI) 44±5 
kg/m2; BSA 2.16±0.16 m2) were studied. Subjects underwent cine volumetric steady 
state free precession CMR before, 3 months after, and 16 months (n=13) following 
surgery. LV endocardial and epicardial borders were manually traced on end-diastolic 
and end-systolic images. LVM and volumes were determined using Simpson’s Rule.
Results: (Table) BMI declined by 16% at 3 mo and by 32% at 16 mo (p<0.001 for all 
comparisons). LVM progressively declined by 18% at 3 mo (p<0.001) and by 32% at 16 
mo (p<0.001 for all comparisons). LVM/height declined by 18% at 3 mo (p<0.001) and by 
32% at 16 mo (p=0.003 vs 3 mo). LVM/BSA declined by 11% at 3 mo (p<0.001) and by 
19% at 16 mo (p=0.24 vs 3 mo). LVM/BMI remained unchanged with weight loss (p=0.5 
for all comparisons).
Conclusion: Among morbidly obese women undergoing major weight loss following 
bariatric surgery, LVM, LVM/BSA, and LVM/height decline significantly while LVM/BMI 
remains constant. The stability of LVM/BMI in the setting of marked weight loss suggests 
that BMI is a principal determinant of LVM in this cohort.
* p < 0.004 vs. preoperative; + p < 0.004 vs. 3 months postoperative
Preoperative 3 Months Postoperative 16 Months Postoperative
Weight (kg) 116±15 98±15 * 79±14 *,+
BMI (kg/m2) 44±5 37±5 * 30±5 *,+
BSA (m2) 2.16±0.16 2.01±0.16 * 1.84±0.17 *,+
LVM (g) 120±23 98±15 * 82±11 *,+
LVM/height (g/m) 74±12 60±8 * 50±7 *,+
LVM/BSA (g/m2) 55±7 49±5 * 45±6 *
LVM/BMI (g/kg/m2) 2.72±0.41 2.66±0.40 2.78±0.53
1030-11 A Novel Ventricular Elastic Support System Reverses 
Remodeling in Heart Failure Patients
William T. Abraham, Inderjit Anand, Juan M. Aranda, Jr., Barry K. Rayburn, John P. 
Boehmer, Frank Grothues, Helmut Klein, Russell J. Ivanhoe, Ohio State University, 
Columbus, OH, Paracor Medical, Inc., Sunnyvale, CA
Background: In patients with HF, left ventricular (LV) remodeling, characterized primarily 
by LV enlargement and decreased EF predicts survival. We tested the hypothesis that 
the HeartNet™ (HN, Paracor Medical, Inc., Sunnyvale CA) Ventricular Elastic Support 
Therapy (VEST), used in addition to standard HF therapy, can produce incremental 
benefits on remodeling.
Methods: 51 patients (age=52±11, 94% males, 80% nonischemic, NYHA II/III 35%/65%) 
were implanted with HN and underwent serial echocardiographic recordings that were 
analyzed by a central core lab. Paired analyses of the LV and RV dimensions, volumes, 
ejection fraction, LV mass, Mitral regurgitation and E/E’ ratio were made at 3, 6 and 12 
month follow up.
Results: LVEDD was found to have a significant downward trend (p = 0.001), and the 
paired changes were also significant at 6 months (p = 0.007) and 12 months (p = 0.002) 
(Figure). Significant reductions were also seen in ESD, EDV, ESV, LV mass, MR, and E/E’ 
at 6 and/or 12 months of HN therapy.
Conclusions: The addition of VEST to optimized HF therapy appears to result in further 
improvements in cardiac structure and systolic function, and a suggestion of improvement 
in diastolic function in a small proof of concept study. This notion is being tested in 
PEERLESS-HF, a prospective randomized controlled trial. 
1030-12 Detection of Systolic Dysfunction by Strain Doppler 
Echocardiography in Patients With Heart Failure and 
Preserved Ejection Fraction
Erberto Carluccio, Paolo Biagioli, Gianfranco Alunni, Adriano Murrone, Valeria Leonelli, 
Paola Pantano, Deborah Cosmi, Giuseppe Ambrosio, Division of Cardiology, University 
of Perugia, School of Medicine, Perugia, Italy
Background: Definition of heart failure with preserved ejection fraction (HFpEF) has 
typically relied on the use of an ejection fraction (EF) value ≥50% as the cutoff point to 
exclude the presence of systolic dysfunction. However, EF may not adequately reflect 
cardiac contractile function. We hypothesized that alterations of contractility could be 
detected in patients with HFpEF by using more sensitive echocardiographic tools, such 
as strain rate imaging.
Methods: Echocardiography with Doppler-derived strain rate was performed in 58 HF 
patients (age 66±14 years): 30 with systolic HF (SHF: EF≤40%), and 28 with preserved 
EF (HFpEF: EF≥50%, end-diastolic volume index<97 ml/m2). Thirty-two normal subjects 
(age 41±12 years) served as control (C). Peak negative strain and strain rate of four walls 
in apical, 4-, and 2-chamber views, were measured and averaged for each patient to 
obtain a global value.
Results: EF was 65±6% in C, 57±7% in HFpEF (p<0.01), and 29±3% in SHF (p<0.001). 
There were no differences in the use of cardiovascular medications between HFpEF 
and SHF. Peak negative global strain-rate velocities were lower in patients with HFpEF 
than in C (-0.87±0.16 s-1 vs -1.37±0.41 s-1, p<0.0001), but higher than in those with 
SHF (-0.55±0.21s-1, p<0.0001 by ANOVA). Similarly, peak negative strain was lower in 
patients with HFpEF than in C (-14.4±3.1% vs -20.5±3.6%, p<0.0001), but greater than 
in patients with SHF (-8.5±4.4%, p<0.0001 by ANOVA). A value of peak global strain ≤ 
-14% (2 SD below the mean value in C) was found in only 6% of C, in 43% of HFpEF, and 
in 90% of SHF. At the analysis of ROC curve peak global strain was more sensitive than 
mean peak systolic motion in predicting systolic dysfunction (p<0.05).
Conclusions: Subtle abnormalities of systolic function appear to be present in patients 
with HF even when ejection fraction and LV volumes are normal (traditionally labeled as 
diastolic heart failure). In HFpEF strain Doppler echocardiography seems to be able to 
detect alterations of myocardial contractility; further investigations may ascertain whether 
HFpEF represents an intermediate stage of systolic dysfunction, from truly normal to SHF.
1030-13 Relationship Between Anemia, N-Terminal-proB Type 
Natriuretic Peptide Level and Short-Term Clinical 
Outcomes in Patients With Suspected Acute Heart Failure
Gordon W. Moe, Zana M. Mariano, Fernando Camacho, St Michael’s Hospital, Toronto, 
ON, Canada
Background: Acute heart failure (HF) has emerged to be a major public health problem. 
While both anemia and elevated circulating N-terminal proB-type natriuretic peptide (NT-
proBNP) have been associated with a poor prognosis in patients with advanced HF, the 
potential relationship between anemia and NTproBNP as well as their impact on short-
term clinical outcome in patients with acute HF has not been fully explored. We therefore 
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investigated the relationship between anemia, NT-proBNP, and hospital readmission rate 
in patients presenting to the emergency department (ED) with dyspnea and suspected 
acute HF using date from the multicenter IMPROVE-CHF study.
Methods: Five hundred patients presenting to seven EDs with dyspnea and suspected 
acute HF had blood NTproBNP and hemoglobin (Hb) levels measured in the ED. Analyses 
were based on ANOVA fitted to the logarithmic NT-proBNP levels using adjudicator 
diagnosis (HF, no HF), anemia (yes, no), gender (male, female), age (<50, 50 to 75, ≥75 
years), estimated glomerular filtration rate (eGFR) (≤60, 60-90, ≥90 ml/min/1.73m2), and 
body mass index (BMI) (≤25, 25-30, ≥30 kg/m2) as explanatory factors.
Results: Anemia, defined by the WHO criteria of Hb <120 g/L in women and <130 g/L in 
men, was present in 183 of the 493 patients (37%). Mean Hb and NT-proBNP was 111±12 
g/L and 5535±7970 pg/ml respectively in the anemic group, and 140±12 g/L and 2935±5179 
pg/ml respectively in non-anemic group (both p<0.0001 versus anemia). All prespecified 
study variables except for gender were significant (p<0.05) in determining NT-proBNP 
values, with higher NT-proBNP values observed in anemic patients, with increasing age, 
adjudicated diagnosis of HF, decreasing eGFR, and lower BMI (< 25 kg/m2). After adjusting 
for other variables in the model, the presence of anemia was the strongest predictor of re-
hospitalization by 60 days (OR=2.60, 95% CI=1.50-4.52, p=0.0007).
Conclusions: Our results indicate that anemia is relatively common in patients with 
suspected acute HF. Anemia, along with older age, diagnosis of HF and reduced eGFR 
and lower BMI increases NT-proBNP levels. Furthermore, anemia is the strongest 
predictor of hospital readmission by 60 days.
1030-14 Myocardial Systolic Function in the Region of Left 
Ventricular Pacing Lead Predicts the Acute Response 
to Cardiac Resynchronization Therapy in Patients With 
Heart Failure Assessed by Two-Dimensional Speckle 
Tracking Echocardiography
Kazuko Norisada, Hiroya Kawai, Yuko Fukuda, Mariko Okada, Maky Furuki, Kazuhiro 
Tatsumi, Toshiya Kataoka, Tetsuari Onishi, Ken-ichi Hirata, Kobe University Graduate 
School of Medicine, Kobe, Japan
Background: Left ventricular (LV) dyssynchrony has been reported to be the important predictor 
of response to cardiac resynchronization therapy (CRT), however, some patients with LV 
dyssynchrony do not respond to CRT. The aim of this study was to investigate the influence of 
the myocardial systolic function in the region of LV pacing lead on the acute response to CRT.
Methods: Twenty patients who had advanced heart failure, depressed LV ejection fraction 
(EF), prolonged QRS duration and substantial LV dyssynchrony assessed by tissue 
Doppler imaging received successful CRT. The LV lead was positioned in the lateral or 
posterolateral vein. Standard echocardiography was performed at baseline and after 
1 week of CRT. In speckle tracking images, LV was separated into 17 segments and 
longitudinal peak systolic strain (S) of each segment was measured. S(all) and S(pl) 
were calculated as an average of S in all of 17 segments, and in 5 posterior and lateral 
segments where LV pacing lead was positioned, respectively. Responders were defined 
at 1 week after CRT initiation by ≥20% EF increase and/or ≥15% end-systolic volume 
decrease with respect to baseline.
Results: Fourteen patients (70%) were responders to CRT. No significant differences were 
observed between responders and non-responders in QRS duration, LV dyssynchrony 
assessed by myocardial velocity, LVEF, LV volumes, and S(all) at baseline. The absolute 
value of S(pl) in responders was significantly higher than that in non-responders at 
baseline (-10±4.6 vs -2.1±3.0, P<0.05). After CRT, the absolute value of S(all) was 
increased significantly in responders compared with the baseline value (-6.8±3.7 vs 
-9.4±4.1, P<0.05), but it was not in non-responders (-4.8±1.8 vs -3.2±3.3).
Conclusions: The reduced systolic function in the region of LV pacing lead was 
associated with ineffective LV pacing and inadequate LV resynchronization, and leads 
to nonresponse to CRT. Preserved systolic function in the region of LV pacing lead may 
predict the response to CRT.
1030-15 Echocardiographic Assessment of Regional Wall 
Motion and Global Systolic Function After Stem Cell 
Transplantation in a Post-Infarction/Reperfusion 
Canine Model
Shuping Ge, Mingxing Xie, Shan Wu, Judy Ober, Harnath Shelat, Jeffrey Towbin, James 
Willerson, Yong-Jian Geng, Baylor College of Medicine/Texas Heart Institute, Houston, 
TX, University of Texas Houston/Texas Heart Institute, Houston, TX
Background: Progressive loss of mature cardiovascular cells constitutes the cellular 
basis for the development of congestive heart failure following ischemic injury. Repair or 
regeneration of myocardium requires growth and differentiation of myogenic stem cells 
after the insult. This study was designed to use a canine infarction-reperfusion model 
to test the hypothesis that transplantation of fetal myogenic stem cells or myoblasts 
improves contractile function of the hearts.
Methods and Results: Experimental myocardial infarction was created by distal left 
anterior descending coronary artery ligation for 3 hours in an open chest canine model. 
After the ligation, the myocardium was reperfused for 30 mins. Phosphorylated buffered 
saline (PBS, Group 1, n = 4), 40 x 106 adipose tissue derived stem cells (Group 2, n = 
4) or fetal myoblasts (Group 3, n = 4) were injected into the ischemic and border areas. 
Transthoracic echocardiography was performed and ECG recorded before and after the 
surgery (day 0, 7 and 30). Echocardiography data acquisition and analysis were performed 
blinded to the treatment grouping. Wall motion score index (WMSI) and ejection fraction 
(EF) of the left ventricle (LV) were determined. Immediately after surgery, there were 
significant regional wall motion (WMSI) and global systolic function (EF) abnormalities in 
all groups. Compared with PBS group, there was no significant improvement in WMSI or 
EF in Group 2. However, there was significant improvement in WMSI in the ischemic and 
aneurysm region after cell implantation (2.0 ± 0.4 vs. 1.5 ± 0.1, p < 0.001) , at 7 days (2.0 
± 0.4 vs. 1.4 ± 0.1, p < 0.001) and at 30 days (1.8 ± 0.4 vs. 1.3 ± 0.1, p < 0.01). There was 
no significant improvement in EF in this group at follow up studies.
Conclusion: Our data suggests that transplantation of fetal myogenic stem cells but not 
adipose tissue derived stem cells offers sustained LV regional wall motion improvement in 
the ischemic/aneurysmal regions. Further and long term follow up is needed to ascertain 
the global functional improvement of the LV function.
1030-16 Urinary N-acetyl-β-D-Glucosaminidase, a Marker of 
Tubular Damage, Is an Independent Predictor of 
Mortality and Associated With the Degree of Renal 
Impairment in Patients With Chronic Heart Failure
Kevin Damman, Gerjan Navis, Tom D. J. Smilde, Adriaan Voors, B. Daan Westenbrink, 
Dirk J. van Veldhuisen, Hans L. Hillege, University Medical Center Groningen, 
Groningen, The Netherlands
Background. Reduced glomerular filtration rate (GFR) is common and related to 
disproportionally reduced renal perfusion in chronic heart failure (CHF), which harbours 
the risk for tubular hypoxic damage. We assessed whether tubular damage is prevalent in 
CHF patients and associated with unfavourable outcome.
Methods. Ninety patients with CHF underwent GFR measurement by Iothalamate clearance. 
Neutrophil gelatinase associated lipocalin (NGAL) and N-acetyl-β-D-glucosaminidase 
(NAG) were determined as selective markers of tubular damage in 24 hours urine collection. 
The primary endpoint consisted of the first occurrence of death, HTx, or CHF admission.
Results. Mean age was 58 ± 11 yr, 78% was male. Mean GFR was 78 ± 26 ml/min/1.73m2. 
Both NGAL and NAG levels were highly elevated in patients with CHF: Median NGAL 109 
(54-253) ng/ml (ref <10) and median NAG 10 (6 - 14) U/gCr (ref <2).
NAG but not NGAL was related to GFR (r =-0,30) and NYHA class (r = 0.25). NAG was a 
strong predictor of outcome: HR 1.61 per 5 U/gCr, p<0.002. In multivariate cox regression 
analysis, NAG was independently associated with outcome (HR 2.17), next to GFR (HR 
1.20). (FIGURE)
Conclusion. Tubular damage, as measured by increased urinary levels of both NAG and 
NGAL, is highly prevalent in patients with CHF. NAG was significantly related to the degree 
of renal impairment, and is a new independent prognostic marker in CHF. This suggests 
that renal impairment may result in structural renal (tubular) damage, and thereby lead 
to impaired prognosis.
1030-17 Percutaneous Transvenous Mitral Annuloplasty: Clinical 
Development of a Novel Coronary Sinus Device
Stefan Sack, Philipp Kahlert, Rainer Hoffmann, Luc Pierard, Patrizio Lancellotti, Victor 
Legrand, Jozef Bartunek, Marc Vanderheyden, Luc Bilodeau, Takahiro Shiota, David 
Marks, Stephen Ellis, for the PTOLEMY Investigators, University Hospital, Essen, 
Germany, Cleveland Clinic Foundation, Cleveland, OH
Background: Mitral regurgitation (MR) frequently accompanies heart failure (HF). MR is 
an independent predictor of morality in patients with ischemic heart disease and HF. The 
quantitative amount of MR, whether at rest or provoked, is associated adverse events 
in a graded fashion. Development of percutaneous mitral annuloplasty techniques 
is promising to mitigate the effect of functional MR in HF. We report the ongoing first-
in-man, intent to implant experience with the Viacor Percutaneous Transvenous Mitral 
Annuloplasty (PTMA™) device in humans. The Viacor PTMA™ device is a non-stented 
coronary sinus mitral annuloplasty device.
Methods: Patients were included with moderate-to-severe functional mitral regurgitation 
and NYHA Class II-IV HF symptoms. Patients were excluded for intrinsic mitral valve 
pathology, left dominant circulation, or significant renal dysfunction. All patients with 
suitable anatomy underwent a diagnostic PTMA™ procedure prior to implant to 
demonstrate reduction in MR.
Results: 21 patients from April 2006 to August 2007, 11 male, age 68 (49-85) enrolled in 
the trial. Baseline ejection fraction was 32% (20-50) with MR graded from 2-4+. 7 (33%) 
had unsuitable anatomy or inability to delivery the PTMA™ catheter. 8/14 (57%) had 
successful diagnostic PTMA™ procedure with a >/= 1 grade reduction in MR. 7 patients 
underwent successful implantation. 2 devices were subsequently removed, one at 7 days 
due to device fracture, and a second when the patient was referred for annuloplasty 
surgery following re-emergence of mitral regurgitation. Sustained improvement in clinical 
parameters, MR, and mitral annular dimensions are noted in 5/5 (100%) of the remaining 
long term implants over 6.5 (5-12) months.
Conclusions: The initial experience with Viacor PTMA™ has demonstrated long-term 
reduction in mitral annular dimensions and mitral regurgitation. This experience is limited 
by unsuitable anatomy or inability to delivery the catheter in 33% of the initial procedures. 
Further refinements in screening techniques and the PTMA device delivery are underway. 
PTMA™ is a promising technique to mitigate functional MR via a percutaneous technique 
in patients with HF.
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1030-18 Visualization of Cardiac Venous System by Multislice 
Computed Tomography: Implication for Percutaneous 
Catheter-Based Mitral Annuloplasty
Antonio Sorgente, Francesco F. Faletra, Quynh A. Truong, Jagmeet P. Singh, Udo 
Hoffman, Rinky Batia, Cristina Conca, Elena Pasotti, Giovanni B. Pedrazzini, Tiziano 
Moccetti, Angelo Auricchio, Cardiocentro Ticino, Lugano, Switzerland, Massachusetts 
General Hospital, Boston, MA
Background: Cardiac CT may provide important information for the planning of 
percutaneous mitral annuloplasty. We evaluated the spatial relationship between the 
coronary sinus (CS), mitral annulus (MA), and coronary arteries in patients presenting 
with a wide range of left atrial volumes and left ventricular functions using 64 multi-slice 
computed tomography (64 MSCT).
Methods: We retrospectively analyzed the CT data sets of 165 patients (age 63.65±12.89 
years, 67.3% men) who underwent standard 64 MSCT (64 x 0.625 mm detector setting 
and collimation, rotation speed 350 msec, pitch adjusted to the heart rate of the patient, 
tube setting 120 kV) for diagnostic evaluation of coronary artery disease. Using original 
axial images and cine data sets reconstructed at 10% increment of the RR cycle, the 
following parameters were measured: CS length (CS-L), CS ostium area (CS-O), axial 
angle (AA) measured as the angle between CS and MA assessed in axial section, the 
area between CS and AV groove, mitral annulus area (MAA), left atrium volume (LAV) and 
LCX (left circumflex artery) - CS relationship referring to MA.
Results: Patients with depressed LVEF had significantly longer (p<0.001) CS; there was a 
good correlation between the CS-L and LAV (R2=0.58, p<0.001) and between CS-L and 
MAA (R2=0.37, p<0.001). Interestingly, patients with a LVEF < 40% showed a more acute 
angle between CS and MA (p<0.001), with a correlation between AA and MAA (R2=0.11, 
p<0.001). In 78% of patients the LCX was located between CS and MA.
Conclusions: Our observations demonstrate an association between a significant and 
progressive shift of the CS from the posterior wall of left atrium to the atrio-ventricular 
groove with an increase of LAV and MAA. In the vast majority of patients LCX impingement 
may be expected. These findings may have important implications for clinical applicability 
of percutaneous mitral annuloplasty.
1030-19 Plasmapheresis: A Potential Immunomodulatory 
Therapy for Patients With Nonischemic 
Cardiomyopathy
Carlos M. Orrego, Keith A. Youker, Rene Celis, Nashwa Khalil, Guillermo Torre-Amione, 
Methodist De Bakey Heart Center, Houston, TX, The Methodist Hospital, Houston, TX
Background: Plasmapheresis, a non specific immunomodulatory therapy, has proven 
efficacy on a variety of autoimmune conditions, including unexplained left ventricular 
dysfunction in heart transplant recipients. Our objectives were: 1. Effect of plasmapheresis 
in Left ventricular ejection fraction (LVEF) 2. Presence of anti-cardiac antibodies.
Methods:Inclusion criteria; non-ischemic cardiomyopathy, NYHA class II-IV, LVEF < 
30 %, and illness duration > 6 months. Patients were treated with 5 plasma exchange 
courses within two weeks, followed by reconstitution with intravenous-gamma globulin 
500 mg/kg. Echocardiograms and RV biopsies were performed at baseline and 6 months. 
Cardiac tissue was stained with a fluorescent labeled antibody to human Ig G and 
photomicrographs taken and quantified in a blinded fashion using the image analysis 
software Image-Pro Plus.
Results: We enrolled 9 patients, age 39.2± 13.6 and illness duration 3.2 years. LVEF 
improved in 7/9 patients; mean LVEF was 22.7%, 30.8 % and 28% at baseline, 3 and 6 
months respectively p < 0.008. Staining for anti-cardiac antibodies showed a reduction in 
signal intensity in 5/6 patients p < 0.05 and reduction in the myocite size p < 0.03. 
Conclusions: Plasmapheresis in patients with non-ischemic cardiomyopathy was 
associated with an improvement in LVEF, reduction in anti-cardiac antibody deposition 
within myocardium and decrease in myocite size. These data support a biological role Ig 
G- mediated injury in the progression of heart failure. 
1030-20 Prediction of Cardiac Resynchronization Therapy 
Response by Tri-Plane Echocardiographic Measures of 
Dyssynchrony
Christopher L. Kaufman, Kevin V. Burns, Daniel R. Kaiser, Aaron S. Kelly, Andrea M. Thelen, 
Alan J. Bank, St. Paul Heart Clinic, Saint Paul, MN, Medtronic, Inc., Minneapolis, MN
Background: Studies have reported that Echo measures of longitudinal and radial 
dyssynchrony are predictive of response to cardiac resynchronization therapy (CRT). 
The purpose of this study was to assess the ability of tri-plane (i.e., longitudinal, radial, 
circumferential) Echo measures of dyssynchrony to predict CRT response. Methods: 
Standard echocardiograms were performed before and after chronic CRT (mean 
follow-up = 4.6 ± 2.1 months) in 70 patients (age = 68±13 yr; 54 male). Longitudinal 
dyssynchrony was calculated as the standard deviation (SD) of time to peak systolic 
velocity (Ts-12) of 12 segments from three apical views. Using short axis views and 
speckle-tracking methods, the SD of time to peak radial (Ts-6rad) and circumferential 
strain (Ts-6circ) in six segments were calculated. CRT Echo response was defined as 
> 15% decrease in left ventricular end systolic volume (LVESV). Results: The CRT Echo 
response rate was 57%. Measures of systolic function improved following CRT. There was 
no difference between responders (CRTR) and non-responders (CRTNR) at baseline for 
ejection fraction (EF; 29 ± 6 vs.27 ± 7%) and ventricular volumes. CRTR, as compared 
to CRTNR, had significantly (p< 0.05) more dyssynchrony at baseline for Ts-12 (50 ± 
15 vs. 41 ± 14 msec) and Ts-6rad (85 ± 58 vs. 43 ± 27 msec). CRTR as compared to 
CRTNR, had significant (p < 0.05) improvements in EF (12 ± 7 vs. 2 ± 4%) and LVESV 
(-44 ± 19 vs. -2 ± 11 mL). CRT significantly (p< 0.05) reduced Ts-12 (-16 ± 12 msec) and 
Ts-6rad (-57 ± 56 msec), but not Ts-6circ (-4 ± 64 msec) in CRTR. Dyssynchrony was 
unchanged in CRTNR. ROC curve analysis indicated significant, but modest sensitivity 
and specificity for Ts-12 (67% and 67%) and Ts-6rad (72% and 60%). However, 90% of 
patients with significant dyssynchrony in both longitudinal and radial planes were Echo 
responders, whereas 13% of patients without dyssynchrony in both planes were Echo 
responders. Baseline QRS duration lacked predictive value for CRT response (ROC area 
under the curve = 0.54, p = 0.53). Conclusion: Circumferential dyssynchrony is not helpful 
in identifying CRT response. The presence of dyssynchrony in both longitudinal and radial 
planes is a strong predictor of remodeling response to CRT.
1030-21 Could Autologous Bone Marrow Transplant for 
Myocardial Regeneration Decrease Cardiovascular Risk 
and Mortality?
Carlos M. Orrego, Boris V. Astudillo, Juan M. Senior, Universidad de Antioquia, Medellin, 
Colombia, Hospital Universitario San Vicente de Paul, Medellin, Colombia
Background: Patients with ischemic cardiomyopathy have a decreased Heart Rate 
Variabilility (HRV), which is associated with ventricular arrhythmias and higher 
cardiovascular mortality . Our objectives were: to evaluate HRV and to document ventricular 
arrhythmias in a 24-hour holter monitoring in patients with ischemic cardiomyopathy 
following autologous bone marrow transplant for myocardial regeneration .
Methods: Inclusion criteria were: age 18-75 years, ischemic cardiomyopathy, ejection 
fraction (EF) < 40%, standard medical treatment and cardiac rehabilitation program for 8 
weeks. Patients had echocardiogram and holter monitoring at baseline, 2 and 6 months 
follow-up. Documentation of ventricular arrhythmias and HRV measured by standard 
deviation of RR interval (NN) SDNN was analyzed.
Results: We enrolled 16 patients, age 52±10, 4 female. We found a statistically significant 
improvement on HRV(SDNN), 65.44 ± 27 ms, 102.12 ± 37.88 ms and 100.23 ± 42.88 ms 
at 2 and 6 months respectively (p= 0.00001). All patients stratified as high cardiovascular 
risk (SDNN < 50 ms) before the procedure turned to intermediate or low risk in the six 
months follow up. In addition, no malignant ventricular arrhythmias were documented. 
Conclusions: Autologous bone marrow transplant for myocardial regeneration did not 
increase risk for ventricular arrhythmias. In addition, there was an increase HRV which 
might decrease cardiovascular mortality and cardiovascular risk. 
1030-22 Right Ventricular Performance by Cardiac Magnetic 
Resonance Imaging in Patients With Pulmonary 
Hypertension
Gerin R. Stevens, Sean Pinney, Mario J. Garcia, Valentin Fuster, Javier Sanz, Mount 
Sinai Medical Center, New York, NY
Background: Cardiac magnetic resonance (CMR) is useful for the evaluation of the right 
ventricle (RV). The goal of this study was to assess the impact of pulmonary hypertension 
(PH) on RV performance using CMR.
Methods: One hundred four patients (110 studies, 77 women) with known or suspected 
PH had right heart catheterization and CMR within one week. Patients with normal resting 
pulmonary pressures were exercised during catheterization. Biventricular volumes, 
ejection fractions, masses and right-to-left ventricular mass ratio were quantified using 
steady state free precession imaging and indexed to body surface area. The ratio of RV 
mass to pulmonary vascular resistance index (PVRI) was used as an indicator of the 
relationship between RV hypertrophy and afterload.
Results: Strong correlations were observed between PVRI and RV mass index (r = 0.73), 
RV ejection fraction (r = -0.75), RV end-systolic volume index (r = 0.69), and right-to-
left ventricular mass ratio (r = 0.76; all p-values <0.0001). The RV mass-to-PVRI ratio 
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was higher in patients with preserved RV ejection fraction (≥50%) than in those with RV 
dysfunction (9.4 ± 6.2 versus 5.7 ± 3.0 g/Wood units x m2, p=0.006).
Conclusions: PH causes progressive changes in RV volumes, mass and function that 
can be quantified with CMR. Compensatory increases in RV mass may help preserve 
RV function in response to elevated pulmonary pressures. Evaluation of RV structure and 
function using CMR may be useful to monitor patients with PH. 
1030-23 Reverse Remodeling Response and Preservation of 
Systolic Synchronicity After Cardiac Contractility 
Modulation Therapy in Advanced Heart Failure Patients
Joseph YS Chan, Qing Zhang, Jeffrey WH Fung, Anna KY Chan, Chun-yan Ma, Gabriel 
WK Yip, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Introduction: Cardiac contractility modulation (CCM) is a new device therapy for patients 
with advanced heart failure, who are currently not candidates for CRT. However, the 
mechanism of its benefit on cardiac function is largely unknown. This study examined 
whether LV systolic synchronicity was affected by CCM, and whether CCM only improved 
systolic function at region of CCM stimulation, i.e. septal function, or beyond.
Methods: 21 patients having NYHA class III heart failure despite optimal medical therapy 
with QRS <120ms received CCM. Serial assessment was performed at baseline and 
3 months. Systolic dyssynchrony was measured by real-time 3D echocardiography 
(RT3DE) (iE33, Philips) using the standard deviation of time to minimal systolic volume of 
12 (SD-Tmsv-12) and 16 LV (SD-Tmsv-16) segments. Myocardial function was measured 
by tissue Doppler imaging (TDI) using peak systolic (Sm) and early diastolic velocity 
(Em).
Results: LV reverse remodeling with reduction in volumes and gain in EF was observed 
by RT3DE at 3 months. Systolic synchronicity was unchanged after CCM (Table). By TDI, 
both mean Sm and lateral Sm improved significantly, with a trend toward a gain in septal 
Sm. However, both mean Em and regional Em were unchanged.
Conclusions: CCM improves global myocardial contractility by benefiting not only the region 
of CCM delivery, but also the remote LV free wall. Systolic synchronicity is unaffected by 
CCM. Also, systolic, but not diastolic, function is improved after the therapy. 
Parameters Baseline 3 months p value
SD-Tmsv-12, ms 22.7±24.4 19.1±13.1 NS
SD-Tmsv-12, % R-R interval 2.6±2.8 2.4±2.0 NS
SD-Tmsv-16, ms 35.1±25.0 31.5±27.1 NS
SD-Tmsv-16, % R-R interval 4.3±3.2 3.9±3.0 NS
LV end-diastolic volume, ml 161±45 154±46 0.001
LV end-systolic volume, ml 119±40 107±40 <0.001
LV ejection fraction, % 27±6 32±7 <0.001
Myocardial performance index 0.73±0.24 0.62±0.19 <0.05
Mean Sm of 12 segments, cm/s 2.1±0.6 2.5±0.5 <0.001
Mean Em of 12 segments, cm/s 3.1±1.5 3.0±1.4 NS
Septal Sm, cm/s 2.3±0.9 2.6±0.8 0.083
Septal Em, cm/s 3.2±1.8 3.0±1.5 NS
Lateral Sm, cm/s 2.0±0.8 2.5±1.0 <0.05
Lateral Em, cm/s 3.4±2.3 3.2±2.2 NS
NYHA class, number of patients 
Class II 
Class III
0 
21
17 
4 <0.001
6-minute hall-walk distance, meters 337±79 369±75 <0.05
1030-24 Evaluation of a Morphology Based Algorithm for 
Automatic Biventricular Capture Verification
Jie Lian, Garth Garner, Hannes Kraetschmer, Dirk Muessig, Micro Systems Engineering 
Inc, Lake Oswego, OR
Background: Effective cardiac resynchronization therapy (CRT) requires consistent 
capture in right ventricle (RV) and left ventricle (LV).
Methods: We tested a new biventricular (BiV) capture verification algorithm based on a 
novel index called ASCI, which quantifies the morphology similarity between intracardiac 
electrogram (IEGM) and a template waveform representing capture paces. An RV or 
LV pace is classified as capture if ASCI is greater than a predefined threshold, or non-
capture otherwise.
Data were collected from 20 patients (16 m, 73 ± 8 yrs) eligible for CRT implantation. 
Leads of different companies were used. Wideband IEGM and surface ECG were 
recorded during RV only, LV only, or BiV pacing with various RV-LV delays (0ms, ±20ms, 
±60ms). Different pace and sense polarity configurations were tested. Template signals 
in each chamber were created from the average of 4 capture beats. Each pace was 
annotated for capture, non-capture, or fusion by reviewing the ECG and IEGM.
Results: A total of 4207 RV and 4954 LV paces are eligible for morphology analysis. The 
calculated ASCI is well separated for capture (0.88 ± 0.11) and non-capture (-0.28 ± 
0.30) paces, with intermediate values for fusions (0.59 ± 0.22; Figure). Both sensitivity 
and specificity of the classification algorithm remain >=99% for any ASCI threshold value 
chosen between 0.38 and 0.54.
Conclusions: In all tested leads and CRT settings, automatic BiV capture verification can 
be accurately performed based on morphology analysis of the IEGM.
1030-25 Central Aortic Stiffness in Patients With Nonischemic 
Dilated Cardiomyopathy
Alexander P. Patrianakos, Frangiskos I. Parthenakis, Dimitris Arfanakis, Evangelos 
A. Zacharis, Eva Nyktari, Marios Foukarakis, Panos E. Vardas, Heraklion University 
Hospital, Heraklion, Crete, Greece
Background: We studied the ventriculo-aortic stiffening in patients with mild to moderate 
heart failure (HF)
Methods: We examined 55 patients (52. 6 ±13, 9 years), with angiographically proven 
non ischaemic dilated cardiomyopathy (NIDC), mild to moderate HF (NYHA II-III), 
in sinus rhythm, LVEF 30.1±8.6 % and 28 healthy individuals. All subjects underwent 
an echocardiographic study . We evaluated the segmental proximal aorta (AO) pulse 
wave velocity (PWV) in the region of aortic arch with a new echo-application [from the 
suprasternal view PW-Doppler tracings of the ascending (just above the right pulmonary 
artery as the standard reference point) and descending aorta (as far as possible) were 
recorded and averaged over 10 cycles at a sweep speed of 200 mm/s]. From the R 
wave of the QRS complex to the onset of the PW-Doppler aortic flow, time 1 (T1) in the 
ascending and time 2 (T2) in the descending aorta were then measured accordingly. 
The distance from the PW-Doppler sample volume in the descending to the ascending 
aorta (adjacent to the right pulmonary artery) was measured on 2D-echo as aortic length 
(AOL), using the open trace method of measurement (Echopac, GE, Horten, Norway). 
PWV was calculated as aortic distance/time.
Results: Patients showed increased PWV (7.4±2.9 vs 4.9±1.3 m/s, p<0.001) compared to 
controls. Patients with advanced LV (restrictive or pseudonormal filling pattern) diastolic 
dysfunction showed increased PWV (8.6±2.5 vs 6.5± 2.9 m/s, p=0.008) compared to 
those with mild diastolic dysfunction . PWV correlated with the LV mass (r=0.33, p=0.001), 
peak PW-TDI systolic wave (r=-0.33, p= 0.01), DTE (r = -0.30, p = 0.02), the mean (septal 
and lateral mitral annulus) early diastolic TDI wave (e’, r = -0.31, p = 0.01) and the early 
transmitral PW-Doppler /e’ wave ratio (r = 0.38, p = 0.01),and the LV diastolic filling pattern 
(r = 0.59, p<0.001).
Conclusions: Patients with NIDC showed increased proximal aortic stiffness that promotes 
an augmentation in LV afterload, which in turn affects both systolic and diastolic LV 
function. The echocardiographic assessment of the regional aorta PWV may be clinically 
important in these patients as an evaluation of the LV afterload.
1030-26 Soothing Warm Therapy Improves the Prognosis in 
Patients With Chronic Heart Failure
Yoshiyuki Ikeda, Masaaki Miyata, Takashi Kihara, Chuwa Tei, Department of Cardiovascular, 
Respiratory and Metabolic Medicine, Kagoshima University, Kagoshima, Japan
Background: We developed a form of thermal therapy, namely Waon therapy (soothing 
warm therapy), that differs from the traditional sauna. We have previously reported 
that repeated thermal therapy improves hemodynamics, peripheral vascular function, 
arrhythmia and clinical symptoms in patients with chronic heart failure (CHF). The aim of 
this study is to investigate the effect of Waon therapy on prognosis of patients with CHF. 
Patients and Methods: We studied 129 consecutive patients with CHF in NYHA functional 
class III or IV who were admitted to our hospital between 1999 and 2000. In Waon therapy 
group, 64 patients were treated with a far infrared-ray dry sauna at 60 degrees centigrade 
for 15 minutes and then kept on bed rest with a blanket for 30 minutes, at least twice a 
week. In control group, 65 patients, matched for age, gender, and NYHA functional class, 
were treated in a traditional treatment for CHF. The follow-up time was scheduled for 5 
years. Results: Recent follow-up data of each patient could be obtained completely. The 
overall survival rate was 84.5% (Kaplan-Meier estimate). 12 patients died in control group 
and 8 patients died in Waon therapy group at the end point of this study. Re-hospitalization 
due to heart failure or cardiac death rate was 68.7% in control group and 31.3% in Waon 
therapy group (p<0.01) at 60 months of follow up (Figure). Conclusion: Repeated Waon 
therapy improved the prognosis in patients with CHF. This therapy is a promising non-
pharmacological therapy for CHF. 
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1030-27 Factors Associated With the Improvement of Left 
Ventricular Systolic Function by Continuous Positive 
Airway Pressure in Patients With Heart Failure and 
Obstructive Sleep Apnea
Ryo Naito, Takatoshi Kasai, Tomotaka Dohi, Hisashi Takaya, Kenichi Maeno, Sugao 
Ishiwata, Minoru Ohno, Tetsu Yamaguchi, Shin-ichi Momomura, Koji Narui, Toranomon 
Hospital, Tokyo, Japan
Background: From the result of several randomized controlled studies, continuous 
positive airway pressure (CPAP) has been established as an effective therapy for OSA 
and underling HF through the increase of left ventricular ejection fraction (LVEF). The 
degree of improvement in LVEF varied from 5 to 9 % in these studies. However, it is not 
clarified which factors relate to the degree of LVEF improvements.
Methods: Consecutive patients with OSA and CHF initiated into CPAP were analyzed. 
Left ventricular ejection fraction (LVEF) was assessed at the baseline and 1 month 
after initiation of CPAP therapy. The association between baseline variables, changes 
in body mass index (BMI), systolic and diastolic blood pressure (BP), heart rate (HR), 
plasma norepinephrine(PNE), Epworth sleepiness scale (ESS) and the degree of LVEF 
improvement was assessed with simple and multiple regression analysis.
Results: Data about 55 patients were analyzed (mean Age 60.7±12.2 years old, 53 males, 
BMI 27.4±5.4 kg/m2). They revealed severe OSA (apnea-hypopnea
index 45.3±16.1 /h) with moderately impaired left ventricular systolic function (LVEF 
37.2±9.8%, NYHA functional class II or III). The LVEF was significantly improved by 1 
month CPAP therapy (+6.0±4.5%, P<0.001) with significant reduction of systolic and 
diastolic BP, HR, PNE and ESS whereas there were no change in BMI. The degree of 
LVEF improvement was associated with age (β=-0.45, P=0.0005), BMI (β=0.65, P<0.001), 
presence or absence of atrial fibrillation (β=-0.27, P=0.04), minimum SO2 (β=-0.30, 
P=0.03), pressure level of CPAP (β=0.42, P=0.001) in simple regression analysis. In the 
multiple regression analysis, younger age (P=0.008) and higher BMI (P<0.001) were the 
significant predictors for higher degree of LVEF improvement by 1 month CPAP therapy.
Conclusion: Among patients with OSA and HF, LVEF was significantly improved by 1 
month CPAP therapy. The degree of LVEF improvement was significantly associated with 
age, BMI, atrial fibrillation, severity of hypoxia, treatment pressure level of CPAP. LVEF 
was more likely to be improved in young obese patients.
1030-28 Impact of Ventricular Restoration on Left Ventricular 
Geometry and Functional Mitral Regurgitation in End-
Stage Cardiomyopathy
Koichi Toda, Kazuhiro Taniguchi, Takenori Yokota, Satoshi Kainuma, Osaka Rosai 
Hospital, Sakai, Japan
Background:Ventricular geometry plays an important role in functional mitral regurgitation 
(FMR). We sought to determine how ventricular restoration affects the geometry of the 
mitral valve and the left ventricle (LV) in end-stage cardiomyopathy.
Methods:We treated 19 end-stage cardiomyopathy patients with FMR whose ejection 
fraction (EF) was lower than 35%. Of those, 10 patients underwent restrictive mitral 
annuloplasty alone (RMAP group), while 9 patients underwent RMAP and LV restoration 
(RMAP+LVR group). For LV restoration, plication stitches (Fontan stitch) were placed 
at the bottom of the papillary muscles to correct those that were apically and laterally 
displaced. Short axis (SA) and long axis (LA) of LV, and tenting height (TH) and coaptation 
length (CL) of the mitral valve, and distance between the anterior and posterior papillary 
muscles (PMD) were measured before and after surgery.
Results:Postoperatively RMAP+LVR group reduced a greater amount of LA than RMAP 
group, while SA decreased similarly in both groups. Echocardiogram showed that TH was 
reduced more in RMAP+LVR group, while CL was significantly increased and FMR was 
well controlled in both groups.
Conclusions:We found that LVR reduced the tenting height of mitral valve and the long 
axis of LV in end-stage cardiomyopathy with FMR. Our results suggest that LVR improves 
leaflet coaptation by correcting LV geometry including leaflet tethering and may be 
relevant to control of FMR as well as reverse remodeling of LV.
The postoperative changes in ventricular and mitral valvular geometry
RMAP RMAP+LVR P-value
% change in long axis of LV 96±6 % 71±11 % p< 0.005
% change in short axis of LV 88±12 % 81±13 NS
% change in tenting height 86±70 % 42±22 % p<0.05
% change in PMD 90±15 % 83±7 % NS
1030-29 Unique Genomic Fingerprint Identifies Women With 
Heart Failure
Maria C. Carles, Lori J. Saunders, Federica Del Monte, Davide Giani, Kindra M. King, 
Seth D. Crosby, James G. Dobson, Jr., Michael R. Bristow, Francis G. Spinale, Naveen 
Pereira, G. William Dec, Marc Semigran, Thomas E. Macgillivray, Roger J. Hajjar, Judith 
K. Gwathmey, Harvard Medical School, Boston, MA
Background: One in 2.6 deaths in women is from heart disease compared to one in 30 
from breast cancer. It well recognized by the medical community that there are significant 
gender related differences in the clinical presentation, disease course, morbidity and 
mortality of women versus men with heart failure. Female-specific gene profiles that 
reflect end-stage idiopathic dilated cardiomyopathy (IDCM) is explored in our work. Our 
findings may help to elucidate the pathogenesis of the disease in women and lead to 
gender specific therapeutic approaches.
Methods: We produced subtractive cDNA libraries using human diseased and normal left 
ventricular (LV) myocardium from IDCM and normal left ventricle RNA samples. Using the 
derived genomic data, we generated a custom human heart failure microarray for IDCM 
containing 1,100 heart specific oligo probes. This array was used to screen 12 female left 
ventricle RNA samples from female patients with IDCM and compared to a pool of normal 
female left ventricle RNA samples (n=10).
Results: Differentially regulated genes were validated using Q-RT-PCR (98% match). 
A group of 41 genes were found to be uniquely de-regulated in female IDCM patients 
compared to data obtained from male IDCM patients. Upon functional clustering analysis 
of the female gene expression pattern, the largest pool of up-regulated genes were 
represented primarily by cell growth factors and carbohydrate metabolism. The functional 
analysis of the down-regulated genes showed the highest percent to be energetics and 
metabolism (46%).
Conclusion: The gene expression pattern which occur in a global cardiomyopathic 
process appears to be gender specific and to involve primarily genes that impact cellular 
metabolism in women. This would suggest that diagnosis, pharmacogenomic approaches 
and toxicogenomics may need to take into account gender differences. Treatments that 
target myocardial energetics might prove more effective in women with heart failure due 
to idiopathic dilated cardiomyopathy.
1030-30 Heart Failure Patients With Preserved Ejection Fraction 
Have a Complex Relationship Between Systolic 
Mechanical Dyssynchrony and QRS Width - Findings 
From the Dyssynchrony Induced by Ventricular 
Exertion in Heart Failure (DIVE-HF) Study
Chih-Chieh Yu, Yi-Chih Wang, Juey-Jen Huang, Kathryn Hilpisch, Rodolphe P. Katra, 
Ling-Ping Lai, Jiunn-Lee Lin, National Taiwan University Hospital, Taipei, Taiwan,ROC
Background: Cardiac resynchronization therapy (CRT) is indicated for heart failure (HF) 
patients (pts) with reduced ejection fraction (EF) and wide QRS complex which is believed 
to be a surrogate measure for systolic mechanical dyssynchrony (SMD). Interestingly, 
recent evidence has established that HF pts with a preserved EF (HFpEF) have SMD as 
well, despite having mainly a narrow QRS. Therefore, the relationship between SMD and 
QRS width in HFpEF remains debatable.
Methods: To investigate this complex relationship, we studied clinical features, ECG 
characteristics, and performed echocardiography with Tissue Doppler in 55 HFpEF pts 
and 10 controls (CTRL). HFpEF pts had compensated HF (NYHA class II-III) for at least 3 
months and were divided into 2 groups (Group 1, EF=35-50%, N=25; Group 2, EF>50%, 
N=30). SMD was defined as standard deviation of the time difference between the QRS 
onset to the peak systolic velocity of 6-basal and 6-mid LV segments of the left ventricle.
Results: Demographics and patient characteristics for Groups 1 and 2 were significantly 
different with Group 1 being younger (56±14 vs. 69±8yrs), having more males (84 vs. 
30%), history of CAD (67 vs. 0%), more diabetes (38 vs. 17%), less hypertension (44 vs. 
100%), and less AF (10 vs. 30%), compared to Group 2. Group 1 had markedly larger 
(p<0.05) chamber dimensions (LVEDD: 57±8mm; LVESD: 46±8mm) compared to Group 
2 (LVEDD: 46±4mm; LVESD: 29±4mm) and CTRL (LVEDD: 47±5mm; LVESD: 30±3mm). 
Group 1 also had significantly (p<0.05) wider QRS duration (99±20ms) and a higher heart 
rate (83±19bpm), compared to Group 2 (92±13ms and 66±10bpm) and CTRL (85±8ms 
and 63±9bpm). Tissue Doppler imaging, however, revealed that Group 1 had significantly 
less SMD (23±10ms) compared to Group 2 (55±12ms) but significantly more than CTRL 
(10±2ms), despite having a wider QRS complex.
Conclusions: These data support previous findings of SMD in a significantly heterogeneous 
HFpEF population despite the narrow QRS. Interestingly, this study proposes for the first 
time that the relationship between SMD and QRS width in this population is more complex 
than in the systolic HF population and may depend on disease etiology, disease history 
and chamber dimensions.
1030-31 Impact of Therapy on Long-Term Survival in Heart 
Failure With Preserved Systolic Function
Pablo Castro, Hugo Verdejo, Marcela Ferrada, Silvana Llevaneras, José Luis Vukasovic, 
Fernando Lanas, Roberto Concepción, Eduardo Garcés, Luis Sepúlveda, Chilean Heart 
Failure Registry (ICARO), Santiago, Chile
Background: The importance of heart failure with preserved systolic function (HF-PSF) 
has been increasingly recognized during the last years. There is sparse evidence on the 
impact of treatment strategies on the outcomes of these patients.
Methods: Prospective registry from 14 Chilean centers. Patients admitted with 
decompensate HF between January 2002 and May 2007. Demographic characteristics, 
echocardiography at admission and prescription at discharge were recorded. Patients with 
LVEF>50% were classified as HF - PSF. Mortality at the end of follow-up was obtained 
from certificate databases. Impact of therapy at discharge on survival was evaluated with 
a Cox’s proportional risk model adjusted for age, gender and concomitant medication.
Results: A total of 637 patients were included, 24.9% HF-PSF. Baseline characteristics are 
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detailed in table 1. There was no difference in long term survival between HF-PSF and HF 
with systolic dysfunction (599±575 vs. 668±573 days for HF-PSF and HF-SD respectively, 
log rank test p=0.21). There were significative differences in discharge therapy between 
both groups. However, only ACE inhibitors/ ARB therapy was associated with a decrease 
in mortality in HF-PSF (HR=0.42, CI95% 0.25-0.72, p=0.02).
Conclusion: HF-PSF is associated with long term mortality similar to patients with HF and 
systolic dysfunction. Despite the lack of precise therapeutic guidelines for this group of 
patients, ACE inhibitors/ARB’s seem to have a positive impact on long-term survival. 
HF-PSF 
n=159
HF-SD 
n=478 p
Age (Mean±SD) 65.5 ±14.4 66.4 ±13.7 0.55
Female (%) 67.2 37.1 <0.01
BMI 26.1±9.3 24.1±9.2 0.05
Diabetes mellitus (%) 25.8 29.1 0.47
History of AMI (%) 13.2 28.1 <0.01
History of Atrial fibrillation (%) 38.9 34.5 0.33
LVEF(%) 61.3±9.5 30.7±9.6 <0.01
QRS (ms) 96.2 ±25.3 105.1± 33.6 <0.01
Therapy at discharge (%)
Betablockers 22 35.3 0.02
ACE inhibitors 53.8 50.3 0.46
ARB 6.9 6.9 1
Spironolactone 30.8 50.1 <0.01
Hidralazine 8.8 14.2 0.1
Nitrates 14.4 23 0.02
Furosemide 62.3 74.2 0.05
Digoxin 18.2 28.6 0.04
Amiodarone 10.6 21.8 <0.01
Calcium channels blockers 11.9 6.5 0.02
1030-32 Does the Presence of the Metabolic Syndrome 
Accelerate Progression of Cardiac Allograft 
Vasculopathy? A Serial Volumetric Intravascular 
Ultrasound Study
Keon-Woong Moon, Stephen J. Nicholls, Ilke Sipahi, Paul Schoenhagen, Samir R. 
Kapadia, Randall C. Starling, Robert E. Hobbs, William A. Magyar, Steven E. Nissen, E. 
Murat Tuzcu, Cleveland Clinic, Cleveland, OH
Background: The development of cardiac allograft vasculopathy (CAV) portends an 
adverse clinical outcome in heart transplant recipients. It has been reported that the 
metabolic syndrome promotes progression of angiographic changes of CAV. This study 
investigated the impact of the metabolic syndrome and associated lipid abnormalities 
on the progression of the volumetric extent of vasculopathy in a large cohort of heart 
transplant recipients.
Methods: Serial intravascular ultrasound examinations were performed at 1 month and 1 
year following heart transplantation. Changes in total atheroma volume were compared 
in patients stratified according to the presence of the metabolic syndrome and the 
triglyceride/high-density lipoprotein ratio at baseline.
Results: 121 heart transplant recipients (54.5±12.6 years, 71.9% male) were studied. Of 
these patients, 28.9% were obese, 46.3% had TG ≥150 mg/dl, 14.9% had a low HDL, 
41.3% had hypertension, 33.9% had fasting glucose ≥100 mg/dL and 25.6% met the 
criteria for the metabolic syndrome. At baseline, total atheroma volume was comparable 
between patients with and without metabolic syndrome (73.7±46.8 vs 61.0±39.6 mm3 
respectively, p=0.15). The presence of the metabolic syndrome (14.1±26.7 vs 13.8±31.7 
mm3, p=0.53) or a TG/HDL ratio ≥3 (10.3±23.1 vs 15.7±33.7 mm3, p=0.72) were not 
associated with a greater change in total atheroma volume. Furthermore, there was no 
relationship between the number of components of the metabolic syndrome and the 
changes in total atheroma volume (p=0.99).
Conclusion: The presence of the metabolic syndrome or associated lipid abnormalities 
was not associated with accelerated progression of CAV, precisely measured by 
volumetric IVUS analysis throughout a length of artery, during the first year after heart 
transplantation.
1030-33 Correlation of Spirituality With Depression and Quality 
of Life in the Chronic Heart Failure Patient
Catherine A. Draus, Genevieve Valencia, Steve Schwartz, Ruth Moore, Arthur Riba, 
Cheryl Nordstrom, Henry Ford Hospital, Detroit, MI, Oakwood Hospital, Dearborn, MI
Background: Chronic Heart Failure is a disease state that can result in decrease 
functional capacity and QOL, which can result in emotional distress, depression and poor 
clinical outcomes. Studies have suggested that spirituality may be a coping strategy that 
helps to mediate clinical outcomes in chronic illness. Little attention has been paid to the 
psychosocial aspects of CHF, particularly the role of spirituality as it relates to emotional 
distress, depression and clinical outcomes. The purpose of this study was to determine if 
any correlation exists between the degree of depression, the patient’s perceived quality of 
life (QOL) and the role that spirituality may have as a coping mechanism.
Methods: Over a one year period, 1170 patients (with NYHA II-IV classification) were 
screened for study eligibility, of which 369 were eligible and 119 (32.2%) agreed to be 
interviewed. A face-to face interview, prior to hospital discharge (baseline), was conducted 
utilizing the Hospital Anxiety and Depression Questionnaire (scores > 8 = depression), 
a Visual Analogue Scale (VAS) and Minnesota Living with Heart Failure Questionnaire 
(MLHFQ) (measures for QOL) and the Spirituality Involvement and Beliefs Scale (SIBS). 
53 (44.5%) were able to be interviewed three months (3MO) post discharge.
Results: Results showed that depression and anxiety were prevalent in the hospitalized 
patient (47% and 55%, respectively). Spirituality remained constant over the 3 month 
observation period. There was no significant relationship of spirituality and emotional 
status at baseline, however, at 3MO, there was a significant inverse relationship between 
spirituality and depression -.325 (p=.01). There was no significant relationship between 
QOL and spirituality, either at baseline or 3MO
Conclusions: During hospitalization spirituality has no effect on patient outcome. Over 
time spirituality may be a coping mechanism, particularly as it relates to depression. 
Evaluation and incorporation of the patient’s spiritual support network may decrease the 
degree of depression and improve outcomes.
1030-34 Asymptomatic Left Ventricular Diastolic Dysfunction 
and Risk of Death in the Community
Walter Abhayaratna, Katrina Abhayaratna, Christine O’Reilly, Satoru Sakuragi, Niels 
Becker, Australian National University, Canberra, Australia
Background: There is limited information regarding the risk of death in asymptomatic 
individuals with left ventricular (LV) diastolic dysfunction and ejection fraction (EF) ≥50% 
(LVDD). In this population-based study, we assessed mortality rates of subjects with 
LVDD without a history or clinical evidence of congestive heart failure.
Methods and Results: We assessed diastolic function using comprehensive Doppler 
echocardiography in 1275 Canberra Heart Study participants (mean age 69 years; 50% 
men). Diastolic dysfunction was classified as mild or advanced (with elevated LV filling 
pressure). Prevalence rates of mild and advanced preclinical LVDD were 26% and 7.5% 
in women, respectively; and 24% and 6.9% in men, respectively. During a mean follow-
up of 4.8 years, there were 61 deaths in preclinical subjects with EF≥50%. Death rates 
among individuals with normal LV diastolic function and mild LVDD were similar (0.8 
vs.1.1 per 100 person-yrs, respectively; p=0.24). However, the rate of death among those 
with advanced LVDD (3.0 per 100 person-yrs) was higher when compared to subjects 
with normal diastolic function and mild LVDD (p<0.01 for both). After adjustment for age, 
sex, EF and cardiovascular risk factors, preclinical advanced LVDD was associated with 
an increased mortality risk (adjusted Hazards Ratio 2.2, CI 1.1 to 4.2).
Conclusion: Community-based adults with preclinical LVDD are at increased risk of death 
only when the condition is advanced and is associated with increased LV filling pressures. 
1030-35 Effect of Degree of Left Ventricular Systolic Dysfunction 
on Systolic Versus Diastolic Asynchrony in Heart 
Failure Patients
Asim M. Rafique, C Thomas Peter, Robert J. Siegel, Kirsten Tolstrup, Tasneem Z. 
Naqvi, Cedars-Sinai Medical Center, Los Angeles, CA, Keck School of Medicine USC, 
Los Angeles, CA
Tissue velocity (TVI) and strain imaging (SI) are commonly used for assessment of mechanical 
asynchrony in heart failure (HF) patients (pts) resistant to medical therapy. There is limited data 
on correlation of these indices with LV function. We hypothesized that pts with preserved EF 
have better velocities and strain in myocardium and less systolic asynchrony. Methods: We 
evaluated 350 NYHA II-IV CHF pts (68±15 yrs, EF 34±11%, 63% M) for mechanical asynchrony 
by TVI and SI. 60 pts had EF ≥ 45% (HiEF) and 290 had EF< 45% (LoEF). We assessed 
myocardial velocities (cm/s), strain (%), displacement (cm) and time to peak systolic/post 
systolic velocity in 12 LV segments. Results: Age (71±15 vs 67±15, p=0.1), NYHA (3±1 vs 3±1, 
p=0.4), QRS (135±35 vs 140±40, p=0.4), asynchrony index (42±21 vs 41±16, p=0.5), septolat 
delay (42±21 vs 41±16, p=0.5) were similar in HiEF vs LoEF. Post systolic Septopost delay 
(69±78 vs 101±105, p=0.04), segments with post systolic contraction (2±3 vs 4±4, p<0.001), 
cardiac index (2.4±0.9 vs 1.9±0.8, p<0.001, LV Size (55±9 vs 62±9, p<0.001) and LV ESV 
(60±24 vs 122±55, p<0.0001) were significantly different in HiEF vs LoEF. Myocardial velocities, 
displacement and strain are significantly better in HiEF (figure). Conclusion: Despite similar 
NYHA class and systolic asynchrony, LoEF pts had lower myocardial velocity, displacement 
and strain and had worse diastolic asynchrony vs HiEF pts. These data suggest that diastolic 
asynchrony is affected in advanced LV dysfunction and should be evaluated.
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1030-36 Comparison of Randomized Early and Late Combined 
(Intramyocardial And Intracoronary) Treatment of 
Postischemic Ventricular Dysfunction With Bone 
Marrow-Derived Mononuclear Cells
Mariann Gyongyosi, Irene Lang, Markus Dettke, Noemi Nyolczas, Silvia Charwat, Gilbert Beran, 
Senta Graf, Heinz Sochor, Dietmar Glogar, Medical University of Vienna, Vienna, Austria
Background: Effect of early (E, 46+/-33 days post-AMI) or late (L, 94+/-52 days post-AMI) 
combined (intramyocardial plus intracoronary) injections of bone marrow (BM)-derived 
autologous mononuclear cells (MNCs) were compared on myocardial perfusion and 
left ventricular ejection fraction (LVEF) in patients with recent AMI and reopening of the 
infarct-related artery (IRA). Methods: Patients with LVEF<45% after AMI were randomized 
to E (n=36, 51+/-10y) or L (n=33, 54+/-11y) groups. Baseline and 6-month follow-up 
global LVEF and resting perfusion defect (RDP) (primary endpoints, measured by gated 
99m-Tc-MIBI myocardial scintigraphy), and the secondary end point parameters as end-
diastolic volume (EDV, measured by gate scintigraphy), wall motion score index (WMSI), 
LV end-diastolic (EDD) and left atrium (LA) diameter measured by echocardiography, 
myocardial voltage values as index of viability of the treated area (NOGA endocardial 
mapping) were compared between the groups. Patients in the E vs L group received 
NOGA-guided intramyocardial injections (382+/-30 million vs 383+/-43 million BM-
MNCs, containing 1.6+/-1% vs 1.7+/-1% CD34+) followed by intracoronary injections of 
4157+/-2395 million vs 3765+/-2548 million BM-MNCs into the open IRA. Results: Trend 
towards improvement in EF was observed in both groups (E: from 38.1+/-10.1 to 41.3+/-
12.9%, p=0.171 and L: from 36.3+/-12.2 to 40.1+/-11.8%, p=0.113) with nonsignificant 
reduction of RPD (E: from 27.6+/-13.7 to 23.4+/-16.3% vs L: from 27.7+/-12.6 to 24.8+/-
13.2%) without difference between groups. Echocardiography resulted in non-significant 
decrease in WMSI and EDD, and a significant reduction in LA diameter in both groups. 
EDV did not change. The myocardial viability of the treated area increased significantly in 
both groups (E: from 8.2+/-2.8 to 10.3+/-2.8 mV, p=0.019 and L: from 7.9+/-3.4 to 9.6+/-
3.4 mV, p=0.047). Multivariate analysis revealed the total number of injected BM MNCs 
as a significant predictor of improvement of perfusion defect size. Conclusions: Combined 
injections of BM MNCs result in moderate improvement in myocardial perfusion and 
LVEF, independently from the time interval between AMI and treatment.
1030-37 Left Ventricular Torsion: An Important Mechanism 
for Maintaining Normal Filling Pressures--A Speckle 
Tracking Echocardiography Study in Normal Subjects
Bogdan A. Popescu, Denisa Muraru, Andreea Teodorescu, Carmen C. Beladan, Monica 
Hirsu, Carmen Ginghina, “Prof. Dr. C. C. Iliescu” Institute of Cardiovascular Diseases, 
Bucharest, Romania
Background: During systole, the apex of the left ventricle (LV) rotates counterclockwise, 
whereas the base rotates clockwise, creating a torsional deformation of the LV. Speckle 
tracking echocardiography (STE) is a suitable technique for measurement of LV rotation 
because of its angle-independence.
Purpose: To determine LV torsion (LVtor) and to assess its relationship with conventional 
echocardiographic parameters and with LV filling pressure in a series of normal subjects.
Methods: We have prospectively enrolled 30 consecutive normal subjects (35±10 years, 
12 men). A comprehensive echocardiogram was performed in all, including LV volumes 
and ejection fraction (Simpson’s method), parameters of LV diastolic function and LV 
longitudinal function. The parasternal basal and apical short-axis planes were recorded 
to quantify basal and apical LV rotation using the EchoPac workstation. LVtor was defined 
as the net difference between rotation angles at the basal and apical planes (measured at 
the time of aortic valve closure, AVC), normalized for LV diastolic longitudinal length. We 
also estimated mean left atrial pressure (LAP) using the ratio of peak early filling velocity 
to flow propagation velocity (E/Vp), previously described as having the best relation to LV 
filling pressures in healthy volunteers: mean LAP=5.27 x E/Vp + 4.66.
Results: Apical rotation at the time of AVC was 13 ± 6º, while basal rotation at the same 
time was - 5 ± 2º. LVtor was 18 ± 7º; normalized LVtor was 2.3 ± 0.9 degree/cm. Estimated 
mean LAP was 11 ± 2 mm Hg. Both LVtor and normalized LVtor had a significant inverse 
correlation with mean LAP (r= -0.54, p=0.003; r= -0,52, p=0.004, respectively) and did not 
correlate with age, gender, LV volumes, LV ejection fraction, parameters of LV diastolic 
function (other than Vp and E/Vp), and of LV longitudinal function (p>0.20 for all). LVtor 
emerged as the best correlate of mean LAP.
Conclusion: LVtor can be assessed non-invasively in clinical practice by STE. It has a 
significant inverse relation with mean LAP: the higher the LVtor, the lower the LA pressure. 
These findings confirm the role of LVtor in the filling of the ventricle at normal pressures, 
thus allowing a normal cardiac performance.
1030-38 Influence of Body Mass Index on Ventricular Vascular 
Stiffening in Healthy Children
Satoru Sakuragi, Katrina Abhayaratna, Christine O’Reilly, Wichat Srikusalanukul, Marc 
Budge, Richard Telford, Walter P. Abhayaratna, Australian National University, Canberra, 
Australia, Canberra Hospital, Canberra, Australia
Background: Childhood obesity is increasingly prevalent in the community is related to 
adverse cardiovascular outcomes. However, information is limited regarding the influence 
of body mass index on early cardiac structural remodeling and alterations in ventricular-
vascular function in healthy children.
Methods: In 214 healthy children (mean age 10.0 +/- 0.33 yrs; 48% boys), we measured 
body mass index (BMI) and assessed ventricular structure and ventricular-vascular 
elastance [arterial elastance (Ea), LV end-systolic elastance (Ees) and LV end-diastolic 
elastance (Ed)] using echocardiography. Carotid-femoral pulse wave velocity (PWV), an 
index of aortic stiffness, was estimated by applanation tonometry.
Results: BMI was correlated positively with PWV and negatively with indexes of ventricular-
vascular elastance (Ea, Ed, Ees) (Table). However, there was no association between 
BMI and indexes of cardiac remodeling including LV relative wall thickness, indexed LV 
mass or left atrial volume. After the adjustment for age, gender, mean arterial pressure 
and heart rate; increasing BMI was associated with higher PWV (p=0.03); and lower Ea 
(p<0.001), Ed (p=0.01) and Ees (p=0.001).
Conclusion: In healthy children, body mass index is independently related to ventricular-
vascular stiffening in the absence of overt cardiac structural remodeling. Further studies 
are required to evaluate whether reduction of body mass will attenuate age-related 
progression in vascular and ventricular stiffness. 
Body Mass Index
Rho p-value 
Carotid-femoral pulse wave velocity 0.19 0.006
Arterial Elastance (Ea) -0.27 0.0001
Operant diastolic elastance (Ed) -0.22 0.002
End-systolic elastance (Ees) -0.21 0.003
Left ventricular mass index 0.07 0.3
Relative wall thickness 0.05 0.47
Indexed left atrial volume -0.03 0.68
1030-39 Does Lowering Filling Pressures by Using Continuously 
Measured Intracardiac Pressures Result in Reduced 
Risk of Heart Failure Event?
Anthony Magalski, Philip Adamson, William T. Abraham, Dale Renlund, Robert Bourge, 
Ven Manda, Brandon Sparks, Lynne Stevenson, on behalf of the COMPASS-HF 
Investigators, Mid America Heart Institute, Kansas City, MO, Brigham and Womens 
Hospital, Boston, MA
Background: The objective of this analysis was to determine if a sustained, lower, 
intracardiac pressure enabled by an investigational Implantable Hemodynamic Monitor 
(IHM) result in reduced heart failure events (HFE).
Methods: 274 HF patients (NYHA class III-IV) were implanted with the Chronicle® IHM in 
the COMPASS-HF clinical study. Intracardiac pressures were continuously collected by 
the device and each patient’s average daily estimated pulmonary arterial diastolic (ePAD) 
pressure was calculated over the 6-randomized month follow-up period. The risk of a HFE 
(hospitalizations, emergency department, or urgent clinic visits requiring IV therapy) was 
compared to the average ePAD pressure using Cox Proportional Hazards regression. 
Patients with at least 1 month of pressure data were included in the analysis (n=263).
Results: Overall, 103 patients (39%) had at least one HFE during follow-up. ePAD 
pressure was related to the risk of HFE (p<0.0001), with higher pressures indicating an 
increased risk. An average ePAD less than 22 mmHg resulted in a significant reduction 
in the risk of event., There was a significant, 69% reduction in the risk of a HFE among 
patients whose daily ePAD was below 22mmHg (p=0.0001).
Conclusions: Maintaining lower filling pressures, as defined by an ePAD of < 22mHg in 
this IHM system, was associated with a significant reduction in the risk of a HFE. These 
results offer insight into the potential role of continuously measured ePAD in guiding HF 
therapy and lowering filling pressures.
1030-40 Adipokines in Coronary Artery Disease and 
Heart Failure: Relationships With Left Ventricle 
Hemodynamics and Cachexia
Charalambos Antoniades, Dimitris Tousoulis, Alexis Antonopoulos, Apostolos Drolias, 
Kyriakoula Marinou, Koumallos Nikolas, Costantinos Bakogiannis, Emmanuel 
Vavuranakis, Nikos Papageorgiou, Christodoulos Stefanadis, University of Athens, 
Athens, Greece
Background: Adiponectin is an adipokine with a protective role in cardiovascular system, 
while resistin and leptin are adipokines with a pro-inflammatory effect. Despite the 
importance of adipokines in cardiovascular disease, the role in end-stage heart failure 
(HF) or stable coronary artery disease (CAD) is unclear. We compared the expression of 
adiponectin, resistin and leptin between patients with HF, CAD and healthy individuals, 
and we examined their association with left ventricular function.
Methods: The study population consisted of 268 individuals: 147 patients with HF (ejection 
fraction of the left ventricle (EF) 32.5±0.5%, 137 with CAD and normal EF (54.4±0.5%) and 
80 healthy individuals matched for age, gender and risk factors for atherosclerosis. EF was 
measured by ultrasound and serum adiponectin, resistin and leptin were measured by ELISA.
Results: Serum resistin was significantly higher in HF (8.6±0.35 ng/ml) compared to CAD 
(6.5±0.3 ng/ml p<0.001) or healthy controls (7.0±0.4ng/ml, p<0.001), while there was 
an inverse association between resistin and EF (rho=-0.294, p=0.0001). Surprisingly, 
adiponectin levels were also significantly greater in patients with HF (26.5±2.1 µg/ml) 
compared to either patients with CAD (14.8±0.9µg/ml, p<0.001) or healthy individuals 
(9.95±0.8µg/ml, p<0.001 vs HF and p=NS vs CAD), and adiponectin was negatively 
correlated with EF (rho=-0.245, p=0.0001). Importantly, serum leptin was significantly 
lower in HF (10.9±0.7 ng/ml) compared to CAD (14.4±1.5ng/ml p<0.05) or healthy 
individuals (13.6±0.7ng/ml, p<0.05), but there was no linear association between leptin 
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and EF. In linear regression, the associations between EF and either resistin or adiponectin 
lost significance when body weight was introduced into the regression models.
Conclusions: Heart failure is associated with elevated resistin and adiponectin but decreased 
leptin levels. Resistin and adiponectin are both inversely associated with EF, but this effect 
is dependent on body weight. These findings indicate that cachexia modifies adipokines 
expression in heart failure, and adipokines may have a role in heart failure syndrome.
ACC.ORAL CONTRIBUTIONS
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819-3 Echo Peak Pressure Index as a New Noninvasive 
Load-Independent Indicator of Ventricular Recovery 
in Patients on Mechanical Circulatory Support: 
Association With Successful Device Removal
Timothy Bachman, Donald Severyn, James Antaki, Dennis McNamara, Robert Kormos, 
John Gorcsan, III, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh 
Medical Center, Pittsburgh, PA
Background: Assessment of left ventricular (LV) function in patients on assist device 
(LVAD) support is difficult because of LV loading. Although preload-adjusted maximal 
power is a useful load-independent marker of LV function on LVAD, it is technically 
complex. We tested a new simplified index using routine echo image data and noninvasive 
pressure to identify LV recovery on LVAD.
Methods: We studied 49 patients, aged 45±17 yrs, with onset of heart failure < 6 months, 
all originally on chronic LVAD as a bridge to transplant. Data were acquired using mid-LV 
short axis echo imaging and non-invasive finger-cuff blood pressure at full LVAD flow and 
during periods of reduced flow (half flow to minimal flow, if tolerated). LV fractional area 
change (FAC) [(end-diastolic area-end-systolic area)/end-diastolic area] and preload-
adjusted maximal power (peak pressure x peak flow)/(end-diastolic area)3/2 were 
calculated. The new echo peak pressure index (EPPI) was calculated as FAC x peak 
pressure. Fifteen patients had LV recovery with successful LVAD removal, 34 remained 
LVAD dependent.
Results: EPPI correlated correlated closely with preload-adjusted maximal power (r=0.87) 
and predicted LV recovery: a cut-off >%34.88mmHg had a sensitivity of 100% and specificity 
of 94%. EPPI was more specific than FAC alone, which had a specificity of 89%.
Conclusions: EPPI is a new noninvasive index that can assess LV recovery on LVAD 
support and predict successful device removal.
1:15 p.m.
819-4 Left Ventricular Torsion and Diastolic Recoil 
Mechanics in Constrictive Pericarditis and Restrictive 
Cardiomyopathy: New Insights With Two-Dimensional 
Speckle Tracking
Partho P. Sengupta, Vijay K. Krishnamoorthy, Walter P. Abhayaratna, Josef Korinek, 
Marek Belohlavek, Thoralf M. Sundt, Krishnaswamy Chandrasekaran, Farouk 
Mookadam, James B. Seward, A. Jamil Tajik, Bijoy K. Khandheria, Mayo Clinic Arizona, 
Scottsdale, AZ, Mayo Clinic, Rochester, MN
Background: Left ventricular (LV) deformation is principally circumferential, resulting in 
LV torsion, where the apex moves counterclockwise and the base moves clockwise as 
viewed from LV apex. Characteristic of LV torsion and subsequent early diastolic recoil in 
patients with constrictive pericarditis (CP) and restrictive cardiomyopathy (RCM) remain 
uninvestigated.
Methods: Longitudinal, radial and circumferential mechanics of the LV were quantified 
by 2D speckle tracking of B-mode cardiac ultrasound images in 26 patients with CP, 19 
patients with RCM, and 21 age matched control subjects.
Results: In comparison to controls, patients with CP had significantly reduced 
circumferential strain (-16±6% vs. -9±6%; P<0.001), torsion (3±1 degree/cm vs. 1±1 
degree/cm; P<0.001), and early diastolic apical untwisting velocities (Er ,116±62 degree/s 
vs. -36±50 degree/s; P<0.001), whereas longitudinal strains, displacement, and early 
diastolic velocities at LV base (Em) were similar to controls. In contrast, patients with 
RCMP showed significantly reduced longitudinal strain (-14±6 % vs. -11±4 %; P<0.01), 
displacement (14.7±2.5 cm vs. 9.8±2.8 cm; P<0.01) and Em (-8.7±1.3 cm/s vs. -4.4±1.1 
cm/s; P<0.01), whereas circumferential strain, torsion and Er were similar to controls. For 
differentiation of CP from RCMP, the area under the curve was significantly higher for Em 
in comparison with Er (0.97 vs. 0.76, respectively; P=0.01). Following pericardiectomy, 
there was a significant decrease in longitudinal early diastolic LV basal myocardial 
velocities (7.4 cm/s vs. 6.8 cm/s; P=0.023), although this reduction was more frequently 
observed in patients with idiopathic CP than those with secondary CP (7/7 [100%] vs. 
7/12 [58%], respectively; P=0.062). Circumferential strain, torsion and Er, however, 
remained unchanged.
Conclusion: Deformation of the LV is constrained in the circumferential direction in CP 
and in the longitudinal direction in RCM. Subsequent early diastolic recoil of LV is also 
attenuated in each of the 2 directions respectively, uniquely differentiating the diastolic 
recoil mechanics of the LV seen in CP and RCM.
1:30 p.m.
819-5 Scar Location by Myocardial Perfusion Imaging 
Predicts Mortality After Cardiac Resynchronization 
Therapy
Evan C. Adelstein, Andrew H. Voigt, Samir Saba, University of Pittsburgh Medical 
Center, Pittsburgh, PA
Background: Lateral scar predicts cardiac resynchronization therapy (CRT) non-response, 
but mortality data are lacking.
Methods: Of 726 pts undergoing CRT at our institution, 226 had clinically indicated 
myocardial perfusion images (MPI). Defects were classified as anterior or lateral; a 
summed perfusion score (SPS) was generated. Mortality data were obtained from the 
Social Security Death Index.
Results: The cohort was 73% male, 67 ± 12 yrs old, with NYHA class 3.1 ± 0.4, QRS 
duration 172 ± 34 ms, and LVEF 22 ± 8%. MPI pts tended to be male. The SPS in pts 
with any lateral defect (n=99) was higher than in pts with no lateral (n=120) defect (mean 
26.5 ± 11.9 vs. 11.3 ± 12.0 [p<0.001]), whereas the SPS in pts with lateral but no anterior 
defects (n=50) and anterior but no lateral defects (n=40) were similar (19.1 ± 9.5 vs. 21.7 
± 13.1 [p=0.3]).
Overall mortality was 20% over 30.3 ± 14.0 mos. Mortality was higher in pts with any 
lateral defect (36% vs. 16%; p<0.001), remaining significant after controlling for SPS and 
gender (HR 2.8 [1.3-6.0]; p=0.01). Controlling for SPS and gender, mortality was 5-fold 
higher in pts with lateral but no anterior scar compared to those with only anterior scar 
(HR 5.0 [1.5-17.2]; p=0.01). Survival was significantly curtailed in pts with any lateral 
defect (HR 2.5 [1.2-4.9]; p=0.01) and in those with only lateral scar (HR 3.8 [1.4-10.2]; 
p<0.01) after controlling for SPS and gender (Figure).
Conclusions: Lateral scar predicts mortality in CRT recipients. This finding merits 
prospective validation. 
1:45 p.m.
819-6 Increased Central Venous Pressure Is Independently 
Related to Reduced Renal Function and Prognosis in a 
Broad Spectrum of Cardiovascular Patients
Kevin Damman, Vincent M. van Deursen, Gerjan Navis, Dirk J. van Veldhuisen, Adriaan 
A. Voors, Hans L. Hillege, University Medical Center Groningen, Groningen, The 
Netherlands
Background. Glomerular filtration rate (GFR) is mainly dependent on renal perfusion. 
However, increased central venous pressure (CVP) may be an important determinant of 
GFR as well. We set out to determine the relative contribution of increased CVP to renal 
function and prognosis in a broad spectrum of cardiovascular patients.
Methods. We evaluated intra-cardiac pressures, cardiac index (CI) and clinical outcome 
in 2,738 consecutive patients undergoing right heart catheterization for a variety of 
indications. Estimated GFR was determined using the sMDRD formula. Chart review was 
done to investigate follow up and demographics. Follow up started after catheterization 
with the primary endpoint of mortality.
Results. Mean age was 59 ± 15 yr, 57% was male. Mean eGFR was 65 ± 24 mL/
min/1.73m2, with a mean CVP of 5 ± 4 mmHg and a CI of 2.9 ± 0.8 L/min/m2. In the 
total population, CVP was an independent predictor of eGFR (r = -0.107, P < 0.001). In 
patients with CI < 2.5 mL/min/m2, CVP was a stronger predictor of eGFR (r = -0.159, P 
< 0.001) (Figure). CVP was a strong independent predictor of mortality: HR 1.15 (1.06 - 
1.25) per SD increase, P =0.001, next to eGFR (HR 1.14 (1.03 - 1.27), P = 0.011) and CI 
(HR 1.18 (1.07-1.31) P = 0.001), both per SD decrease.
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Conclusion. Increased CVP is an important determinant of reduced GFR. Furthermore, 
CVP is a strong and independent predictor of mortality in a broad spectrum of 
cardiovascular patients. Therefore, CVP should be regarded as an important risk factor 
for renal impairment and prognosis.
2:00 p.m.
819-7 Selection of UNOS Status 1A Candidates for Mechanical 
Circulatory Support as Bridge-to-Transplantation (BTT): 
Analysis of UNOS/OPTN 2000-2005
Katherine Lietz, Mario C. Deng, Jeffrey Morgan, Yoshifumi Naka, Donna Mancini, 
Columbia University, New York, NY
Background: Despite the high priority allocation and availability of mechanical circulatory 
support (MCS), 18% of the medically managed UNOS status 1A candidates die without 
MCS while awaiting heart transplantation (HT). Decision to advance therapy to MCS is 
often difficult, as there are no strict criteria who and when would be most likely to benefit 
from BTT. In order to identify pts, for whom MCS would be favored over waiting for HT, we 
analyzed outcomes of the U.S. population of medically managed status 1A candidates.
Methods: Between Jan 2000 and Dec 2006, a total of 3,711 pts were listed de novo as 
UNOS status 1A candidates in the U.S., including 2,208 (59%) who were initially treated 
medically and 1,503 (41%) rescued with BTT before the day of listing. Of the 2,208 
medically managed pts, 451 (20%) subsequently underwent BTT. Pts were followed until 
HT, death, removal from the waiting list or Sept 1, 2007.
Results: The use of MCS in medically managed status 1A candidates was associated 
with increased probability of survival and/or HT from 66.5% to 87.1% at 3-months*. By 
multivariate analysis the risk factors for death and/or not receiving HT within 24 days 
(median time to HT) in medically managed pts included the presence of intra-aortic 
balloon pump* or ventilator support*, SCr > 1.5 mg%*, age > 60 yrs*, albumin 2.5 g%*, 
ABO blood type O* and weight > 89 kg*. The time when the predicted probability of 
1-month survival and/or HT decreased below the average 85% 1-month survival benefit 
of MCS alone, varied between days and weeks depending on the pts risk profile.
Conclusions: Elective MCS implantation as BTT should be strongly considered in 
medically managed UNOS status 1A candidates at high risk of death and/or anticipated 
long waiting time to HT. The predicted 1-month survival in pts with the identified risk 
factors for death or with projected long wait times to HT may help guide the optimal timing 
for device implantation.
* p<0.001
2:15 p.m.
819-8 The Effects of Intracoronary CD34+ Stem Cell 
Transplantation In Patients With End-Stage Dilative 
Cardiomyopathy
Bojan Vrtovec, Matjaz Sever, Luka Lezaic, Dragoslav Domanovic, Gregor Poglajen, 
Peter Cernelc, Jurij Fettich, Branislav Radovancevic, Ljubljana University Medical 
Center, Ljubljana, Slovenia
Background. Although recent evidence suggests that transcoronary autologous 
transplantation of bone marrow stem cells represents a therapeutic option for patients 
with healed myocardial infarction, its effects in dilative cardiomyopathy remain undefined. 
We investigated the effects of intracoronary CD34+ cell transplantation in patients with 
end-stage dilative cardiomyopathy.
Methods. Of 21 patients with end-stage dilative cardiomyopathy who were evaluated for 
heart transplantation, 11 were randomised to receive intracoronary transplantation of 
autologous CD34+ cells (SC group), and 10 received no stem cell therapy (Controls). In 
the SC group stem cells were mobilised by daily subcutaneous injections of filgrastim, 
CD34+ cells were collected via apheresis and labelled with technetium. Patients uderwent 
myocardial perfusion scintigraphy for myocardial viability assessment and the collected 
CD34+ cells were injected intracoronary in the artery supplying the segments of reduced 
tracer accumulation.
Results. At baseline, the two groups did not differ with regards to age, gender, left 
ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDD), 
plasma proBNP, heart rate variability, QT variability, or concurrent medications. At 3 
months we found an improvement of LVEF and LVEDD in the SC Group (LVEF: from 
24.2±5.1% to 33.7±4.3%; P=0.004; LVEDD: from 6.9±1.3 cm 6.4±1.1 cm; P=0.03), but not 
in the Controls (LVEF: from 25.2±5.2% to 26.1±7.9%; P=0.44; LVEDD: from 6.7±1.4 cm 
6.6±1.5 cm; P=0.42). We found a significant improvement in 6-minute walk distance only 
in the SC Group (from 301±12 m to 405±31 m; P=0.001 vs. from 305±27 m to 307±24 m 
in Controls; P=0.72). Plasma proBNP levels in the SC Group showed a trend to decrease 
(from 2182±872 ng/l to 1810±700 ng/l; P=0.12). We found no significant differences in 
arrhythmia occurrence and electrophysiological parameters between the groups.
Conclusions. Transcoronary autologous CD34+ transplantation appears to be associated 
with reverse remodelling and improved exercise capacity in patients with end-stage 
dilative cardiomyopathy, without an increase in arrhythmia risk.
